Note: Descriptions are shown in the official language in which they were submitted.
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
ANTI-HK2 CHIMERIC ANTIGEN RECEPTOR (CAR)
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted
electronically in ASCII format and is hereby incorporated by reference in its
entirety. Said
ASCII copy, created on June 30, 2020, is named JBI6124W0PCT1 SL.txt and is
562,160 bytes in size.
TECHNICAL FIELD
The invention relates to hK2-targeting chimeric antigen receptors (CARs)
comprising
hK2-targeting single-chain variable fragments and engineered hK2-targeting
immune cells
expressing the CARs. Also provided are nucleic acids and expression vectors
encoding the
CARs, recombinant cells containing the vectors, and compositions comprising
the
engineered immune cells expressing the hK2-targeting CARs. Methods of making
the
CARs, and engineered immune cells, and methods of using the engineered immune
cells to
treat conditions including cancer are also provided.
BACKGROUND
Prostate cancer is the second most frequently diagnosed cancer and the sixth
leading cause
of cancer death in males, accounting for 14% (903,500) of the total new cancer
cases and
6% (258,400) of the total cancer deaths in males worldwide. The course of
prostate cancer
from diagnosis to death is best categorized as a series of clinical stages
based on the extent
of disease, hormonal status, and absence or presence of detectable metastases:
localized
disease, rising levels of prostate-specific antigen (PSA) after radiation
therapy or surgery
with no detectable metastases, and clinical metastases in the non-castrate or
castrate stage.
Although surgery, radiation, or a combination of both can be curative for
patients with
localized disease, a significant proportion of these patients have recurrent
disease as
evidenced by a rising level of PSA, which can lead to the development of
metastases,
especially in the high-risk group¨a transition to the lethal stage of the
disease.
1
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Androgen depletion therapy (ADT) is the standard treatment with a generally
predictable
outcome: decline in PSA, a period of stability in which the tumor does not
proliferate,
followed by rising PSA and regrowth as castration-resistant disease.
Historically, ADT
has been the standard of care for patients with metastatic prostate cancer.
Kallikrein related peptidase 2 (hK2, HK2) is a trypsin-like enzyme with
androgen
receptor (AR)-driven expression specific to prostate tissue and prostate
cancer. hK2 is
activated by Transmembrane Protease, Serine 2 (TMPRSS2) and secreted into the
ducts of
the prostate, where it initiates a cascade that cleaves semenogelin, the
extracellular matrix
in ejaculate, to enhance sperm motility. hK2 expression is restricted to the
prostate and
prostate cancer tissue, however it has recently been demonstrated that hK2 was
detectable
in breast cancer lines and primary patient samples after appropriate
activation of the AR-
pathway by steroid hormones (U.S. Pat. Publ. No. 2018/0326102). Similar to
PSA,
retrograde release of catalytically inactive hK2 into the blood occurs when
the highly
structured organization of the prostate is compromised upon hypertrophy or
malignant
transformation.
T cell therapy utilizes isolated T cells that have been genetically modified
to enhance their
specificity for a specific tumor associated antigen. Genetic modification may
involve the
expression of a chimeric antigen receptor (CAR) or an exogenous T cell
receptor to
provide new antigen specificity onto the T cell. T cells expressing chimeric
antigen
receptors (CAR-T cells) can induce tumor immunoreactivity. There is a need for
better
cancer therapies utilizing CAR-T cells.
SUMMARY
Disclosed herein are chimeric antigen receptors (CARs), e.g., CARs that target
a human
Kallikrein-2 (hK2), cells comprising the CARs, vectors encoding the CARs,
e.g.,
recombinant expression vectors, and nucleic acid molecules encoding the CARs,
methods
of making the CARs, compositions, polypeptides, proteins, nucleic acids, host
cells,
populations of cells and methods of treating disorders, e.g., cancer, using
the disclosed
CARs.
2
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one aspect is provided a chimeric antigen receptor (CAR) comprising:
(a) an extracellular domain comprising an scFv that specifically binds to the
human
Kallikrein-2 (hK2) antigen,
(b) a transmembrane domain, and
(c) an intracellular signaling domain optionally comprising at least one co-
stimulatory domain.
In some embodiments, the CAR further comprises
(d) a CD8a-hinge region,
wherein the transmembrane domain comprises a CD8a transmembrane region
(CD8a-TM) polypeptide; and
wherein the intracellular signaling domain comprises a co-stimulatory domain
comprising a TNF receptor superfamily member 9 (CD137) component and a primary
signaling domain comprising a T-cell surface glycoprotein CD3 zeta chain
(CD3z)
component.
In some embodiments, the CD8a-hinge region comprises an amino acid sequence
that is at
least 90% identical to SEQ ID NO: 25, 269, 270, 271, or 272;
the transmembrane domain comprises an amino acid sequence that is
at least 90% identical to SEQ ID NO: 26; and/or
the intracellular signaling domain comprises a co-stimulatory
domain having an amino acid sequence that is at least 90% identical to SEQ ID
NO: 27, and a primary signaling domain having an amino acid sequence that is
at least 90% identical to SEQ ID NO: 28.
In another aspect is provided a chimeric antigen receptor (CAR) comprising an
extracellular antigen-binding domain, a transmembrane domain and an
intracellular
signaling domain, where the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 64, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 66;
3
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 314, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 315, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 311;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 309, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 310, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 311;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 65, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 66;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 73, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 66;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 86, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 87, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 88;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 92, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 93, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 94;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 103, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 104;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid
4
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
sequence of SEQ ID NO: 106, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 104;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 107, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 108, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 109;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 110, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 111, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 109;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 112, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 113;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 114, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 113;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 115, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 116, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 117;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 118, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 119, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 117;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 120, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 121, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 122; or
5
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 123, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 124, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 122,
where the extracellular antigen-binding domain binds the hK2 antigen.
In another aspect is provided a chimeric antigen receptor (CAR) comprising an
extracellular antigen-binding domain, a transmembrane domain and an
intracellular
signaling domain, where the extracellular antigen-binding domain comprises:
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, and a light chain CDR3 having the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 70, and a light chain CDR3 having the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 90, and a light chain CDR3 having the amino acid sequence of SEQ
ID
NO: 91;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 95, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 96, and a light chain CDR3 having the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 312, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 313, and a light chain CDR3 having the amino acid sequence of
SEQ
ID NO: 91;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 having the amino acid
sequence
6
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
of SEQ ID NO: 90, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 126, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 71;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 128, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 129, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 130;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 125, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 131, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 132;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 133, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 134, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 135;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 136, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 137, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 138; or
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 haying the amino acid
sequence of
SEQ ID NO: 127, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 139,
where the extracellular antigen-binding domain binds the hK2 antigen.
In some embodiments, the extracellular antigen-binding domain further
comprises:
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 haying the amino acid
sequence
7
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
of SEQ ID NO: 69, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 71; or
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 68, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 70, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 90, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 95, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 96, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 312, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 313, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 90, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 126, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 71;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 128, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 129, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 130;
8
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 125, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 131, and a light chain CDR3 having the amino acid sequence of
SEQ
ID NO: 132;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 133, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 134, and a light chain CDR3 having the amino acid sequence of
SEQ
ID NO: 135;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 136, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 137, and a light chain CDR3 having the amino acid sequence of
SEQ
ID NO: 138; or
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 127, and a light chain CDR3 having the amino acid sequence of
SEQ
ID NO: 139.
In another aspect is provided a chimeric antigen receptor (CAR), comprising an
extracellular antigen-binding domain, a transmembrane domain and an
intracellular
signaling domain, wherein the extracellular antigen-binding domain comprises:
a light chain variable domain (VL) comprising an amino acid sequence selected
from SEQ ID NOS: 1, 2, 3, 74, 75, 147, 148, 149, 150, 151, 152 and 318; and/or
a heavy chain variable domain (VH) comprising an amino acid sequence selected
from SEQ ID NOS: 4, 5, 6, 76, 77, 140, 141, 142, 143, 144, 145, 146 and 317;
wherein the extracellular antigen-binding domain binds the human
Kallikrein-2 (hK2) antigen.
In some embodiments, the extracellular antigen-binding domain comprises:
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 1 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 4;
9
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 2 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 2 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 1 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 1 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 2 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 5;
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 74 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 76;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 75 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 77;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 147 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 140;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 75 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 141;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 75 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 140;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 148 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 142;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 149 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 143;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 150 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 144;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 151 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 145;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 152 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 146;
11
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 318 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 317.
In some embodiments, the extracellular antigen-binding domain comprises a
single-chain
variable fragment (scFv). In some embodiments, the scFv comprises a linker
polypeptide
between the light chain variable region (VL) and the heavy chain variable
region (VH). In
some embodiments, the linker polypeptide comprises an amino acid sequence of
SEQ ID
NO: 7. In some embodiments, the scFv comprises an amino acid sequence selected
from
the group consisting of SEQ ID NOS: 8-23, 169-184 and 340-343. In some
embodiments,
the extracellular antigen-binding domain comprises a signal polypeptide. In
some
embodiments, the signal polypeptide comprises an amino acid sequence of SEQ ID
NO:
24.
In some embodiments, the intracellular signaling domain comprises a
polypeptide
component selected from the group consisting of a TNF receptor superfamily
member 9
(CD137) component, a T-cell surface glycoprotein CD3 zeta chain (CD3z)
component, a
cluster of differentiation (CD27) component, a cluster of differentiation
superfamily
member component, and a combination thereof. In some embodiments, the CD137
component comprises an amino acid sequence of SEQ ID NO: 27. In some
embodiments,
the CD3z component comprises an amino acid sequence of SEQ ID NO: 28. In some
embodiments, the intracellular signaling domain comprises an amino acid
sequence of
SEQ ID NO: 45. In some embodiments, the transmembrane domain comprises a CD8a
transmembrane region (CD8a-TM) polypeptide. In some embodiments, the CD8a-TM
polypeptide comprises an amino acid sequence of SEQ ID NO: 26.
In various embodiments, the CAR further comprises a hinge region linking the
transmembrane domain to the extracellular antigen-binding domain. In some
embodiments, the hinge region is a CD8a-hinge region. In some embodiments, the
CD8a-
hinge region comprises an amino acid sequence of SEQ ID NO: 25, 269, 270, 271,
or 272.
In some embodiments, the extracellular antigen-binding domain comprises an
amino acid
sequence selected from the group consisting of SEQ ID NOS: 29-44, 78-81, 221-
236, and
12
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
273-308. In some embodiments, the CAR comprises an amino acid sequence
selected from
the group consisting of SEQ ID NOS: 46-61, 82-85 and 205-220.
In another aspect is provided an isolated lymphocyte expressing any of the
above-
described CARs. In some embodiments, the lymphocyte is a T lymphocyte. In some
embodiments, the lymphocyte is a natural killer (NK) cell.
Also provided is an isolated nucleic acid molecule encoding any of the above-
described
CARs. Also provided is a vector comprising the nucleic acid molecule. In
addition, a cell
expressing the nucleic acid molecule is also provided.
Further provided is a pharmaceutical composition comprising an effective
amount of any
of the above lymphocytes, and a pharmaceutically acceptable excipient.
In one aspect, the present disclosure provides a CAR according to the present
disclosure
for use in a method of therapy.
In one aspect, the present disclosure provides a lymphocyte according to the
present
disclosure for use in a method of therapy.
In one aspect, the present disclosure provides a composition, e.g. a
pharmaceutical
composition, according to the present disclosure for use in a method of
therapy.
In one aspect, the present disclosure provides a CAR according to the present
disclosure
for use in a method of treating cancer.
In one aspect, the present disclosure provides a lymphocyte according to the
present
disclosure for use in a method of treating cancer.
In one aspect, the present disclosure provides a composition, e.g. a
pharmaceutical
composition, according to the present disclosure for use in a method of
treating cancer.
In one embodiment, the cancer is prostate cancer.
In one embodiment, the cancer is androgen receptor (AR) expressing breast
cancer.
In another aspect is provided a method of treating a subject having cancer.
The method
comprises administering a therapeutically effective amount of any of the above
lymphocytes to a subject in need thereof, whereby the lymphocyte induces
killing of
13
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
cancer cells in the subject. In some embodiments, the cancer is prostate
cancer. In some
embodiments, the cancer is androgen receptor (AR) expressing breast cancer.
In another aspect is provided a method of targeted killing of a cancer cell,
the method
comprising contacting the cancer cell with any of the above lymphocytes,
whereby the
lymphocyte induces killing of the cancer cell. In some embodiments, the cancer
cell is a
prostate cancer cell. In some embodiments, the cancer is androgen receptor
(AR)
expressing breast cancer.
In another aspect is provided a method of detecting the presence of cancer in
a subject,
comprising:
(a) contacting a cell sample obtained from the subject with any of the
above CARS, thereby forming a CAR-cell complex, and
(b) detecting the complex, wherein detection of the complex is
indicative of the presence of cancer in the subject.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing will be apparent from the following more particular description
of example
embodiments, as illustrated in the accompanying drawings.
This patent application file contains at least one drawing executed in color.
Copies of this
patent application with color drawing(s) will be provided by the Office upon
request and
payment of the necessary fee.
Figures 1A-1C show the construction and expression of hK2 CAR on human T
cells.
Figure 1A shows a schematic illustration of the construct for the hK2 CARS;
TM:
transmembrane. Figures 1B and 1C show hK2 CAR expression on T cells-surface.
Primary
human T cells were electroporated with no mRNA (MOCK) or 10[Ig of mRNA
expressing
either an hK2 scFv CAR or irrelevant control CAR. 24 hours post-
electroporation CAR
surface expression was measured by flow cytometry following staining with 2
p,g/m1
biotinylated L-protein and streptavidin-conjugated PE (Figure 1B) or
biotinylated hK2 (1
p.g/m1) and streptavidin-conjugated PE (Figure 1C).
14
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Figure 2 shows cytotoxicity of hK2-expressing tumor cells by CAR-T cells in 20-
hour
flow based assay at the indicated effector-to-target cell (E/T) ratio. 24
hours after transient
transfection, target cells (Vcap and DU145) were labeled with Cell Trace
Violet (CTV)
fluorescent dye and then co-cultured with hK2 CAR-T cells. Mock T cells served
as
negative effector controls. Percent killing is the ratio of the absolute
number of live
(viability dye negative) target (CTV positive) cells remaining in the co-
culture relative to
the number of live targets cultured without CAR-T cells.
Figures 3A-3B show real-time hK2-specific CAR-T cell-mediated cytotoxicity.
Normalized cell index (CI) plot for target cells (Figure 3A) VCap (5E4) and
(Figure 3B)
DU145 (5E3) incubated with Mock, lOng mRNA electroporated (24 hours post
transfection) hK2 11B6 CAR LH or control CAR-T cells at different E:T ratios
for
approximately 72 hours. When seeded alone, target cells adhere to the plate
and proliferate,
increasing the CI readout. When T cells were added to target cells, hK2 CAR-
and control
CAR-T cells caused hK2 (+) VCap cell cytolysis and subsequent progressive
decrease in
CI at an E/T ratio from 5:1 to 0.156:1. The reduction in CI value after
addition of effector
cells reflects the loss of viability of target cells. A parallel experiment
using hK2(-)
DU145 target cells was also performed, as shown in (Figure 3B); at the E:T
ratios tested in
this experiment, hK2 and control CAR T cells did not reduce CI after addition
which
displayed no cytolytic activity. The Y-axis is the normalized CI generated by
the RTCA
software and displayed in real time. X-axis is the time of cell culture and
treatment time in
hour. Mean values of the CI were plotted standard deviation.
Figure 4 shows Thl cytokine interferon-y (IFN-y) production of antigen-
stimulated CAR-
T cells. Supernatant was collected from xCELLigence based killing assay (see
Figures
3A-3B) approximately 70 hours co-culture (VCap#5E4, DU145#5E3). hK2 CAR LH-and
Control CAR modified T cells secrete IFN-y during co-culture with hK2-
expressing VCap
cells, but not hK2-negative DU145 cells. Mean IFN-y concentration standard
deviation
(pg/ml) from duplicate cultures is shown.
Figures 5A-5B show that 11B6 thermally stabilized scFvs CAR clones were
evaluated in
the JNL reporter assay for antigen-dependent activity. Figure 5A shows Jurkat
cells
containing the luciferase gene driven by the signaling-responsive NFAT
promoter (termed
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
JNL cells), were transduced with the various hK2 CAR constructs. Expression
was
determined by biotinylated hK2 followed by streptavidin-conjugated PE. Figure
5B shows
binding between the CAR construct and its cognate cellular antigen (hK2 on
target cells)
leads to luciferase expression in the JNL cells. JNL cells containing the
indicated CAR
clones and un-transduced JNL cells (UTD) were co-cultured with target cells
lines (VCap
or DU145 cells) and luciferase activity was measured as luminescence
intensity. Clones
were considered active when the luminescence intensity exceeded 1.5-fold the
level of
UTD cells in the presence of antigen-expressing cells.
Figure 6 shows hK2 CAR expression on T cells-surface. Primary human T cells
were
transduced with 11B6 thermally stabilized and parental scFvs based CAR
lentivirus
(multiplicity of infection (MOI): 3) and CAR expression was determined by
biotinylated
hK2 (1[1g/m1) followed by streptavidin-conjugated PE 14 days post
transduction.
Figures 7A-7B show that 11B6 thermally stabilized scFv CAR-T cells were
evaluated in
the real-time IncuCyte killing assay for antigen-dependent cytotoxicity.
Thermally
stabilized hK2 CAR-T cells and parental 11B6 CAR-Ts were co-incubated with
VCaP
cells (Figure 7A) and PC3 cells (Figure 7B) for 88 hours. Effector-to-target
(E/T) ratio
was calculated based on CAR expression data (see Figure 6). Target cells were
stably
expressing a red nuclear dye which was measured by IncuCyte imaging system in
a real-
time fashion. Tumor cell growth inhibition (%) =(Initial Viable Target Cell
Number-
Current Viable Target Cell Number)/Initial Viable Cell Number*100 (%).
Figure 7C shows percent tumor cell growth inhibition of hK2 positive VCaP
cells at
effector:target ratio of 1:1 or 0.5:1 by T cells transduced with CAR1-10 or
the parental
11B6 EL or 11B6 LH. in the real-time IncuCyte killing assay assessing antigen-
dependent cytotoxicity. Tumor cell growth inhibition (%) =(Initial Viable
Target Cell
Number-Current Viable Target Cell Number)/Initial Viable Cell Number*100 (%).
Figure 7D shows percent tumor cell growth inhibition of PC3 cells at
effector:target ratio
of 1:1 by T cells transduced with CAR1-10 or the parental 11B6 EL or 11B6 LH.
in the
real-time IncuCyte killing assay assessing antigen-dependent cytotoxicity.
Tumor cell
growth inhibition (%) =(Initial Viable Target Cell Number-Current Viable
Target Cell
Number)/Initial Viable Cell Number*100 (%).
16
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Figure 7E shows percent tumor cell growth inhibition of hK2 positive VCaP
cells by
CAR-T cells transduced with CAR17 (B413HL in the Figure), CAR18 (B413LH in the
Figure), CAR19 (B359HL in the Figure) and CAR20 (B359LH in the Figure) in the
real-
time IncuCyte killing assay assessing antigen-dependent cytotoxicity. Tumor
cell growth
inhibition (%) =(Initial Viable Target Cell Number-Current Viable Target Cell
Number)/Initial Viable Cell Number*100 (%).
Figure 7F shows percent tumor cell growth inhibition of hK2 negative DU145
cells by
CAR-T cells transduced with CAR17 (B413HL in the Figure), CAR18 (B413LH in the
Figure), CAR19 (B359HL in the Figure) and CAR20 (B359LH in the Figure) in the
real-
time IncuCyte killing assay assessing antigen-dependent cytotoxicity. Tumor
cell growth
inhibition (%) =(Initial Viable Target Cell Number-Current Viable Target Cell
Number)/Initial Viable Cell Number*100 (%).
Figure 8 shows cytokine release by hK2 lenti-CAR-T cells. Supernatant
collected from
overnight (approximately 20 hours) co-culture of hK2 CAR-T cells with VCap
cells at 1:1
of E/T ratio was analyzed using 13-plex Milliplex Human High Sensitivity T
cell kit
(HSTCMAG28SPMX13). hK2 CAR modified T cells secrete cytokines during co-
culture
with hK2-expressing VCap cells, but minimal for un-transduced T cells (UTD).
Mean
cytokine concentration standard deviation (pg/ml) from duplicate cultures is
shown.
Figure 9 shows IFN-y release by hK2 lenti-CAR-T cells. Supernatant collected
from
overnight (approximately 20 hours) co-culture of hK2 CAR-T cells with VCap,
DU145
(5E4 cells) cells at 1:1 of E/T ratio. hK2 CAR modified T cells secrete IFN-y
during co-
culture with hK2-expressing VCap cells, but not hK2-negative DU145 cells. Mean
IFN-y
concentration standard deviation (pg/ml) from duplicate cultures is shown.
CD3/28 beads
stimulated T cells and T cells only were used as positive and negative
controls,
respectively.
Figures 10A-10E show the results from an hK2 CAR-T cells proliferation assay.
(Figures
10A, 10C) hK2 CAR and un-transduced (UTD) T cells were labelled with CellTrace
Violet (CTV; 5[IM) and co-cultured with hK2 (+) VCap and hK2 (-) DU145 cells.
Five
days post co-culture, cells were harvested and stained with CD3, CD25, NearIR
live/dead
17
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Dye and hK2 CAR. Flow cytometric analysis was performed on a Fortessa flow
cytometer
with Flowjo software. Lymphocytes were identified by live CD3, and the
frequencies of
CAR+T cells with CTV dye dilution and activation marker CD25 were determined.
(Figures 10B, 10D) CD3/28 beads stimulated T cells and T cells only were used
as
positive and negative controls, respectively. The data in Figure 10E shows
that hK2
CAR+ T cells proliferate more robustly than CD3/28 beads positive control
after 5 days of
coculture with VCap cells. Different CAR constructs engineered T cells have
different
proliferation activity and displayed different CAR+ T cells counts. The CAR+ T
cells
counts based on mean absolute cell count +/- SEM from three technical
replicates.
Figures 11A-11B show the results of assays to determine the level of
expression of hK2
CARs on primary T cells using biotin-labeled hK2 protein. Figure 11A is a
schematic
illustration of the construct for the hK2 CARs; TM: transmembrane. In Figure
11B,
primary human T cells were transduced with novel hK2 scFvs based KL2B413 HL&LH
and rehumanized 11B6 KL2B359 HL&LH CARS lentivirus (MOI 3) and CAR expression
was determined by biotinylated hK2(lug/m1) followed by streptavidin-conjugated
PE 14
day post transduction. Figure 11B provides a summary of the percentage of hK2
CAR + T
cells (% positive) detected by novel KL2B413 HL&LH and rehumanized 11B6
KL2B359
HL&LH CARS analyzed. As shown, different clones have different CAR expression
level,
ranges from 45.1% to 59.9%. All CAR T cells were normalized to the equal CAR+
T cells
.. for subsequent functional assays.
Figures 12A-12B show the results of evaluation of novel hK2 KL2B413 and
rehumanized
11B6 CAR clones in the JNL reporter assay for antigen-dependent activity. In
Figure
12A, Jurkat cells containing the luciferase gene driven by the signaling-
responsive NFAT
promoter (termed JNL cells), were transduced with the various hK2 CAR
constructs.
Expression was determined by biotinylated hK2 followed by streptavidin-
conjugated PE.
CAR expression in transduced JNL cells was confirmed for the selected clones
with 46-
50% of cells expression on rehumanized 11B6 KL2B359 CARs and 73.7-96% of cells
on
KL2B413 CARs. The data shown in Figure 12B indicates that binding between the
hK2
CAR construct and its cognate cellular antigen (hK2 on target cells) leads to
luciferase
expression in the JNL cells. JNL cells containing the indicated CAR clones and
JNL cells
18
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
(UTD) were co-cultured with target cells lines (VCap, LNCap/Hk2, LNCap, C4-2B,
22Rv1 or DU145 cells) and luciferase activity was measured as luminescence
intensity.
Clones were considered active when the luminescence intensity exceeded 1.5-
fold the level
of UTD cells in the presence of antigen-expressing cells. No antigen-dependent
activation
was found for the novel KL2B413 and rehumanized 11B6 HL&LH CARs.
Figures 13A-13B show the results of an evaluation of HK2 CAR-T cells in the
real-time
IncuCyte killing assay for antigen-dependent cytotoxicity. HK2 CAR-T cells
were co-
incubated with HK2+ VCaP cells (Fig. 13A) and HK2- DU145 cells (Fig. 13B) for
96
hours. The Effector-to-Target (ET) ratio was calculated based on CAR
expression data
(Fig. 11B). Target cells were stably expressing a red nuclear dye which was
measured by
IncuCyte imaging system in a real-time fashion. Tumor cell growth inhibition
(%) =(Initial
Viable Target Cell Number-Current Viable Target Cell Number)/Initial Viable
Cell
Number*100 (%)
Figure 14 illustrates data showing Thl cytokine IFN-gamma production of
antigen-
stimulated CAR-T Cells. IFN-y produced by cytotoxic T cells is critical for
exerting
immune surveillance of tumors, which can directly inhibit proliferation and
induce
apoptosis of some malignancies in vivo and in vitro. To determine whether hK2
CAR-
modified human T cells were able to recognize and activated by hK2 (+) tumor
cells,
primary T cells containing the indicated CAR clones and control untransduced T
cells
(UTD) were co-cultured with target cells lines (LNCap/Hk2, LNCap, C4-2B, 22Rv1
or
DU145 cells) and supernatant were collected for IFN-g concentration
measurement. As
shown, hK2 CAR modified T cells secrete IFN-gamma during co-culture with hK2-
expressing LNCap/hK2 cells, even very low Hk2 expressing C4-2B and LNCap cells
but
not hK2-negative DU145 cells. Undisclosed control CAR secreted much higher
amount of
IFN- y due to the much higher antigen expression level than hK2. Mean IFN-y
concentration SD (pg/ml) from duplicate cultures is shown.
Figure 15 shows the results of a CD107a degranulation assay to evaluate hK2
CART
cells' antitumor activity. Target cells (5 x 104) were cocultured with an
equal number of
effector cells in 0.1m1 per well in a 96-well plate. Control wells contained T
cells alone.
Anti-CD107a (5p1 per well) was added in addition to lOsample of monensin (BD
19
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Biosciences) and incubated for 4 hours at 37 C. Cells were washed two times
with PBS,
stained for expression of the hK2 CAR, CD3, and CD8 and analyzed on a flow
cytometer
BD Fortessa. As shown, the presence of hK2 antigen on Vcap cells leads to an
increase in
CD107A+ hK2 CAR(+) T cells, but not in hK2 CAR(-) and UTD T cells measured by
flow
cytometry, whereas only the background staining(<2%) was seen in the CAR T
cells only
without tumor cells stimulation. Phorbol 12-myristate 13-acetate (PMA) in
combination
with ionomycin(eBioscienceTM Cell Stimulation Cocktail; 500X) was a consistent
inducer
of CD107a cell surface expression in this 4-hour cell culture model, which was
used as a
positive control. Results are shown for representative donor T cells and are
reproducible in
multiple donors.
Figures 16A-16D show the results of a hK2 CAR T cell proliferation assay. hK2
CAR
and untransduced (UTD) T cells were labelled with CellTrace Violet(CTV; 5uM)
and co-
cultured with HK2 (+) VCap and HK2 (-) DU145 cells. Five days post co-culture,
cells
were harvested and stained with CD3, CD25, NearIR live/dead Dye and hK2 CAR.
Flow
cytometric analysis was performed on a Fortessa flow cytometer with Flowjo
software.
Lymphocytes were identified by live CD3, and the frequencies of CAR+T cells
with CTV
dye dilution and activation marker CD25 were determined. By gating on CD3+ T
cells, as
shown in Figures 16A-16B, the hK2(+) Vcap cells but not hK2(-) DU145 cells
promoted
the all CAR constructs engineered T cells proliferation and upregulation of
activation
.. marker CD25, as shown in Figures 16C-16D. CD3/28 beads stimulated T cells
and T cells
only were used as positive and negative controls, respectively. T cells only
without any
stimulation do not proliferate, and CD3/28 beads stimulated T cells displayed
equivalent
proliferation pattern. As shown, hK2 CAR+ T cells proliferate more robustly
than CD3/28
beads positive control after 5 days of coculture with VCap cells. Different
CAR constructs
engineered T cells have different proliferation activity and displayed
different CAR+ T
cells counts. The summary of percentage of proliferating T cells and CD25
expressing T
cells based on mean absolute cell count +/- SEM from duplicate is shown in
Figures 16B
and 16D.
Figure 17A shows the sequence alignment of the VH domains of mullB6, hullB6,
KL2B357, KL2B358, KL2B359, KL2B360, HCF3 and HCG5. Figure 17A discloses SEQ
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
ID NOS 317, 5, 140, 141, 77, 140, 6, 4 and 345, respectively, in order of
appearance.
Figure 17B shows the protected segments mapped onto the sequence of hK2
antigen to
visualize the binding epitopes of hK2 antibodies identified through HIDX-MS.
Figure 17B
discloses SEQ ID NOS 351, 351, 351, 351, 351 and 351, respectively, in order
of
appearance.
DETAILED DESCRIPTION
A description of example embodiments follows.
The present disclosure provides for chimeric antigen receptors (CARs) that
target human
Kallikrein-2 (hK2), cells comprising such CARs, and methods of treating cancer
(e.g.,
prostate cancer or AR-expressing breast cancer) using the CARs described
herein.
The CARs of the invention have antigen specificity for hK2. The phrases "have
antigen
specificity" and "elicit antigen-specific response" as used herein mean that
the CAR can
specifically bind to and immunologically recognize an antigen, such that
binding of the
CAR to the hK2 antigen elicits an immune response. Methods of testing the CARs
for
antigen specificity and for the ability to recognize target cells are known in
the art.
The disclosure also provides related nucleic acids, recombinant expression
vectors, host
cells, populations of cells, antibodies, or antigen binding portions thereof,
and
pharmaceutical compositions relating to the CARs of the invention.
Several aspects of the invention are described below, with reference to
examples for
illustrative purposes only. It should be understood that numerous specific
details,
relationships, and methods are set forth to provide a full understanding of
the invention.
One having ordinary skill in the relevant art, however, will readily recognize
that the
invention can be practiced without one or more of the specific details or
practiced with
other methods, protocols, reagents, cell lines and animals. The present
invention is not
limited by the illustrated ordering of acts or events, as some acts may occur
in different
orders and/or concurrently with other acts or events. Furthermore, not all
illustrated acts,
steps or events are required to implement a methodology in accordance with the
present
invention. Many of the techniques and procedures described, or referenced
herein, are well
21
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
understood and commonly employed using conventional methodology by those
skilled in
the art.
Unless otherwise defined, all terms of art, notations and other scientific
terms or
terminology used herein are intended to have the meanings commonly understood
by
those of skill in the art to which this invention pertains. In some cases,
terms with
commonly understood meanings are defined herein for clarity and/or for ready
reference,
and the inclusion of such definitions herein should not necessarily be
construed to
represent a substantial difference over what is generally understood in the
art. It will be
further understood that terms, such as those defined in commonly-used
dictionaries,
should be interpreted as having a meaning that is consistent with their
meaning in the
context of the relevant art and/or as otherwise defined herein.
When a list is presented, unless stated otherwise, it is to be understood that
each individual
element of that list, and every combination of that list, is a separate
embodiment. For
example, a list of embodiments presented as "A, B, or C" is to be interpreted
as including
the embodiments, "A," "B," "C," "A or B," "A or C," "B or C," or "A, B, or C."
Definitions
As used in this specification and the appended claims, the singular forms "a,"
"an," and
"the" include plural referents unless the content clearly dictates otherwise.
Thus, for
example, reference to "a cell" includes a combination of two or more cells,
and the like.
The transitional terms "comprising," "consisting essentially of," and
"consisting of' are
intended to connote their generally accepted meanings in the patent
vernacular; that is, (i)
comprising," which is synonymous with "including," "containing," or
"characterized by,"
is inclusive or open-ended and does not exclude additional, unrecited elements
or method
steps; (ii) "consisting of' excludes any element, step, or ingredient not
specified in the
claim; and (iii) "consisting essentially of' limits the scope of a claim to
the specified
materials or steps "and those that do not materially affect the basic and
novel
characteristic(s)" of the claimed invention. Embodiments described in terms of
the phrase
22
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
"comprising" (or its equivalents) also provide as embodiments those
independently
described in terms of "consisting of' and "consisting essentially of."
"Activation" or "stimulation" or "activated" or "stimulated" refers to
induction of a change
in the biologic state of a cell resulting in expression of activation markers,
cytokine
production, proliferation or mediating cytotoxicity of target cells. Cells may
be activated
by primary stimulatory signals. Co-stimulatory signals can amplify the
magnitude of the
primary signals and suppress cell death following initial stimulation
resulting in a more
durable activation state and thus a higher cytotoxic capacity. A "co-
stimulatory signal"
refers to a signal, which in combination with a primary signal, such as
TCR/CD3 ligation,
leads to T cell and/or NK cell proliferation and/or upregulation or
downregulation of key
molecules.
"Antigen binding fragment" or "antigen binding domain" refers to a portion of
the protein
that binds an antigen. Antigen binding fragments may be synthetic,
enzymatically
obtainable or genetically engineered polypeptides and include portions of an
immunoglobulin that bind an antigen, such as the VH, the VL, the VH and the
VL, Fab,
Fab', F(ab')2, Fd and Fv fragments, domain antibodies (dAb) consisting of one
VH domain
or one VL domain, shark variable IgNAR domains, camelized VH domains, VEIH
domains, minimal recognition units consisting of the amino acid residues that
mimic the
CDRs of an antibody, such as FR3-CDR3-FR4 portions, the HCDR1, the HCDR2
and/or
the HCDR3 and the LCDR1, the LCDR2 and/or the LCDR3, alternative scaffolds
that bind
an antigen, and multispecific proteins comprising the antigen binding
fragments. Antigen
binding fragments (such as VH and VL) may be linked together via a synthetic
linker to
form various types of single antibody designs where the VH/VL domains may pair
intramolecularly, or intermolecularly in those cases when the VH and VL
domains are
expressed by separate single chains, to form a monovalent antigen binding
domain, such as
single chain Fv (scFv) or diabody. Antigen binding fragments may also be
conjugated to
other antibodies, proteins, antigen binding fragments or alternative scaffolds
which may be
monospecific or multispecific to engineer bispecific and multispecific
proteins.
"Cancer" refers to a broad group of various diseases characterized by the
uncontrolled
growth of abnormal cells in the body. Unregulated cell division and growth
results in the
23
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
formation of malignant tumors that invade neighboring tissues and may also
metastasize to
distant parts of the body through the lymphatic system or bloodstream. A
"cancer" or
cancer tissue" can include a tumor.
"Full length antibody" is comprised of two heavy chains (HC) and two light
chains (LC)
inter-connected by disulfide bonds as well as multimers thereof (e.g. IgM).
Each heavy
chain is comprised of a heavy chain variable domain (VH) and a heavy chain
constant
domain, the heavy chain constant domain comprised of subdomains CH1, hinge,
CH2 and
CH3. Each light chain is comprised of a light chain variable domain (VL) and a
light
chain constant domain (CL). The VH and the VL may be further subdivided into
regions
of hypervariability, termed complementarity determining regions (CDR),
interspersed with
framework regions (FR). Each VH and VL is composed of three CDRs and four FR
segments, arranged from amino-to-carboxy-terminus in the following order: FR1,
CDR1,
FR2, CDR2, FR3, CDR3 and FR4.
"Human antibody" refers to an antibody that is optimized to have minimal
immune
response when administered to a human subject. Variable regions of human
antibody are
derived from human immunoglobulin sequences. If human antibody contains a
constant
region or a portion of the constant region, the constant region is also
derived from human
immunoglobulin sequences. Human antibody comprises heavy and light chain
variable
regions that are "derived from" sequences of human origin if the variable
regions of the
human antibody are obtained from a system that uses human germline
immunoglobulin or
rearranged immunoglobulin genes. Such exemplary systems are human
immunoglobulin
gene libraries displayed on phage, and transgenic non-human animals such as
mice or rats
carrying human immunoglobulin loci. "Human antibody" typically contains amino
acid
differences when compared to the immunoglobulins expressed in humans due to
differences between the systems used to obtain the human antibody and human
immunoglobulin loci, introduction of somatic mutations or intentional
introduction of
substitutions into the frameworks or CDRs, or both. Typically, "human
antibody" is at
least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98% or 99% identical in amino acid sequence to an
amino
acid sequence encoded by human germline immunoglobulin or rearranged
24
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
immunoglobulin genes. In some cases, "human antibody" may contain consensus
framework sequences derived from human framework sequence analyses, for
example as
described in Knappik et al., (2000) J Mol Biol 296:57-86, or a synthetic HCDR3
incorporated into human immunoglobulin gene libraries displayed on phage, for
example
as described in Shi et al., (2010) J Mol Biol 397:385-96, and in Int. Patent
Publ. No.
W02009/085462. Antibodies in which at least one CDR is derived from a non-
human
species are not included in the definition of "human antibody".
"Humanized antibody" refers to an antibody in which at least one CDR is
derived from
non-human species and at least one framework is derived from human
immunoglobulin
sequences. Humanized antibody may include substitutions in the frameworks so
that the
frameworks may not be exact copies of expressed human immunoglobulin or human
immunoglobulin germline gene sequences.
"Isolated" refers to a homogenous population of molecules (such as synthetic
polynucleotides or polypeptides) which have been substantially separated
and/or purified
away from other components of the system the molecules are produced in, such
as a
recombinant cell, as well as a protein that has been subjected to at least one
purification or
isolation step. "Isolated" refers to a molecule that is substantially free of
other cellular
material and/or chemicals and encompasses molecules that are isolated to a
higher purity,
such as to 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% purity.
"Modulate" refers to either enhanced or decreased ability of a test molecule
to mediate an
enhanced or a reduced response (i.e., downstream effect) when compared to the
response
mediated by a control or a vehicle.
"Natural killer cell" and "NK cell" are used interchangeably and synonymously
herein.
NK cell refers to a differentiated lymphocyte with a CD16+ CD56+ and/or CD57+
TCR-
phenotype. NK cells are characterized by their ability to bind to and kill
cells that fail to
express "self- MHC/HLA antigens by the activation of specific cytolytic
enzymes, the
ability to kill tumor cells or other diseased cells that express a ligand for
NK activating
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
receptors, and the ability to release protein molecules called cytokines that
stimulate or
inhibit the immune response.
"Specifically binds," "specific binding," "specifically binding" or "binds"
refer to a
proteinaceous molecule binding to an antigen or an epitope within the antigen
with greater
affinity than for other antigens. Typically, the proteinaceous molecule binds
to the antigen
or the epitope within the antigen with an equilibrium dissociation constant
(KD) of about
1x10-7 M or less, for example about 5x10-8 M or less, about 1x10-8 M or less,
about 1x10-9
M or less, about 1x10-1 M or less, about 1x10-" M or less, or about 1x10-12 M
or less,
typically with the KD that is at least one hundred fold less than its KD for
binding to a non-
specific antigen (e.g., BSA, casein). In the context of the prostate
neoantigens described
here, "specific binding" refers to binding of the proteinaceous molecule to
the prostate
neoantigen without detectable binding to a wild-type protein the neoantigen is
a variant of.
"Tumor cell" or a "cancer cell" refers to a cancerous, pre-cancerous or
transformed cell,
either in vivo, ex vivo, or in tissue culture, that has spontaneous or induced
phenotypic
changes. These changes do not necessarily involve the uptake of new genetic
material.
Although transformation may arise from infection with a transforming virus and
incorporation of new genomic nucleic acid, uptake of exogenous nucleic acid or
it can also
arise spontaneously or following exposure to a carcinogen, thereby mutating an
endogenous gene. Transformation/cancer is exemplified by morphological
changes,
immortalization of cells, aberrant growth control, foci formation,
proliferation,
malignancy, modulation of tumor specific marker levels, invasiveness, tumor
growth in
suitable animal hosts such as nude mice, and the like, in vitro, in vivo, and
ex vivo.
The term "chimeric antigen receptor" or "CAR" as used herein is defined as a
cell-surface
receptor comprising an extracellular target-binding domain, a transmembrane
domain and
an intracellular signaling domain, all in a combination that is not naturally
found together
on a single protein. This particularly includes receptors wherein the
extracellular domain
and the intracellular signaling domain are not naturally found together on a
single receptor
protein. The chimeric antigen receptors of the present invention are intended
primarily for
use with lymphocyte such as T cells and natural killer (NK) cells.
26
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
The terms "T cell" and "T lymphocyte" are interchangeable and used
synonymously
herein. As used herein, T cell includes thymocytes, naive T lymphocytes,
immature T
lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T
lymphocytes.
A T cell can be a T helper (Th) cell, for example a T helper 1 (Thl) or a T
helper 2 (Th2)
cell. The T cell can be a helper T cell (HTL; CD4+ T cell) CD4+ T cell, a
cytotoxic T cell
(CTL; CD8+ T cell), a tumor infiltrating cytotoxic T cell (TIL; CD8+ T cell),
CD4+CD8+
T cell, or any other subset of T cells. Other illustrative populations of T
cells suitable for
use in particular embodiments include naive T cells and memory T cells. Also
included
are "NKT cells", which refer to a specialized population of T cells that
express a semi-
invariant 43 T-cell receptor, but also express a variety of molecular markers
that are
typically associated with NK cells, such as NK1.1. NKT cells include NK1.1+
and NK1.1-,
as well as CD4+, CD4-, CD8+ and CD8- cells. The TCR on NKT cells is unique in
that it
recognizes glycolipid antigens presented by the MEC I-like molecule CD Id. NKT
cells
can have either protective or deleterious effects due to their abilities to
produce cytokines
.. that promote either inflammation or immune tolerance. Also included are
"gamma-delta T
cells (76 T cells)," which refer to a specialized population that to a small
subset of T cells
possessing a distinct TCR on their surface, and unlike the majority of T cells
in which the
TCR is composed of two glycoprotein chains designated a- and 3-TCR chains, the
TCR in
76 T cells is made up of a 7-chain and a 6-chain. 76 T cells can play a role
in
.. immunosurveillance and immunoregulation, and were found to be an important
source of
IL-17 and to induce robust CD8+ cytotoxic T cell response. Also included are
"regulatory
T cells" or "Tregs", which refer to T cells that suppress an abnormal or
excessive immune
response and play a role in immune tolerance. Tregs are typically
transcription factor
Foxp3-positive CD4+T cells and can also include transcription factor Foxp3-
negative
regulatory T cells that are IL-10-producing CD4+T cells.
The terms "natural killer cell" and "NK cell" are interchangeable and used
synonymously
herein. As used herein, NK cell refers to a differentiated lymphocyte with a
CD 16+
CD56+ and/or CD57+ TCR- phenotype. NK cells are characterized by their ability
to bind
to and kill cells that fail to express "self- MEC/HLA antigens by the
activation of specific
cytolytic enzymes, the ability to kill tumor cells or other diseased cells
that express a
27
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
ligand for NK activating receptors, and the ability to release protein
molecules called
cytokines that stimulate or inhibit the immune response.
As used herein, the term "antigen" refers to any agent (e.g., protein,
peptide,
polysaccharide, glycoprotein, glycolipid, nucleic acid, portions thereof, or
combinations
thereof) molecule capable of being bound by a T-cell receptor. An antigen is
also able to
provoke an immune response. An example of an immune response may involve,
without
limitation, antibody production, or the activation of specific immunologically
competent
cells, or both. A skilled artisan will understand that an antigen need not be
encoded by a
gene" at all. It is readily apparent that an antigen can be generated
synthesized or can be
derived from a biological sample, or might be macromolecule besides a
polypeptide. Such
a biological sample can include, but is not limited to a tissue sample, a
tumor sample, a cell
or a fluid with other biological components, organisms, subunits of
proteins/antigens,
killed or inactivated whole cells or lysates.
The terms "antibody" and "antibodies" refer to monoclonal antibodies,
multispecific
antibodies, human antibodies, humanized antibodies, chimeric antibodies,
single-chain Fvs
(scFv), single chain antibodies, Fab fragments, F(ab') fragments, disulfide-
linked Fvs
(sdFv), intrabodies, minibodies, diabodies and anti-idiotypic (anti-Id)
antibodies
(including, e.g., anti-Id antibodies to antigen-specific TCR), and epitope-
binding fragments
of any of the above. The terms "antibody" and "antibodies" also refer to
covalent diabodies
such as those disclosed in U.S. Pat. Appl. Pub. 2007/0004909 and Ig-DARTS such
as those
disclosed in U.S. Pat. Appl. Pub. 2009/0060910. Antibodies useful as a TCR-
binding
molecule include immunoglobulin molecules and immunologically active fragments
of
immunoglobulin molecules, i.e., molecules that contain an antigen-binding
site.
Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and
IgY),
class (e.g., IgG1 , IgG2, IgG3, IgG4, IgMl, IgM2, IgAl and IgA2) or subclass.
The term "host cell" means any cell that contains a heterologous nucleic acid.
The
heterologous nucleic acid can be a vector (e.g., an expression vector). For
example, a host
cell can be a cell from any organism that is selected, modified, transformed,
grown, used or
manipulated in any way, for the production of a substance by the cell, for
example the
expression by the cell of a gene, a DNA or RNA sequence, a protein or an
enzyme. An
28
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
appropriate host may be determined. For example, the host cell may be selected
based on
the vector backbone and the desired result. By way of example, a plasmid or
cosmid can
be introduced into a prokaryote host cell for replication of several types of
vectors.
Bacterial cells such as, but not limited to DH5a, JM109, and KCB, SURE
Competent
Cells, and SOLOPACK Gold Cells, can be used as host cells for vector
replication and/or
expression. Additionally, bacterial cells such as E. coli LE392 could be used
as host cells
for phage viruses. Eukaryotic cells that can be used as host cells include,
but are not
limited to yeast (e.g., YPH499, YPH500 and YPH501), insects and mammals.
Examples
of mammalian eukaryotic host cells for replication and/or expression of a
vector include,
but are not limited to, HeLa, NIH3T3, Jurkat, 293, COS, CHO, Saos, and PC12.
Host cells of the present disclosure include T cells and natural killer cells
that contain
DNA or RNA sequences encoding the CAR and that express the CAR on the cell
surface.
Host cells may be used for enhancing T cell activity, natural killer cell
activity, treatment
of cancer, and treatment of autoimmune disease.
"Activation" or "stimulation" means to induce a change in the cells' biologic
state by
which the cells (e.g., T cells and NK cells) express activation markers,
produce cytokines,
proliferate and/or become cytotoxic to target cells. All these changes can be
produced by
primary stimulatory signals. Co-stimulatory signals can amplify the magnitude
of the
primary signals and suppress cell death following initial stimulation
resulting in a more
durable activation state and thus a higher cytotoxic capacity. A "co-
stimulatory signal"
refers to a signal, which in combination with a primary signal, such as
TCR/CD3 ligation,
leads to T cell and/or NK cell proliferation and/or upregulation or
downregulation of key
molecules.
The term "proliferation" refers to an increase in cell division, either
symmetric or
asymmetric division of cells. The term "expansion" refers to the outcome of
cell division
and cell death.
The term "differentiation" refers to a method of decreasing the potency or
proliferation of a
cell or moving the cell to a more developmentally restricted state.
29
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
The terms "express" and "expression" mean allowing or causing the information
in a gene
or DNA sequence to become produced, for example producing a protein by
activating the
cellular functions involved in transcription and translation of a
corresponding gene or DNA
sequence. A DNA sequence is expressed in or by a cell to form an "expression
product"
such as a protein. The expression product itself, e.g., the resulting protein,
may also be said
to be "expressed" by the cell. An expression product can be characterized as
intracellular,
extracellular or transmembrane.
The term "transfection" means the introduction of a "foreign" (i.e., extrinsic
or
extracellular) nucleic acid into a cell using recombinant DNA technology. The
term
"genetic modification" means the introduction of a "foreign" (i.e., extrinsic
or
extracellular) gene, DNA or RNA sequence to a host cell, so that the host cell
will express
the introduced gene or sequence to produce a desired substance, typically a
protein or
enzyme coded by the introduced gene or sequence. The introduced gene or
sequence may
also be called a "cloned" or "foreign" gene or sequence, may include
regulatory or control
sequences operably linked to polynucleotide encoding the chimeric antigen
receptor, such
as start, stop, promoter, signal, secretion, or other sequences used by a
cell's genetic
machinery. The gene or sequence may include nonfunctional sequences or
sequences with
no known function. A host cell that receives and expresses introduced DNA or
RNA has
been "genetically engineered." The DNA or RNA introduced to a host cell can
come from
any source, including cells of the same genus or species as the host cell, or
from a different
genus or species.
The term "transduction" means the introduction of a foreign nucleic acid into
a cell using a
viral vector.
The term "regulatory element" refers to any cis-acting genetic element that
controls some
aspect of the expression of nucleic acid sequences. In some embodiments, the
term
promoter" comprises essentially the minimal sequences required to initiate
transcription.
In some embodiments, the term "promoter" includes the sequences to start
transcription,
and in addition, also include sequences that can upregulate or downregulate
transcription,
commonly termed "enhancer elements" and "repressor elements", respectively.
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
As used herein, the term "operatively linked," and similar phrases, when used
in reference
to nucleic acids or amino acids, refer to the operational linkage of nucleic
acid sequences
or amino acid sequence, respectively, placed in functional relationships with
each other.
For example, an operatively linked promoter, enhancer elements, open reading
frame, 5'
and 3' UTR, and terminator sequences result in the accurate production of a
nucleic acid
molecule (e.g., RNA). In some embodiments, operatively linked nucleic acid
elements
result in the transcription of an open reading frame and ultimately the
production of a
polypeptide (i.e., expression of the open reading frame). As another example,
an
operatively linked peptide is one in which the functional domains are placed
with
appropriate distance from each other to impart the intended function of each
domain.
By "enhance" or "promote," or "increase" or "expand" or "improve" refers
generally to the
ability of a composition contemplated herein to produce, elicit, or cause a
greater
physiological response (i.e., downstream effects) compared to the response
caused by
either vehicle or a control molecule/composition. A measurable physiological
response
may include an increase in T cell expansion, activation, effector function,
persistence,
and/or an increase in cancer cell death killing ability, among others apparent
from the
understanding in the art and the description herein. In certain embodiments,
an "increased"
or "enhanced" amount can be a "statistically significant" amount, and may
include an
increase that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more
times (e.g., 500,
1000 times) (including all integers and decimal points in between and above 1,
e.g., 1.5,
1.6, 1.7. 1.8, etc.) the response produced by vehicle or a control
composition.
By "decrease" or "lower," or "lessen," or "reduce," or "abate" refers
generally to the
ability of composition contemplated herein to produce, elicit, or cause a
lesser
physiological response (i.e., downstream effects) compared to the response
caused by
either vehicle or a control molecule/composition. In certain embodiments, a
"decrease" or
"reduced" amount can be a "statistically significant" amount, and may include
a decrease
that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times
(e.g., 500, 1000 times)
(including all integers and decimal points in between and above 1, e.g., 1.5,
1.6, 1.7. 1.8,
etc.) the response (reference response) produced by vehicle, a control
composition, or the
response in a particular cell lineage.
31
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
The term "effective" applied to dose or amount refers to that quantity of a
compound or
pharmaceutical composition that is sufficient to result in a desired activity
upon
administration to a subject in need thereof. Note that when a combination of
active
ingredients is administered, the effective amount of the combination may or
may not
include amounts of each ingredient that would have been effective if
administered
individually. The exact amount required will vary from subject to subject,
depending on
the species, age, and general condition of the subject, the severity of the
condition being
treated, the particular drug or drugs employed, the mode of administration,
and the like.
The phrase "pharmaceutically acceptable", as used in connection with
compositions
described herein, refers to molecular entities and other ingredients of such
compositions
that are physiologically tolerable and do not typically produce untoward
reactions when
administered to a mammal (e.g., a human). Preferably, the term
"pharmaceutically
acceptable" means approved by a regulatory agency of the Federal or a state
government or
listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for
use in
mammals, and more particularly in humans.
The term "protein" is used herein encompasses all kinds of naturally occurring
and
synthetic proteins, including protein fragments of all lengths, fusion
proteins and modified
proteins, including without limitation, glycoproteins, as well as all other
types of modified
proteins (e.g., proteins resulting from phosphorylation, acetylation,
myristoylation,
palmitoylation, glycosylation, oxidation, formylation, amidation,
polyglutamylation, ADP-
ribosylation, pegylation, biotinylation, etc.).
The terms "nucleic acid", "nucleotide", and "polynucleotide" encompass both
DNA and
RNA unless specified otherwise. By a "nucleic acid sequence" or "nucleotide
sequence" is
meant the nucleic acid sequence encoding an amino acid; these terms may also
refer to the
nucleic acid sequence including the portion coding for any amino acids added
as an artifact
of cloning, including any amino acids coded for by linkers.
The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with
which the
compound is administered. Such pharmaceutical carriers can be sterile liquids,
such as
water and oils, including those of petroleum, animal, vegetable or synthetic
origin, such as
32
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or
aqueous solution
saline solutions and aqueous dextrose and glycerol solutions are preferably
employed as
carriers, particularly for injectable solutions. Alternatively, the carrier
can be a solid
dosage form carrier, including but not limited to one or more of a binder (for
compressed
pills), a glidant, an encapsulating agent, a flavorant, and a colorant.
Suitable
pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences"
by E.W.
Martin.
The term "about" or "approximately" includes being within a statistically
meaningful
range of a value. Such a range can be within an order of magnitude, preferably
within
50%, more preferably within 20%, still more preferably within 10%, and even
more
preferably within 5% of a given value or range. The allowable variation
encompassed by
the term "about" or "approximately" depends on the particular system under
study, and can
be readily appreciated by one of ordinary skill in the art.
"Kallikrein related peptidase 2", "hK2", or "k1k2" refers to a known protein
which is also
called kallikrein-2, glandular kallikrein 2, or EIK2. hK2 is produced as a
preproprotein and
cleaved during proteolysis to generate active protease. All hK2 isoforms and
variants are
encompassed in "hK2". The amino acid sequences of the various isoforms are
retrievable
from GenBank accession numbers NP 005542.1 NP 001002231.1 and NP 001243009.
The amino acid sequence of a full length hK2 is shown in SEQ ID NO: 62. The
sequence
-- includes the signal peptide (residues 1-18) and the pro-peptide region
(residues 19-24).
The terminology used herein is for the purpose of describing particular
embodiments only
and is not intended to be limiting. As used herein, the indefinite articles
"a", "an" and "the"
should be understood to include plural reference unless the context clearly
indicates
otherwise.
Chimeric Anti2en Receptors
The present invention relates generally to the use of T cells genetically
modified to stably
express a desired chimeric antigen receptor. A chimeric antigen receptor (CAR)
is an
artificially constructed hybrid protein or polypeptide containing the antigen
binding
33
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
domains of an antibody (scFv) linked to T-cell signaling domains.
Characteristics of CARs
can include their ability to redirect T-cell specificity and reactivity toward
a selected target
in a non-MHC-restricted manner, exploiting the antigen-binding properties of
monoclonal
antibodies. The non-MEIC-restricted antigen recognition gives T cells
expressing CARs the
ability to recognize antigens independent of antigen processing, thus
bypassing a major
mechanism of tumor evasion. Moreover, when expressed in T-cells, CARs
advantageously
do not dimerize with endogenous T cell receptor (TCR) alpha and beta chains.
The CARs described herein provide recombinant polypeptide constructs
comprising at
least an extracellular antigen binding domain, a transmembrane domain and an
intracellular
signaling domain (also referred to herein as "a cytoplasmic signaling domain")
comprising
a functional signaling domain derived from a stimulatory molecule as defined
below. T
cells expressing a CAR are referred to herein as CAR T cells, CAR-T cells or
CAR
modified T cells, and these terms are used interchangeably herein. The cell
can be
genetically modified to stably express an antibody binding domain on its
surface,
conferring novel antigen specificity that is MHC independent.
In some instances, the T cell is genetically modified to stably express a CAR
that combines
an antigen recognition domain of a specific antibody with an intracellular
domain of the
CD3-zeta chain or FcyRI protein into a single chimeric protein. In one
embodiment, the
stimulatory molecule is the zeta chain associated with the T cell receptor
complex.
An "intracellular signaling domain," or a "cytoplasmic signaling domain", as
used herein,
refers to an intracellular portion of a molecule. It is the functional portion
of the protein
which acts by transmitting information within the cell to regulate cellular
activity via
defined signaling pathways by generating second messengers or functioning as
effectors by
responding to such messengers. The intracellular signaling domain generates a
signal that
promotes an immune effector function of the CAR containing cell, e.g., a CAR-T
cell.
Examples of immune effector function, e.g., in a CAR-T cell, include cytolytic
activity and
helper activity, including the secretion of cytokines.
In an embodiment, the intracellular signaling domain can comprise a primary
intracellular
signaling domain. Example primary intracellular signaling domains include
those derived
34
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
from the molecules responsible for primary stimulation, or antigen dependent
simulation. In
an embodiment, the intracellular signaling domain can comprise a co-
stimulatory
intracellular domain. Example co-stimulatory intracellular signaling domains
include those
derived from molecules responsible for co-stimulatory signals, or antigen
independent
stimulation. For example, in the case of a CAR-T, a primary intracellular
signaling domain
can comprise a cytoplasmic sequence of a T cell receptor, and a co-stimulatory
intracellular
signaling domain can comprise cytoplasmic sequence from co-receptor or co-
stimulatory
molecule.
A primary intracellular signaling domain can comprise a signaling motif which
is known
as an immunoreceptor tyrosine-based activation motif or ITAM. Examples of ITAM
containing primary cytoplasmic signaling sequences include, but are not
limited to, those
derived from CD3-zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon,
CD5, CD22, CD79a, CD79b, and CD66d DAP10 and DAP12.
The term "zeta" or alternatively "zeta chain", "CD3-zeta" or "TCR-zeta" is
defined as the
.. protein provided as GenBank Acc. No. BAG36664.1, or the equivalent residues
from a
nonhuman species, e.g., murine, rabbit, primate, mouse, rodent, monkey, ape
and the like,
and a "zeta stimulatory domain" or alternatively a "CD3-zeta stimulatory
domain" or a
"TCR-zeta stimulatory domain" is defined as the amino acid residues from the
cytoplasmic domain of the zeta chain that are sufficient to functionally
transmit an initial
signal necessary for T cell activation. At times, e.g. in or the aspects
and/or embodiments
of the disclosure, the "zeta stimulatory domain" or a "CD3-zeta stimulatory
domain" is
also referred to as "primary signaling domain". In one aspect, the cytoplasmic
domain of
CD3-zeta stimulatory domain comprises residues 52 through 164 of GenBank Acc.
No.
BAG36664.1 or the equivalent residues from a non-human species, e.g., mouse,
rodent,
monkey, ape and the like, that are functional orthologs thereof. In a
preferred embodiment,
the intracellular signaling domain comprises a CD3-zeta stimulatory domain. In
one aspect, the
"zeta stimulatory domain" or a "CD3-zeta stimulatory domain" is the sequence
provided
as SEQ ID NO: 28, or a sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 28.
The term "co-stimulatory molecule" refers to the cognate binding partner on a
T cell that
specifically binds with a co-stimulatory ligand, thereby mediating a co-
stimulatory
response by the T cell, such as, but not limited to, proliferation. Co-
stimulatory molecules
are cell surface molecules other than antigen receptors or their ligands that
are required for
an efficient immune response. Co-stimulatory molecules include, but are not
limited to an
MEC class 1 molecule, BTLA and a Toll ligand receptor, as well as 0X40, CD2,
CD27,
CD28, CDS, ICAM-1, LFA-1 (CD11a/CD18) and 4-1BB (CD137).
A co-stimulatory intracellular signaling domain can be the intracellular
portion of a co-
stimulatory molecule. A co-stimulatory molecule can be represented in the
following
protein families: TNF receptor proteins, Immunoglobulin-like proteins,
cytokine receptors,
integrins, signaling lymphocytic activation molecules (SLAM proteins), and
activating NK
cell receptors. Examples of such molecules include CD27, CD28, 4-1BB (CD137),
0X40,
GITR, CD30, MyD88, CD40, ICOS, BAFFR, HVEM, lymphocyte function-associated
antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, and a
ligand that specifically binds with CD83, and the like.
The intracellular signaling domain can comprise the entire intracellular
portion, or the
entire native intracellular signaling domain, of the molecule from which it is
derived, or a
functional fragment thereof.
The term "4-1BB" or alternatively "CD137" refers to a member of the TNFR
superfamily
with an amino acid sequence provided as GenBank Acc. No. AAA62478.2, or the
equivalent residues from a nonhuman species, e.g., mouse, rodent, monkey, ape
and the
like; and a "4-1BB co-stimulatory domain" is defined as amino acid residues
214-255 of
GenBank accession no. AAA62478.2, or the equivalent residues from a non-human
species,
e.g., mouse, rodent, monkey, ape and the like. At times, e.g. in aspects
and/or embodiments
of the disclosure, the "4-1BB co-stimulatory domain" is also referred to as
"co-stimulatory
domain".
36
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In a preferred embodiment, the intracellular signaling domain comprises a
costimulatory
intracellular signaling domain, wherein the costimulatory intracellular
signaling domain is
a 4-1BB costimulatory domain or "CD137 co-stimulatory domain". In one aspect,
the "4-
1BB co-stimulatory domain" or "CD137 co-stimulatory domain" is the sequence
provided
as SEQ ID NO: 27 or the equivalent residues from a non-human species, e.g.,
mouse,
rodent, monkey, ape and the like, or a sequence having at least 50, at least
55, at least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 27. In a preferred embodiment the 4-1BB costimulatory
domain is the
sequence provided as SEQ ID No:27.
In one embodiment, a transmembrane domain that naturally is associated with
one of the
domains in the CAR is used. In another embodiment, the transmembrane domain
can be
selected or modified by amino acid substitution to avoid binding of such
domains to the
transmembrane domains of the same or different surface membrane proteins to
minimize
interactions with other members of the receptor complex. In one example
embodiment, the
transmembrane domain comprises the CD8a hinge domain. In one embodiment, the
CAR
comprises a CD8a hinge domain and a CD8a transmembrane domain.
In some embodiments, the cytoplasmic signaling domain further comprises one or
more
functional signaling domains derived from at least one co-stimulatory molecule
as defined
herein. In one embodiment, the co-stimulatory molecule is chosen from 4-1BB
(i.e.,
CD137), CD27, CD3-zeta and/or CD28. CD28 is a T cell marker important in T
cell co-
stimulation. CD27 is a member of the tumor necrosis factor receptor
superfamily and acts
as a co-stimulatory immune checkpoint molecule. 4-1BB transmits a potent co-
stimulatory
signal to T cells, promoting differentiation and enhancing long-term survival
of T
lymphocytes. CD3-zeta associates with TCRs to produce a signal and contains
immunoreceptor tyrosine-based activation motifs (ITAMs). In another
embodiment, the
co-stimulatory molecule is MyD88 or CD40.
In one embodiment, the CAR comprises an intracellular hinge domain comprising
CD8
and an intracellular T cell receptor signaling domain comprising CD28, 4-1BB,
and CD3-
37
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
zeta. In another embodiment, the CAR comprises an intracellular hinge domain
and an
intracellular T cell receptor signaling domain comprising CD28, 4-1BB, and CD3-
zeta,
wherein the hinge domain comprises all or part of the extracellular region of
CD8, CD4 or
CD28; all or part of an antibody constant region; all or part of the FcyRIIIa
receptor, an
IgG hinge, an IgM hinge, an IgA hinge, an IgD hinge, an IgE hinge, or an Ig
hinge. The
IgG hinge may be from IgG1 , IgG2, IgG3, IgG4, IgM1 , IgM2, IgAl, IgA2, IgD,
IgE, or a
chimera thereof.
CARs described herein provide recombinant polypeptide constructs comprising at
least an
extracellular antigen binding domain, a transmembrane domain and an
intracellular
signaling domain (also referred to herein as "a cytoplasmic signaling domain")
comprising,
e.g., a functional signaling domain derived from a stimulatory molecule as
defined below
In one embodiment, the CAR comprises a chimeric fusion protein comprising an
extracellular antigen recognition domain, a transmembrane domain and an
intracellular
signaling domain comprising a functional signaling domain derived from a
stimulatory
molecule. In one embodiment, the CAR comprises a chimeric fusion protein
comprising an
extracellular antigen recognition domain, a transmembrane domain and an
intracellular
signaling domain comprising a functional signaling domain derived from a co-
stimulatory
molecule and a functional signaling domain derived from a stimulatory
molecule. In one
embodiment, the CAR comprises a chimeric fusion protein comprising an
extracellular
antigen recognition domain, a transmembrane domain and an intracellular
signaling
domain comprising at least two functional signaling domains derived from one
or more co-
stimulatory molecule(s) and a functional signaling domain derived from a
stimulatory
molecule.
The CARs of the invention can be designed to comprise the CD28 and/or 4-1BB
signaling
domain by itself or be combined with any other desired cytoplasmic domain(s)
useful in
the context of the CARs of the invention. In one embodiment, the cytoplasmic
domain of
the CAR can further comprise the signaling domain of CD3-zeta. For example,
the
cytoplasmic domain of the CAR can include but is not limited to CD3-zeta, 4-
1BB and
CD28 signaling modules and combinations thereof.
38
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one embodiment, the CAR comprises a hinge domain comprising a CD8a hinge
domain, a CD8a transmembrane domain, and an intracellular signaling domain
comprising
4-1BB, and CD3-zeta. In one embodiment, the CAR comprises a hinge domain
comprising
a CD8a hinge domain, a CD8a transmembrane domain, and an intracellular
signaling
domain comprising CD28, 4-1BB, and CD3-zeta.
In another embodiment, the CAR comprises a CD8a hinge domain, a CD8a
transmembrane domain, and an intracellular signaling domain comprising the
signaling
domain of CD3-zeta and a 4-1BB costimulatory domain.
In another embodiment, the CAR comprises a CD8a-hinge region comprising the
amino acid
sequence of SEQ ID NO: 25; a transmembrane domain comprising the amino acid
sequence of SEQ ID NO: 26; and an intracellular signaling domain comprising a
co-
stimulatory domain comprising an amino acid sequence of SEQ ID NO: 27, and a
primary
signaling domain comprising an amino acid sequence of SEQ ID NO: 28.
Accordingly, the invention provides CAR T cells and methods of their use for
adoptive
therapy.
The disclosure further provides variants, e.g., functional variants, of the
CARs, nucleic
acids, polypeptides, and proteins described herein. "Variant" refers to a
polypeptide or a
polynucleotide that differs from a reference polypeptide or a reference
polynucleotide by
.. one or more modifications for example, substitutions, insertions or
deletions. The term
"functional variant" as used herein refers to a CAR, polypeptide, or protein
having
substantial or significant sequence identity or similarity to a parent CAR,
polypeptide, or
protein, which functional variant retains the biological activity of the CAR,
polypeptide, or
protein for which it is a variant. Functional variants encompass, e.g., those
variants of the
.. CAR, polypeptide, or protein described herein (the parent CAR, polypeptide,
or protein)
that retain the ability to recognize target cells to a similar extent, the
same extent, or to a
higher extent, as the parent CAR, polypeptide, or protein. In reference to the
parent CAR,
polypeptide, or protein, the functional variant can, for example, be at least
about 30%,
about 40%, about 50%, about 60%, about 75%, about 80%, about 85%, about 90%,
about
91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about
98%,
39
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
about 99% or more identical in amino acid sequence to the parent CAR,
polypeptide, or
protein.
Herein, the structure of polypeptides is in places defined on the basis of %
sequence
identity with a recited reference sequence (with a given SEQ ID NO). In this
context, %
sequence identity between two amino acid sequences may be determined by
comparing
these two sequences aligned in an optimum manner and in which the amino acid
sequence
to be compared can comprise additions or deletions with respect to the
reference sequence
for an optimum alignment between these two sequences. The percentage of
identity is
calculated by determining the number of identical positions for which the
amino acid
residue is identical between the two sequences, by dividing this number of
identical
positions by the total number of positions in the comparison window and by
multiplying
the result obtained by 100 in order to obtain the percentage of identity
between these two
sequences. Typically, the comparison window with correspond to the full length
of the
sequence being compared. For example, it is possible to use the BLAST program,
"BLAST 2 sequences" (Tatusova et al, "Blast 2 sequences - a new tool for
comparing
protein and nucleotide sequences", FEMS Microbiol Lett. 174:247-250) available
on the
site http://www.ncbi.nlm.nih.gov/ gorf/b12.html, the parameters used being
those given by
default (in particular for the parameters "open gap penalty": 5, and
"extension gap
penalty": 2; the matrix chosen being, for example, the matrix "BLOSUM 62"
proposed by
the program), the percentage of identity between the two sequences to be
compared being
calculated directly by the program. Determining sequence identity of a query
sequence to
a reference sequence is within the ability of the skilled person and can be
performed using
commercially available analysis software such as BLASTTm.
A functional variant can, for example, comprise the amino acid sequence of the
parent
CAR, polypeptide, or protein with at least one conservative amino acid
substitution. In
another embodiment, the functional variants can comprise the amino acid
sequence of the
parent CAR, polypeptide, or protein with at least one non-conservative amino
acid
substitution. In this case, the non-conservative amino acid substitution may
not interfere
with or inhibit the biological activity of the functional variant. The non-
conservative amino
acid substitution may enhance the biological activity of the functional
variant such that the
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
biological activity of the functional variant is increased as compared to the
parent CAR,
polypeptide, or protein.
Amino acid substitutions of the inventive CARS may be conservative amino acid
substitutions. Conservative amino acid substitutions are known in the art, and
include
amino acid substitutions in which one amino acid having certain physical
and/or chemical
properties is exchanged for another amino acid that has the same or similar
chemical or
physical properties. For example, the conservative amino acid substitution can
be an acidic
amino acid substituted for another acidic amino acid (e.g., Asp or Glu), an
amino acid with
a nonpolar side chain substituted for another amino acid with a nonpolar side
chain (e.g.,
Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Val, etc.), a basic amino acid
substituted for
another basic amino acid (Lys, Arg, etc.), an amino acid with a polar side
chain substituted
for another amino acid with a polar side chain (Asn, Cys, Gln, Ser, Thr, Tyr,
etc.), etc.
The CAR, polypeptide, or protein can consist essentially of the specified
amino acid
sequence or sequences described herein, such that other components e.g., other
amino
acids, do not materially change the biological activity of the functional
variant.
The CARs, polypeptides, and proteins of embodiments of the disclosure
(including
functional portions and functional variants) can be of any length, i.e., can
comprise any
number of amino acids, provided that the CARS, polypeptides, or proteins (or
functional
portions or functional variants thereof) retain their biological activity,
e.g., the ability to
specifically bind to an antigen, detect diseased cells (e.g., cancer cells) in
a host, or treat or
prevent disease in a host, etc. For example, the polypeptide can be about 50
to about 5000
amino acids long, such as about 50, about 70, about 75, about 100, about 125,
about 150,
about 175, about 200, about 225, about 250, about 275, about 300, about 325,
about 350,
about 375, about 400, about 425, about 450, about 475, about 500, about 525,
about 550,
about 575, about 600, about 625, about 650, about 675, about 700, about 725,
about 750,
about 775, about 800, about 825, about 850, about 875, about 900, about 925,
about 950,
about 975, about 1000 or more amino acids in length. The polypeptides of the
invention
also include oligopeptides.
41
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
The CARS, polypeptides, and proteins of embodiments of the invention
(including
functional portions and functional variants of the invention) can comprise
synthetic amino
acids in place of one or more naturally-occurring amino acids. Such synthetic
amino acids
are known in the art, and include, for example, aminocyclohexane carboxylic
acid,
norleucine, a-amino n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine,
trans-3-
and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, a-(2-
amino-2-
norbornane)-carboxylic acid, a,y-diaminobutyric acid, a,3-diaminopropionic
acid,
homophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, fl-
phenylserine f3-
hydroxyphenylalanine, phenylglycine, a-naphthylalanine, cyclohexylalanine,
cyclohexylglycine, N'-benzyl-N'-methyl-lysine, N',N'-dibenzyl-lysine, 6-
hydroxylysine,
ornithine, a-aminocyclopentane carboxylic acid, a-aminocyclohexane carboxylic
acid, a-
aminocycloheptane carboxylic acid, indoline-2-carboxylic acid, 1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid
monoamide, and a-tert-butylglycine.
The CARS, polypeptides, and proteins of embodiments of the invention
(including
functional portions and functional variants) can be subject to post-
translational
modifications. They can be glycosylated, esterified, N-acylated, amidated,
carboxylated,
phosphorylated, esterified, cyclized via, e.g., a disulfide bridge, or
converted into an acid
addition salt. In some embodiments, they are dimerized or polymerized, or
conjugated.
The CARS, polypeptides, and/or proteins of embodiments of the invention
(including
functional portions and functional variants thereof) can be obtained by
methods known in the
art. Suitable methods of de novo synthesizing polypeptides and proteins are
described in
references, such as Chan et al., Fmoc Solid Phase Peptide Synthesis, Oxford
University
Press, Oxford, United Kingdom, 2000; Peptide and Protein Drug Analysis, ed.
Reid, R.,
Marcel Dekker, Inc. ,2000; and Epitope Mapping, ed. Westwood et al., Oxford
University
Press, Oxford, United Kingdom, 2001. Also, polypeptides and proteins can be
recombinantly produced using the nucleic acids described herein using standard
recombinant methods. See, for instance, Sambrook et al., Molecular Cloning: A
Laboratory Manual, 3rd ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
2001;
and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing
Associates
42
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
and John Wiley & Sons, NY, 1994. Further, some of the CARs, polypeptides, and
proteins
of the invention (including functional portions and functional variants
thereof) can be
isolated and/or purified from a source, such as a plant, a bacterium, an
insect, a mammal,
etc. Methods of isolation and purification are known in the art.
Alternatively, the CARs,
polypeptides, and/or proteins described herein (including functional portions
and
functional variants thereof) can be commercially synthesized. In this respect,
the CARs,
polypeptides, and proteins can be synthetic, recombinant, isolated, and/or
purified.
Examples of modified nucleotides that can be used to generate the recombinant
nucleic
acids utilized to produce the polypeptides described herein include, but are
not limited to,
5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine,
xanthine, 4-
acetylcytosine, 5-(carboxyhydroxymethyl) uracil, carboxymethylaminomethy1-2-
thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, N6-substituted
adenine, 7-
methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethy1-2-thiouracil,
beta-D-
mannosylqueosine, 5"-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-
N6-
isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil,
queuosine,
beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-
methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-
methylcytosine, 5-methylcytosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-
thiouracil, 4-
thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, 3-(3-amino-3-
N-2-
carboxypropyl) uracil, and 2,6-diaminopurine.
The nucleic acid can comprise any isolated or purified nucleotide sequence
which encodes
any of the CARs, polypeptides, or proteins, or functional portions or
functional variants
thereof. Alternatively, the nucleotide sequence can comprise a nucleotide
sequence which
is degenerate to any of the sequences or a combination of degenerate
sequences.
Some embodiments of the invention also provide an isolated or purified nucleic
acid
comprising a nucleotide sequence which is complementary to the nucleotide
sequence of
any of the nucleic acids described herein or a nucleotide sequence which
hybridizes under
stringent conditions to the nucleotide sequence of any of the nucleic acids
described herein.
43
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
The nucleotide sequence which hybridizes under stringent conditions may
hybridize under
high stringency conditions. By "high stringency conditions" is meant that the
nucleotide
sequence specifically hybridizes to a target sequence (the nucleotide sequence
of any of the
nucleic acids described herein) in an amount that is detectably stronger than
non-specific
hybridization. High stringency conditions include conditions which would
distinguish a
polynucleotide with an exact complementary sequence, or one containing only a
few
scattered mismatches from a random sequence that happened to have a few small
regions
(e.g., 3-12 bases) that matched the nucleotide sequence. Such small regions of
complementarity are more easily melted than a full-length complement of 14-17
or more
bases, and high stringency hybridization makes them easily distinguishable.
Relatively
high stringency conditions would include, for example, low salt and/or high
temperature
conditions, such as provided by about 0.02-0.1 M NaCl or the equivalent, at
temperatures
of about 50-70 C. Such high stringency conditions tolerate little, if any,
mismatch
between the nucleotide sequence and the template or target strand, and are
particularly
suitable for detecting expression of any of the CARS described herein. It is
generally
appreciated that conditions can be rendered more stringent by the addition of
increasing
amounts of formamide.
In an embodiment, the nucleic acids of the invention can be incorporated into
a recombinant
expression vector. The present disclosure provides recombinant expression
vectors
comprising any of the nucleic acids of the invention. As used herein, the term
"recombinant
expression vector" means a genetically-modified oligonucleotide or
polynucleotide
construct that permits the expression of an mRNA, protein, polypeptide, or
peptide by a
host cell, when the construct comprises a nucleotide sequence encoding the
mRNA, protein,
polypeptide, or peptide, and the vector is contacted with the cell under
conditions sufficient
to have the mRNA, protein, polypeptide, or peptide expressed within the cell.
The vectors
described herein are not naturally-occurring as a whole; however, parts of the
vectors can be
naturally-occurring. The described recombinant expression vectors can comprise
any type
of nucleotides, including, but not limited to DNA and RNA, which can be single-
stranded
or double-stranded, synthesized or obtained in part from natural sources, and
which can
contain natural, non-natural or altered nucleotides. The recombinant
expression vectors can
44
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
comprise naturally-occurring or non-naturally-occurring internucleotide
linkages, or both
types of linkages. The non-naturally occurring or altered nucleotides or
internucleotide
linkages do not hinder the transcription or replication of the vector.
In an embodiment, the recombinant expression vector of the invention can be
any suitable
recombinant expression vector, and can be used to transform or transfect any
suitable host.
Suitable vectors include those designed for propagation and expansion or for
expression or
both, such as plasmids and viruses. The vector can be selected from the group
consisting of
the pUC series (Fermentas Life Sciences, Glen Burnie, Md.), the pBluescript
series
(Stratagene, LaJolla, Calif.), the pET series (Novagen, Madison, Wis.), the
pGEX series
(Pharmacia Biotech, Uppsala, Sweden), and the pEX series (Clontech, Palo Alto,
Calif.).
Bacteriophage vectors, such as 2GT10, kGT11, 2EMBL4, and 2NM1149, kZapII
(Stratagene) can be used. Examples of plant expression vectors include pBI01,
pBI01.2,
pBI121, pBI101.3, and pBIN19 (Clontech). Examples of animal expression vectors
include
pEUK-C1, pMAM, and pMAMneo (Clontech). The recombinant expression vector may
be
a viral vector, e.g., a retroviral vector, e.g., a gamma retroviral vector.
In an embodiment, the recombinant expression vectors of the invention are
prepared using
standard recombinant DNA techniques described in, for example, Sambrook et
al., supra,
and Ausubel et al., supra. Constructs of expression vectors, which are
circular or linear,
can be prepared to contain a replication system functional in a prokaryotic or
eukaryotic
host cell. Replication systems can be derived, e.g., from ColE1, 5V40, 2p,
plasmid, k,
bovine papilloma virus, and the like.
The recombinant expression vector may comprise regulatory sequences, such as
transcription and translation initiation and termination codons, which are
specific to the
type of host (e.g., bacterium, plant, fungus, or animal) into which the vector
is to be
introduced, as appropriate, and taking into consideration whether the vector
is DNA- or
RNA-based.
The recombinant expression vector can include one or more marker genes, which
allow for
selection of transformed or transfected hosts. Marker genes include biocide
resistance, e.g.,
resistance to antibiotics, heavy metals, etc., complementation in an
auxotrophic host to
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
provide prototrophy, and the like. Suitable marker genes for the described
expression
vectors include, for instance, neomycin/G418 resistance genes, histidinol x
resistance
genes, histidinol resistance genes, tetracycline resistance genes, and
ampicillin resistance
genes.
The recombinant expression vector can comprise a native or normative promoter
operably
linked to the nucleotide sequence encoding the CAR, polypeptide, or protein
(including
functional portions and functional variants thereof), or to the nucleotide
sequence which is
complementary to or which hybridizes to the nucleotide sequence encoding the
CAR,
polypeptide, or protein. The selection of promoters, e.g., strong, weak,
tissue-specific,
inducible and developmental-specific, is within the ordinary skill of the
artisan. Similarly,
the combining of a nucleotide sequence with a promoter is also within the
skill of the
artisan. The promoter can be a non-viral promoter or a viral promoter, e.g., a
cytomegalovirus (CMV) promoter, an RSV promoter, an 5V40 promoter, or a
promoter
found in the long-terminal repeat of the murine stem cell virus.
The recombinant expression vectors can be designed for either transient
expression, for
stable expression, or for both. Also, the recombinant expression vectors can
be made for
constitutive expression or for inducible expression.
Further, the recombinant expression vectors can be made to include a suicide
gene. As
used herein, the term "suicide gene" refers to a gene that causes the cell
expressing the
suicide gene to die. The suicide gene can be a gene that confers sensitivity
to an agent, e.g.,
a drug, upon the cell in which the gene is expressed, and causes the cell to
die when the
cell is contacted with or exposed to the agent. Suicide genes are known in the
art and
include, for example, the Herpes Simplex Virus (HSV) thymidine kinase (TK)
gene,
cytosine deaminase, purine nucleoside phosphorylase, and nitroreductase.
Included in the scope of the invention are conjugates, e.g., bioconjugates,
comprising any of
the CARs, polypeptides, or proteins (including any of the functional portions
or variants
thereof), host cells, nucleic acids, recombinant expression vectors,
populations of host cells,
or antibodies, or antigen binding portions thereof Conjugates, as well as
methods of
synthesizing conjugates in general, are known in the art (See, for instance,
Hudecz, F.,
46
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Methods Ma Biol. 298: 209-223 (2005) and Kirin etal., Inorg Chem. 44(15): 5405-
5415
(2005)).
An embodiment of the invention further provides an antibody, or antigen
binding portion
thereof, which binds, e.g., specifically binds, to an epitope of the CARs of
the invention.
The antibody can be any type of immunoglobulin that is known in the art.
Immunoglobulins
may be assigned to five major classes, IgA, IgD, IgE, IgG and IgM. IgA and IgG
are further
classified as the isotypes IgAl, IgA2, IgGl, IgG2, IgG3 and IgG4. Antibody
light chains of
vertebrate species can be assigned to one of two types, kappa (x) and lambda
(X), based on
the amino acid sequences of their constant domains. The antibody can be of any
class or
isotype.
The antibodies include immunoglobulin molecules including monoclonal
antibodies
including murine, human, humanized and chimeric monoclonal antibodies,
polyclonal,
antigen-binding fragments, bispecific or multispecific antibodies, monomeric,
dimeric,
tetrameric or multimeric antibodies, single chain antibodies, domain
antibodies and any
other modified configuration of the immunoglobulin molecule that comprises an
antigen
binding site of the required specificity. The antibody can be a naturally-
occurring antibody,
e.g., an antibody isolated and/or purified from a mammal, e.g., a murine,
primate, mouse,
rabbit, goat, horse, chicken, hamster, human, etc. Alternatively, the antibody
can be an
engineered (e.g., genetically-engineered) antibody.
Humanized antibodies have antigen binding sites derived from non-human species
and the
variable region frameworks are derived from human immunoglobulin sequences.
Human
antibodies have heavy and light chain variable regions in which both the
framework and
the antigen binding site are derived from sequences of human origin.
Also, the antibody can have any level of affinity or avidity for the
functional portion of the
CAR. In some embodiments, the antibody may bind the hK2 antigen with a range
of
affinities (KD). In one embodiment according to the invention, and in some
embodiments
of each and every one of the numbered embodiments listed below, the antibody
binds to
the hK2 antigen with high affinity, for example, with a KD equal to or less
than about 10-7
M, such as but not limited to, 1-9.9 (or any range or value therein, such as
1, 2, 3, 4, 5, 6, 7,
47
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
8, or 9)x10-8M, 10-9M, 1010
M, 10-11M, 10-12 M, 10-13 M, 10-14 M, 10-15 M or any
range or value therein, as determined by surface plasmon resonance or the
Kinexa method,
as practiced by those of skill in the art. One example affinity is equal to or
less than 1 x10'
M. Another example affinity is equal to or less than 1 x10-9 M.
Methods of testing antibodies for the ability to bind to any functional
portion of the CARs
are known in the art and include any antibody-antigen binding assay, such as,
for example,
radioimmunoassay (RIA), Western blot, enzyme-linked immunosorbent assay
(ELISA),
immunoprecipitation, and competitive inhibition assays.
Suitable methods of making antibodies are known in the art. For instance,
standard
hybridoma methods are described in, e.g., Kohler and Milstein, Eur. I
Immunol., 5, 511-
519 (1976), Harlow and Lane (eds.), Antibodies: A Laboratory Manual, CSH Press
(1988),
and C. A. Janeway et al. (eds.), Immunobiology, 5th Ed., Garland Publishing,
New York,
N.Y. (2001)). Alternatively, other methods, such as EBV-hybridoma methods
(Haskard
and Archer, J. Immunol. Methods, 74(2), 361-67 (1984), and Roder et al.,
Methods
Enzymol., 121, 140-67 (1986)), and bacteriophage vector expression systems
(see, e.g.,
Huse et al., Science, 246, 127581 (1989)) are known in the art. Further,
methods of
producing antibodies in non-human animals are described in, e.g., U.S. Patent
Nos.
5,545,806, 5,569,825, and 5,714,352, and U.S. Patent Application Publication
No.
2002/0197266 Al).
Phage display can also be used to generate an antibody. In this regard, phage
libraries
encoding antigen-binding variable (V) domains of antibodies can be generated
using
standard molecular biology and recombinant DNA techniques (see, e.g., Sambrook
et al.,
supra, and Ausubel et al., supra). Phage encoding a variable region with the
desired
specificity are selected for specific binding to the desired antigen (i.e.,
hK2), and a
complete or partial antibody is reconstituted comprising the selected variable
domain.
Nucleic acid sequences encoding the reconstituted antibody are introduced into
a suitable
cell line, such as a myeloma cell used for hybridoma production, such that
antibodies
having the characteristics of monoclonal antibodies are secreted by the cell
(see, e.g.,
Janeway et al., supra, Huse et al., supra, and U.S. Pat. No. 6,265,150).
48
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Antibodies can be produced by transgenic mice that are transgenic for specific
heavy and
light chain immunoglobulin genes. Such methods are known in the art and
described in, for
example U.S. Patent Nos. 5,545,806 and 5,569,825, and Janeway et al., supra.
Methods for generating humanized antibodies are known in the art and are
described in, for
example, Janeway et al., supra, U.S. Patent Nos. 5,225,539, 5,585,089 and
5,693,761,
European Patent No. 0239400 Bl, and United Kingdom Patent No. 2188638.
Humanized
antibodies can also be generated using the antibody resurfacing technology
described in
U.S. Patent No. 5,639,641 and Pedersen et al., J. Mol. Biol., 235, 959-973
(1994).
Antibodies, as utilized herein, can be multiple or single chain, or intact
immunoglobulins,
and may be derived from natural sources or from recombinant sources.
Antibodies can be
tetramers of immunoglobulin molecules.
The term "antibody fragment" refers to at least one portion of an intact
antibody, or
recombinant variants thereof, that retains the antigen binding properties of
the parental full
length antibody. It refers to, for example, the antigen binding domain, e.g.,
an antigenic
determining variable region of an intact antibody, that is sufficient to
confer recognition and
binding, e.g., specific binding of the antibody fragment to a target, such as
an antigen.
"Antigen- binding fragment" refers to a portion of an immunoglobulin molecule.
Examples of antibody fragments include, but are not limited to, Fab, Fab',
F(a131)2, and Fv
fragments, single chain antibodies (scFv), linear antibodies, single domain
antibodies such
as sdAb (either VL or VH), camelid VEIH domains, and multi-specific antibodies
formed
from antibody fragments.
The term "scFv" refers to a protein comprising at least one antibody fragment
comprising a
variable region of a light chain and at least one antibody fragment comprising
a variable
region of a heavy chain. In some embodiments, the light and heavy chain
variable regions
are contiguously linked via a short flexible polypeptide linker, and capable
of being
expressed as a single chain polypeptide, and wherein the scFv retains the
specificity of the
intact antibody from which it is derived. Unless specified, as used herein an
scFv may have
the VL and VH variable regions in either order, e.g., with respect to the N-
terminal and C-
terminal ends of the polypeptide, the scFv may comprise VL-linker-VH or may
comprise
VH-linker-VL.
49
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
An embodiment of the invention also provides antigen binding portions of any
of the
antibodies described herein. The antigen binding portion can be any portion
that has at
least one antigen binding site, such as Fab, F(a131)2, dsFv, sFv, diabodies,
and triabodies.
In some embodiments, antigen-binding fragments are heavy chain complementarity
determining regions (HCDR) 1, 2 and/or 3, light chain complementarity
determining
regions (LCDR) 1, 2 and/or 3, a heavy chain variable region (VH), or a light
chain variable
region (VL), Fab, F(a131)2, Fd and Fv fragments and domain antibodies (dAb)
comprising
(e.g., consisting of) either one VH domain or one VL domain. VH and VL domains
may be
linked together via a linker, e.g., a synthetic linker.
"Complementarity determining regions (CDR)" are antigen binding sites in an
antibody.
CDRs may be defined using various terms: (i) Complementarity Determining
Regions
(CDRs), three in the VH (HCDR1, HCDR2, HCDR3) and three in the VL (LCDR1,
LCDR2, LCDR3) are based on sequence variability (Wu and Kabat, J Exp Med
132:211-
50, 1970; Kabat et al., Sequences of Proteins of Immunological Interest, 5th
Ed. Public
Health Service, National Institutes of Health, Bethesda, Md., 1991). (ii)
"Hypervariable
regions", "HVR", or "HV", three in the VH (H1, H2, H3) and three in the VL
(L1, L2, L3)
refer to the regions of an antibody variable domains which are hypervariable
in structure as
defined by Chothia and Lesk (Chothia and Lesk, Mol Biol 196:901-17, 1987). The
International ImMunoGeneTics (IMGT) database (http://www imgt org) provides a
standardized numbering and definition of antigen-binding sites. The
correspondence
between CDRs, HVs and IMGT delineations is described in Lefranc et al., Dev
Comparat
Immunol 27:55-77, 2003. The term "CDR", "HCDR1", "HCDR2", "HCDR3", "LCDR1",
"LCDR2" and "LCDR3" as used herein includes CDRs defined by any of the methods
described supra, Kabat, Chothia or IMGT, unless otherwise explicitly stated in
the
specification.
Also, the antibody, or antigen binding portion thereof, can be modified to
comprise a
detectable label, such as, for instance, a radioisotope, a fluorophore (e.g.,
fluorescein
isothiocyanate (FITC), phycoerythrin (PE)), an enzyme (e.g., alkaline
phosphatase,
horseradish peroxidase), and element particles (e.g., gold particles).
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Also provided by the present disclosure is a nucleic acid comprising a
nucleotide sequence
encoding any of the CARs, polypeptides, or proteins described herein
(including functional
portions and functional variants thereof).
The portion of the CAR comprising an antibody or antibody fragment thereof may
exist in
a variety of forms where the antigen binding domain is expressed as part of a
contiguous
polypeptide chain including, for example, a single domain antibody fragment
(sdAb), a
scFv and a human chimeric or humanized antibody (Harlow et al., 1999, In:
Using
Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, N.Y.;
Harlow et
al., 1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor, N.Y.;
Houston et al.,
1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science
242:423-426).
In one aspect, the antigen binding domain of a CAR composition of the
invention
comprises an antibody fragment. In one aspect, the CAR comprises an antibody
fragment
that comprises a scFv.
The term "recombinant antibody" refers to an antibody which is generated using
recombinant DNA technology, such as, for example, an antibody expressed by a
bacteriophage or yeast expression system. The term should also be construed to
mean an
antibody which has been generated by the synthesis of a DNA molecule encoding
the
antibody and which DNA molecule expresses an antibody protein, or an amino
acid
sequence specifying the antibody, wherein the DNA or amino acid sequence has
been
obtained using recombinant DNA or amino acid sequence technology which is
available
and known in the art.
The term "antigen" refers to a molecule that provokes an immune response. This
immune
response may involve either antibody production, or the activation of specific
immunologically-competent cells, or both. The skilled artisan will understand
that any
macromolecule, including virtually all proteins or peptides, can serve as an
antigen.
Furthermore, antigens can be derived from recombinant or genomic DNA. A
skilled
artisan will understand that any DNA, which comprises a nucleotide sequences
or a partial
nucleotide sequence encoding a protein that elicits an immune response
therefore encodes
an "antigen" as that term is used herein. Furthermore, one skilled in the art
will understand
that an antigen need not be encoded solely by a full-length nucleotide
sequence of a gene.
51
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
It is apparent that the present disclosure includes, but is not limited to,
the use of partial
nucleotide sequences of more than one gene and that these nucleotide sequences
are
arranged in various combinations to encode polypeptides that elicit the
desired immune
response.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain binds the hK2 antigen.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 1, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 4;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
.. acid sequence of SEQ ID NO: 2, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 4;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 3, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 6;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 3, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 4;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 2, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 6;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 1, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 6;
52
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 3, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 5;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 1, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 5;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 2, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 5;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 74, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 76;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 75, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 77;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 147, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 140;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 75, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 141;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 75, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 140;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 148, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 142;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 149, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 143;
53
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 150, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 144;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
.. acid sequence of SEQ ID NO: 151, and heavy chain CDR1, CDR2, and CDR3 from
a
variable region comprising an amino acid sequence of SEQ ID NO: 145;
light chain CDR1, CDR2, and CDR3 from a variable region comprising an amino
acid sequence of SEQ ID NO: 152, and heavy chain CDR1, CDR2, and CDR3 from a
variable region comprising an amino acid sequence of SEQ ID NO: 146;
a light chain CDR1, CDR2, and CDR3 from a variable region comprising an
amino acid sequence of SEQ ID NO: 318 and a heavy chain CDR1, CDR2, and CDR3
from a variable region comprising an amino acid sequence of SEQ ID NO: 317;
wherein the extracellular antigen-binding domain binds the hK2 antigen.
In one embodiment the extracellular antigen-binding domain comprises light
chain CDR1,
CDR2, and CDR3 from a variable region comprising an amino acid sequence of SEQ
ID
NO: 1, and heavy chain CDR1, CDR2, and CDR3 from a variable region comprising
an
amino acid sequence of SEQ ID NO: 4.
In one embodiment the extracellular antigen-binding domain comprises light
chain CDR1,
CDR2, and CDR3 from a variable region comprising an amino acid sequence of SEQ
ID
NO: 2, and heavy chain CDR1, CDR2, and CDR3 from a variable region comprising
an
amino acid sequence of SEQ ID NO: 4.
In one embodiment the extracellular antigen-binding domain comprises light
chain CDR1,
CDR2, and CDR3 from a variable region comprising an amino acid sequence of SEQ
ID
NO: 3, and heavy chain CDR1, CDR2, and CDR3 from a variable region comprising
an
amino acid sequence of SEQ ID NO: 6.
In one embodiment the extracellular antigen-binding domain comprises light
chain CDR1,
CDR2, and CDR3 from a variable region comprising an amino acid sequence of SEQ
ID
NO: 3, and heavy chain CDR1, CDR2, and CDR3 from a variable region comprising
an
amino acid sequence of SEQ ID NO: 4.
54
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one embodiment the extracellular antigen-binding domain comprises light
chain CDR1,
CDR2, and CDR3 from a variable region comprising an amino acid sequence of SEQ
ID
NO: 2, and heavy chain CDR1, CDR2, and CDR3 from a variable region comprising
an
amino acid sequence of SEQ ID NO: 6.
In one embodiment the extracellular antigen-binding domain comprises light
chain CDR1,
CDR2, and CDR3 from a variable region comprising an amino acid sequence of SEQ
ID
NO: 1, and heavy chain CDR1, CDR2, and CDR3 from a variable region comprising
an
amino acid sequence of SEQ ID NO: 6.
In one embodiment the extracellular antigen-binding domain comprises light
chain CDR1,
CDR2, and CDR3 from a variable region comprising an amino acid sequence of SEQ
ID
NO: 3, and heavy chain CDR1, CDR2, and CDR3 from a variable region comprising
an
amino acid sequence of SEQ ID NO: 5.
In one embodiment the extracellular antigen-binding domain comprises light
chain CDR1,
CDR2, and CDR3 from a variable region comprising an amino acid sequence of SEQ
ID
NO: 1, and heavy chain CDR1, CDR2, and CDR3 from a variable region comprising
an
amino acid sequence of SEQ ID NO: 5.
In one embodiment the extracellular antigen-binding domain comprises light
chain CDR1,
CDR2, and CDR3 from a variable region comprising an amino acid sequence of SEQ
ID
NO: 2, and heavy chain CDR1, CDR2, and CDR3 from a variable region comprising
an
amino acid sequence of SEQ ID NO: 5.
In one embodiment the extracellular antigen-binding domain comprises light
chain CDR1,
CDR2, and CDR3 from a variable region comprising an amino acid sequence of SEQ
ID
NO: 74, and heavy chain CDR1, CDR2, and CDR3 from a variable region comprising
an
amino acid sequence of SEQ ID NO: 76.
In one embodiment the extracellular antigen-binding domain comprises light
chain CDR1,
CDR2, and CDR3 from a variable region comprising an amino acid sequence of SEQ
ID
NO: 75, and heavy chain CDR1, CDR2, and CDR3 from a variable region comprising
an
amino acid sequence of SEQ ID NO: 77.
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
In one embodiment the extracellular antigen-binding domain comprises light
chain
CDR1, CDR2, and CDR3 from a variable region comprising an amino acid sequence
of
SEQ ID NO: 147, and heavy chain CDR1, CDR2, and CDR3 from a variable region
comprising an amino acid sequence of SEQ ID NO: 140.
In one embodiment the extracellular antigen-binding domain comprises light
chain
CDR1, CDR2, and CDR3 from a variable region comprising an amino acid sequence
of
SEQ ID NO: 75, and heavy chain CDR1, CDR2, and CDR3 from a variable region
comprising an amino acid sequence of SEQ ID NO: 141.
In one embodiment the extracellular antigen-binding domain comprises light
chain
CDR1, CDR2, and CDR3 from a variable region comprising an amino acid sequence
of
SEQ ID NO: 75, and heavy chain CDR1, CDR2, and CDR3 from a variable region
comprising an amino acid sequence of SEQ ID NO: 140.
In one embodiment the extracellular antigen-binding domain comprises light
chain
CDR1, CDR2, and CDR3 from a variable region comprising an amino acid sequence
of
SEQ ID NO: 148, and heavy chain CDR1, CDR2, and CDR3 from a variable region
comprising an amino acid sequence of SEQ ID NO: 142
In one embodiment the extracellular antigen-binding domain comprises light
chain
CDR1, CDR2, and CDR3 from a variable region comprising an amino acid sequence
of
SEQ ID NO: 149, and heavy chain CDR1, CDR2, and CDR3 from a variable region
comprising an amino acid sequence of SEQ ID NO: 143.
In one embodiment the extracellular antigen-binding domain comprises light
chain
CDR1, CDR2, and CDR3 from a variable region comprising an amino acid sequence
of
SEQ ID NO: 150, and heavy chain CDR1, CDR2, and CDR3 from a variable region
comprising an amino acid sequence of SEQ ID NO: 144.
In one embodiment the extracellular antigen-binding domain comprises light
chain
CDR1, CDR2, and CDR3 from a variable region comprising an amino acid sequence
of
SEQ ID NO: 151, and heavy chain CDR1, CDR2, and CDR3 from a variable region
comprising an amino acid sequence of SEQ ID NO: 145.
In one embodiment the extracellular antigen-binding domain comprises light
chain
CDR1, CDR2, and CDR3 from a variable region comprising an amino acid sequence
of
56
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 152, and heavy chain CDR1, CDR2, and CDR3 from a variable region
comprising an amino acid sequence of SEQ ID NO: 146.
In one embodiment the extracellular antigen-binding domain comprises a light
chain
CDR1, CDR2, and CDR3 from a variable region comprising an amino acid sequence
of
SEQ ID NO: 318 and a heavy chain CDR1, CDR2, and CDR3 from a variable region
comprising an amino acid sequence of SEQ ID NO: 317.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a heavy chain CDR1 having an amino acid sequence selected from the group
consisting of SEQ ID NO: 63, SEQ ID NO: 72, SEQ ID NO: 86, SEQ ID NO: 92, SEQ
ID NO: 102, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 110, SEQ ID NO: 115,
SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 123, SEQ ID NO: 309, and SEQ ID
NO: 314, and conservative modifications thereof, wherein the extracellular
antigen-
binding domain binds the hK2 antigen.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a heavy chain CDR2 having an amino acid sequence selected from the group
consisting of SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 73, SEQ ID NO: 87, SEQ
ID NO: 93, SEQ ID NO: 103, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 111,
SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 119, SEQ ID NO:
121, SEQ ID NO: 124, SEQ ID NO: 310, and SEQ ID NO: 315, and conservative
modifications thereof, wherein the extracellular antigen-binding domain binds
the hK2
antigen.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
57
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a heavy chain CDR3 having an amino acid sequence selected from the group
consisting of SEQ ID NO: 66, SEQ ID NO: 88, SEQ ID NO: 94, SEQ ID NO: 104, SEQ
ID NO: 109, SEQ ID NO: 113, SEQ ID NO: 117, SEQ ID NO: 122, and SEQ ID NO:
311, and conservative modifications thereof, wherein the extracellular antigen-
binding
domain binds the hK2 antigen.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 64, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 66;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 314, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 315, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 311;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 309, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 310, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 311;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 65, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 66;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 73, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 66; or
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 86, a heavy chain CDR2 having the amino acid
sequence
58
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
of SEQ ID NO: 87, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 88;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 92, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 93, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 94;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 103, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 104;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 106, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 104;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 107, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 108, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 109;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 110, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 111, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 109;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 112, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 113;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 114, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 113;
59
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 115, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 116, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 117;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 118, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 119, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 117;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 120, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 121, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 122; or
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 123, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 124, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 122,
wherein the extracellular antigen-binding domain binds the hK2 antigen.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 63, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 64,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 314, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
315,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 311.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 309, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
310,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 311.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
ID NO: 63, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 65,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
.. ID NO: 72, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
73,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66;
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 86, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 87,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 88.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 92, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 93,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 94.
.. In one embodiment the extracellular antigen-binding domain comprises a
heavy chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 102, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
103,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 104.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
.. complementarity determining region 1 (CDR1) having the amino acid sequence
of SEQ
ID NO: 105, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
106,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 104.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
.. ID NO: 107, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
108,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 109.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 110, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
111,
.. and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 109.
61
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 102, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
112,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 113.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 105, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
114,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 113.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 115, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
116,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 117.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 118, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
119,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 117.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 120, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
121,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 122.
In one embodiment the extracellular antigen-binding domain comprises a heavy
chain
complementarity determining region 1 (CDR1) having the amino acid sequence of
SEQ
ID NO: 123, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
124,
and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 122.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a light chain CDR1 having an amino acid sequence selected from the group
consisting of SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 89, SEQ ID NO: 95, SEQ
ID NO: 97, SEQ ID NO: 125, SEQ ID NO: 128, SEQ ID NO: 133, SEQ ID NO: 136, and
62
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 312, and conservative modifications thereof, wherein the
extracellular
antigen-binding domain binds the hK2 antigen.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a light chain CDR2 having an amino acid sequence selected from the group
consisting of SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 90, SEQ ID NO: 96, SEQ
ID NO: 126, SEQ ID NO: 137, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 134,
SEQ ID NO: 137, and SEQ ID NO: 313, and conservative modifications thereof,
wherein
the extracellular antigen-binding domain binds the hK2 antigen.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a light chain CDR3 having an amino acid sequence selected from the group
consisting of SEQ ID NO: 71, SEQ ID NO: 91, SEQ ID NO: 130, SEQ ID NO: 132,
SEQ
ID NO: 135, SEQ ID NO: 138, and SEQ ID NO: 139, and conservative modifications
thereof, wherein the extracellular antigen-binding domain binds the hK2
antigen.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, and a light chain CDR3 having the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 70, and a light chain CDR3 having the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 having the amino acid
sequence
63
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
of SEQ ID NO: 90, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 95, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 96, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 312, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 313, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 90, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 126, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 71;
a light chain complementarity determining region 1 (CDR1) haying the amino
.. acid sequence of SEQ ID NO: 128, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 129, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 130;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 125, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 131, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 132;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 133, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 134, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 135;
64
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 136, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 137, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 138; or
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 127, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 139,
wherein the extracellular antigen-binding domain binds the hK2 antigen.
In one embodiment the extracellular antigen-binding domain comprises a light
chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ ID
NO: 67, a light chain CDR2 haying the amino acid sequence of SEQ ID NO: 69,
and a
light chain CDR3 haying the amino acid sequence of SEQ ID NO: 71.
.. In one embodiment the extracellular antigen-binding domain comprises a
light chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ
ID NO: 68, a light chain CDR2 haying the amino acid sequence of SEQ ID NO: 70,
and
a light chain CDR3 haying the amino acid sequence of SEQ ID NO: 71
In one embodiment the extracellular antigen-binding domain comprises a light
chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ
ID NO: 89, a light chain CDR2 haying the amino acid sequence of SEQ ID NO: 90,
and
a light chain CDR3 haying the amino acid sequence of SEQ ID NO: 91.
In one embodiment the extracellular antigen-binding domain comprises a light
chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ
ID NO: 95, a light chain CDR2 haying the amino acid sequence of SEQ ID NO: 96,
and
a light chain CDR3 haying the amino acid sequence of SEQ ID NO: 71.
In one embodiment the extracellular antigen-binding domain comprises a light
chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ
ID NO: 312, a light chain CDR2 haying the amino acid sequence of SEQ ID NO:
313,
and a light chain CDR3 haying the amino acid sequence of SEQ ID NO: 91.
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
In one embodiment the extracellular antigen-binding domain comprises a light
chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ
ID NO: 89, a light chain CDR2 haying the amino acid sequence of SEQ ID NO: 90,
and
a light chain CDR3 haying the amino acid sequence of SEQ ID NO: 91.
In one embodiment the extracellular antigen-binding domain comprises a light
chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ
ID NO: 67, a light chain CDR2 haying the amino acid sequence of SEQ ID NO:
126,
and a light chain CDR3 haying the amino acid sequence of SEQ ID NO: 71.
In one embodiment the extracellular antigen-binding domain comprises a light
chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ
ID NO: 128, a light chain CDR2 haying the amino acid sequence of SEQ ID NO:
129,
and a light chain CDR3 haying the amino acid sequence of SEQ ID NO: 130.
In one embodiment the extracellular antigen-binding domain comprises a light
chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ
ID NO: 125, a light chain CDR2 haying the amino acid sequence of SEQ ID NO:
131,
and a light chain CDR3 haying the amino acid sequence of SEQ ID NO: 132.
In one embodiment the extracellular antigen-binding domain comprises a light
chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ
ID NO: 133, a light chain CDR2 haying the amino acid sequence of SEQ ID NO:
134,
and a light chain CDR3 haying the amino acid sequence of SEQ ID NO: 135.
In one embodiment the extracellular antigen-binding domain comprises a light
chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ
ID NO: 136, a light chain CDR2 haying the amino acid sequence of SEQ ID NO:
137,
and a light chain CDR3 haying the amino acid sequence of SEQ ID NO: 138.
In one embodiment the extracellular antigen-binding domain comprises a light
chain
complementarity determining region 1 (CDR1) haying the amino acid sequence of
SEQ
ID NO: 97, a light chain CDR2 haying the amino acid sequence of SEQ ID NO:
127,
and a light chain CDR3 haying the amino acid sequence of SEQ ID NO: 139.
66
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 64, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 70, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71;
67
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 314, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 315, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
311, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 312, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 313, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 91;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 103, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
104, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 128, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 129, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 130;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 107, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 108, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
109, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 125, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 131, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 132;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 112, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
68
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
113, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 133, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 134, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 135;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 115, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 116, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
117, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 136, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 137, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 138; or
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 120, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 121, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
122, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 127, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 138;
wherein the extracellular antigen-binding domain binds the hK2 antigen.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 64, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71;
69
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 70, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 314, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 315, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
311, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 312, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 313, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 91;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 103, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
104, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 128, a light chain CDR2 having the amino acid
sequence
.. of SEQ ID NO: 129, a light chain CDR3 having the amino acid sequence of SEQ
ID
NO: 130;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 107, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 108, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
109, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 125, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 131, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 132;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
.. sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid
sequence of
SEQ ID NO: 112, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
113, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 133, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 134, a light chain CDR3 having the amino acid sequence of SEQ ID
.. NO: 135;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 115, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 116, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
117, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 136, a light chain CDR2 having the amino acid
sequence
71
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
of SEQ ID NO: 137, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 138;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 120, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 121, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
122, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 127, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 138;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 73, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 73, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 70, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 73, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71;
72
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 73, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 73, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 309, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 310, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
311, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 312, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 313, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 91;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 106, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
104, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 128, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 129, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 130;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 110, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 111, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
73
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
109, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 125, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 131, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 132;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 114, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
113, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 133, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 134, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 135;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 118, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 119, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
117, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 136, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 137, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 138;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 123, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 124, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
122, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 127, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 139;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 120, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 121, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
122, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid
sequence
74
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
of SEQ ID NO: 127, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 139; or
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 86, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 87, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
88, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 90, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
91;
wherein the extracellular antigen-binding domain binds the hK2 antigen.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of SEQ
ID NO: 64, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66,
and a
light chain complementarity determining region 1 (CDR1) having the amino acid
sequence
of SEQ ID NO: 67, a light chain CDR2 having the amino acid sequence of SEQ ID
NO:
69, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 70, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 314, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 315, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
311, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 312, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 313, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 91.
In one embodiment, the extracellular antigen-binding domain comprises:
76
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 103, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
104, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 128, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 129, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 130.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 107, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 108, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
109, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 125, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 131, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 132.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 112, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
113, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 133, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 134, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 135.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 115, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 116, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
117, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 136, a light chain CDR2 having the amino acid
sequence
77
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
of SEQ ID NO: 137, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 138.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 120, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 121, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
122, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 127, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 138.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 73, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 73, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 70, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 73, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
78
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 73, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 73, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 309, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 310, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
311, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 312, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 313, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 91.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 106, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
79
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
104, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 128, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 129, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 130.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 110, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 111, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
109, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 125, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 131, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 132.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 114, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
113, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 133, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 134, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 135.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 118, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 119, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
117, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 136, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 137, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 138.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 123, a heavy chain CDR2 having the amino acid sequence
of
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 124, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
122, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 127, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 139.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 120, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 121, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
122, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 127, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 139.
In one embodiment, the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 86, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 87, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
88, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 90, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
91.
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a light chain variable region (LCVR) comprising an amino acid sequence
selected from
the group consisting of SEQ ID NOS: 1-3, or a heavy chain variable region
(HCVR)
comprising an amino acid sequence selected from the group consisting of SEQ ID
NOS:
4-6, or a combination of a LCVR comprising an amino acid sequence selected
from the
group consisting of SEQ ID NOS: 1-3, and a HCVR comprising an amino acid
sequence
81
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
selected from the group consisting of SEQ ID NOS: 4-6, wherein the
extracellular
antigen-binding domain binds the hK2 antigen.
In one embodiment, the extracellular antigen-binding domain comprises:
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
1
and a heavy chain variable region comprising an amino acid sequence of SEQ ID
NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
2
and a heavy chain variable region comprising an amino acid sequence of SEQ ID
NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
3
and a heavy chain variable region comprising an amino acid sequence of SEQ ID
NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
3
and a heavy chain variable region comprising an amino acid sequence of SEQ ID
NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
2
and a heavy chain variable region comprising an amino acid sequence of SEQ ID
NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
1
and a heavy chain variable region comprising an amino acid sequence of SEQ ID
NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
1
and a heavy chain variable region comprising an amino acid sequence of SEQ ID
NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
2
and a heavy chain variable region comprising an amino acid sequence of SEQ ID
NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
3
and a heavy chain variable region comprising an amino acid sequence of SEQ ID
NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
74 and a heavy chain variable region comprising an amino acid sequence of SEQ
ID NO:
76; a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 75
and a heavy chain variable region comprising an amino acid sequence of SEQ ID
NO: 77;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
147 and a heavy chain variable region comprising an amino acid sequence of SEQ
ID NO:
140;
82
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
75 and a heavy chain variable region comprising an amino acid sequence of SEQ
ID NO:
141;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
75 and a heavy chain variable region comprising an amino acid sequence of SEQ
ID NO:
140;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
148 and a heavy chain variable region comprising an amino acid sequence of SEQ
ID NO:
142;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
149 and a heavy chain variable region comprising an amino acid sequence of SEQ
ID NO:
143;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
150 and a heavy chain variable region comprising an amino acid sequence of SEQ
ID NO:
144;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
151 and a heavy chain variable region comprising an amino acid sequence of SEQ
ID NO:
145;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
152 and a heavy chain variable region comprising an amino acid sequence of SEQ
ID NO:
146;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
318 and a heavy chain variable region comprising an amino acid sequence of SEQ
ID NO:
317.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 1 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 4.
83
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 2 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 4.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 3 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 6.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 3 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 4.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 2 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 6.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 1 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 6.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 1 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 5.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 2 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 5.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 3 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 5.
.. In one embodiment, the extracellular antigen-binding domain comprises a
light chain
variable region comprising an amino acid sequence of SEQ ID NO: 74 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 76.
84
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 75 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 77.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 147 and a
heavy chain
variable region comprising an amino acid sequence of SEQ ID NO: 140.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 75 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 141.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 75 and a heavy
chain
variable region comprising an amino acid sequence of SEQ ID NO: 140.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 148 and a
heavy chain
variable region comprising an amino acid sequence of SEQ ID NO: 142.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 149 and a
heavy chain
variable region comprising an amino acid sequence of SEQ ID NO: 143.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
.. variable region comprising an amino acid sequence of SEQ ID NO: 150 and a
heavy chain
variable region comprising an amino acid sequence of SEQ ID NO: 144.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 151 and a
heavy chain
variable region comprising an amino acid sequence of SEQ ID NO: 145.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 152 and a
heavy chain
variable region comprising an amino acid sequence of SEQ ID NO: 146.
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence of SEQ ID NO: 318 and a
heavy chain
variable region comprising an amino acid sequence of SEQ ID NO: 317.
In one embodiment, the extracellular antigen-binding domain comprises:
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 1 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 2 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 3 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 6;
86
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 3 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 2 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 3 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 1 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
87
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 3 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 1 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 2 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 74 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
88
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 76;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 75 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 77;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 147 and a heavy chain
variable
region comprising an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 140;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 75 and a heavy chain
variable region
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 141;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 75 and a heavy chain
variable region
89
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
comprising an amino acid sequence having at least 50, at least 55, at least
60, at least 65,
at least 70, at least 75, at least 80, at least 85, at least 90, at least 91,
at least 92, at least 93,
at least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NO: 140;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 148 and a heavy chain
variable
region comprising an amino acid sequence having at least 50, at least 55, at
least 60, at
-- least 65, at least 70, at least 75, at least 80, at least 85, at least 90,
at least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 142;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 149 and a heavy chain
variable
region comprising an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 143;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 150 and a heavy chain
variable
region comprising an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 144;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
or at least 99%, sequence identity with SEQ ID NO: 151 and a heavy chain
variable
region comprising an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 145;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 152 and a heavy chain
variable
region comprising an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 146;
a light chain variable region comprising an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 318 and a heavy chain
variable
region comprising an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 317.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 1 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
91
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 4.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 2 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 4.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 3 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 6.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 3 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 4.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
92
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 2 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 6.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 3 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 4.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 1 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 6.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
.. sequence identity with SEQ ID NO: 3 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
93
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 5.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 1 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 5.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at
least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at
least 98 or at least
99%, sequence identity with SEQ ID NO: 2 and a heavy chain variable region
comprising
an amino acid sequence having at least 50, at least 55, at least 60, at least
65, at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 5.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 74 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 76.
94
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 75 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94,at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 77.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 147 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 140.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 75 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 141.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
sequence identity with SEQ ID NO: 75 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 140.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 148 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94,
at least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ
ID NO: 142.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 149 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 143.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 150 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
96
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 144.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 151 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 145.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 152 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 146.
In one embodiment, the extracellular antigen-binding domain comprises a light
chain
variable region comprising an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 318 and a heavy chain variable region
comprising an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 317.
In one embodiment, the extracellular antigen-binding domain comprises a scFv.
In some
embodiments, the scFv comprises a linker polypeptide between the light chain
variable
97
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
region and the heavy chain variable region. In certain embodiments, the
extracellular
antigen-binding domain is a scFv which comprises an amino acid sequence
selected from
the group consisting of SEQ ID NOS: 8-23, 169-184 and 340-343, and
specifically binds
to a hK2 polypeptide (e.g., a human hK2 polypeptide having the amino acid
sequence of
SEQ ID NO: 62, or fragments thereof).
In recombinant expression systems, the linker is a peptide linker and may
include any
naturally occurring amino acid. Exemplary amino acids that may be included
into the
linker are Gly, Ser Pro, Thr, Glu, Lys, Arg, Ile, Leu, His and The. The linker
should have
a length that is adequate to link the VH and the VL in such a way that they
form the correct
conformation relative to one another so that they retain the desired activity,
such as binding
to hK2.
The linker may be about 5-50 amino acids long. In some embodiments, the linker
is about
10-40 amino acids long. In some embodiments, the linker is about 10-35 amino
acids
long. In some embodiments, the linker is about 10-30 amino acids long. In some
.. embodiments, the linker is about 10-25 amino acids long. In some
embodiments, the
linker is about 10-20 amino acids long. In some embodiments, the linker is
about 15-20
amino acids long. In some embodiments, the linker is 6 amino acids long. In
some
embodiments, the linker is 7 amino acids long. In some embodiments, the linker
is 8
amino acids long. In some embodiments, the linker is 9 amino acids long. In
some
embodiments, the linker is 10 amino acids long. In some embodiments, the
linker is 11
amino acids long. In some embodiments, the linker is 12 amino acids long. In
some
embodiments, the linker is 13 amino acids long. In some embodiments, the
linker is 14
amino acids long. In some embodiments, the linker is 15 amino acids long. In
some
embodiments, the linker is 16 amino acids long. In some embodiments, the
linker is 17
amino acids long. In some embodiments, the linker is 18 amino acids long. In
some
embodiments, the linker is 19 amino acids long. In some embodiments, the
linker is 20
amino acids long. In some embodiments, the linker is 21 amino acids long. In
some
embodiments, the linker is 22 amino acids long. In some embodiments, the
linker is 23
amino acids long. In some embodiments, the linker is 24 amino acids long. In
some
embodiments, the linker is 25 amino acids long. In some embodiments, the
linker is 26
98
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
amino acids long. In some embodiments, the linker is 27 amino acids long. In
some
embodiments, the linker is 28 amino acids long. In some embodiments, the
linker is 29
amino acids long . In some embodiments, the linker is 30 amino acids long. In
some
embodiments, the linker is 31 amino acids long. In some embodiments, the
linker is 32
amino acids long. In some embodiments, the linker is 33 amino acids long. In
some
embodiments, the linker is 34 amino acids long. In some embodiments, the
linker is 35
amino acids long. In some embodiments, the linker is 36 amino acids long. In
some
embodiments, the linker is 37 amino acids long. In some embodiments, the
linker is 38
amino acids long. In some embodiments, the linker is 39 amino acids long. In
some
embodiments, the linker is 40 amino acids long. Exemplary linkers that may be
used are
Gly rich linkers, Gly and Ser containing linkers, Gly and Ala containing
linkers, Ala and
Ser containing linkers, and other flexible linkers.
In one embodiment, the linker polypeptide comprises an amino acid sequence of
SEQ ID
NO: 7. In one embodiment, the linker polypeptide comprises an amino acid
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NO: 7. In
one
embodiment, the linker polypeptide comprises an amino acid sequence of any one
of
SEQ ID NOS: 237-268. In one embodiment, the linker polypeptide comprises an
amino
acid sequence having at least 50, at least 55, at least 60, at least 65, at
least 70, at least 75,
at least 80, at least 85, at least 90, at least 91, at least 92, at least 93,
at least 94, at least 95,
at least 96, at least 97, at least 98 or at least 99%, sequence identity with
any one of SEQ
ID NOS: 237-268.
In one embodiment, the scFv comprises an amino acid sequence selected from the
group
consisting of SEQ ID NOS: 8-23, 169-184 and 340-343. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 8, or the sequence of SEQ ID NO: 8. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
99
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 9, or the sequence of SEQ ID NO:9. In one embodiment, the scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 10, or the sequence of SEQ ID NO:10. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 11, or the sequence of SEQ ID NO:11. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 12, or the sequence of SEQ ID NO:12. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 13, or the sequence of SEQ ID NO:13. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 14, or the sequence of SEQ ID NO:14. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 15, or the sequence of SEQ ID NO:15. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 16, or the sequence of SEQ ID NO:16. In one embodiment, the
scFv
100
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 17, or the sequence of SEQ ID NO:17. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 18, or the sequence of SEQ ID NO:18. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 19, or the sequence of SEQ ID NO:19. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 20, or the sequence of SEQ ID NO:20. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 21, or the sequence of SEQ ID NO:21. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 22, or the sequence of SEQ ID NO:22. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 23, or the sequence of SEQ ID NO:23. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
101
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
with SEQ ID NO: 169, or the sequence of SEQ ID NO:169. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 170, or the sequence of SEQ ID NO:170. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 171, or the sequence of SEQ ID NO:171. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 172, or the sequence of SEQ ID NO:172. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 173, or the sequence of SEQ ID NO:173. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 174, or the sequence of SEQ ID NO:174. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 175, or the sequence of SEQ ID NO:175. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 176, or the sequence of SEQ ID NO:176. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
102
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 177, or the sequence of SEQ ID NO:177. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 178, or the sequence of SEQ ID NO:178. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 179, or the sequence of SEQ ID NO:179. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 180, or the sequence of SEQ ID NO:180. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 181, or the sequence of SEQ ID NO:181. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 182, or the sequence of SEQ ID NO:182. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 183, or the sequence of SEQ ID NO:183. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 184, or the sequence of SEQ ID NO:184. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
103
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 340, or the sequence of SEQ ID NO:340. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 341, or the sequence of SEQ ID NO:341. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 342, or the sequence of SEQ ID NO:342. In one embodiment, the
scFv
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 343, or the sequence of SEQ ID NO:343.
In one embodiment, the extracellular antigen-binding domain comprises a signal
polypeptide. The signal polypeptide may be positioned at the N-terminus of the
extracellular antigen binding domain that binds hK2. The signal polypeptide
may be
optionally cleaved from the extracellular antigen binding domain during
cellular
processing and localization of the CAR to the cellular membrane. Any of
various signal
polypeptides known to one of skill in the art may be used as the signal
polypeptide. Non-
limiting examples of peptides from which the signal polypeptides may be
derived include
FcER, human immunoglobulin (IgG) heavy chain (HC) variable region, CD8a, or
any of
various other proteins secreted by T cells. In various embodiments, the signal
polypeptide is compatible with the secretory pathway of a T cell. In some
embodiments,
the signal polypeptide comprises an amino acid sequence of SEQ ID NO: 24. In
one
embodiment, the signal polypeptide comprises an amino acid sequence having at
least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97,at least 98
or at least 99%, sequence identity with SEQ ID NO: 24.
104
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one aspect, the disclosure provides a CAR, comprising an extracellular
antigen-
binding domain, a transmembrane domain and an intracellular signaling domain,
wherein
the extracellular antigen-binding domain comprises an amino acid sequence
selected
from the group consisting of SEQ ID NOS: 29-44, 78-81, 221-236, and 273-308.
Another
feature of the CAR having an extracellular antigen-binding domain comprising
an amino
acid sequence selected from the group consisting of SEQ ID NOS: 29-44, 78-81,
221-
236, and 273-308 is that the extracellular antigen-binding domain binds the
hK2 antigen.
In one embodiment, the intracellular signaling domain comprises a polypeptide
component
selected from the group consisting of a TNF receptor superfamily member 9
(CD137)
component, a T-cell surface glycoprotein CD3 zeta chain (CD3z) component, a
cluster of
differentiation (CD27) component, a cluster of differentiation superfamily
member (such
as, e.g., CD28 or inducible T-cell co-stimulator (ICOS)) component, and a
combination
thereof.
In one embodiment, the CD137 component comprises an amino acid sequence of SEQ
ID
NO: 27. In one embodiment, the CD137 component comprises an amino acid
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NO: 27.
In one embodiment, the CD3z component comprises an amino acid sequence of SEQ
ID
NO: 28. In one embodiment, the CD3z component comprises an amino acid sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NO: 28.
In one embodiment, the intracellular signaling domain comprises an amino acid
sequence
of SEQ ID NO: 45. In one embodiment, the intracellular signaling domain
comprises an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 45.
105
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
In one embodiment, the transmembrane domain comprises a CD8a transmembrane
region
(CD8a-TM) polypeptide. In some embodiments, the CD8a-TM polypeptide comprises
an
amino acid sequence of SEQ ID NO: 26. In some embodiments, the CD8a-TM
polypeptide comprises an amino acid sequence having at least 50, at least 55,
at least 60,
at least 65, at least 70, at least 75, at least 80, at least 85, at least 90,
at least 91, at least 92,
at least 93, at least 94, at least 95, at least 96, at least 97, at least 98
or at least 99%,
sequence identity with SEQ ID NO: 26.
In one embodiment, the transmembrane domain comprises at least the
transmembrane
region(s) of) the a, 0 or chain of the T-cell receptor, CD28, CD3 epsilon,
CD45, CD4,
CD5, CD8, CD8a, CD9, CD16, CD22, CD33, CD37, CD40, CD64, CD80, CD86, CD134,
CD137, CD154. In another embodiment, the transmembrane domain comprises at
least the
transmembrane domain of or
FccRly and 43, MB1 (Iga.), B29 or CD3- 7, or ii. In
another embodiment, the transmembrane domain is synthetic, e.g., comprising
predominantly hydrophobic residues such as leucine and valine, a triplet of
phenylalanine,
or tryptophan.
In one embodiment, the CAR further comprises a hinge region linking the
transmembrane
domain to the extracellular antigen-binding domain. In some embodiments, the
hinge
region is a CD8a-hinge region. In some embodiments, CD8a-hinge region
comprises an
amino acid sequence of SEQ ID NO: 25. In some embodiments, the CD8a-hinge
region
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 25. In some embodiments, the hinge region comprises the
sequence
EPKSCDKTHTCPPCP (SEQ ID NO: 269), or comprises an amino acid sequence having
at least 50, at least 55, at least 60, at least 65, at least 70, at least 75,
at least 80, at least 85,
at least 90, at least 91, at least 92, at least 93, at least 94, at least 95,
at least 96, at least 97,
at least 98 or at least 99%, sequence identity with EPKSCDKTHTCPPCP (SEQ ID
NO:
269). In some embodiments, the hinge region comprises the sequence
ERKCCVECPPCP
(SEQ ID NO: 270), or comprises an amino acid sequence having at least 50, at
least 55, at
least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at
least 90, at least 91, at
106
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at
least 98 or at least
99%, sequence identity with ERKCCVECPPCP (SEQ ID NO: 270). In some
embodiments, the hinge region comprises the sequence
ELKTPLGDTTHTCPRCP(EPKSCDTPPPCPRCP)3 (SEQ ID NO: 271), or comprises an
amino acid sequence haying at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with
ELKTPLGDTTHTCPRCP(EPKSCDTPPPCPRCP)3 (SEQ ID NO: 271),. In some
embodiments, the hinge region comprises the sequence ESKYGPPCPSCP (SEQ ID NO:
272), or comprises an amino acid sequence haying at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with ESKYGPPCPSCP (SEQ ID NO: 272).
In one embodiment, the CAR comprises an extracellular antigen-binding domain,
a hinge
region, a transmembrane domain and an intracellular signaling domain. In one
such
embodiment, the hinge region is a CD8a hinge region, the transmembrane domain
is a
CD8a-TM domain, and the intracellular signaling domain comprises a CD3-zeta
domain
and a 4-1BB/CD137 domain.
In one such embodiment, the hinge region is a CD8a hinge region comprising the
amino
.. acid sequence of SEQ ID No: 25, the transmembrane domain is a CD8a-TM
domain
comprising the amino acid sequence of SEQ ID NO: 26, and the intracellular
signaling
domain comprises a CD3-zeta domain and a 4-1BB/CD137 domain comprising an
amino
acid sequence of SEQ ID NO: 45.
In another embodiment, the hinge region is a CD8a hinge region comprising the
amino
acid sequence of SEQ ID No: 25, the transmembrane domain is a CD8a-TM domain
comprising the amino acid sequence of SEQ ID NO: 26, and the intracellular
signaling
domain comprises a 4-1BB/CD137 domain comprising the amino acid sequence of
SEQ
ID NO 27, and a CD3-zeta domain comprising the amino acid sequence of SEQ ID
NO:
28.
In one embodiment, the extracellular antigen-binding domain comprises an amino
acid
sequence selected from the group consisting of SEQ ID NOS: 29-44, 78-81, 221-
236, and
107
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
273-308. In one embodiment, the extracellular antigen-binding domain comprises
an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 29, or the sequence of SEQ ID NO:29. In one embodiment, the extracellular
antigen-
binding domain comprises an amino acid sequence having at least 50, at least
55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 30, or the sequence of SEQ ID NO:30. In one
embodiment, the extracellular antigen-binding domain comprises an amino acid
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NO: 31,
or the
sequence of SEQ ID NO:31. In one embodiment, the extracellular antigen-binding
domain
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 32, or the sequence of SEQ ID NO:32. In one embodiment, the
extracellular antigen-binding domain comprises an amino acid sequence having
at least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 33, or the sequence of SEQ
ID
NO:33. In one embodiment, the extracellular antigen-binding domain comprises
an amino
acid sequence having at least 50, at least 55, at least 60, at least 65, at
least 70, at least 75,
at least 80, at least 85, at least 90, at least 91, at least 92, at least 93,
at least 94, at least 95,
at least 96, at least 97, at least 98 or at least 99%, sequence identity with
SEQ ID NO: 34,
or the sequence of SEQ ID NO:34. In one embodiment, the extracellular antigen-
binding
domain comprises an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 35, or the sequence of SEQ ID NO:35. In one
embodiment, the
108
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
extracellular antigen-binding domain comprises an amino acid sequence having
at least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 36, or the sequence of SEQ
ID
NO:36. In one embodiment, the extracellular antigen-binding domain comprises
an amino
acid sequence having at least 50, at least 55, at least 60, at least 65, at
least 70, at least 75,
at least 80, at least 85, at least 90, at least 91, at least 92, at least 93,
at least 94, at least 95,
at least 96, at least 97, at least 98 or at least 99%, sequence identity with
SEQ ID NO: 37,
or the sequence of SEQ ID NO:37. In one embodiment, the extracellular antigen-
binding
domain comprises an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 38, or the sequence of SEQ ID NO:38. In one
embodiment, the
extracellular antigen-binding domain comprises an amino acid sequence having
at least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 39, or the sequence of SEQ
ID
NO:39. In one embodiment, the extracellular antigen-binding domain comprises
an amino
acid sequence having at least 50, at least 55, at least 60, at least 65, at
least 70, at least 75,
at least 80, at least 85, at least 90, at least 91, at least 92, at least 93,
at least 94, at least 95,
at least 96, at least 97, at least 98 or at least 99%, sequence identity with
SEQ ID NO: 40,
or the sequence of SEQ ID NO:40. In one embodiment, the extracellular antigen-
binding
domain comprises an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 41, or the sequence of SEQ ID NO:41. In one
embodiment, the
extracellular antigen-binding domain comprises an amino acid sequence having
at least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 42, or the sequence of SEQ
ID
NO:42. In one embodiment, the extracellular antigen-binding domain comprises
an amino
109
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
acid sequence having at least 50, at least 55, at least 60, at least 65, at
least 70, at least 75,
at least 80, at least 85, at least 90, at least 91, at least 92, at least 93,
at least 94, at least 95,
at least 96, at least 97, at least 98 or at least 99%, sequence identity with
SEQ ID NO: 43,
or the sequence of SEQ ID NO:43. In one embodiment, the extracellular antigen-
binding
domain comprises an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 44, or the sequence of SEQ ID NO:44. In one
embodiment, the
extracellular antigen-binding domain comprises an amino acid sequence having
at least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 78, or the sequence of SEQ
ID
NO:78. In one embodiment, the extracellular antigen-binding domain comprises
an amino
acid sequence having at least 50, at least 55, at least 60, at least 65, at
least 70, at least 75,
at least 80, at least 85, at least 90, at least 91, at least 92, at least 93,
at least 94, at least 95,
at least 96, at least 97, at least 98 or at least 99%, sequence identity with
SEQ ID NO: 79,
or the sequence of SEQ ID NO:79. In one embodiment, the extracellular antigen-
binding
domain comprises an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 80, or the sequence of SEQ ID NO: 80. In one
embodiment, the
extracellular antigen-binding domain comprises an amino acid sequence having
at least 50,
at least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90,
at least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98
or at least 99%, sequence identity with SEQ ID NO: 81, or the sequence of SEQ
ID
NO:81. In one embodiment, the extracellular antigen-binding domain comprises
an amino
acid sequence having at least 50, at least 55, at least 60, at least 65, at
least 70, at least 75,
at least 80, at least 85, at least 90, at least 91, at least 92, at least 93,
at least 94, at least 95,
at least 96, at least 97, at least 98 or at least 99%, sequence identity with
SEQ ID NO: 221,
or the sequence of SEQ ID NO:221. In one embodiment, the extracellular antigen-
binding
domain comprises an amino acid sequence having at least 50, at least 55, at
least 60, at
110
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 222, or the sequence of SEQ ID NO:222. In one
embodiment,
the extracellular antigen-binding domain comprises an amino acid sequence
having at least
50, at least 55, at least 60, at least 65, at least 70, at least 75, at least
80, at least 85, at least
90, at least 91, at least 92, at least 93, at least 94, at least 95, at least
96, at least 97, at least
98 or at least 99%, sequence identity with SEQ ID NO: 223, or the sequence of
SEQ ID
NO:223. In one embodiment, the extracellular antigen-binding domain comprises
an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 224, or the sequence of SEQ ID NO:224. In one embodiment, the
extracellular
antigen-binding domain comprises an amino acid sequence having at least 50, at
least 55,
at least 60, at least 65, at least 70, at least 75, at least 80, at least 85,
at least 90, at least 91,
at least 92, at least 93, at least 94, at least 95, at least 96, at least 97,
at least 98 or at least
99%, sequence identity with SEQ ID NO: 225, or the sequence of SEQ ID NO:225.
In one
embodiment, the extracellular antigen-binding domain comprises an amino acid
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NO: 226,
or the
sequence of SEQ ID NO:226. In one embodiment, the extracellular antigen-
binding
domain comprises an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 227, or the sequence of SEQ ID NO:227. In one
embodiment,
the extracellular antigen-binding domain comprises an amino acid sequence
having at least
50, at least 55, at least 60, at least 65, at least 70, at least 75, at least
80, at least 85, at least
90, at least 91, at least 92, at least 93, at least 94, at least 95, at least
96, at least 97, at least
98 or at least 99%, sequence identity with SEQ ID NO: 228, or the sequence of
SEQ ID
NO:228. In one embodiment, the extracellular antigen-binding domain comprises
an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
111
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 229, or the sequence of SEQ ID NO:229. In one embodiment, the
extracellular
antigen-binding domain comprises an amino acid sequence having at least 50, at
least 55,
at least 60, at least 65, at least 70, at least 75, at least 80, at least 85,
at least 90, at least 91,
at least 92, at least 93, at least 94, at least 95, at least 96, at least 97,
at least 98 or at least
99%, sequence identity with SEQ ID NO: 230, or the sequence of SEQ ID NO:230.
In one
embodiment, the extracellular antigen-binding domain comprises an amino acid
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NO: 231,
or the
sequence of SEQ ID NO:231. In one embodiment, the extracellular antigen-
binding
domain comprises an amino acid sequence having at least 50, at least 55, at
least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 232, or the sequence of SEQ ID NO:232. In one
embodiment,
the extracellular antigen-binding domain comprises an amino acid sequence
having at least
50, at least 55, at least 60, at least 65, at least 70, at least 75, at least
80, at least 85, at least
90, at least 91, at least 92, at least 93, at least 94, at least 95, at least
96, at least 97, at least
98 or at least 99%, sequence identity with SEQ ID NO: 233, or the sequence of
SEQ ID
NO:233. In one embodiment, the extracellular antigen-binding domain comprises
an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 234, or the sequence of SEQ ID NO:234. In one embodiment, the
extracellular
antigen-binding domain comprises an amino acid sequence having at least 50, at
least 55,
at least 60, at least 65, at least 70, at least 75, at least 80, at least 85,
at least 90, at least 91,
at least 92, at least 93, at least 94, at least 95, at least 96, at least 97,
at least 98 or at least
99%, sequence identity with SEQ ID NO: 235, or the sequence of SEQ ID NO:235.
In one
embodiment, the extracellular antigen-binding domain comprises an amino acid
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
112
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NO: 236,
or the
sequence of SEQ ID NO:236.
CAR constructs and immunoresponsive cells expressing CARs
The term "encoding" refers to the inherent property of specific sequences of
nucleotides
in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates
for
synthesis of other polymers and macromolecules in biological processes having
either a
defined sequence of nucleotides (e.g., rRNA, tRNA and mRNA) or a defined
sequence of
amino acids and the biological properties resulting therefrom. Thus, a gene,
cDNA, or
RNA, encodes a protein if transcription and translation of mRNA corresponding
to that
gene produces the protein in a cell or other biological system. Both the
coding strand, the
nucleotide sequence of which is identical to the mRNA sequence, and the non-
coding
strand, used as the template for transcription of a gene or cDNA, can be
referred to as
encoding the protein or other product of that gene or cDNA.
Unless otherwise specified, a "nucleotide sequence encoding an amino acid
sequence"
includes all nucleotide sequences that are degenerate versions of each other
and that
encode the same amino acid sequence. The phrase nucleotide sequence that
encodes a
protein or a RNA may also include introns to the extent that the nucleotide
sequence
encoding the protein may in some version contain an intron(s).
The term "expression vector" refers to a vector comprising a recombinant
polynucleotide
comprising expression control sequences operatively linked to a nucleotide
sequence to be
expressed. An expression vector comprises sufficient cis-acting elements for
expression;
other elements for expression can be supplied by the host cell or in an in
vitro expression
system. Expression vectors include all those known in the art, including
cosmids, plasmids
(e.g., naked or contained in liposomes) and viruses (e.g., lentiviruses,
retroviruses,
adenoviruses, and adeno-associated viruses) that incorporate the recombinant
polynucleotide.
113
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one embodiment, the present disclosure provides a cell expressing the
nucleic acid
molecule encoding for a CAR. In one embodiment, the CAR of the present
disclosure
comprises an amino acid sequence selected from the group consisting of SEQ ID
NOS: 46-
61, 82-85 and 205-220. In some embodiments, the CAR of the present disclosure
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 46, or the sequence of SEQ ID NO: 46. In some embodiments, the
CAR
of the present disclosure comprises an amino acid sequence having at least 50,
at least 55,
at least 60, at least 65, at least 70, at least 75, at least 80, at least 85,
at least 90, at least 91,
at least 92, at least 93, at least 94, at least 95, at least 96, at least 97,
at least 98 or at least
99%, sequence identity with SEQ ID NO: 47, or the sequence of SEQ ID NO: 47.
In some
embodiments, the CAR of the present disclosure comprises an amino acid
sequence having
at least 50, at least 55, at least 60, at least 65, at least 70, at least 75,
at least 80, at least 85,
at least 90, at least 91, at least 92, at least 93, at least 94, at least 95,
at least 96, at least 97,
at least 98 or at least 99%, sequence identity with SEQ ID NO: 48, or the
sequence of SEQ
ID NO: 48. In some embodiments, the CAR of the present disclosure comprises an
amino
acid sequence having at least 50, at least 55, at least 60, at least 65, at
least 70, at least 75,
at least 80, at least 85, at least 90, at least 91, at least 92, at least 93,
at least 94, at least 95,
at least 96, at least 97, at least 98 or at least 99%, sequence identity with
SEQ ID NO: 49,
or the sequence of SEQ ID NO: 49. In some embodiments, the CAR of the present
disclosure comprises an amino acid sequence having at least 50, at least 55,
at least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 50, or the sequence of SEQ ID NO: 50. In some
embodiments,
the CAR of the present disclosure comprises an amino acid sequence having at
least 50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 51, or the sequence of SEQ ID
NO: 51.
In some embodiments, the CAR of the present disclosure comprises an amino acid
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
114
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with SEQ
ID NO: 52, or
the sequence of SEQ ID NO: 52. In some embodiments, the CAR of the present
disclosure
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 53, or the sequence of SEQ ID NO: 53. In some embodiments, the
CAR
of the present disclosure comprises an amino acid sequence having at least 50,
at least 55,
at least 60, at least 65, at least 70, at least 75, at least 80, at least 85,
at least 90, at least 91,
at least 92, at least 93, at least 94, at least 95, at least 96, at least 97,
at least 98 or at least
99%, sequence identity with SEQ ID NO: 54, or the sequence of SEQ ID NO: 54.
In some
embodiments, the CAR of the present disclosure comprises an amino acid
sequence having
at least 50, at least 55, at least 60, at least 65, at least 70, at least 75,
at least 80, at least 85,
at least 90, at least 91, at least 92, at least 93, at least 94, at least 95,
at least 96, at least 97,
at least 98 or at least 99%, sequence identity with SEQ ID NO: 55, or the
sequence of SEQ
ID NO: 55. In some embodiments, the CAR of the present disclosure comprises an
amino
acid sequence having at least 50, at least 55, at least 60, at least 65, at
least 70, at least 75,
at least 80, at least 85, at least 90, at least 91, at least 92, at least 93,
at least 94, at least 95,
at least 96, at least 97, at least 98 or at least 99%, sequence identity with
SEQ ID NO: 56,
or the sequence of SEQ ID NO: 56. In some embodiments, the CAR of the present
disclosure comprises an amino acid sequence having at least 50, at least 55,
at least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 57, or the sequence of SEQ ID NO: 57. In some
embodiments,
the CAR of the present disclosure comprises an amino acid sequence having at
least 50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 58, or the sequence of SEQ ID
NO: 58.
In some embodiments, the CAR of the present disclosure comprises an amino acid
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
115
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 96, at least 97, at least 98 or at least 99%, sequence identity with SEQ
ID NO: 59, or
the sequence of SEQ ID NO: 59. In some embodiments, the CAR of the present
disclosure
comprises an amino acid sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NO: 60, or the sequence of SEQ ID NO: 60. In some embodiments, the
CAR
of the present disclosure comprises an amino acid sequence having at least 50,
at least 55,
at least 60, at least 65, at least 70, at least 75, at least 80, at least 85,
at least 90, at least 91,
at least 92, at least 93, at least 94, at least 95, at least 96, at least 97,
at least 98 or at least
99%, sequence identity with SEQ ID NO: 61, or the sequence of SEQ ID NO: 61.
In some
embodiments, the CAR of the present disclosure comprises an amino acid
sequence having
at least 50, at least 55, at least 60, at least 65, at least 70, at least 75,
at least 80, at least 85,
at least 90, at least 91, at least 92, at least 93, at least 94, at least 95,
at least 96, at least 97,
at least 98 or at least 99%, sequence identity with SEQ ID NO: 82, or the
sequence of SEQ
ID NO: 82. In some embodiments, the CAR of the present disclosure comprises an
amino
acid sequence having at least 50, at least 55, at least 60, at least 65, at
least 70, at least 75,
at least 80, at least 85, at least 90, at least 91, at least 92, at least 93,
at least 94, at least 95,
at least 96, at least 97, at least 98 or at least 99%, sequence identity with
SEQ ID NO: 83,
or the sequence of SEQ ID NO: 83. In some embodiments, the CAR of the present
disclosure comprises an amino acid sequence having at least 50, at least 55,
at least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 84, or the sequence of SEQ ID NO: 84. In some
embodiments,
the CAR of the present disclosure comprises an amino acid sequence having at
least 50, at
.. least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 85, or the sequence of SEQ ID
NO: 85.
In some embodiments, the CAR of the present disclosure comprises an amino acid
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with SEQ
ID NO: 205, or
116
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
the sequence of SEQ ID NO: 205. In some embodiments, the CAR of the present
disclosure comprises an amino acid sequence having at least 50, at least 55,
at least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NO: 206, or the sequence of SEQ ID NO: 206. In some
embodiments, the CAR of the present disclosure comprises an amino acid
sequence having
at least 50, at least 55, at least 60, at least 65, at least 70, at least 75,
at least 80, at least 85,
at least 90, at least 91, at least 92, at least 93, at least 94, at least 95,
at least 96, at least 97,
at least 98 or at least 99%, sequence identity with SEQ ID NO: 207, or the
sequence of
SEQ ID NO: 207. In some embodiments, the CAR of the present disclosure
comprises an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 208, or the sequence of SEQ ID NO: 208. In some embodiments, the CAR of
the
.. present disclosure comprises an amino acid sequence having at least 50, at
least 55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 209, or the sequence of SEQ ID NO: 209. In
some
embodiments, the CAR of the present disclosure comprises an amino acid
sequence having
.. at least 50, at least 55, at least 60, at least 65, at least 70, at least
75, at least 80, at least 85,
at least 90, at least 91, at least 92, at least 93, at least 94, at least 95,
at least 96, at least 97,
at least 98 or at least 99%, sequence identity with SEQ ID NO: 210, or the
sequence of
SEQ ID NO: 210. In some embodiments, the CAR of the present disclosure
comprises an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
.. least 75, at least 80, at least 85, at least 90, at least 91, at least 92,
at least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 211, or the sequence of SEQ ID NO: 211. In some embodiments, the CAR of
the
present disclosure comprises an amino acid sequence having at least 50, at
least 55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
.. 92, at least 93, at least 94, at least 95, at least 96, at least 97, at
least 98 or at least 99%,
sequence identity with SEQ ID NO: 212, or the sequence of SEQ ID NO: 212. In
some
117
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
embodiments, the CAR of the present disclosure comprises an amino acid
sequence having
at least 50, at least 55, at least 60, at least 65, at least 70, at least 75,
at least 80, at least 85,
at least 90, at least 91, at least 92, at least 93, at least 94, at least 95,
at least 96, at least 97,
at least 98 or at least 99%, sequence identity with SEQ ID NO: 213, or the
sequence of
SEQ ID NO: 213. In some embodiments, the CAR of the present disclosure
comprises an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 214, or the sequence of SEQ ID NO: 214. In some embodiments, the CAR of
the
present disclosure comprises an amino acid sequence having at least 50, at
least 55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 215, or the sequence of SEQ ID NO: 215. In
some
embodiments, the CAR of the present disclosure comprises an amino acid
sequence having
at least 50, at least 55, at least 60, at least 65, at least 70, at least 75,
at least 80, at least 85,
at least 90, at least 91, at least 92, at least 93, at least 94, at least 95,
at least 96, at least 97,
at least 98 or at least 99%, sequence identity with SEQ ID NO: 216, or the
sequence of
SEQ ID NO: 216. In some embodiments, the CAR of the present disclosure
comprises an
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 217, or the sequence of SEQ ID NO: 217. In some embodiments, the CAR of
the
present disclosure comprises an amino acid sequence having at least 50, at
least 55, at least
60, at least 65, at least 70, at least 75, at least 80, at least 85, at least
90, at least 91, at least
92, at least 93, at least 94, at least 95, at least 96, at least 97, at least
98 or at least 99%,
sequence identity with SEQ ID NO: 218, or the sequence of SEQ ID NO: 218. In
some
embodiments, the CAR of the present disclosure comprises an amino acid
sequence having
at least 50, at least 55, at least 60, at least 65, at least 70, at least 75,
at least 80, at least 85,
at least 90, at least 91, at least 92, at least 93, at least 94, at least 95,
at least 96, at least 97,
at least 98 or at least 99%, sequence identity with SEQ ID NO: 219, or the
sequence of
SEQ ID NO: 219. In some embodiments, the CAR of the present disclosure
comprises an
118
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
amino acid sequence having at least 50, at least 55, at least 60, at least 65,
at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NO: 220, or the sequence of SEQ ID NO: 220.
In certain embodiments, the CAR may comprise a signal polypeptide. In certain
embodiments the signal peptide is at the N-terminus of the CAR sequence. In
certain
embodiments the signal peptide is at the C-terminus of the CAR sequence. In
certain
embodiments, the signal peptide comprises or consists of the amino acid
sequence of SEQ
ID No: 24.
Herein, the structure of nucleic acid molecules is in places defined in the
basis of %
sequence identity with a recited reference sequence (with a given SEQ ID NO).
In this
context, % sequence identity regarding nucleic acid molecules refers to the
similarity
between at least two different nucleic acid sequences. When a position in both
of the two
compared sequences is occupied by the same base e.g., if a position in each of
two DNA
molecules is occupied by adenine, then the molecules are identical at that
position, The
percent of identity between two sequences is a function of the number of
matching or
homologous positions shared by the two sequences divided by the number of
positions
compared and multiplied by 100. For example, if 6 of 10 of the positions in
two sequences
are matched or homologous then the two sequences are 60% identical (or
homologous). By
way of example, the DNA sequences ATTGCC and TATGGC share 50% identity (or
homology). Generally, a comparison is made when two sequences are aligned to
give
maximum homology. The respective percent identity can be determined by
standard
alignment algorithms, for example, the Basic Local Alignment Search Tool
(BLAST)
described by Altshul et al. ((1990) J. MoI. Biol. 215:403-10); the algorithm
of Needleman
et al. ((1970) J. MoI. Biol. 48:444-53); or the algorithm of Meyers et al.
((1988) Comput.
Appl. Biosci. 4:11-17). A set of parameters may be the Blosum 62 scoring
matrix with a
gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of
5. The percent
identity between two nucleotide sequences can also be determined using the
algorithm of
Meyers and Miller ((1989) CABIOS 4:11-17), which has been incorporated into
the
119
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length
penalty
of 12, and a gap penalty of 4. The percent identity is usually calculated by
comparing
sequences of similar length.
In various embodiments, the nucleic acid molecule encoding for a CAR comprises
a
nucleic acid sequence of any one of SEQ ID NOS: 153-160. In various
embodiments, the
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with any
one of SEQ ID
NOS: 153-160.
In various embodiments, the nucleic acid molecule encoding for a CAR comprises
a
nucleic acid sequence of any one of SEQ ID NOS: 161-168. In various
embodiments, the
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprises a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with any
one of SEQ ID
NOS: 161-168.
In various embodiments, the nucleic acid molecule encoding for a CAR comprises
a
nucleic acid sequence of any one of SEQ ID NOS: 195-204. In various
embodiments, the
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprises a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with any
one of SEQ ID
NOS: 195-204.
In various embodiments, the nucleic acid molecule encoding for a CAR comprises
a
nucleic acid sequence of any one of SEQ ID NOS: 320-325. In various
embodiments, the
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprises a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
120
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with any
one of SEQ ID
NOS: 320-325.
In various embodiments, the nucleic acid molecule encoding for a CAR comprises
a
.. nucleic acid sequence of any one of SEQ ID NOS: 326-331. In various
embodiments, the
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprises a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with any
one of SEQ ID
NOS: 326-331.
In various embodiments, the nucleic acid molecule encoding for a CAR comprises
a
nucleic acid sequence of any one of SEQ ID NOS: 336-339. In various
embodiments, the
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprises a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with any
one of SEQ ID
NOS: 336-339.
In an embodiment, the nucleic acid molecule encoding for a CAR comprises a
nucleic acid
sequence comprising a sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NOS: 153, or the sequence of SEQ ID No:153. In an embodiment, the
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
.. least 80, at least 85, at least 90, at least 91, at least 92, at least 93,
at least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with SEQ
ID NOS: 154,
or the sequence of SEQ ID No:154. In an embodiment, the nucleic acid molecule
encoding
for a CAR comprises a nucleic acid sequence comprising a sequence having at
least 50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
121
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
at least 99%, sequence identity with SEQ ID NOS: 155, or the sequence of SEQ
ID
No:155. In an embodiment, the nucleic acid molecule encoding for a CAR
comprises a
nucleic acid sequence comprising a sequence having at least 50, at least 55,
at least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NOS: 156, or the sequence of SEQ ID No:156. In an
embodiment,
the nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a sequence having at least 50, at least 55, at least 60, at least
65, at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NOS: 157, or the sequence of SEQ ID No:157. In an embodiment, the nucleic acid
molecule encoding for a CAR comprises a nucleic acid sequence comprising a
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NOS: 158,
or the
sequence of SEQ ID No:158. In an embodiment, the nucleic acid molecule
encoding for a
CAR comprises a nucleic acid sequence comprising a sequence having at least
50, at least
55, at least 60, at least 65, at least 70, at least 75, at least 80, at least
85, at least 90, at least
91, at least 92, at least 93, at least 94, at least 95, at least 96, at least
97, at least 98 or at
least 99%, sequence identity with SEQ ID NOS: 159, or the sequence of SEQ ID
No:159.
In an embodiment, the nucleic acid molecule encoding for a CAR comprises a
nucleic acid
sequence comprising a sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NOS: 160, or the sequence of SEQ ID No:160. In an embodiment, the
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with SEQ
ID NOS: 161,
or the sequence of SEQ ID No:161. In an embodiment, the nucleic acid molecule
encoding
for a CAR comprises a nucleic acid sequence comprising a sequence having at
least 50, at
122
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NOS: 162, or the sequence of SEQ
ID
No:162. In an embodiment, the nucleic acid molecule encoding for a CAR
comprises a
nucleic acid sequence comprising a sequence having at least 50, at least 55,
at least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NOS: 163, or the sequence of SEQ ID No:163. In an
embodiment,
the nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a sequence having at least 50, at least 55, at least 60, at least
65, at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NOS: 164, or the sequence of SEQ ID No:164. In an embodiment, the nucleic acid
molecule encoding for a CAR comprises a nucleic acid sequence comprising a
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NOS: 165,
or the
sequence of SEQ ID No:165. In an embodiment, the nucleic acid molecule
encoding for a
CAR comprises a nucleic acid sequence comprising a sequence having at least
50, at least
55, at least 60, at least 65, at least 70, at least 75, at least 80, at least
85, at least 90, at least
91, at least 92, at least 93, at least 94, at least 95, at least 96, at least
97, at least 98 or at
least 99%, sequence identity with SEQ ID NOS: 166, or the sequence of SEQ ID
No:166.
In an embodiment, the nucleic acid molecule encoding for a CAR comprises a
nucleic acid
sequence comprising a sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NOS: 167, or the sequence of SEQ ID No:167. In an embodiment, the
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with SEQ
ID NOS: 168,
123
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
or the sequence of SEQ ID No:168. In an embodiment, the nucleic acid molecule
encoding
for a CAR comprises a nucleic acid sequence comprising a sequence having at
least 50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NOS: 195, or the sequence of SEQ
ID
No:195. In an embodiment, the nucleic acid molecule encoding for a CAR
comprises a
nucleic acid sequence comprising a sequence having at least 50, at least 55,
at least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NOS: 196, or the sequence of SEQ ID No:196. In an
embodiment,
the nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a sequence having at least 50, at least 55, at least 60, at least
65, at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NOS: 197, or the sequence of SEQ ID No:197. In an embodiment, the nucleic acid
molecule encoding for a CAR comprises a nucleic acid sequence comprising a
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NOS: 198,
or the
sequence of SEQ ID No:198. In an embodiment, the nucleic acid molecule
encoding for a
CAR comprises a nucleic acid sequence comprising a sequence having at least
50, at least
55, at least 60, at least 65, at least 70, at least 75, at least 80, at least
85, at least 90, at least
91, at least 92, at least 93, at least 94, at least 95, at least 96, at least
97, at least 98 or at
least 99%, sequence identity with SEQ ID NOS: 199, or the sequence of SEQ ID
No:199.
.. In an embodiment, the nucleic acid molecule encoding for a CAR comprises a
nucleic acid
sequence comprising a sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NOS: 200, or the sequence of SEQ ID No:200. In an embodiment, the
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
124
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with SEQ
ID NOS: 201,
or the sequence of SEQ ID No:201. In an embodiment, the nucleic acid molecule
encoding
for a CAR comprises a nucleic acid sequence comprising a sequence having at
least 50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NOS: 202, or the sequence of SEQ
ID
No:202. In an embodiment, the nucleic acid molecule encoding for a CAR
comprises a
nucleic acid sequence comprising a sequence having at least 50, at least 55,
at least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NOS: 203, or the sequence of SEQ ID No:203. In an
embodiment,
the nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a sequence having at least 50, at least 55, at least 60, at least
65, at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NOS: 204, or the sequence of SEQ ID No:204. In an embodiment, the nucleic acid
molecule encoding for a CAR comprises a nucleic acid sequence comprising a
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NOS: 320,
or the
sequence of SEQ ID No:320. In an embodiment, the nucleic acid molecule
encoding for a
CAR comprises a nucleic acid sequence comprising a sequence having at least
50, at least
55, at least 60, at least 65, at least 70, at least 75, at least 80, at least
85, at least 90, at least
91, at least 92, at least 93, at least 94, at least 95, at least 96, at least
97, at least 98 or at
least 99%, sequence identity with SEQ ID NOS: 321, or the sequence of SEQ ID
No:321.
In an embodiment, the nucleic acid molecule encoding for a CAR comprises a
nucleic acid
sequence comprising a sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
.. least 94, at least 95, at least 96, at least 97, at least 98 or at least
99%, sequence identity
with SEQ ID NOS: 322, or the sequence of SEQ ID No:322. In an embodiment, the
125
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with SEQ
ID NOS: 323,
or the sequence of SEQ ID No:323. In an embodiment, the nucleic acid molecule
encoding
for a CAR comprises a nucleic acid sequence comprising a sequence having at
least 50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NOS: 324, or the sequence of SEQ
ID
No:324. In an embodiment, the nucleic acid molecule encoding for a CAR
comprises a
nucleic acid sequence comprising a sequence having at least 50, at least 55,
at least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NOS: 325, or the sequence of SEQ ID No:325. In an
embodiment,
the nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a sequence having at least 50, at least 55, at least 60, at least
65, at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NOS: 326, or the sequence of SEQ ID No:326. In an embodiment, the nucleic acid
molecule encoding for a CAR comprises a nucleic acid sequence comprising a
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NOS: 327,
or the
sequence of SEQ ID No:327. In an embodiment, the nucleic acid molecule
encoding for a
CAR comprises a nucleic acid sequence comprising a sequence having at least
50, at least
55, at least 60, at least 65, at least 70, at least 75, at least 80, at least
85, at least 90, at least
91, at least 92, at least 93, at least 94, at least 95, at least 96, at least
97, at least 98 or at
least 99%, sequence identity with SEQ ID NOS: 328, or the sequence of SEQ ID
No:328.
In an embodiment, the nucleic acid molecule encoding for a CAR comprises a
nucleic acid
sequence comprising a sequence having at least 50, at least 55, at least 60,
at least 65, at
least 70, at least 75, at least 80, at least 85, at least 90, at least 91, at
least 92, at least 93, at
126
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 94, at least 95, at least 96, at least 97, at least 98 or at least 99%,
sequence identity
with SEQ ID NOS: 329, or the sequence of SEQ ID No:329. In an embodiment, the
nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a
sequence having at least 50, at least 55, at least 60, at least 65, at least
70, at least 75, at
least 80, at least 85, at least 90, at least 91, at least 92, at least 93, at
least 94, at least 95, at
least 96, at least 97, at least 98 or at least 99%, sequence identity with SEQ
ID NOS: 330,
or the sequence of SEQ ID No:330. In an embodiment, the nucleic acid molecule
encoding
for a CAR comprises a nucleic acid sequence comprising a sequence having at
least 50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NOS: 331, or the sequence of SEQ
ID
No:331. In an embodiment, the nucleic acid molecule encoding for a CAR
comprises a
nucleic acid sequence comprising a sequence having at least 50, at least 55,
at least 60, at
least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at
least 91, at least 92, at
least 93, at least 94, at least 95, at least 96, at least 97, at least 98 or
at least 99%, sequence
identity with SEQ ID NOS: 336, or the sequence of SEQ ID No:336. In an
embodiment,
the nucleic acid molecule encoding for a CAR comprises a nucleic acid sequence
comprising a sequence having at least 50, at least 55, at least 60, at least
65, at least 70, at
least 75, at least 80, at least 85, at least 90, at least 91, at least 92, at
least 93, at least 94, at
least 95, at least 96, at least 97, at least 98 or at least 99%, sequence
identity with SEQ ID
NOS: 337, or the sequence of SEQ ID No:337. In an embodiment, the nucleic acid
molecule encoding for a CAR comprises a nucleic acid sequence comprising a
sequence
having at least 50, at least 55, at least 60, at least 65, at least 70, at
least 75, at least 80, at
least 85, at least 90, at least 91, at least 92, at least 93, at least 94, at
least 95, at least 96, at
least 97, at least 98 or at least 99%, sequence identity with SEQ ID NOS: 338,
or the
sequence of SEQ ID No:338. In an embodiment, the nucleic acid molecule
encoding for a
CAR comprises a nucleic acid sequence comprising a sequence having at least
50, at least
55, at least 60, at least 65, at least 70, at least 75, at least 80, at least
85, at least 90, at least
91, at least 92, at least 93, at least 94, at least 95, at least 96, at least
97, at least 98 or at
least 99%, sequence identity with SEQ ID NOS: 339, or the sequence of SEQ ID
No:339.
127
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one aspect, the present disclosure provides isolated immunoresponsive cells
comprising
the CARs described herein. In some embodiments, the isolated immunoresponsive
cell is
transduced with the CAR, for example, the CAR is constitutively expressed on
the surface
of the immunoresponsive cell. In certain embodiments, the isolated
immunoresponsive cell
is further transduced with at least one co-stimulatory ligand such that the
immunoresponsive cell expresses the at least one co-stimulatory ligand. In
certain
embodiments, the at least one co-stimulatory ligand is selected from the group
consisting
of 4-1BBL, CD48, CD70, CD80, CD86, OX4OL, TNFRSF14, and combinations thereof.
In certain embodiments, the isolated immunoresponsive cell is further
transduced with at
least one cytokine such that the immunoresponsive cell secretes the at least
one cytokine.
In certain embodiments, the at least cytokine is selected from the group
consisting of IL-2,
IL-3, IL-6, IL-7, IL-11, IL-12, IL-15, IL-17, IL-21, and combinations thereof.
In some
embodiments, the isolated immunoresponsive cell is selected from the group
consisting of
a T lymphocyte (T cell), a Natural Killer (NK) cell, a cytotoxic T lymphocyte
(Cm), a
regulatory T cell, a human embryonic stem cell, a lymphoid progenitor cell, a
T cell-
precursor cell, and a pluripotent stem cell from which lymphoid cells may be
differentiated.
In one embodiment, the CAR T cells of the disclosure can be generated by
introducing a
lentiviral vector comprising a desired CAR, for example, a CAR comprising anti-
hK2,
CD8a hinge and transmembrane domain, and human 4-1BB and CD3-zeta signaling
domains, into the cells. The CAR T cells of the invention are able to
replicate in vivo
resulting in long-term persistence that can lead to sustained tumor control.
Embodiments of the invention further provide host cells comprising any of the
recombinant
expression vectors described herein. As used herein, the term "host cell"
refers to any type
of cell that can contain the recombinant expression vector. The host cell can
be a eukaryotic
cell, e.g., plant, animal, or algae, fungi, or can be a prokaryotic cell,
e.g., bacteria or
protozoa. The host cell can be a cultured cell or a primary cell, i.e.,
isolated directly from an
organism, e.g., a human. The host cell can be an adherent cell or a suspended
cell, i.e., a cell
that grows in suspension. Suitable host cells are known in the art and
include, for instance,
DH5a E.coli cells, Chinese hamster ovarian cells, monkey VERO cells, COS
cells,
128
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
HEK293 cells, and the like. For purposes of amplifying or replicating the
recombinant
expression vector, the host cell may be a prokaryotic cell, e.g., a DH5a cell.
For purposes
of producing a recombinant CAR, polypeptide, or protein, the host cell may be
a
mammalian cell. The host cell may be a human cell. While the host cell can be
of any cell
type, can originate from any type of tissue, and can be of any developmental
stage, the host
cell may be a peripheral blood lymphocyte (PBL). The host cell may be a T
cell.
For purposes herein, the T cell can be any T cell, such as a cultured T cell,
e.g., a primary
T cell, or a T cell from a cultured T cell line, e.g., Jurkat, SupT1, etc., or
a T cell obtained
from a mammal. If obtained from a mammal, the T cell can be obtained from
numerous
sources, including but not limited to bone marrow, blood, lymph node, the
thymus, or other
tissues or fluids. T cells can also be enriched for or purified. The T cell
may be a human T
cell. The T cell may be a T cell isolated from a human. The T cell can be any
type of T cell
and can be of any developmental stage, including but not limited to, CD4+/CD8+
double
positive T cells, CD8+ T cells (e.g., cytotoxic T cells), CD4+ helper T cells,
e.g., Thi and
Th2 cells, peripheral blood mononuclear cells (PBMCs), peripheral blood
leukocytes
(PBLs), tumor infiltrating cells, memory T cells, naive T cells, and the like.
The T cell may
be a CD8+ T cell or a CD4+ T cell.
Also provided are a population of cells comprising at least one host cell
described herein.
The population of cells can be a heterogeneous population comprising the host
cell
comprising any of the recombinant expression vectors described, in addition to
at least one
other cell, e.g., a host cell (e.g., a T cell), which does not comprise any of
the recombinant
expression vectors, or a cell other than a T cell, e.g., a B cell, a
macrophage, an
erythrocyte, a neutrophil, a hepatocyte, an endothelial cell, an epithelial
cell, a muscle cell,
a brain cell, etc. Alternatively, the population of cells can be a
substantially homogeneous
population, in which the population comprises mainly host cells (e.g.,
consisting
essentially of) comprising the recombinant expression vector. The population
also can be a
clonal population of cells, in which all cells of the population are clones of
a single host
cell comprising a recombinant expression vector, such that all cells of the
population
comprise the recombinant expression vector. In one embodiment, the population
of cells is
129
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a clonal population comprising host cells comprising a recombinant expression
vector as
described herein.
Pharmaceutical Compositions/Administration
In embodiments of the present disclosure, the CAR-expressing cells may be
provided in
compositions, e.g., suitable pharmaceutical composition(s) comprising the CAR-
expressing cells and a pharmaceutically acceptable carrier. In one aspect, the
present
disclosure provides pharmaceutical compositions comprising an effective amount
of a
lymphocyte expressing one or more of the CARs described and a pharmaceutically
acceptable excipient. Pharmaceutical compositions of the present disclosure
may comprise
a CAR-expressing cell, e.g., a plurality of CAR-expressing cells, as described
herein, in
combination with one or more pharmaceutically or physiologically acceptable
carriers,
excipients or diluents. As used herein, the term "in combination with" means
that two or
more therapeutic agents are be administered to a subject together in a
mixture, concurrently
as single agents or sequentially as single agents in any order.
A pharmaceutically acceptable carrier can be an ingredient in a pharmaceutical
composition, other than an active ingredient, which is nontoxic to the
subject.
A pharmaceutically acceptable carrier can include, but is not limited to, a
buffer, excipient,
stabilizer, or preservative. Examples of pharmaceutically acceptable carriers
are solvents,
dispersion media, coatings, antibacterial and antifungal agents, isotonic and
absorption
delaying agents, and the like that are physiologically compatible, such as
salts, buffers,
antioxidants, saccharides, aqueous or non-aqueous carriers, preservatives,
wetting agents,
surfactants or emulsifying agents, or combinations thereof. The amounts of
pharmaceutically acceptable carrier(s) in the pharmaceutical compositions may
be
determined experimentally based on the activities of the carrier(s) and the
desired
characteristics of the formulation, such as stability and/or minimal
oxidation.
Such compositions may comprise buffers such as acetic acid, citric acid,
formic acid,
succinic acid, phosphoric acid, carbonic acid, malic acid, aspartic acid,
histidine, boric
acid, Tris buffers, FIEPPSO, EMPES, neutral buffered saline, phosphate
buffered saline
130
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
and the like; carbohydrates such as glucose, mannose, sucrose or dextrans,
mannitol;
proteins; polypeptides or amino acids such as glycine; antioxidants; chelating
agents such
as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); antibacterial
and
antifungal agents; and preservatives.
Compositions of the present disclosure can be formulated for a variety of
means of
parenteral or non-parenteral administration. In one embodiment, the
compositions can be
formulated for infusion or intravenous administration. Compositions disclosed
herein can
be provided, for example, as sterile liquid preparations, e.g., isotonic
aqueous solutions,
emulsions, suspensions, dispersions, or viscous compositions, which may be
buffered to a
desirable pH. Formulations suitable for oral administration can include liquid
solutions,
capsules, sachets, tablets, lozenges, and troches, powders liquid suspensions
in an
appropriate liquid and emulsions.
The term "pharmaceutically acceptable," as used herein with regard to
pharmaceutical
compositions, means approved by a regulatory agency of the Federal or a state
government
or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia
for use in
animals and/or in humans.
In one aspect, the disclosure relates to administering a genetically modified
T cell
expressing a CAR for the treatment of a subject having cancer or at risk of
having cancer
using lymphocyte infusion. In at least one embodiment, autologous lymphocyte
infusion is
used in the treatment. Autologous PBMCs are collected from a subject in need
of treatment
and T cells are activated and expanded using the methods described herein and
known in
the art and then infused back into the subject.
In one aspect, the disclosure relates generally to the treatment of a subject
at risk of
developing cancer. The invention also includes treating a malignancy or an
autoimmune
disease in which chemotherapy and/or immunotherapy in a subject results in
significant
immunosuppression, thereby increasing the risk of the subject developing
cancer. In one
aspect, the present disclosure provides methods of preventing cancer, the
methods
comprising administering an amount of a lymphocyte expressing one or more of
the CARs
described to a subject in need thereof.
131
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In one aspect, the present disclosure provides methods of treating a subject
having cancer,
the methods comprising administering a therapeutically effective amount of a
lymphocyte
expressing one or more of the CARs described to a subject in need thereof,
whereby the
lymphocyte induces or modulates killing of cancer cells in the subject.
In another aspect, the present disclosure provides methods of reducing tumor
burden in a
subject having cancer, the methods comprising administering a therapeutically
effective
amount of a lymphocyte expressing one or more of the CARs described herein to
a subject
in need thereof, whereby the lymphocyte induces killing of cancer cells in the
subject. In
another aspect, the present disclosure provides methods of increasing survival
of a subject
having cancer, the methods comprising administering a therapeutically
effective amount of
a lymphocyte expressing one or more of the CARs described to a subject in need
thereof,
whereby the survival of the subject is lengthened. Generally, the lymphocytes
expressing
the CAR(s) induce killing of cancer cells in the subject and result in
reduction or
eradication of the tumors/cancer cells in the subject. A non-limiting list of
cancers,
inclusive of metastatic lesions, that can be targeted, includes prostate
cancer and prostate-
derived cancer. In one embodiment, the cancer being treated in a subject is
prostate
cancer. In some embodiments, the cancer is an androgen receptor (AR)
expressing breast
cancer.
In one aspect, the methods described herein are applicable to treatment of
noncancerous
conditions that are at risk of developing into a cancerous condition, such as,
e.g., enlarged
prostate, benign prostate hyperplasia (BPH), and high PSA levels in absence of
diagnosed
prostate cancer.
In one aspect, methods of treating a subject having cancer are provided that
comprise
administering a therapeutically effective amount of a lymphocyte expressing a
CAR, the
CAR having an extracellular antigen-binding domain that binds the hK2 antigen,
to a
subject in need thereof, whereby the lymphocyte induces killing of cancer
cells in the
subject. In some embodiments, the at least one of the CARs comprises an amino
acid
sequence selected from the group consisting of SEQ ID NOS: 46-61, 82-85 and
205-220.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
132
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 46, or the sequence of SEQ ID
NO: 46.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 47, or the sequence of SEQ ID
NO: 47.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 48, or the sequence of SEQ ID
NO: 48.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 49, or the sequence of SEQ ID
NO: 49.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 50, or the sequence of SEQ ID
NO: 50.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 51, or the sequence of SEQ ID
NO: 51.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 52, or the sequence of SEQ ID
NO: 52.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 53, or the sequence of SEQ ID
NO: 53.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
133
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 54, or the sequence of SEQ ID
NO: 54.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
.. least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 55, or the sequence of SEQ ID
NO: 55.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 56, or the sequence of SEQ ID
NO: 56.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
.. at least 99%, sequence identity with SEQ ID NO: 57, or the sequence of SEQ
ID NO: 57.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 58, or the sequence of SEQ ID
NO: 58.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 59, or the sequence of SEQ ID
NO: 59.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
.. least 55, at least 60, at least 65, at least 70, at least 75, at least 80,
at least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 60, or the sequence of SEQ ID
NO: 60.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
.. least 91, at least 92, at least 93, at least 94, at least 95, at least 96,
at least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 61, or the sequence of SEQ ID
NO: 61.
134
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 82, or the sequence of SEQ ID
NO: 82.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 83, or the sequence of SEQ ID
NO: 83.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 84, or the sequence of SEQ ID
NO: 84.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 85, or the sequence of SEQ ID
NO: 85.
In some embodiments, the CAR comprises an amino acid sequence having at least
50, at
least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at
least 85, at least 90, at
least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at
least 97, at least 98 or
at least 99%, sequence identity with SEQ ID NO: 205, or the sequence of SEQ ID
NO:
205. In some embodiments, the CAR comprises an amino acid sequence having at
least
50, at least 55, at least 60, at least 65, at least 70, at least 75, at least
80, at least 85, at least
90, at least 91, at least 92, at least 93, at least 94, at least 95, at least
96, at least 97, at least
98 or at least 99%, sequence identity with SEQ ID NO: 206, or the sequence of
SEQ ID
NO: 206. In some embodiments, the CAR comprises an amino acid sequence having
at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 207, or the
sequence of SEQ
ID NO: 207. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
135
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 98 or at least 99%, sequence identity with SEQ ID NO: 208, or the
sequence of SEQ
ID NO: 208. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 209, or the
sequence of SEQ
ID NO: 209. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 210, or the
sequence of SEQ
ID NO: 210. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 211, or the
sequence of SEQ
ID NO: 211. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 212, or the
sequence of SEQ
ID NO: 212. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 213, or the
sequence of SEQ
ID NO: 213. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 214, or the
sequence of SEQ
ID NO: 214. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 215, or the
sequence of SEQ
ID NO: 215. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
136
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 216, or the
sequence of SEQ
ID NO: 216. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 217, or the
sequence of SEQ
ID NO: 217. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 218, or the
sequence of SEQ
ID NO: 218. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 219, or the
sequence of SEQ
ID NO: 219. In some embodiments, the CAR comprises an amino acid sequence
having at
least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at
least 80, at least 85, at
least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at
least 96, at least 97, at
least 98 or at least 99%, sequence identity with SEQ ID NO: 220, or the
sequence of SEQ
ID NO: 220.
In one aspect, a method of targeted killing of a cancer cell is disclosed, the
method
comprising contacting the cancer cell with a lymphocyte expressing one or more
of the
CARs described, whereby the lymphocyte induces killing of the cancer cell. A
non-
limiting list of cancer cells, inclusive of metastatic cancer cells, that can
be targeted include
prostate cancer, and combinations thereof. In one embodiment, the cancer cell
is a prostate
cancer cell.
Pharmaceutical compositions of the present disclosure may be administered in a
manner
appropriate to the disease to be treated (or prevented). The quantity and
frequency of
administration will be determined by such factors as the condition of the
subject, and the
type and severity of the subject's disease, although appropriate dosages may
be determined
by clinical trials.
137
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
The terms "treat" or "treatment" refer to therapeutic treatment wherein the
object is to slow
down (lessen) an undesired physiological change or disease, or provide a
beneficial or
desired clinical outcome during treatment. Beneficial or desired clinical
outcomes include
alleviation of symptoms, diminishment of extent of disease, stabilized (i.e.,
not worsening)
state of disease, delay or slowing of disease progression, amelioration or
palliation of the
disease state, and/or remission (whether partial or total), whether detectable
or
undetectable. "Treatment" can also mean prolonging survival as compared to
expected
survival if a subject was not receiving treatment. Those in need of treatment
include those
subjects already with the undesired physiological change or disease as well as
those
subjects prone to have the physiological change or disease.
"Prevent," "preventing," "prevention," or "prophylaxis" of a disease or
disorder means
preventing that a disorder occurs in a subject.A "therapeutically effective
amount" or
"effective amount", used interchangeably herein, refers to an amount
effective, at dosages
and for periods of time necessary, to achieve a desired therapeutic result. A
therapeutically
.. effective amount may vary according to factors such as the disease state,
age, sex, and
weight of the individual, and the ability of a therapeutic or a combination of
therapeutics to
elicit a desired response in the individual. Example indicators of an
effective therapeutic or
combination of therapeutics that include, for example, improved wellbeing of
the patient,
reduction of a tumor burden, arrested or slowed growth of a tumor, and/or
absence of
.. metastasis of cancer cells to other locations in the body.
As used herein, the term "subject" refers to an animal. The terms "subject"
and "patient"
may be used interchangeably herein in reference to a subject. As such, a
"subject" includes
a human that is being treated for a disease, or prevention of a disease, as a
patient. The
methods described herein may be used to treat an animal subject belonging to
any
classification. Examples of such animals include mammals. Mammals, include,
but are not
limited to, mammals of the order Rodentia, such as mice and hamsters, and
mammals of the
order Logomorpha, such as rabbits. The mammals may be from the order
Carnivora,
including Felines (cats) and Canines (dogs). The mammals may be from the order
Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order
Perssodactyla,
including Equines (horses). The mammals may be of the order Primates, Ceboids,
or
138
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Simoids (monkeys) or of the order Anthropoids (humans and apes). In one
embodiment,
the mammal is a human.
When a therapeutically effective amount is indicated, the precise amount of
the
compositions of the present disclosure to be administered can be determined by
a physician
with consideration of individual differences in age, weight, tumor size,
extent of infection or
metastasis, and condition of the subject. It can generally be stated that a
pharmaceutical
composition comprising the T cells described herein may be administered at a
dosage of
about 104 to about 1010 cells/kg body weight, in some instances about 105 to
about 106
cells/kg body weight, including all integer values within those ranges. In
some
embodiments, a pharmaceutical composition comprising the T cells described
herein may
be administered at a dosage of about 106 cells/kg body weight. T cell
compositions may
also be administered multiple times at these dosages. The cells can be
administered by using
infusion techniques that are commonly known in immunotherapy (see, e.g.,
Rosenberg et
al., New Eng. J. of Med. 319:1676, 1988).
Delivery systems useful in the context of embodiments of the invention may
include time-
released, delayed release, and sustained release delivery systems such that
the delivery of
the T cell compositions occurs prior to, and with sufficient time to cause,
sensitization of
the site to be treated. The composition can be used in conjunction with other
therapeutic
agents or therapies. Such systems can avoid repeated administrations of the
composition,
thereby increasing convenience to the subject and the physician, and may be
particularly
suitable for certain composition embodiments of the invention.
Many types of release delivery systems are available and known to those of
ordinary skill in
the art. They include polymer base systems such as poly(lactide-glycolide),
copolyoxalates,
polyesteramides, polyorthoesters, polycaprolactones, polyhydroxybutyric acid,
and
polyanhydrides. Microcapsules of the foregoing polymers containing drugs are
described in,
for example, U.S. Pat. No. 5,075,109. Delivery systems also include non-
polymer systems
that are lipids including sterols such as cholesterol, cholesterol esters, and
fatty acids or
neutral fats such as mono-di- and tri-glycerides; sylastic systems; peptide
based systems;
hydrogel release systems; wax coatings; compressed tablets using conventional
binders and
excipients; partially fused implants; and the like. Specific examples include,
but are not
139
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
limited to: (a) erosional systems in which the active composition is contained
in a form
within a matrix such as those described in U.S. Patent Nos. 4,452,775;
4,667,014;
4,748,034; and 5,239,660 and (b) diffusional systems in which an active
component
permeates at a controlled rate from a polymer such as described in U.S. Patent
Nos.
3,854,480 and 3,832,253. In addition, pump-based hardware delivery systems can
be used,
some of which are adapted for implantation.
In certain aspects, it may be desirable to administer activated T cells to a
subject and then
subsequently redraw blood (or have an apheresis performed), activate the T
cells according
to the present disclosure, and reinfuse the subject with these activated and
expanded T
cells. This process can be carried out multiple times every few weeks. In
certain aspects, T
cells can be activated from blood draws of from 10 cc to 400 cc. In certain
aspects, T cells
are activated from blood draws of 20 cc, 30 cc, 40 cc, 50 cc, 60 cc, 70 cc, 80
cc, 90 cc, or
100 cc.
The administration of the CAR-T cells and compositions may be carried out in
any
manner, e.g., by parenteral or nonparenteral administration, including by
aerosol
inhalation, injection, infusions, ingestion, transfusion, implantation or
transplantation. For
example, the CAR-T cells and compositions described herein may be administered
to a
patient trans-arterially, intradermally, subcutaneously, intratumorally,
intramedullary,
intranodally, intramuscularly, by intravenous (i.v.) injection, or
intraperitoneally. In one
.. aspect, the compositions of the present disclosure are administered by i.v.
injection. In one
aspect, the compositions of the present disclosure are administered to a
subject by
intradermal or subcutaneous injection. The compositions of T cells may be
injected, for
instance, directly into a tumor, lymph node, tissue, organ, or site of
infection.
Administration can be autologous or non-autologous. For example,
immunoresponsive
cells expressing a human Kallikrein-2 (e.g., hK2)-specific CAR can be obtained
from one
subject, and administered to the same subject or a different, compatible
subject. Peripheral
blood derived T cells of the present disclosure, or expanded T cells (e.g., in
vivo, ex vivo or
in vitro derived) can be administered via, e.g., intravenous injection,
localized injection,
systemic injection, catheter administration, or parenteral administration.
140
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In particular embodiments, subjects may undergo leukapheresis, wherein
leukocytes are
collected, enriched, or depleted ex vivo to select and/or isolate the cells of
interest, e.g., T
cells. These T cell isolates may be expanded by methods known in the art and
treated such
that one or more CAR constructs of the present disclosure may be introduced,
thereby
creating a CAR-T cell. Subjects in need thereof may subsequently undergo
standard
treatment with high dose chemotherapy followed by peripheral blood stem cell
transplantation. In certain aspects, following or concurrent with the
transplant, subjects
receive an infusion of the expanded CAR-T cells. In one aspect, expanded cells
are
administered before or following surgery.
The dosage administered to a patient having a malignancy is sufficient to
alleviate or at
least partially arrest the disease being treated ("therapeutically effective
amount"). The
dosage of the above treatments to be administered to a subject will vary with
the precise
nature of the condition being treated and the recipient of the treatment. The
scaling of
dosages for human administration can be performed according to practices
generally
accepted in the art.
The CAR T cells of the invention can undergo in vivo T cell expansion and can
establish
hK2-specific memory cells that persist at high levels for an extended amount
of time in
blood and bone marrow. In some instances, the CAR T cells of the invention
infused into a
subject can eliminate cancer cells, e.g., prostate cancer cells or AR-
expressing breast
cancer, in vivo in subjects with advanced chemotherapy-resistant cancer.
In one embodiment, a CAR of the present disclosure is introduced into T cells,
e.g., using
in vitro transcription, and the subject (e.g., human) receives an initial
administration of
CAR-T cells of the disclosure, and one or more subsequent administrations of
the CAR-T
cells, wherein the one or more subsequent administrations are administered
less than 15
days, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5,4, 3, or 2 days after the
previous administration.
In one embodiment, more than one administration of the CAR-T cells are
administered to
the subject (e.g., human) per week, e.g., 2, 3, or 4 administrations of the
CAR-T cells are
administered per week. In one embodiment, the subject receives more than one
administration of the CAR-T cells per week (e.g., 2, 3 or 4 administrations
per week)
(also referred to herein as a cycle), followed by a week of no CAR-T cell
administrations,
141
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
and then one or more additional administration of the CAR-T cells (e.g., more
than one
administration of the CAR-T cells per week) is administered to the subject. In
another
embodiment, the subject receives more than one cycle of CAR-T cells, and the
time
between each cycle is less than 10, 9, 8, 7, 6, 5, 4, or 3 days. In one
embodiment, the
CAR-T cells are administered every other day for 3 administrations per week.
In one
embodiment, the CAR-T cells are administered for at least two, three, four,
five, six,
seven, eight or more weeks.
In one embodiment, administration may be repeated after one day, two days,
three days,
four days, five days, six days, one week, two weeks, three weeks, one month,
five weeks,
six weeks, seven weeks, two months, three months, four months, five months,
six months
or longer. Repeated courses of treatment are also possible, as is chronic
administration.
The repeated administration may be at the same dose or at a different dose.
The CAR-T cells may be administered in the methods of the invention by
maintenance
therapy, such as, e.g., once a week for a period of 6 months or more.
In one embodiment, CAR-T cells are generated using lentiviral viral vectors,
such as
lentivirus. CAR-T cells generated with such viral vectors will generally have
stable CAR
expression.
In one embodiment, CAR-T cells transiently express CAR vectors for 4, 5, 6, 7,
8, 9, 10,
11, 12, 13, 14, 15 days after transduction. Transient expression of CARs can
be affected by
RNA CAR vector delivery. In one embodiment, the CAR RNA is transduced into the
T
cell by electroporation.
If a patient is at high risk of generating an anti-CAR antibody response
during the course
of transient CAR therapy (such as those generated by RNA transductions), CAR-T
infusion breaks should not last more than ten to fourteen days.
A CAR-expressing cell described herein may be used in combination with other
known
agents and therapies. Administered "in combination", as used herein, means
that two (or
more) different treatments are delivered to the subject during the course of
the subject's
treatment e.g., the two or more treatments are delivered after the subject has
been
diagnosed with the cancer and before the cancer has been cured or eliminated
or treatment
142
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
has ceased for other reasons. In some embodiments, the delivery of one
treatment is still
occurring when the delivery of the second begins, so that there is overlap in
terms of
administration. This is sometimes referred to herein as "simultaneous" or
"concurrent
delivery". In other embodiments, the delivery of one treatment ends before the
delivery of
the other treatment begins. In some embodiments of either case, the treatment
is more
effective because of combined administration. For example, the second
treatment is more
effective, e.g., an equivalent effect is seen with less of the second
treatment, or the second
treatment reduces symptoms to a greater extent, than would be seen if the
second treatment
were administered in the absence of the first treatment, or the analogous
situation is seen
with the first treatment. In some embodiments, delivery is such that the
reduction in a
symptom, or other parameter related to the disorder is greater than what would
be
observed with one treatment delivered in the absence of the other. The effect
of the two
treatments can be partially additive, wholly additive, or greater than
additive. The delivery
can be such that an effect of the first treatment delivered is still
detectable when the
second is delivered.
In one embodiment, other therapeutic agents such as factors may be
administered before,
after, or at the same time (simultaneous with) as the CAR-T cells, including,
but not
limited to, interleukins, as well as colony stimulating factors, such as G-, M-
and GM-CSF,
and interferons.
The CAR-expressing cell described herein and the at least one additional
therapeutic agent
can be administered simultaneously, in the same or in separate compositions,
or
sequentially. For sequential administration, the CAR-expressing cell described
herein can
be administered first, and the additional agent can be administered second, or
the order of
administration can be reversed.
In further embodiments, the CAR-expressing cells described herein may be used
in a
treatment regimen in combination with surgery, radiation, chemotherapy,
immunosuppressive agents, antibodies, or other immunoablative agents. In
another
embodiment, the CAR-expressing cell described herein can be used in
combination with
an anti-androgen treatment. In one embodiment, the subject can be administered
an agent
143
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
which enhances the activity of a CAR-expressing cell. For example, in one
embodiment,
the agent can be an agent which inhibits an inhibitory molecule.
A description of example embodiments follows.
1. A chimeric antigen receptor (CAR) comprising:
(a) an extracellular domain comprising an scFv that specifically binds to the
human
Kallikrein-2 (hK2) antigen,
(b) a transmembrane domain, and
(c) an intracellular signaling domain optionally comprising at least one co-
stimulatory domain.
2. The CAR of embodiment 1, further comprising
(d) a CD8a-hinge region,
wherein the transmembrane domain comprises a CD8a transmembrane region
(CD8a-TM) polypeptide; and
wherein the intracellular signaling domain comprises a co-stimulatory domain
comprising
a TNF receptor superfamily member 9 (CD137) component and a primary signaling
domain comprising a T-cell surface glycoprotein CD3 zeta chain (CD3z)
component.
3. The CAR of embodiment 2, wherein
(b) the CD8a-hinge region comprises an amino acid sequence that is at least
90% identical to SEQ ID NO: 25, 269, 270, 271, or 272;
(c) the transmembrane domain comprises an amino acid sequence that is
at least 90% identical to SEQ ID NO: 26; and/or
(d) the intracellular signaling domain comprises a co-stimulatory
domain having an amino acid sequence that is at least 90% identical to SEQ ID
NO: 27, and a primary signaling domain having an amino acid sequence that is
at least 90% identical to SEQ ID NO: 28.
4. A chimeric antigen receptor (CAR), comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
144
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 64, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 66;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 314, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 315, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 311;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 309, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 310, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 311;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 65, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 66; or
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 73, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 66;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 86, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 87, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 88;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 92, a heavy chain CDR2 having the amino acid
sequence
of SEQ ID NO: 93, and a heavy chain CDR3 having the amino acid sequence of SEQ
ID NO: 94
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid
145
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
sequence of SEQ ID NO: 103, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 104;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 106, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 104;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 107, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 108, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 109;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 110, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 111, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 109;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 112, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 113;
a heavy chain complementarity determining region 1 (CDR1) having the amino
.. acid sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 114, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 113;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 115, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 116, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 117;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 118, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 119, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 117;
146
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 120, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 121, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 122; or
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 123, a heavy chain CDR2 having the amino acid
sequence of SEQ ID NO: 124, and a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 122;
wherein the extracellular antigen-binding domain binds the hK2 antigen.
5. A chimeric antigen receptor (CAR), comprising an extracellular
antigen-binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, and a light chain CDR3 having the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid
sequence
.. of SEQ ID NO: 70, and a light chain CDR3 having the amino acid sequence of
SEQ ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 90, and a light chain CDR3 having the amino acid sequence of SEQ
ID
NO: 91;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 95, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 96, and a light chain CDR3 having the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 312, a light chain CDR2 having the amino acid
sequence
147
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
of SEQ ID NO: 313, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 haying the amino acid
sequence
.. of SEQ ID NO: 90, and a light chain CDR3 haying the amino acid sequence of
SEQ ID
NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 126, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 71;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 128, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 129, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 130;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 125, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 131, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 132;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 133, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 134, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 135;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 136, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 137, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 138; or
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 127, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 139,
wherein the extracellular antigen-binding domain binds the hK2 antigen.
148
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
6. The CAR according to embodiment 4, wherein the extracellular antigen-
binding
domain further comprises:
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 69, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 68, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 70, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 90, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 95, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 96, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 71;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 312, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 313, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 89, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 90, and a light chain CDR3 haying the amino acid sequence of SEQ
ID
NO: 91;
a light chain complementarity determining region 1 (CDR1) haying the amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 haying the amino acid
sequence
of SEQ ID NO: 126, and a light chain CDR3 haying the amino acid sequence of
SEQ
ID NO: 71;
149
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 128, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 129, and a light chain CDR3 having the amino acid sequence of
SEQ
ID NO: 130;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 125, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 131, and a light chain CDR3 having the amino acid sequence of
SEQ
ID NO: 132;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 133, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 134, and a light chain CDR3 having the amino acid sequence of
SEQ
ID NO: 135;
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 136, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 137, and a light chain CDR3 having the amino acid sequence of
SEQ
ID NO: 138; or
a light chain complementarity determining region 1 (CDR1) having the amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 127, and a light chain CDR3 having the amino acid sequence of
SEQ
ID NO: 139.
7. The CAR according to embodiment 6, wherein the extracellular antigen-
binding domain
comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 64, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
.. 71;
150
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
.. acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 70, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID
NO:
71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
66, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 314, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 315, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
151
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
311, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 312, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 313, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 91;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 103, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
104, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 128, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 129, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 130;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 107, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 108, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
109, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 125, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 131, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 132;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 112, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
113, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 133, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 134, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 135;
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 115, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 116, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
117, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 136, a light chain CDR2 having the amino acid
sequence
152
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
of SEQ ID NO: 137, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 138; or
a heavy chain complementarity determining region 1 (CDR1) having the amino
acid
sequence of SEQ ID NO: 120, a heavy chain CDR2 having the amino acid sequence
of
SEQ ID NO: 121, a heavy chain CDR3 having the amino acid sequence of SEQ ID
NO:
122, and a light chain complementarity determining region 1 (CDR1) having the
amino
acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid
sequence
of SEQ ID NO: 127, a light chain CDR3 having the amino acid sequence of SEQ ID
NO: 138.
8. The CAR according to embodiment 6, wherein the extracellular antigen-
binding
domain comprises: a heavy chain complementarity determining region 1 (CDR1)
having the amino acid sequence of SEQ ID NO: 86, a heavy chain CDR2 having the
amino acid sequence of SEQ ID NO: 87, a heavy chain CDR3 having the amino acid
sequence of SEQ ID NO: 88, and a light chain complementarity determining
region 1
(CDR1) having the amino acid sequence of SEQ ID NO: 89, a light chain CDR2
having
the amino acid sequence of SEQ ID NO: 90, a light chain CDR3 having the amino
acid
sequence of SEQ ID NO: 91.
9. A chimeric antigen receptor (CAR), comprising an extracellular antigen-
binding
domain, a transmembrane domain and an intracellular signaling domain, wherein
the
extracellular antigen-binding domain comprises:
a light chain variable domain (VL) comprising an amino acid sequence
selected from SEQ ID NOS: 1, 2, 3, 74, 75, 147, 148, 149, 150, 151, 152 and
318;
and/or
a heavy chain variable domain (VH) comprising an amino acid sequence
selected from SEQ ID NOS: 4, 5, 6, 76, 77, 140, 141, 142, 143, 144, 145, 146
and
317;
wherein the extracellular antigen-binding domain binds the human
Kallikrein-2 (hK2) antigen.
153
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
10. The CAR of embodiment 9, wherein the extracellular antigen-binding
domain
comprises:
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 1 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 2 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 2 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 1 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 2 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 5; or
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 1 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 5;
154
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 74 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 76;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 75 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 77;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 147 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 140;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 75 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 141;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 75 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 140;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 148 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 142;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 149 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 143;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 150 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 144;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 151 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 145;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 152 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 146;
155
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 318 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 317.
11. The CAR of any of embodiments 1-10, wherein the extracellular antigen-
binding domain comprises a single-chain variable fragment (scFv).
12. The CAR of embodiment 11, wherein the scFv comprises a linker
polypeptide
between the light chain variable region (VL) and the heavy chain variable
region (VH).
13. The CAR of embodiment 12, wherein the linker polypeptide comprises an
amino acid sequence of SEQ ID NO: 7.
14. The CAR of any of embodiments 11-12, wherein the scFv comprises an
amino
acid sequence selected from the group consisting of SEQ ID NOS: 8-23, 169-184
and
340-343.
15. The CAR of any of embodiments 1-14, wherein the extracellular antigen-
binding domain comprises a signal polypeptide.
16. The CAR of embodiment 15, wherein the signal polypeptide comprises an
amino
acid sequence of SEQ ID NO: 24.
17. The CAR of any of embodiments 4-16, wherein the intracellular signaling
domain
comprises a polypeptide component selected from the group consisting of a TNF
receptor
superfamily member 9 (CD137) component, a T-cell surface glycoprotein CD3 zeta
chain
(CD3z) component, a cluster of differentiation (CD27) component, a cluster of
differentiation superfamily member component, and a combination thereof.
18. The CAR of embodiment 17, wherein the CD137 component comprises an
amino
acid sequence of SEQ ID NO: 27.
156
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
19. The CAR of embodiment 17 or embodiment 18, wherein the CD3z
component
comprises an amino acid sequence of SEQ ID NO: 28.
20. The CAR of any one of embodiments 17-19, wherein the intracellular
signaling
domain comprises an amino acid sequence of SEQ ID NO: 45.
21. The CAR of any of embodiments 2-20, wherein the transmembrane domain
comprises a CD8a transmembrane region (CD8a-TM) polypeptide.
22. The CAR of embodiment 21, wherein the CD8a-TM polypeptide comprises
an amino acid sequence of SEQ ID NO: 26.
23. The CAR of any of embodiments 4-22, further comprising a hinge
region linking the transmembrane domain to the extracellular antigen-binding
domain.
24. The CAR of embodiment 23, wherein the hinge region is a CD8a-hinge
region.
25. The CAR of embodiment 24, wherein the CD8a-hinge region comprises an
amino
acid sequence of SEQ ID NO: 25, 279, 280, 281, or 282.
26. The CAR of any of embodiments 1-25, wherein the extracellular antigen-
binding domain comprises an amino acid sequence selected from the group
consisting
of SEQ ID NOS: 29-44, 78-81, 221-236, and 273-308.
27. The CAR of any of embodiments 1-26, wherein the CAR comprises an amino
acid sequence selected from the group consisting of SEQ ID NOS: 46-61, 82-85
and 205-
220.
28. An isolated lymphocyte expressing the CAR of any of claims 1-27.
157
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
29. The isolated lymphocyte of embodiment 28, wherein the lymphocyte is
a T
lymphocyte.
30. The isolated lymphocyte of embodiment 28, wherein the lymphocyte is a
natural killer (NK) cell.
31. An isolated nucleic acid molecule encoding the CAR of any of
embodiments 1-
30.
32. A vector comprising the nucleic acid molecule of embodiment 31.
33. A cell expressing the nucleic acid molecule of embodiment 31.
34. A pharmaceutical composition, comprising an effective amount of the
lymphocyte of any of embodiments 28-30.
35. A pharmaceutical composition, comprising an effective amount of the
lymphocyte of any of embodiments 28-30 and a pharmaceutically acceptable
excipient.
36. The CAR of any of embodiments 1-27 or the pharmaceutical composition of
embodiments 34 or 35 for use in therapy.
37. The CAR of any of embodiments 1-27 or the pharmaceutical composition of
embodiments 34 or 35 for use in a method of treating a subject having cancer.
38. A method of treating a subject having cancer, the method comprising:
administering a therapeutically effective amount of the lymphocyte of any of
embodiments 28-30 to a subject in need thereof, whereby the lymphocyte
induces killing of cancer cells in the subject.
158
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
39. The method of embodiment 38, or the CAR or the pharmaceutical
composition
for use in a method of embodiment 37, wherein the cancer is prostate cancer or
androgen receptor-expressing breast cancer.
40. The method of embodiment 38, or the CAR or the pharmaceutical
composition
for use in a method of embodiment 37, wherein the cancer is prostate cancer.
41. The method of embodiment 38, or the CAR or the pharmaceutical
composition
for use in a method of embodiment 37, wherein the cancer is androgen receptor-
expressing breast cancer.
42. A method of targeted killing of a cancer cell, the method comprising:
contacting the cancer cell with the lymphocyte of any of embodiments 28-
30,whereby
the lymphocyte induces killing of the cancer cell.
43. The method of embodiment 42, wherein the cancer cell is a prostate
cancer cell
or androgen receptor-expressing breast cancer cell.
44. A method of detecting the presence of cancer in a subject, comprising:
(c) contacting a cell sample obtained from the subject with the CAR of
any one of embodiments 1-27, thereby forming a CAR-cell complex, and
(d) detecting the complex, wherein detection of the complex is
indicative of the presence of cancer in the subject.
Preferably the embodiment is performed in vitro.
45. The CAR of embodiment 1, wherein the transmembrane domain comprises a
CD8a-TM polypeptide comprising an amino acid sequence of SEQ ID NO: 26.
46. The CAR of embodiment 2, wherein the transmembrane domain comprises a
CD8a-TM polypeptide comprising an amino acid sequence of SEQ ID NO: 26.
159
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
47. The CAR of embodiment 2 or 46, wherein the wherein the CD8a hinge
region
comprises an amino acid sequence of SEQ ID NO: 25.
48. The CAR of embodiment 2 or 47, wherein the CD137 component comprises an
amino acid sequence of SEQ ID NO: 27.
49. The CAR of embodiment 2, 47 or 48, wherein the CD3z component comprises
an
amino acid sequence of SEQ ID NO: 28.
50. The CAR of embodiment 3, wherein
(b) the CD8a-hinge region comprises an amino acid sequence that is at least
90, 91, 92, 93, 94, 95, 96, 97, 98 or 99 % identical to SEQ ID NO: 25, 269,
270,
271, or 272, preferably wherein the CD8a-hinge region comprises an amino acid
sequence
that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99 % identical to SEQ
ID NO: 25;
(c) the transmembrane domain comprises an amino acid sequence that is
at least 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO: 26;
and/or
(d) the intracellular signaling domain comprises a co-stimulatory
domain haying an amino acid sequence that is at least 90, 91, 92, 93, 94, 95,
96, 97, 98 or
99% identical to SEQ ID NO: 27, and a primary signaling domain haying an amino
acid
sequence that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical
to SEQ ID NO:
28.
51. The CAR of embodiment 3, wherein the CD8a hinge region comprises an
amino
acid sequence of SEQ ID NO: 25.
52. The CAR of embodiment 3, wherein the CD8a-TNI polypeptide comprises an
amino acid sequence of SEQ ID NO: 26.
53. The CAR of embodiment 3, wherein the CD137 component comprises an amino
acid sequence of SEQ ID NO: 27.
160
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
54. The CAR of embodiment 3õ wherein the CD3z component comprises an
amino
acid sequence of SEQ ID NO: 28.
55. The CAR of embodiment 3, wherein
(b) the CD8a-hinge region comprises the amino acid sequence of SEQ ID NO: 25;
(c) the transmembrane domain comprises the amino acid sequence of SEQ ID NO:
26; and
(d) the intracellular signaling domain comprises a co-stimulatory
domain comprising an amino acid sequence of SEQ ID NO: 27, and a primary
signaling
domain comprising an amino acid sequence of SEQ ID NO: 28.
56. The CAR of embodiments 45-55, wherein the extracellular antigen-
binding
domain comprises an amino acid sequence selected from the group consisting
of SEQ ID NOS: 29-44, 78-81, 221-236, and 273-308.
57. The CAR of any of embodiments 45-55, wherein the CAR comprises an
amino
acid sequence selected from the group consisting of SEQ ID NOS: 46-61, 82-85
and 205-220.
58. An isolated lymphocyte expressing the CAR of any of claims 45-55.
59. The isolated lymphocyte of embodiment 58, wherein the lymphocyte is
a T
lymphocyte.
60. The isolated lymphocyte of embodiment 58, wherein the lymphocyte is a
natural killer (NK) cell.
61. An isolated nucleic acid molecule encoding the CAR of any of
embodiments
45-55.
62. A vector comprising the nucleic acid molecule of embodiment 61.
161
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
63. A cell expressing the nucleic acid molecule of embodiment 61.
64. A pharmaceutical composition, comprising an effective amount of the
lymphocyte of any of embodiments 58-60.
65. A pharmaceutical composition, comprising an effective amount of the
lymphocyte of any of embodiments 58-60 and a pharmaceutically acceptable
excipient.
66. The CAR of any of embodiments 45-55 or the pharmaceutical composition
of
embodiments 64 or 65 for use in therapy.
67. The CAR of any of embodiments 45-55 or the pharmaceutical composition
of
embodiments 64 or 65 for use in a method of treating a subject having cancer.
68. A method of treating a subject having cancer, the method comprising:
administering a therapeutically effective amount of the lymphocyte of any of
embodiments 58-60 to a subject in need thereof, whereby the lymphocyte
induces killing of cancer cells in the subject.
69. The method of embodiment 68, or the CAR or the pharmaceutical
composition
for use in a method of embodiment 67, wherein the cancer is prostate cancer or
androgen receptor-expressing breast cancer.
70. The method of embodiment 68, or the CAR or the pharmaceutical
composition
for use in a method of embodiment 67, wherein the cancer is prostate cancer.
71. The method of embodiment 68, or the CAR or the pharmaceutical
composition
for use in a method of embodiment 67, wherein the cancer is androgen receptor-
expressing breast cancer.
162
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
72. A method of targeted killing of a cancer cell, the method
comprising:
contacting the cancer cell with the lymphocyte of any of embodiments 58-60,
whereby
the lymphocyte induces killing of the cancer cell.
73. The method of embodiment 72, wherein the cancer cell is a prostate
cancer cell
or androgen receptor-expressing breast cancer cell.
74. A method of detecting the presence of cancer in a subject,
comprising:
(a) contacting a cell sample obtained from the subject with the CAR of
any one of embodiments 45-55, thereby forming a CAR-cell complex, and
(b) detecting the complex, wherein detection of the complex is
indicative of the presence of cancer in the subject.
Preferably the embodiment is performed in vitro.
EXAMPLES
The following examples are provided to further describe some of the
embodiments
disclosed herein. The examples are intended to illustrate, not to limit, the
disclosed
embodiments.
Example 1: Construction and expression of hK2 scFv CARs with 11B6 scFv
hK2 CAR constructs comprising an scFv derived from the hK2-targeting antibody
11B6
were constructed as illustrated in Figure 1A. Dynabeads Human T-Expander
CD3/CD28
stimulated T cells were subjected to electroporation, then washed three times
with OPTI-
MEM (Invitrogen), and resuspended in OPTI-MEM at the final concentration of
50E6/ml.
Subsequently, 0.1 ml of the cells (5E6) was mixed with lOug of IVT CAR
encoding RNA
and electroporated in a 2-mm Gap cuvette (Harvard Apparatus BTX, Holliston,
MA, USA)
163
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
using BTX ECM830 (Harvard Apparatus BTX, Holliston, MA, USA) by pressing the
pulse" button one time. (Settings: 500 Volts, 750 [tsec Pulse Length and
single(1) pulse,
100m5ec interval.) Post electroporation, the T cells were transferred to a 6-
well plate and
immediately put back into a 37 C incubator. Primary human T cells were
electroporated
with no mRNA (MOCK) or 10[Ig of mRNA expressing either an hK2 scFy CAR or
irrelevant control CAR. 24 hours post-electroporation CAR surface expression
was
measured by flow cytometry following staining with 2 Kg/mlbiotinylated L-
protein and
streptavidin-conjugated PE (Figure 1B) or biotinylated hK2 (1 pg/m1) and
streptavidin-
conjugated PE (Figure 1C).
Twenty-four hours post electroporation, the T cells were counted. 1E5 T cells
were
collected for each. The cells were washed with FACS buffer twice using 200
[IL/well of
FACS buffer for microtiter plates, with the supernatant discarded. All wells
were stained
with 1000 staining buffer containing Protein L (Genscript, Cat. No.
M000971:500;2ug/m1), incubated for at least 30 minutes at 4 C while being
protected from
light. The cells were washed by adding FACS Buffer twice, using 150 [IL/well
for
microtiter plates with FACS buffer. Centrifugation at 400x g was performed for
4 minutes
at room temperature. The supernatant was then discarded. All wells were
stained with
1000 Streptavidin-R-Phycoerythrin (SA-PE;1:250) and Live/dead Fixable Near-IR
Dead
Cell Stain dye (1:1000), incubated for at least 30 minutes at 4 C while being
protected
from light. The cells were then ready for flow cytometry analysis.
As shown in Figure 1B, protein L staining was observed on both HK2 EL & LH
CARs
(41.4% and 66.3%, respectively), whereas only the background staining (-5.5%)
was seen
in the control T cells that were T cells without mRNA electroporation. As
shown in Figure
1C, CAR expression on primary human T cells also could be detected via J&J
internal
biotin-labeled recombinant HK2 protein (Biotin-Hk2 protein,Lot:20180810, CBIS
ID:KL2W12.CB.003, 2.4mg/ml, 1mM Benzamidine) followed by SA-PE. As shown, T
cells can efficiently express HK2 LH CAR (82.7%) as measured by flow
cytometry,
whereas only the background staining(-1.73% or 1.19%) was seen in the control
T cells
that were T cells without mRNA electroporation or undisclosed control CAR (non-
HK2
specific). Results are shown for representative donor T cells and were
reproducible in
164
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
multiple donors (at least n = 3). +Biotin label (EZ-LinkTM Sulfo-NHS-LC-
Biotin, Thermo
Fisher Scientific cat#:21327)
Example 2: Tumor cell ki11in2 by hK2 CAR-T cells
Co-culture for CellTrace Violet (CTV, Thermo Fisher Scientific Catalog
number: C34557) based cytotoxicity assay using flow cytometer was performed as
follows.
T cells were prepared as follows. Twenty-four hours post EP, T cells were
counted and
resuspended at the concentration needed for the most concentrated/desired E:T.
The T
cells were added at 100 p1/well of assay (2x106 cells/ml; plated 100p1 in a
10:1 E:T ratio,
i.e., 2E5 T cells per 2E4 target cells). A stock of the 10:1 E:T concentration
was made,
with two-fold serial dilutions made with complete T cell media (Optimizer
w/CTS, 5%
Human Serum, 1% GlutaMax) to 0.3125:1. The T cells were plated (1000/well) in
triplicate using a 96 well round bottom tissue culture treated plate.
CTV labeled target cells were prepared as follows. 20 [IL DMSO was added to a
vial of
CTV staining solution. This stock solution was diluted into 20 mL of PBS
(warmed to
37 C) for a 5 [IM staining solution. 10E6 tumor cells were collected, washed
with PBS
twice and resuspended in 4E6/m1 (2.5m1). An equal volume (2.5m1) of CTV
staining
solution was added. The cells were incubated for 20 minutes in a 37 C
incubator. 40
ml PRMI+20% FBS was added to the cells to absorb any unbound dye. The cells
were
incubated for 5 minutes. The cells were centrifuged for 5 minutes at 400 x g.
The cell
pellet was resuspended in pre-warmed RPMI+10%FBS medium. In the meantime, T
cells
were seeded at the desired E/T ratio described above. The tumor cell lines
Vcap (HK2+)
and DU145(HK2-) were recounted, and then the cells were resuspended in 2E5/m1
and
1001.11 in duplicate. The cells were co-incubated with labelled tumor cell
lines in a flat-
bottom 96-well plate.
A cytotoxicity assay was performed as follows using a flow cytometer. After 20
hours of
co-culture, all of the cells were transferred to a U-bottom 96-well plate and
washed. After
20 hours of co-culture all of the cells were collected from a flat-bottom 96-
well plate and
165
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
transferred to a U-bottom 96-well plate, and then washed. 30 pl of 0.25%
trypsin was
added to all the wells and incubated for 5 minutes in a 37 C incubator. After
5 minutes, all
of the tumor cells were collected to a U-bottom 96-well plate. The cells were
centrifuged
and washed for 5 minutes at 400 x g twice. The cell pellet was then
resuspended in diluted
(1:1000) LIVE/DEADTM Fixable Near-IR staining dye (100 pl). The cells were
incubated
for 30 mins at 4 C, and washed with FACS buffer twice by centrifuging the
cells for 5
minutes at 400 x g. After washing, all of the cells were fixed for 10 minutes
using 100 pl
of BD CytofixTM Fixation Buffer (500 FACS buffer +50p1Fixation Buffer). The
cells
were centrifuged and washed for 5 minutes at 400 x g once. The cell pellet was
resuspended in FACS buffer. Stained samples were analyzed by multicolor flow
cytometry after the end of the incubation period.
The percentage of cytotoxic activity was calculated using the following
equation:
% specific death = % Near IR+CTV+(dead) cells - % spontaneous Near IR
+CTV+ / (100% - % spontaneous Near IR +CTV+ (dead) cells) x 100%.
Twenty-four hours after transient transfection, target cells (Vcap and DU145)
were labeled
with Cell Trace Violet (CTV) fluorescent dye and then co-cultured with hK2 CAR-
T cells.
Mock T cells served as negative effector controls. Cells were co-cultured for
20 hours at
the indicated effector-to-target cell (E/T) ratio shown in Figure 2. Percent
killing is the
ratio of the absolute number of live (viability dye negative) target (CTV
positive) cells
remaining in the co-culture relative to the number of live targets cultured
without CAR-T
cells. As shown, hK2 CAR LH T cells specifically and efficiently lysed the
hK2(+) human
prostate cancer cell lines VCap cells, but not K2 (-) DU145 cells E/T ratios
of 10:1 to
0.3125:1, whereas only the background cytotoxicity was seen in the T cells
that were
Mock or hK2 HL CAR.
hK2-specific CAR-T cells were also tested for real-time cytotoxicity using
xCELLigence
as a real-time cell analysis system as a potency assay for immune cell-
mediated cytolysis
of target cells.
50 pL of target cancer cell culturing media was added to each well of the 96-
well E-Plates
(ACEA Biosciences), and the background impedance was measured and displayed as
a
166
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Cell Index. Then, adherent target cells VCap and DU145 were dissociated and
seeded at a
density of 5E4 (VCap), 5E3 (DU145) cells/well of the E-Plate in a volume of
100 pL, and
allowed to passively adhere on the electrode surface. Post seeding, the E-
Plate was kept at
ambient temperature inside a laminar flow hood for 30 minutes and then
transferred to the
RTCA MP instrument inside a cell culture incubator. Data recording was
initiated
immediately at 15-minute intervals for the entire duration (96 hours) of the
experiment.
At the time treatment was applied (24 hours post cancer cells seeding), data
acquisition
was paused, 50 uL of media was removed from each well, and effector CART cells
were
added at different effector to target (E:T) ratios in a volume of 50 pL. HK2
CAR+ and
undisclosed control CAR (non-HK2 specific) T cells were resuspended. Two-fold
dilutions were then performed in duplicate in a 96-well plate (from 5:1 to
0.156:1 E/T
ratio). Target plus Mock effector controls (no RNA electroporation T cells)
were also
added to the target cells.
Target cells VCap (5E4) and DU145 (5E3) incubated with Mock, 10p.g mRNA
electroporated (24 hours post transfection) hK2 11B6 CAR LH or control CAR-T
cells at
different E/T ratios for approximately 72 hours. Normalized cell index (CI)
plots for VCap
and DU145 are shown in Figure 3A and Figure 3B, respectively. When seeded
alone,
target cells adhere to the plate and proliferate, increasing the CI readout.
When T cells
were added to target cells, hK2 CAR- and control CAR-T cells cause cell
cytolysis and
subsequent progressive decrease in CI.
Example 3: Cytokine production of hK2 CAR-T cells
Without wishing to be bound by theory, IFN-y produced by cytotoxic T cells
could allow
for exertion of immune surveillance of tumors, which can directly inhibit
proliferation and
induce apoptosis of some malignancies in vivo and in vitro. To determine
whether hK2
CAR-modified human T cells were able to recognize and be activated by hK2 (+)
tumor
cells, the supernatant was collected from xCELLigence-based killing assay, as
described in
Example 2 and Figures 3A-3B. After about 70 hours co-culture, the supernatant
was
167
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
collected and assayed by ELISA according to the directions provided with the
ELISA kit
(Human IFN-y ELISA MAXTM Deluxe, BioLegend, Cat#:430106).
Thl cytokine interferon-y (IFN-y) production of antigen-stimulated CAR-T cells
is shown
in Figure 4. hK2 CAR LH- and control CAR modified T cells secrete IFN-y during
co-
culture with hK2-expressing VCap cells in a E:T ratio-dependent manner, but
not hK2-
negative DU145 cells. Undisclosed control CAR secreted much higher amount of
IFN-
due to the much higher antigen expression level than hK2. Mean IFN-y
concentration
SD (pg/ml) from duplicate cultures is shown.
Example 4: Generation and characterization of thermally stabilized scFvs CAR
constructs
The anti-HK2 antibody clone 11B6 was identified by immunization of BALB/c mice
with
recombinant HK2 by Vaisanen et al (Clinical Chemistry 50:9, 1607-1617 (2004).
Humanization of the murine-derived clone 11B6 was performed by the method
described in
Singh et al., MAbs. 2015;7(4):778-91. Because the exodomain of wild-type 11B6
as scFv
did not retain binding at elevated temperature (55 C), humanization was
performed as scFv
and the E. coli- expressed supernatants from the humanized variants were
incubated at 60
C for 15 minutes, followed by screening for binding to recombinant HK2 using
ELISA.
Ten hK2-targeting CARs containing a thermally stabilized scFv derived from the
antibody
11B6 were generated.
Description and SEQ ID NOS of the ten CAR constructs containing thermally
stabilized
scFvs are provided in Table 1.
Table 1. CAR constructs with 11B6 thermally stabilized scFvs
# of construct Description SEQ ID NO
1 III HCG5 LCD6 20AA 46
2 HLHCG5LCHumanized20AA 47
3 III HCF3 LCB7 20AA 48
4 EL HCG5 LCB7 20AA 49
168
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
LH LCD6 HCG5 20AA 50
6 LH LCHumanized HCF3 20AA 51
7 LH LCHumanized HCG5 20AA 52
8 LH LCB7 HCF3 20AA 53
9 LH LCB7 HCG5 20AA 54
LH LCD6 HCF3 20AA 55
To identify different scFv based CAR with antigen independent activation via
Jurkat-
LuciaTM NFAT Cells (JNLs). Nuclear factor of activated T-cells (NFAT) is a
family of
transcription factors first identified as a regulator of immune cells. T cell
activation leads
to calcium influx, activating calcineurin that dephosphorylates serine rich
nuclear
5 localization signal at the N-terminus of NFAT, leading to nuclear import
of NFAT.
Without wishing to be bound by theory, tonic signaling due to scFv clustering
could be
subsequently detected by Firefly luciferase driven by NFAT promoter in JNL
reporter cell
line.
JNL cells, i.e., Jurkat cells containing the luciferase gene driven by the
signaling-
10 responsive NFAT promoter, were transduced with the various CAR
constructs. Binding
between the CAR construct and its cognate cellular antigen (hK2 on target
cells) leads to
luciferase expression in the JNL cells.
Lentiviral transduction was performed as follows. JNL cells were harvested and
re-
suspended to 1E6/ml. 500 IA of JNL cells and lentiviral virus were added at a
MOI of 3,
and mixed by pipetting up and down. The mixture was incubate in a 37 C
incubator for 24
hours. 500 p1 JNL media was added to each well, with culturing continued in a
37 C
incubator. The cells were transferred to a T25 flask on day 4. At days 5-6,
transduction
validation was performed. 150 IA of cells was harvested to examine CAR
expression via
appropriate detection reagent for the specific CAR you are using (e.g. biotin-
hk2 Protein is
used to detect hk2 CAR). The JNL cells were maintained at 5x105/m1 until
enough cells
were obtained to either freeze down or use in the assay.
The thermally stabilized scFvs CARs were evaluated in a JNL reporter assay for
antigen-
dependent activity. Jurkat cells containing the luciferase gene driven by the
signaling-
169
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
responsive NFAT promoter (termed JNL cells) were transduced with the various
hK2 CAR
constructs. The assay was performed as follows. Coculturing with target cell
lines was
performed at an effector to target ratio of 2:1. The JNL cells were spun down
to remove
any secreted luciferase in the medium; the JNL cells were then resuspend in
fresh media at
4x105/ml. The cells were harvested. Then, both antigen-positive and antigen-
negative
target cell lines were prepared at 2E5/ml. 100 IA JNL was added to 100 IA
target cells.
For the JNL-only control, 100 IA media was added instead of target cells. For
positive
control, JNL cells only or CAR JNL cells were added to lx Cell Stimulation
Cocktail and
incubate in a 37 C incubator for 24 hours. 150 IA of the supernatant was
harvested into a
96-well plate and centrifuged to remove cells. 100 IA of supernatant was
transferred from
the plate to a solid bottom black plate. Then, 100 IA QUANTI-luc lucia
detection reagent
was added. The mixture was incubated at room temperature for 5 minutes before
reading
with Envision multiplate reader.
CAR expression was determined by biotinylated hK2 followed by streptavidin-
conjugated
PE, with the results shown in Figure 5A. CAR expression in transduced JNL
cells was
confirmed for all of the selected clones with 60-75% of cells showing
detectable
expression across the different clones and parental 11B6 CARs. JNL cells
containing the
indicated CAR clones and un-transduced JNL cells (UTD) were co-cultured with
target
cells lines (VCap or DU145 cells) and luciferase activity was measured as
luminescence
intensity. Clones were considered active when the luminescence intensity
exceeded 1.5-
fold the level of UTD cells in the presence of antigen-expressing cells.
The binding between the CAR construct and its cognate cellular antigen (hK2 on
target
cells) leads to luciferase expression in the JNL cells (Figure 5B). JNL cells
containing the
indicated CAR clones and JNL cells (untransduced, hereinafter "UTD") were co-
cultured
with target cells lines (VCap or DU145 cells) and luciferase activity was
measured as
luminescence intensity. Clones were considered active when the luminescence
intensity
exceeded 1.5-fold the level of UTD cells in the presence of antigen-expressing
cells. No
antigen-dependent activation was found for all the 10 clones and parental 11B6
CAR HL
and LH.
170
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Example 5: Expression of thermally stabilized scFvs CARs on T cells
To evaluate the function of thermally stabilized 11B6 CARs T cells and pick
top candidate
construct, 11B6 thermally stabilized and parental scEvs based CAR T cells were
generated using lentiviral transduction. Primary human T cells were transduced
with
11B6 thermally stabilized and parental scEvs based CAR lentivirus with a
multiplicity of
infection (MOI) of 3. CAR expression was determined by biotinylated hK2 (1
g/m1)
followed by streptavidin-conjugated PE 14 days post transduction.
The experimental protocol is as follows.
Lentiviral packaging was undertaken. 14E6 LentiXTM 293T cells were seeded per
150
mm2 round-bottomed CorningTM BioCoatTM Collagen I coated culture dish, and
incubated
at 37 C overnight using DMEM+10% FBS medium.
With LentiXTM 293T cells at the ideal confluency of 80-85%, the following was
prepared.
Culture media was replaced with 21m1 293T growth media. Lipofectamine 2000 was
diluted at room temperature and equilibrated OptiMEM. Diluted Lipofectamine
2000 was
added to mixed plasmids drop-wise, and mixed well. The mixture was incubated
at room
temperature for 25 minutes. The transfection mixture was added to Lenti-X 293T
cells
dropwise, with the plate gently swirled to mix. The mixture was incubated in a
37 C
incubator. Lentivirus was harvested 24 and 48 hours post transfection. The
above
reagents are summarized in the Table 2.
Table 2
Reagent Amount per 15cm
dish
pMDLg/p 18 pg
pRSV.Rev 18 pg
pMD2.G 7 pg
Transfer (CAR) plasmid 15 pg
171
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
OptiMEM 15000
Lentiviral concentration was performed as follows. Lentivirus-containing
supernatants
were harvested and centrifuged at 500 x g for 10 min if excessive 293T cells
are floating
around before filtering through 0.45 p.m cellulose acetate filters.
Supernatant was
transferred to a sterile container, combined with 1/3 volume of Lenti-X
Concentrator
(Clontech, Cat. # 631232), and mixed by gentle inversion. The mixture was
incubated at
4 C overnight. The sample was centrifuged at 1,500 x g for 45 minutes at 4 C,
with a
white pellet visible after centrifugation. The supernatant was carefully
removed without
disturbing the pellet. Residual supernatants were removed with a pipette after
a brief
centrifugation at 1,500 x g. The pellet was gently resuspended in 1/10 of the
original
volume using cold T cell growth. The virus was aliquoted in 200 pl and
immediately
stored at ¨80 C.
Viral titering was performed as follows. Log-phase SupT1 was grown in complete
RPMI.
100 pl 20,000 SupT1 cells/ml were seeded per well in a flat 96-well plate.
Virus titration
.. was then performed in 96-well round bottom plates). 100 pl media was added
to all the
wells in the plate. A virus aliquot was thawed from -80 C freezer with one's
hands. The
aliquot was pipetted up and down to mix well, with 50 pl virus added to the
first well,
followed by thorough mixing. A serial 1:3 dilution was performed by pipetting
50 pl virus
to the next well. Then, 50 pl media was added to primary Ab only, secondary Ab
only,
and un-transduced controls. 50 pl of each was transferred from the titration
plate to 100 pl
SupT1 cells in the assay plate with a multi-channel pipette, and incubated at
37 C
overnight. 100 pl of pre-warmed media was added to each sample, and incubated
another
two days. The transduction efficiency was determined by flow cytometry.
Samples were
transferred to a round bottom 96 well plate and spun at 1400 RPM for 3
minutes. The
supernatant was discarded quickly, followed by blotting to remove excessive
media in the
hood. The wash was repeated with 150 pl FACS buffer. A staining protocol
appropriate
for CAR constructs was then undertaken. Samples were resuspended in 150 pl
FACS
buffer before flow cytometry analysis.
172
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Viral titer calculation: Titer = (% CAR positive/100) x 2x104 x 20 x dilution
factor
To exclude multiple copy integrations, titers with the closest transduction to
20% is used.
T-cell activation, transduction and expansion was performed as follows. A vial
of naïve T
cells was thawed in a water bath and added drop-wise to a 15 ml conical tube
containing 9
ml of pre-warmed T-cell media (TCM CTS OpTmizer T Cell Expansion SFM+5% human
serum +IL-2 100IU/m1). The cryovial was washed with 1 ml of media to recover
maximum number, and spun at 300 x g for 8 minutes at room temperature. The
pellet was
resuspended in fresh 10 ml TCM, counted, and resuspended to 1E6 cells per
milliner. 5E5
cells were added per well in 24-well plate. 1.5x106 CD3/CD28 beads were added
per well
in 500 pl volume such that the total volume was 1 ml per well. Twenty-four
hours post
activation, virus was thawed at room temperature. Virus was added at a
multiplicity of
infection (MOI) of 3, gently swirled to mix, and returned to the plate at the
incubator.
(The lentiviral functional titer was previously determined with SupT1 titer
assay.) One
well was reserved for Untransduced (UTD) in which is no virus added.
Twenty four hours post-transduction, 1 ml TCM was added to each well.
Penicillin-
Streptomycin was added from this point onward (Day 2). On days 3-5, 4 ml TCM
was
added for each 2 ml of cells and transferred to a T25 tissue culture treated
flask. The flasks
were placed horizontally in the incubator (Day 3). Equal volume of TCM was
added for T-
cell culture (Day 4). On days 5-14, the cells were checked every other day,
with the
viability, size and total cell count recorded. The cell density was adjusted
to one million
cells per mL. The ideal time of harvest is donor dependent and determined by
the cell size
and the fold of expansion. Cells were generally frozen when the cell size was
less than 8
p.m based on the MOXI flow cell counter with the 100 to 200-fold of expansion.
Lentiviral transduction efficiency was checked on harvest day as follows.
Cultures were
mixed well. 100 pl of T-cells was harvested to a corresponding well in 96-well
plate with
100 pl FACS Buffer, mixed, and spun at 1300 RPM for 3 minutes at room
temperature.
The cells were resuspended in 200 pl FACS buffer and centrifugation repeated
at 4 C.
173
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
The cells were resuspended in 100 p1 of Biotin labeled hK2 (1 pg/m1 diluted in
FACS
buffer) and incubated on ice for 30 minutes. 100 IA of FACS buffer was added,
and spun
washed at 4 C. The spin wash was repeated after adding another 200 pi FACS
buffer.
Staining with 100 pi of master solution containing secondary antibody SA-PE
(1:250), live
dead fixable stain (1:500), aCD3, aCD4 and aCD8 antibodies was performed on
ice for 30
minutes. 100 pi FACS buffer was added and spun wash at 4 C, discarded and re-
suspended in 200 pi FACS buffer before spin washing at 4 C. The samples were
resuspended in 100 pi FACS Buffer before analyzing by flow cytometry.
Cell harvest and freezing was performed as follows. The final cell count was
determined.
The culture was harvested and centrifuged at 300 x g for 10 minutes at room
temperature.
The culture was resuspended in a smaller volume of media to fit in a 50 ml
conical tube.
The tubes were placed in magnets at 4 C for 10 minutes to "de-bead". The cells
were
gently transferred from the tube to minimize disturbing the beads / magnet,
and the exact
volume recorded. Counting was repeated. Centrifugation was performed at 300 x
g for 10
minutes, with the supernatant discarded. Cells were frozen in CS-10 CryoStor
cell
cryopreservation media in a cooling container. The containers were immediately
transferred to -80 C for 24-48 hours before permanent storage in liquid
Nitrogen. The
results are shown in Figure 6, and confirm hK2 CAR expression on the surface
of the
transduced T cells. Summary of the percentage of hK2 CAR + T cells (%
positive)
detected by each of the 10 thermally stabilized clones and parental 11B6 HL &
LH
analyzed is provided. As shown, different clones have different CAR expression
level,
ranges from 17.9% to 42.7%. All CAR T cells were normalized to the equal CAR+
T cells
for subsequent functional assays.
Example 6: Tumor cell killing by 11B6 thermally stabilized scFy CAR-T cells
11B6 thermally stabilized scFv CAR-T cells were evaluated in the real-time
IncuCyte
killing assay for antigen-dependent cytotoxicity. Thermally stabilized hK2 CAR-
T cells
and parental 11B6 CAR-T cells were co-incubated with VCaP cells (Figure 7A)
and PC3
cells (Figure 7B) for 88 hours. Effector-to-target (E/T) ratio was calculated
based on CAR
174
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
expression data (Figure 6). Target cells were stably expressing a red nuclear
dye which
was measured by IncuCyte imaging system in a real-time fashion. Tumor cell
growth
inhibition (%) =(Initial Viable Target Cell Number-Current Viable Target Cell
Number)/Initial Viable Cell Number*100 (%).
scFv CAR-T cells also were evaluated in the real-time IncuCyte tumor killing
assay for
antigen-dependent cytotoxicity. Thermally stabilized hK2 CAR-T cells and
parental 11B6
CAR-T cells were co-incubated with VCaP cells (Figure 7C) or PC3 cells (Figure
7D) for
88 hours at effector:target ratio of 1:1 or 0.5:1 which was calculated based
on CAR
expression data. CAR-T cells transduced with CAR17, CAR18, CAR19 and CAR20
were
co-incubated with hK2 positive VCaP cells and hK2 negative DU145 cells for 96
hours at
effector-to-target (ET) ratio of 1:1 or 0.5:1 which was calculated based on
CAR expression
on T cells. The percent tumor cell growth inhibition over time of CAR-T cells
transduced
with CAR17, CAR18, CAR19 and CAR20 is shown in Figure 7E for VCap cells and in
Figure 7F for DU145 cells. Target cells were stably expressing a red nuclear
dye which
.. was measured by IncuCyte imaging system in a real-time fashion. Tumor cell
growth
inhibition (%) =(Initial Viable Target Cell Number-Current Viable Target Cell
Number)/Initial Viable Cell Number*100 (%). Tested CAR-T cells achieved
approximately 100% TGI whereas the untransduced control did not demonstrate
any TGI.
No TGI was observed with the tested CAR-T cells in hK2 negative DU145 cells.
Example 7: Cytokine production of 11B6 thermally stabilized scFy CAR-T cells
Supernatant was collected from overnight (approximately 20 hours) co-culture
of hK2
CAR-T cells with VCap cells at 1:1 of E/T ratio and was analyzed using 13-plex
Milliplex
Human High Sensitivity T cell kit (HSTCMAG28SPMX13). hK2 CAR modified T cells
secrete cytokines during co-culture with hK2-expressing VCap cells, but
minimal for un-
transduced T cells (UTD). The results of cytokine release by hK2 lenti-CAR-T
cells are
shown in Figure 8.
Supernatant was collected from overnight (approximately 20 hours) co-culture
of hK2
CAR-T cells with VCap, DU145 (5E4 cells) cells at 1:1 of E/T ratio. hK2 CAR
modified T
175
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
cells secrete IFN-y during co-culture with hK2-expressing VCap cells, but not
hK2-
negative DU145 cells. CD3/28 beads stimulated T cells and T cells only were
used as
positive and negative controls, respectively. IFN-y release by hK2 lenti-CAR-T
cells is
shown in Figure 9. (The protocol of Example 3 was used.) Mean IFN-y
concentration
SD (pg/ml) from duplicate cultures is shown. CD3/28 beads stimulated T cells
and T cells
only were used as positive and negative controls, respectively. As shown,
different
thermally stabilized CAR T cells produce different amount of IFN-gamma when co-
culture
with hK2 (+) VCap cells, which is associated with cytotoxic activity during
cell-mediated
immune response.
Example 8: Proliferation of hK2 CAR-T cells
hK2 CAR-T cells were evaluated in a proliferation assay. T-cell proliferation
is an
important in vitro parameter of in vivo immune function. To further evaluate
the function
of thermally stabilized 11B6 CARs T cells and pick top candidate construct,
11B6
thermally stabilized and parental scFvs based CAR T cells were labeled with
CTV to
assess T cell proliferation.
hK2 CAR and un-transduced (UTD) T cells were labelled with CellTrace Violet
(CTV;
5[IM) and co-cultured with hK2 (+) VCap and hK2 (-) DU145 cells. Five days
post co-
culture, cells were harvested and stained with CD3, CD25, NearIR live/dead Dye
and hK2
CAR. Flow cytometric analysis was performed on a Fortessa flow cytometer with
Flowjo
software. Lymphocytes were identified by live CD3, and the frequencies of CAR-
T cells
with CTV dye dilution and activation marker CD25 were determined. By gating on
hK2
CAR+ T cells, as shown, the hK2(+) Vcap cells but not hK2(-) DU145 cells
promoted the
all CAR constructs engineered T cells proliferation and upregulation of
activation marker
CD25 (Figures 10A, 10C). CD3/28 beads stimulated T cells and T cells only were
used as
positive and negative controls, respectively. T cells only without any
stimulation do not
proliferate and CD3/28 beads stimulated T cells displayed equivalent
proliferation pattern
(Figures 10B, 10D). As shown in Figure 10E, hK2 CAR+ T cells proliferate more
robustly than CD3/28 beads positive control after 5 days of coculture with
VCap cells.
176
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Different CAR constructs engineered T cells have different proliferation
activity and
displayed different CAR+ T cells counts. The CAR+ T cells counts based on mean
absolute cell count +/- SEM from three technical replicates.
The protocol is as follows. The tumor cells Vcap and DU145 were collected,
washed twice
with PBS, and resuspended in 10E6/m1 in PBS containing 100ug/m1Mitomycin C
(MMC)
for 1.5 hours in a 37 C incubator so as to block tumor cells proliferation. 20
L of DMSO
was added to a vial of CTV staining solution. 5 1 of the solution was diluted
into 5mL
(1:1000) PBS (warmed to 37 C) to provide a 5 M staining solution. The 2E6 T
cells
were counted, collected, washed with PBS twice, and resuspended in 4E6/m1
(0.5m1). An
equal volume (0.5 ml) of CTV staining solution was added. The cells were
incubated for
minutes at 37 C. Then, 4 ml PRIVII+20% FBS was added to the cells to absorb
any
unbound dye. The cells were incubated for 5 minutes, and centrifuged for 5
minutes at 400
x g. The cell pellet was resuspended in pre-warmed RPMI+10%FBS medium. The T
cells
were counted, and 1E5 cells(100p1) were seeded in 96-wells flat bottom-plate.
15 In the meantime, MMC-treated tumor cells hK2(+) VCap and EIK2(-) DU145
were
collected and counted after 1.5 hours, and then resuspended at 1E6/ml. 1E5 of
the cells
(100 p1) were cocultured with T cells in a 96-well plate. T cells alone, and T
cells added
3:1 CD3/28 beads to cells ratio, were used as negative and positive controls,
respectively.
After 5 days of co-culture, all of the cells were collected from each well.
The cells were
20 centrifuged and washed for 5 minutes at 400 x g twice, then stained
hK2CAR, CD3, CD8
and CD25, live/dead (Near-IR) in 96-well U bottom plate. After washing, all
cells were
fixed for 10 minutes using 100 p1 BD CytofixTM Fixation Buffer (50p1 FACS
buffer
+50p1Fixation Buffer). The stained samples were analyzed by multicolor flow
cytometry
after the end of the incubation period.
Data analysis was performed as follows. A CTV histogram was prepared. The CTV
undiluted gate was set to encompass the far-right peak (CTV bright) of T cells
cultured
alone, and the CTV diluted gate to capture the rest of the population. This
was applied to
all samples.
177
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Example 9: Construction and expression of hK2 scFv CARs with anti-HK2 scFv
hK2 CAR constructs comprising an scFv derived from the novel anti-HK2 scFv
were
constructed as illustrated in Figure 11A.
To evaluate the function of these novel anti-HK2 scFv CARs T cells and to pick
a top
candidate construct, hK2 HL and \ LH CAR-T cells were generated using
lentiviral
transduction. Primary human T cells were transduced with hK2 CAR HL and LH,
novel
scFvs based CAR lentivirus with a multiplicity of infection (MOI) of 3. CAR
expression
was determined by biotinylated hK2 (1ng/m1) followed by streptavidin-
conjugated PE 14
days post transduction.
The experimental protocol is as follows.
Lentiviral packaging was undertaken. 14E6 LentiXTM 293T cells were seeded per
150
mm2 round-bottomed CorningTM BioCoatTM Collagen I coated culture dish, and
incubated
at 37 C overnight using DMEM+10% FBS medium.
With LentiXTM 293T cells at the ideal confluency of 80-85%, the following was
prepared.
Culture media was replaced with 21m1 293T growth media. Lipofectamine 2000 was
diluted at room temperature and equilibrated OptiMEM. Diluted Lipofectamine
2000 was
added to mixed plasmids drop-wise, and mixed well. The mixture was incubated
at room
temperature for 25 minutes. The transfection mixture was added to Lenti-X 293T
cells
dropwise, with the plate gently swirled to mix. The mixture was incubated in a
37 C
incubator. Lentivirus was harvested 24 and 48 hours post transfection. The
above
reagents are summarized in the Table 3.
Table 3
Reagent Amount per 15cm
dish
pMDLg/p 18 Kg
pRSV.Rev 18 Kg
178
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
pMD2.G 7 p.g
Transfer (CAR) plasmid 15 Kg
OptiMEM 15000
Lentiviral concentration was performed as follows. Lentivirus-containing
supernatants
were harvested and centrifuged at 500 x g for 10 min if excessive 293T cells
are floating
around before filtering through 0.45 p.m cellulose acetate filters.
Supernatant was
transferred to a sterile container, combined with 1/3 volume of Lenti-X
Concentrator
(Clontech, Cat. # 631232), and mixed by gentle inversion. The mixture was
incubated at
4 C overnight. The sample was centrifuged at 1,500 x g for 45 minutes at 4 C,
with a
white pellet visible after centrifugation. The supernatant was carefully
removed without
disturbing the pellet. Residual supernatants were removed with a pipette after
a brief
centrifugation at 1,500 x g. The pellet was gently resuspended in 1/10 of the
original
volume using cold T cell growth. The virus was aliquoted in 200 pl and
immediately
stored at ¨80 C.
Viral titering was performed as follows. Log-phase SupT1 was grown in complete
RPMI.
100 pl 20,000 SupT1 cells/ml were seeded per well in a flat 96-well plate.
Virus titration
was then performed in 96-well round bottom plates). 100 pl media was added to
all the
wells in the plate. A virus aliquot was thawed from -80 C freezer with one's
hands. The
aliquot was pipetted up and down to mix well, with 50 pl virus added to the
first well,
followed by thorough mixing. A serial 1:3 dilution was performed by pipetting
50 pl virus
to the next well. Then, 50 pl media was added to primary Ab only, secondary Ab
only,
and un-transduced controls. 50 pl of each was transferred from the titration
plate to 100 pl
SupT1 cells in the assay plate with a multi-channel pipette, and incubated at
37 C
overnight. 100 pl of pre-warmed media was added to each sample, and incubated
another
two days. The transduction efficiency was determined by flow cytometry.
Samples were
transferred to a round bottom 96 well plate and spun at 1400 RPM for 3
minutes. The
supernatant was discarded quickly, followed by blotting to remove excessive
media in the
hood. The wash was repeated with 150 pl FACS buffer. A staining protocol
appropriate
179
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
for CAR constructs was then undertaken. Samples were resuspended in 150 pl
FACS
buffer before flow cytometry analysis.
Viral titer calculation: Titer = (% CAR positive/100) x 2x104 x 20 x dilution
factor
To exclude multiple copy integrations, titers with the closest transduction to
20% is used.
T-cell activation, transduction and expansion was performed as follows. A vial
of naïve T
cells was thawed in a water bath and added drop-wise to a 15 ml conical tube
containing 9
ml of pre-warmed T-cell media (TCM CTS OpTmizer T Cell Expansion SFM+5% human
serum +IL-2 100IU/m1). The cryovial was washed with 1 ml of media to recover
maximum number, and spun at 300 x g for 8 minutes at room temperature. The
pellet was
resuspended in fresh 10 ml TCM, counted, and resuspended to 1E6 cells per
milliner. 5E5
cells were added per well in 24-well plate. 1.5x106 CD3/CD28 beads were added
per well
in 500 pl volume such that the total volume was 1 ml per well. Twenty-four
hours post
activation, virus was thawed at room temperature. Virus was added at a
multiplicity of
infection (MOI) of 3, gently swirled to mix, and returned to the plate at the
incubator.
(The lentiviral functional titer was previously determined with SupT1 titer
assay.) One
well was reserved for Untransduced (UTD) in which is no virus added.
Twenty four hours post-transduction, 1 ml TCM was added to each well.
Penicillin-
Streptomycin was added from this point onward (Day 2). On days 3-5, 4 ml TCM
was
added for each 2 ml of cells and transferred to a T25 tissue culture treated
flask. The flasks
were placed horizontally in the incubator (Day 3). Equal volume of TCM was
added for T-
cell culture (Day 4). On days 5-14, the cells were checked every other day,
with the
viability, size and total cell count recorded. The cell density was adjusted
to one million
cells per mL. The ideal time of harvest is donor dependent and determined by
the cell size
and the fold of expansion. Cells were generally frozen when the cell size was
less than 8
p.m based on the MOXI flow cell counter with the 100 to 200-fold of expansion.
Lentiviral transduction efficiency was checked on harvest day as follows.
Cultures were
mixed well. 100 pl of T-cells was harvested to a corresponding well in 96-well
plate with
100 pl FACS Buffer, mixed, and spun at 1300 RPM for 3 minutes at room
temperature.
The cells were resuspended in 200 pl FACS buffer and centrifugation repeated
at 4 C.
180
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
The cells were resuspended in 100 p1 of Biotin labeled hK2 (1 pg/m1 diluted in
FACS
buffer) and incubated on ice for 30 minutes. 100 p.1 of FACS buffer was added,
and spun
washed at 4 C. The spin wash was repeated after adding another 200 pi FACS
buffer.
Staining with 100 pi of master solution containing secondary antibody SA-PE
(1:250), live
dead fixable stain (1:500), aCD3, aCD4 and aCD8 antibodies was performed on
ice for 30
minutes. 100 pi FACS buffer was added and spun wash at 4 C, discarded and re-
suspended in 200 pi FACS buffer before spin washing at 4 C. The samples were
resuspended in 100 pi FACS Buffer before analyzing by flow cytometry.
Cell harvest and freezing was performed as follows. The final cell count was
determined.
The culture was harvested and centrifuged at 300 x g for 10 minutes at room
temperature.
The culture was resuspended in a smaller volume of media to fit in a 50 ml
conical tube.
The tubes were placed in magnets at 4 C for 10 minutes to "de-bead". The cells
were
gently transferred from the tube to minimize disturbing the beads / magnet,
and the exact
volume recorded. Counting was repeated. Centrifugation was performed at 300 x
g for 10
minutes, with the supernatant discarded. Cells were frozen in CS-10 CryoStor
cell
cryopreservation media in a cooling container. The containers were immediately
transferred to -80 C for 24-48 hours before permanent storage in liquid
Nitrogen. The
results are shown in Figure 11B, and confirm hK2 CAR expression on the surface
of the
transduced T cells. A summary of the percentage of hK2 CAR + T cells (%
positive)
detected by novel KL2B413 HL&LH and rehumanized 11B6 KL2B359 HL&LH CARS
analyzed is provided. As shown, different clones have different CAR expression
level,
ranges from 45.1% to 59.9%. All CAR T cells were normalized to the equal CAR+
T cells
for subsequent functional assays.
.. Example 10: Generation of anti-hK2 antibodies and scFvs
Antibody generation from humanization of parental m11B6 antibody.
A parental mouse anti-HK2 antibody, ml 1B6 has been described in Vaisanen et
al
(Clinical Chemistry 50:9, 1607-1617 (2004)). Humanized 11B6 (referred herein
to as
181
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
hullB6) has been generated and described in U.S. Pat. No. 9,345,782 and U.S.
Pat. No.
10,100,125.
Engineering of hul 1B6 were initiated to generate additional anti-HK2
antibodies with
improved properties, such as improved thermostability. Residue positions were
identified
in hull B6 frameworks which could potentially be altered to improve
thermostability of
hullB6 using modeling. The positions identified were residues P41, 149, M70,
and A88 in
the VH and S80, L82, A88 and Y91 in the VL (residue numbering according to the
amino
acid sequences of hullB6 VH of SEQ ID NO: 5 and hullB6 VL of SEQ ID NO: 2).
Binary combinatorial scFv libraries were generated in the orientation VH-
linker-VL in
which one of the variable regions represented the combinatorial library and
the second one
being the parental hullB6 VH or VL. Linker sequence of
GGSEGKSSGSGSESKSTGGS (SEQ ID NO: 7) was used to conjugate the VH/VL
regions. The engineered scFvs were expressed in E coh and the produced scFvs
in the
supernatants were tested for binding to human hK2 by ELISA and compared to the
binding
of hullB6. Any new variants exhibiting binding comparable to hullB6 were
consolidated
and further tested for binding to human hK2 after incubation of the
supernatants at 55 C,
60 C, and 65 C for 10 minutes. The molecules which retained comparable binding
to
hullB6 after incubation at 55 C, 60 C, and 65 C and improved thermostability
were
matrixed in both orientations (VH-linker-VL; VL-linker-VH) and converted to
mammalian
scFvs for further characterization. The matrixed scFvs were also incorporated
into CAR
constructs and further characterized as further described in Example 11.
In addition, another humanization of parental mouse 11B6 was performed
following the
approach outlined by Singh et al (MAbs. 2015;7(4):778-91). with extensive germ
line
variation and careful screening of the variants for enhanced thermal
stability. Based on
sequence conservation, the human heavy chain germline IGHV4-30 and the light
chain
germline IGKV3D-11, were chosen for framework adaption. A binary scFv library
was
constructed with residues comprising a select set of somatic hypermutation
sites and
mouse/human germline variations. The variants were cloned and expressed in E.
coli as
described above. The supernatants were screened at different temperatures in
single point
ELISA for enhanced thermal stability. A mouse/human chimeric 11B6 scFv was
used as
182
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
parental control. Clone KL2B359 which maintained binding activity similar to
murine
11B6 and a Tm value of 67 C was converted to scFv-Fc and CAR-T for additional
profiling. The measured affinity (KD) of KL2B359 to hK2 by SPR was ¨0.7 ¨ 1nM.
HCF3-LCD6, HCG5-LCB7, KL2B357, KL2B358 and KL2B360 also resulted from this
campaign and were further characterized for functionality.
Antibody generation using transgenic mice (Ablexis ) and transgenic rats
(OmniRat ) expressing human immunoglobulin loci.
The OmniRat contains a chimeric human/rat IgH locus (comprising 22 human VHS,
all
human D and JH segments in natural configuration linked to the rat CH locus)
together with
fully human IgL loci (12 Vics linked to Jic-Cx and 16 Vks linked to J2-C2).
(see
e.g., Osborn, et al. (2013) J Immunol 190(4): 1481-1490). Accordingly, the
rats exhibit
reduced expression of rat immunoglobulin, and in response to immunization, the
introduced human heavy and light chain transgenes undergo class switching and
somatic
mutation to generate high affinity chimeric human/rat IgG monoclonal
antibodies with
fully human variable regions. The preparation and use of OmniRat , and the
genomic
modifications carried by such rats, is described in W014/093908.
Ablexis mice generate antibodies having human variable domains linked to
human CH1
and CL domains, chimeric human/mouse hinge region, and mouse Fc regions.
Ablexis
Kappa Mouse and Lambda Mouse strains are distinguished by which of their heavy
chains
are human or mouse as noted below. Antibodies produced by the Kappa Mouse lack
sequence derived from mouse Vii, DH and JH exons and mouse Vic, Jic and Cx
exons. The
endogenous mouse Igk is active in the Kappa Mouse. The human Igx chains
comprise
approximately 90-95% of the naive repertoire and mouse Igk chains comprise
approximately 5-10% of the naive repertoire in this strain. Antibodies
produced by the
Lambda Mouse lack sequence derived from mouse Vii, DH and JH exons and mouse
Vk,
and Ck exons. The endogenous mouse Igx is active in the Lambda Mouse. The
human Igk
chains comprise approximately 40% of the naive repertoire and mouse Igx chains
comprise
approximately 60% of the naive repertoire. The preparation and use of Ablexis
, and the
genomic modifications carried by such mice, is described in W011/123708.
183
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Ablexis mice and OmniRats rats were immunized with soluble full length KLK2
protein
(human Kallikrein-2 6-His protein).
human Kallikrein-2 6-His protein
VPLIEGRIVGGWECEKHSQPWQVAVYSHGWAHCGGVLVEIPQWVLTAAHCLKKN
SQVWLGRHNLFEPEDTGQRVPVSHSFPHPLYNMSLLKHQSLRPDEDSSEIDLMLLR
LSEPAKITDVVKVLGLPTQEPALGTTCYASGWGSIEPEEFLRPRSLQCVSLHYSEKV
TEFMLCAGLWTGGKDTCGGDSGGPLVCNGVLQGITSWGPEPCALPEKPAVYTKV
VHYRKWIKDTIAANPHREIHHH (SEQ ID NO: 319)
Lymphocytes from Ablexis mice and OniRats rats were extracted from lymph nodes
and
fusions performed by cohorts. Cells were combined and sorted for CD138
expression.
Hybridoma screening was performed in high throughput miniaturized MSD format
using
soluble hK2 antigen. Approximately >300 samples were identified to be hK2
binders. The
binding of >300 anti-hKLK2 supernatant samples to human KLK2 protein was
measured
by single cycle kinetics method by Biacore 8K SPR. Additionally the
supernatant samples
were tested for binding to human KLK3 protein as well. In parallel,
supernatants were also
tested for binding to KLK2 expressing cell lines VCap and negative cell line
DU145 by
Flow Cytometry. Selected cell binders were moved forward to scFy conversion in
both
VH-VL and VLNH orientation and thermal stability tests as described above.
KL2B413,
KL2B30, KL2B53 and KL2B242 resulted from the Ablexis mice immunization
campaign.
KL2B467 and KL2B494 resulted from the OmniRat immunization campaign.
Antibodies generated through the various immunization and humanization
campaigns
described above were expressed in a fab format, a mAb format, a scFy format in
the VH-
linker-VL orientation or a scFy format in VL-linker-VH orientation and were
further
analyzed as described below. The linker sequence of SEQ ID NO: 7 described
above was
used to conjugate the VH/VL regions.
Example 11. Structural characterization of anti KLK2 antibodies
Sequences of antibody variable domains and scFy antibody fragments which
showed
highest performance in intracellular assay are provided herein. Variable
domains were
184
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
expressed in a Fab format, a scFv format in the VH-linker-VL orientation or a
scFv format
in VL-linker-VH orientation.
Variable domains VII, VL and CDRs
Table 4 shows the VH and VL amino acid sequences of selected anti-hK2
antibodies.
Table 5 shows the Kabat HCDR1, HCDR2 and HCDR3 of selected anti-hK2 selected
antibodies. Table 6 shows the Kabat LCDR1, LCDR2 and LCDR3 of the selected
anti-
hK2 antibodies. Table 7 shows the AbM HCDR1, HCDR2 and HCDR3 of selected anti-
hK2 antibodies. Table 8 shows the AbM LCDR1, LCDR2 and LCDR3 of the anti-hK2.
Table 9 summarizes the variable domain sequence and SEQ ID NO of selected hK2
antibodies. Table 10 shows the protein and DNA SEQ ID NOs for the VH and VL
regions.
Table 4. VII and VL amino acid sequences of selected anti-hK2 antibodies.
mAb VII VII amino acid VII SEQ VL name VL amino acid VL SEQ
name name Sequence ID NO: sequence ID NO:
m 1 1B6 m 1 1B6_ DVQLQESGPGL 317 m11B6_V DIVLTQSPASLAVS 318
VH VKPSQSLSLTCT L LGQRATISCRASES
VTGNSITSDYA VEYFGTSLMHWY
WNW1RQFPGNR RQKPGQPPKLLIY
LEWMGYISY SG AA SNVESGVPARF
S TTY SP SLKSRF S SGSGSGTDFSLNIQ
ITRDTSKNQFFL PVEEDDFSMYFCQ
QLNSVTPEDTAT QTRKVPYTFGGGT
YFCATGYYYGS KLEIK
GFWGQGTLVTV
SS
hl 1B6 hul 1B6_ QVQLQESGPGL 5 hul 1B6_V DIVLTQSPDSLAVS 2
VH VKP SD TL SLTCA L LGERATINCKASE
VS GNSITSDYAW SVEYFGTSLMHW
NWIRQPPGKGLE YQQKPGQPPKLLI
WIGYISYSGSTT YAASNRESGVPDR
YNPSLKSRVTMS FSGSGSGTDFTLTI
RD TSKNQF SLKL SSLQAEDVAVYYC
SSVTAVDTAVY QQTRKVPYTFGQG
YCATGYYYGSG TKLEIK
FWGQGTLVTVS
HCF3- HCF3_V QVQLQESGPGL 6 LCD6_VL DIVLTQSPDSLAVS 1
LCD6 H VKP SD TL SLTCA LGERATINCKASE
VS GNSITSDYAW SVEYFGTSLMHW
NWIRQFPGKGLE YQQKPGQPPKLLI
WIGYISYSGSTT YAASNRESGVPDR
YNPSLKSRVTIS FSGSGSGTDFTLTI
185
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
RDTSKNQFSLKL Q SVQAEDVSVYFC
S SVTPVDTAVY QQTRKVPYTFGQG
YCATGYYYGSG TKLEIK
FWGQGTLVTVS
S
HC G5 - HCG5_V QVQLQE S GP GL 4 LCB7_VL DIVLTQSPD SLAVS 3
LCB7 H VKP SD TL SLTCA LGERATINCKASE
VS GNSITSDYAW SVEYFGTSLMHW
NWIRQFPGKGLE YQQKPGQPPKLLI
WMGYISYSGST YAASNRESGVPDR
TYNP SLKSRVTI F S GS GS GTDFTLTI
SRDTSKNQFSLK S SVQAEDVAVYY
L S SVTPVDTAVY CQQTRKVPYTFGQ
YCATGYYYGSG GTKLEIK
FWGQGTLVTVS
S
KL2B 3 KL2B 35 QVQLQE S GP GL 140 KL2B357_ DIVLTQSPD SLAVS 147
57 7_VH VKPSQTLSLTCT VL LGERATINCRASES
VS GNSITSDYAW VEYFGTSLMHWY
NWIRQFPGKGLE QQKPGQPPKLLIY
WIGYISY S GS TT AA SNVE S GVPDRF
YNPSLKSRVTIS S GS GS GTDFTLTIS
RD TSKNQF SLKL SLQAEDVAVYFCQ
S SVTAADTAVY QTRKVPYTFGGGT
YCATGYYYGSG KVEIK
FWGQGTLVTVS
S
KL2B 3 KL2B 35 QVQLQE S GP GL 141 KL2B 358_ EIVLTQ SPATL SL S 75
58 8_VH VKPSQTLSLTCT VL PGERATL SCRASE
VS GNSITSDYAW SVEYFGTSLMHW
NWIRQPPGKGLE YQQKPGQPPRLLI
WIGYISY S GS TT YAASNVESGIPAR
YNPSLKSRVTIS F S GS GS GTDFTLTI
RD TSKNQF SLKL S SVEPEDFAVYFC
S SVTAADTAVY QQTRKVPYTFGGG
YCATGYYYGSG TKVEIK
FWGQGTLVTVS
S
KL2B 3 KL2B 35 QVQLQE S GP GL 77 KL2B 359_ EIVLTQ SPATL SL S 75
59 9_VH VKPSQTLSLTCT VL PGERATL SCRASE
VS GNSITSDYAW SVEYFGTSLMHW
NWIRQFPGKRLE YQQKPGQPPRLLI
WIGYISY S GS TT YAASNVESGIPAR
YNPSLKSRVTIS F S GS GS GTDFTLTI
RD TSKNQF SLKL S SVEPEDFAVYFC
S SVTAADTAVY QQTRKVPYTFGGG
YCATGYYYGSG TKVEIK
FWGQGTLVTVS
S
186
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
KL2B 3 KL2B 36 QVQLQE S GP GL 140 KL2B 360_ EIVLTQ SPATL SL S 75
60 O_VH VKPSQTLSLTCT VL PGERATL SCRASE
VS GNSITSDYAW SVEYFGTSLMHW
NWIRQFPGKGLE YQQKPGQPPRLLI
WIGYISY S GS TT YAASNVESGIPAR
YNPSLKSRVTIS F S GS GS GTDFTLTI
RD TSKNQF SLKL S SVEPEDFAVYFC
S SVTAADTAVY QQTRKVPYTFGGG
YCATGYYYGSG TKVEIK
FWGQGTLVTVS
S
KL2B 4 KL2B 41 EVQLVES GGGL 76 KL2B413_ EIVLTQ SP SFL SAS 74
13 3_VH VQPGGSLRL SCA VL VGDRVTITCRASQ
AS GFTFS SYWM GIS SYL SWYQQKP
TWVRQAPGKGL GKAPKLLIYATST
EWVANIKQD GS LQS GVP SRF S GS GS
ERYYVD SVKGR GTEFTLTIS SLQPE
FTISRDNAKNSL DFATYYCQQLNSY
YLQMNSLRAED PRTFGQGTKVEIK
TAVYYCARDQN
YDILTGHYGMD
VVVGQGTTVTVS
S
KL2B 3 KL2B 30 QVQLQE S GP GL 142 KL2B3O_V DIQMTQ SP SFL SAS 148
0 VH VKPSETL SLTCT L VGDRVTITCRASQ
VS GGSIS SYYWS GIS SYLAWYQQKP
WIRQPPGKGLE GKAPKFLIYAAST
WIGYIYYS GS TN LQS GVP SRF S GS GS
YNPSLKSRVTIS GTEFTLTIS SLQPE
VD TSKNQF SLKL DFATYYCQQLNSY
S SVTAADTAVY PLTFGGGTKVEIK
YCAGTTIFGVVT
PNFYYGM DVW
GQGTTVTVS S
KL2B 5 KL2B 53 EVQLVES GGGV 143 KL2B53_V DIVMTQ SP S SL SAS 149
3 VH VQPGRSLRLS CV L VGDRVTITCRASQ
AS GFTFS SYDIH DISNYLAWYQQKP
WVRQAPGKGLE GKVPKFLIYAAST
WVAIISYDGSKK LHS GVP SRF S GS GS
DYTD SVKGRFTI GTDFTLTIS SLQPE
SRDNSKNTLYL DVATYYCQKYNS
QM D SLRVED SA APYTFGQGTRLEI
VY S CARES GWS K
HYYYYGMDVVV
GQGTMVTVS S
KL2B 2 KL2B 24 QVQLQE S GP GL 144 KL2B 242_ SYELTQPP S VS VSP 150
42 2_VH VKPSETL SLTCT VL GETASITCS GDQL
VS GGSIS SYYWS GENYACWYQQKP
WLRQPAGSGLE GQSPVLVIYQD SK
WIGRLYVS GFTN RP SGIPERF SGSNS
YNPSLKSRVTL S GNTATLTIS GTQA
LDP SRNQL SLKL LDEADYYCQAWD
S SVTAADTAVY NS IVVFGGGTKLT
YCAGD S GNYW VL
187
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
GWFDPWGQGTL
VT VS S
KL2B 4 KL2B46 QVQLVESGGGV 145 KL2B467_ QSVLTQPPSVSVA 151
67 7_VH VQPGRSLRLS CA VL PGQTASITCGGDNI
AS GFTFSYYGM GSKSVHWYQQKP
HWVRQAPGKGL GQAPVLVVYDNS
EWVAFISYDGSN DRPSGIPERFSGSN
KYYADSVKGRF SGTTATLTISRVEA
TISRDNSKNTLY GDEADYYCQVWD
LQMNSLRAEDT S SSDHPVVFGGGT
AVYYCAHLPYS KVTV
GSYWAFDYWG
QGTQVTVSS
KL2B 4 KL2B49 QVQLVESGGGL 146 KL2B494_ S SELTQPPSVSVAP 152
94 4_VH VQPGGSLRL SCA VL GQTARITCGGNNI
AS GFTFSHYAMS GSKSVHWYQQKP
WVRQAPGKGLE GQAPVLVVYDD S
WVSTIGGSGGST DRPSGIPERFSGSN
YYADSVKGRFTI SGNTATLTISRVEA
SRDNSKNTLYL GDEADYYCQVWD
QMNSLRAEDTA S SSDHVVFGGGTK
VYYCAKPHIVM LTVL
VTALLYDGMDV
WGQGTMVTVS S
Table 5. Kabat HCDR1, HCDR2 and HCDR3 amino acid sequences of selected anti-
KLK2 antibodies.
Kabat HCDR1 Kabat HCDR2 Kabat HCDR3
mAb Sequence SEQ ID Sequence SEQ ID Sequence SEQ ID
name NO: NO: NO:
m11B6 SDYAWN 63 YISYSGSTTYSP 64 GYYYGSGF 66
SLKS
hullB6 SDYAWN 63 YISYSGSTTYNP 65 GYYYGSGF 66
SLKS
HCF3- SDYAWN 63 YISYSGSTTYNP 65 GYYYGSGF 66
LCD6 SLKS
HC G5- SDYAWN 63 YISYSGSTTYNP 65 GYYYGSGF 66
LCB7 SLKS
188
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
KL2B35 SDYAWN 63 YISYSGSTTYNP 65 GYYYGSGF 66
7 SLKS
KL2B35 SDYAWN 63 YISYSGSTTYNP 65 GYYYGSGF 66
8 SLKS
KL2B35 SDYAWN 63 YISYSGSTTYNP 65 GYYYGSGF 66
9 SLKS
KL2B 36 SDYAWN 63 YISYSGSTTYNP 65 GYYYGSGF 66
0 SLKS
KL2B 41 SYWMT 314 NR(QDGSERYY 315 DQNYDILTGHYG 311
3 VD S VKG MDV
KL2B 30 SYYWS 102 YIYYSGSTNYN 103 TTIFGVVTPNFYY 104
PSLKS GMDV
KL2B53 SYDIE1 107 IISYDGSKKDYT 108 ESGWSHYYYYG 109
DSVKG MDV
KL2B 24 SYYWS 102 RLYVSGFTNYN 112 D SGNYWGWFDP 113
2 PSLKS
KL2B 46 YYGMH 115 FISYDGSNKYY 116 LPYSGSYWAFDY 117
7 AD S VKG
KL2B 49 HYAMS 120 TIGGSGGSTYY 121 PHIVMVTALLYD 122
4 AD S VKG GMDV
Table 6. Kabat LCDR1, LCDR2 and LCDR3 amino acid sequences of selected anti-
hK2 antibodies.
Kabat LCDR1 Kabat LCDR2 Kabat LCDR3
mAb Sequence SEQ Sequence SEQ ID Sequence SEQ ID
name ID NO NO NO
m11B6 RASESVEYFG 67 AASNVES 69 QQTRKVPYT 71
TSLMH
hul 1B6 KASESVEYFG 68 AASNRES 70 QQTRKVPYT 71
TSLMH
HCF3- KASESVEYFG 68 AASNRES 70 QQTRKVPYT 71
LCD6 TSLMH
HCG5- KASESVEYFG 68 AASNRES 70 QQTRKVPYT 71
LCB7 TSLMH
KL2B35 RASESVEYFG 67 AASNVES 126 QQTRKVPYT 71
7 TSLMH
KL2B35 RASESVEYFG 67 AASNVES 126 QQTRKVPYT 71
8 TSLMH
KL2B35 RASESVEYFG 67 AASNVES 69 QQTRKVPYT 71
9 TSLMH
KL2B36 RASESVEYFG 67 AASNVES 126 QQTRKVPYT 71
0 TSLMH
KL2B41 RASQGISSYLS 312 ATSTLQS 313 QQLNSYPRT 91
3
KL2B30 RASQGISSYL 128 AASTLQS 129 QQLNSYPLT 130
A
189
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
KL2B53 RASQDISNYL 125 AASTLHS 131
QKYNSAPYT 132
A
KL2B24 SGDQLGENY 133 QDSKRPS 134
QAWDNSIVV 135
2 AC
KL2B46 GGDNIGSKSV 136 DNSDRPS 137
QVWDSSSDH 138
7 H PVV
KL2B49 GGNNIGSKSV 97 DDSDRPS 127
QVWDSSSDH 139
4 H VV
Table 7. AbM HCDR1, HCDR2 and HCDR3 amino acid sequences of selected anti-
hK2 antibodies.
AbM HCDR1 AbM HCDR2 AbM HCDR3
mAb name Sequence SEQ ID Sequence SEQ Sequence SEQ
ID NO.
NO. ID NO
ml 1B6 GNSITSDYA 72 YISYSGSTT 73 GYYYGSGF 66
WN
hul 1B6 GNSITSDYA 72 YISYSGSTT 73 GYYYGSGF 66
WN
HCF3- GNSITSDYA 72 YISYSGSTT 73 GYYYGSGF 66
LCD6 WN
HCG5- GNSITSDYA 72 YISYSGSTT 73 GYYYGSGF 66
LCB7 WN
KL2B357 GNSITSDYA 72 YISYSGSTT 73 GYYYGSGF 66
WN
KL2B358 GNSITSDYA 72 YISYSGSTT 73 GYYYGSGF 66
WN
KL2B359 GNSITSDYA 72 YISYSGSTT 73 GYYYGSGF 66
WN
KL2B360 GNSITSDYA 72 YISYSGSTT 73 GYYYGSGF 66
WN
KL2B 413 GFTFS SYW 309 NIKQDGSER 310 DQNYDILTGHY 311
MT Y GMDV
KL2B 30 GGSISSYY 105 YIYYSGSTN 106 TTIFGVVTPNFY 104
WS YGMD V
KL2B 53 GFTFSSYDI 110 IISYDGSKKD 111 ES GWSHYYYYG 109
H MDV
KL2B242 GGSISSYY 105 RLYVSGFTN 114 DSGNYWGWFDP 113
WS
KL2B467 GFTFSYY 118 FISYDGSNK 119 LPYSGSYWAFD 117
Y Y
KL2B494 GFTFSHYA 123 TIGGSGGST 124 PHIVMVTALLY 122
MS YY DGMD V
Table 8. AbM LCDR1, LCDR2 and LCDR3 amino acid sequences of selected anti-hK2
antibodies.
AbM LCDR1 AbM LCDR2 AbM LCDR3
190
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
mAb name Sequence SEQ ID Sequence SEQ ID Sequence SEQ ID
NO. NO NO.
m11B6 RASESVEYF 67 AASNVES 69 QQTRKVPYT 71
GTSLMH
hullB6 KASESVEYF 68 AASNRES 70 QQTRKVPYT 71
GTSLMH
HCF3-LCD6 KASESVEYF 68 AASNRES 70 QQTRKVPYT 71
GTSLMH
HCG5-LCB7 KASESVEYF 68 AASNRES 70 QQTRKVPYT 71
GTSLMH
KL2B357 RASESVEYF 67 AASNVES 126 QQTRKVPYT 71
GTSLMH
KL2B358 RASESVEYF 67 AASNVES 126 QQTRKVPYT 71
GTSLMH
KL2B359 RASESVEYF 67 AASNVES 69 QQTRKVPYT 71
GTSLMH
KL2B360 RASESVEYF 67 AASNVES 126 QQTRKVPYT 71
GTSLMH
KL2B413 RASQGISSY 312 ATSTLQS 313 QQLNSYPRT 91
LS
KL2B30 RASQGISSY 128 AASTLQS 129 QQLNSYPLT 130
LA
KL2B53 RASQDISNY 125 AASTLHS 131 QKYNSAPYT 132
LA
KL2B242 SGDQLGENY 133 QDSKRPS 134 QAWDNSIVV 135
AC
KL2B467 GGDNIGSKS 136 DNSDRPS 137 QVWDSSSDHP 138
VH VV
KL2B494 GGNNIGSKS 97 DDSDRPS 127 QVWDSSSDHV 139
VH V
Table 9. Amino acid sequences and SEQ ID NO summary of the variable domains of
selected anti-hK2 antibodies
Antibody Region Amino acid sequence SEQ ID
NO:
m11B6 HCDR1 SDYAWN 63
HCDR2 YISYSGSTTYSPSLKS 64
HCDR3 GYYYGSGF 66
LICDR1 RASESVEYFGTSLMH 67
LCDR2 AASNVES 69
LCDR3 QQTRKVPYT 71
VH DVQLQESGPGLVKPSQSLSLTCTVTGNSITSDY 317
(m11B6_VH) AWNWIRQFPGNRLEWMGYISYSGSTTYSPSL
191
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
KSRFSITRDTSKNQFFLQLNSVTPEDTATYFCA
TGYYYGSGFWGQGTLVTVSS
VL DIVLTQSPASLAVSLGQRATISCRASESVEYFG 318
(m11B6_VL) TSLMHWYRQKPGQPPKLLIYAASNVESGVPA
RFSGSGSGTDFSLNIQPVEEDDFSMYFCQQTR
KVPYTFGGGTKLEIK
h11B6 HCDR1 SDYAWN 63
HCDR2 YISYSGSTTYNPSLKS 65
HCDR3 GYYYGSGF 66
LICDR1 KASESVEYFGTSLMH 68
LCDR2 AASNRES 70
LCDR3 QQTRKVPYT 71
VH QVQLQESGPGLVKPSDTL SLTCAVSGNSIT SD 5
(hullB6_VH YAWNWIRQPPGKGLEWIGYISYSGSTTYNPSL
) KSRVTMSRDTSKNQFSLKLSSVTAVDTAVYY
CATGYYYGSGFWGQGTLVTVSS
VL DIVLTQSPDSLAVSLGERATINCKASESVEYFG 2
(hullB6_VL TSLMHWYQQKPGQPPKLLIYAASNRESGVPD
) RFSGSGSGTDFTLTISSLQAEDVAVYYCQQTR
KVPYTFGQGTKLEIK
HCF3- HCDR1 SDYAWN 63
LCD6 HCDR2 YISYSGSTTYNPSLKS 65
HCDR3 GYYYGSGF 66
LICDR1 KASESVEYFGTSLMH 68
LCDR2 AASNRES 70
LCDR3 QQTRKVPYT 71
VH QVQLQESGPGLVKPSDTL SLTCAVSGNSIT SD 6
(HCF3_VH) YAWNWIRQFPGKGLEWIGYISYSGSTTYNPSL
KSRVTISRDTSKNQFSLKLSSVTPVDTAVYYC
ATGYYYGSGFWGQGTLVTVSS
VL DIVLTQSPDSLAVSLGERATINCKASESVEYFG 1
(LCD6_VL) TSLMHWYQQKPGQPPKLLIYAASNRESGVPD
192
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
RFSGSGSGTDFTLTIQSVQAEDVSVYFCQQTR
KVPYTFGQGTKLEIK
HCG5- HCDR1 SDYAWN 63
LCB7 HCDR2 YISYSGSTTYNPSLKS 65
HCDR3 GYYYGSGF 66
LICDR1 KASESVEYFGTSLMH 68
LCDR2 AASNRES 70
LCDR3 QQTRKVPYT 71
VH QVQLQESGPGLVKPSDTLSLTCAVSGNSITSD 4
(HCG5_VH) YAWNWIRQFPGKGLEWMGYISYSGSTTYNPS
LKSRVTISRDTSKNQFSLKLSSVTPVDTAVYY
CATGYYYGSGFWGQGTLVTVSS
VL DIVLTQSPDSLAVSLGERATINCKASESVEYFG 3
(LCB7_VL) TSLMHWYQQKPGQPPKLLIYAASNRESGVPD
RFSGSGSGTDFTLTISSVQAEDVAVYYCQQTR
KVPYTFGQGTKLEIK
KL2B357 HCDR1 SDYAWN 63
HCDR2 YISYSGSTTYNPSLKS 100 or
65
HCDR3 GYYYGSGF 66
LICDR1 RASESVEYFGTSLMH 67
LCDR2 AASNVES 126
LCDR3 QQTRKVPYT 71
VH QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDY 140
(KL2B357_V AWNWIRQFPGKGLEWIGYISYSGSTTYNPSLK
H) SRVTISRDTSKNQFSLKLSSVTAADTAVYYCA
TGYYYGSGFWGQGTLVTVSS
VL DIVLTQSPDSLAVSLGERATINCRASESVEYFG 147
(KL2B_357_ TSLMHWYQQKPGQPPKLLIYAASNVESGVPD
VL) RFSGSGSGTDFTLTISSLQAEDVAVYFCQQTR
KVPYTFGGGTKVEIK
KL2B358 HCDR1 SDYAWN 63
HCDR2 YISYSGSTTYNPSLKS 65
HCDR3 GYYYGSGF 66
193
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
LICDR1 RASESVEYFGT SLMH 67
LCDR2 AASNVES 126
LCDR3 QQTRKVPYT 71
VH QVQLQESGPGLVKPSQTL SLTCTVSGNSIT SDY 141
(KL2B358_V AWNWIRQPPGKGLEWIGYISYSGSTTYNPSLK
H) SRVTISRDT SKNQFSLKLSSVTAADTAVYYCA
TGYYYGSGFWGQGTLVTVSS
VL EIVLTQSPATLSLSPGERATLSCRASESVEYFG 75
(KL2B_358_ TSLMHWYQQKPGQPPRLLIYAASNVESGIPAR
VL) FSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKV
PYTFGGGTKVEIK
KL2B359 HCDR1 SDYAWN 63
HCDR2 YISYSGSTTYNPSLKS 65
HCDR3 GYYYGSGF 66
LICDR1 RASESVEYFGT SLMH 67
LCDR2 AA SNVE S 69
LCDR3 QQTRKVPYT 71
VH QVQLQESGPGLVKPSQTL SLTCTVSGNSIT SDY 77
(KL2B359_V AWNWIRQFPGKRLEWIGYISYSGSTTYNPSLK
H) SRVTISRDT SKNQFSLKLSSVTAADTAVYYCA
TGYYYGSGFWGQGTLVTVSS
VL EIVLTQSPATLSLSPGERATLSCRASESVEYFG 75
(KL2B_359_ TSLMHWYQQKPGQPPRLLIYAASNVESGIPAR
VL) FSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKV
PYTFGGGTKVEIK
KL2B360 HCDR1 SDYAWN 63
HCDR2 YISYSGSTTYNPSLKS 65
HCDR3 GYYYGSGF 66
LICDR1 RASESVEYFGT SLMH 67
LCDR2 AA SNVE S 69
LCDR3 QQTRKVPYT 71
194
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
VH QVQLQESGPGLVKPSQTL SLTCTVSGNSIT SDY 140
(KL2B360_V AWNWIRQFPGKGLEWIGYISYSGSTTYNPSLK
H) SRVTISRDT SKNQFSLKLSSVTAADTAVYYCA
TGYYYGSGFWGQGTLVTVSS
VL EIVLTQSPATLSLSPGERATLSCRASESVEYFG 75
(KL2B_360_ TSLMHWYQQKPGQPPRLLIYAASNVESGIPAR
VL) FSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKV
PYTFGGGTKVEIK
KL2B413 HCDR1 SYWMT 314
HCDR2 NIKQDGSERYYVDSVKG 315
HCDR3 DQNYDILTGHYGMDV 311
LICDR1 RASQGISSYLS 312
LCDR2 AT STL QS 313
LCDR3 QQLNSYPRT 91
VH EVQLVESGGGLVQPGGSLRL SCAASGFTFS SY 76
(KL2B413_V WMTWVRQAPGKGLEWVANIKQDGSERYYV
H) DSVKGRFTISRDNAKNSLYLQMNSLRAEDTA
VYYCARDQNYDILTGHYGMDVWGQGTTVTV
SS
VL EIVLTQSPSFLSASVGDRVTITCRASQGISSYLS 74
(KL2B_413_ WYQQKPGKAPKLLIYATSTLQSGVPSRFSGSG
VL) SGTEFTLTISSLQPEDFATYYCQQLNSYPRTFG
QGTKVEIK
KL2B30 HCDR1 SYYWS 102
HCDR2 YIYYSGSTNYNPSLKS 103
HCDR3 TTIFGVVTPNFYYGMDV 104
LICDR1 RASQGISSYLA 128
LCDR2 AASTLQS 129
LCDR3 QQLNSYPLT 130
VH QVQLQESGPGLVKPSETLSLTCTVSGGSISSYY 142
(KL2B3O_V WSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKS
H) RVTISVDTSKNQFSLKL SSVTAADTAVYYCAG
TTIFGVVTPNFYYGMDVWGQGTTVTVSS
195
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
VL DIQMTQSPSFLSASVGDRVTITCRASQGISSYL 148
(KL2B3O_V AWYQQKPGKAPKFLIYAASTLQSGVPSRFSGS
L) GSGTEFTLTISSLQPEDFATYYCQQLNSYPLTF
GGGTKVEIK
KL2B53 HCDR1 SYDIH 107
HCDR2 IISYDGSKKDYTDSVKG 108
HCDR3 ESGWSHYYYYGMDV 109
LICDR1 RASQDISNYLA 125
LCDR2 AASTLHS 131
LCDR3 QKYNSAPYT 132
VH EVQLVESGGGVVQPGRSLRLSCVASGFTFSSY 143
(KL2B53_V DIHWVRQAPGKGLEWVAIISYDGSKKDYTDS
H) VKGRFTISRDNSKNTLYLQMDSLRVED SAVY
SCARESGWSHYYYYGMDVWGQGTMVTVSS
VL DIVMTQSPSSLSASVGDRVTITCRASQDISNYL 149
(KL2B53_V AWYQQKPGKVPKFLIYAASTLHSGVPSRFSGS
L) GSGTDFTLTISSLQPEDVATYYCQKYNSAPYT
FGQGTRLEIK
KL2B242 HCDR1 SYYWS 102
HCDR2 RLYVSGFTNYNPSLKS 112
HCDR3 DSGNYWGWFDP 113
LICDR1 SGDQLGENYAC 133
LCDR2 QDSKRPS 134
LCDR3 QAWDNSIVV 135
VH QVQLQESGPGLVKPSETLSLTCTVSGGSISSYY 144
(KL2B242_V WSWLRQPAGSGLEWIGRLYVSGFTNYNPSLK
H) SRVTLSLDPSRNQLSLKLSSVTAADTAVYYCA
GDSGNYWGWFDPWGQGTLVTVSS
VL SYELTQPPSVSVSPGETASITCSGDQLGENYAC 150
(KL2B242_V WYQQKPGQSPVLVIYQDSKRPSGIPERFSGSN
L) SGNTATLTISGTQALDEADYYCQAWDNSIVVF
GGGTKLTVL
KL2B467 HCDR1 YYGMH 115
196
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
HCDR2 FISYDGSNKYYADSVKG 116
HCDR3 LPYSGSYWAFDY 117
LICDR1 GGDNIGSKSVH 136
LCDR2 DNSDRPS 137
LCDR3 QVWD SS SDHPVV 138
VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSYY 145
(KL2B467_V GMHWVRQAPGKGLEWVAFISYDGSNKYYAD
H) SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAHLPYSGSYWAFDYWGQGTQVTVSS
VL QSVLTQPPSVSVAPGQTASITCGGDNIGSKSVH 151
(KL2B467_V WYQQKPGQAPVLVVYDNSDRPSGIPERFSGS
L) NSGTTATLTISRVEAGDEADYYCQVWDS S SD
HPVVFGGGTKVTV
KL2B494 HCDR1 HYAMS 120
HCDR2 TIGGSGGSTYYADSVKG 121
HCDR3 PHIVMVTALLYDGMDV 122
LICDR1 GGNNIGSKSVH 97
LCDR2 DDSDRPS 127
LCDR3 QVWD SS SDHVV 139
VH QVQLVESGGGLVQPGGSLRLSCAASGFTFSHY 146
(KL2B494 V AMSWVRQAPGKGLEWVSTIGGSGGSTYYAD
_
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
H) YYCAKPHIVMVTALLYDGMDVWGQGTMVT
VS S
VL SSELTQPPSVSVAPGQTARITCGGNNIGSKSVH 152
KL2B494_ WYQQKPGQAPVLVVYDDSDRPSGIPERFSGS
V (
NSGNTATLTISRVEAGDEADYYCQVWDS S SD
L) HVVFGGGTKLTVL
Table 10. SEQ ID NO: DNA sequences of the VII and VI, domains of selected hK2
antibodies.
Antibody VH VL VH VL
Protein Protein cDNA cDNA
SEQ ID SEQ SEQ ID SEQ ID
NO: ID NO NO: NO:
m11B6 317 318 320 326
197
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
hullB6 5 2 321 327
HCF3-LCD6 6 1 322 328
HCG5-LCB7 4 3 323 329
KL2B357 140 147 153 161
KL2B358 141 75 154 162
KL2B359 77 75 324 330
KL2B360 140 75 155 163
KL2B413 76 74 325 331
KL2B30 142 148 156 164
KL2B53 143 149 157 165
KL2B242 144 150 158 166
KL2B467 145 151 159 167
KL2B494 146 152 160 168
Consensus VII and VI, sequences
Figure 17A shows the sequence alignment of the VH domains of mullB6, hullB6,
KL2B357, KL2B358, KL2B359, KL2B360, HCF3 and HCG5. FIG.2 shows the sequence
alignment of the VL domains of mullB6, hullB6, KL2B357, KL2B358, KL2B359,
KL2B360, LDC6 and LCB7. Consensus amino acid sequence of SEQ ID NO: 344 and
SEQ ID NO:345 were determined for the VH and VL domains, respectively. HCDR
and
LCDR residues are underlined.
SEQ ID NO: 344
QVQLQESGPGLVKPSX1TLSLTCX2VSGNSITSDYAWNVVIRQX3PGKGLEWX4GYIS
YSGSTTYNPSLKSRVTIVISRDTSKNQFSLKLSSVTX5X6DTAVYYCATGYYYGSGF
WGQGTLVTVSS
Where,
X1 is D or Q;
X2 is A or T;
X3 is P or F;
X4 is I or M;
X5 is A or P; or
X6 is V or A.
SEQ ID NO: 345
198
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
X1IVLTQSPX2x3LX4X5SX6GERATX6X8CX9ASESVEYFGTSLMEIWYQQKPGOPPX10
LLIYAASNXi iESGX12PX13RFSGSGSGTDFTLTIX14SLQX15EDX16AVYXt7CQQTRKV
PYTFG X18GTKX19EIK
X1 is D or E;
X2 is D or A;
X3 is S or T;
X4 is A or S;
X5 is V or L;
X6 is L or P;
X7 is I or L;
X8 is N or S;
X9 is R or K;
X10 is K or R;
X11 is V or R;
X12 is V or I;
X13 is A or D;
X14 is Q or S;
X15 is P or A;
X16 is F or V;
X17 is Y or F;
X18 is Q or G; and
X19 is L or V.
Fab-Fc and scFvs
The hK2 specific VH/VL regions were engineered as VH-CH1-linker CH2-CH3 and VL-
CL and expressed as IgG2 or IgG4 or were engineered as scFvs in either the VH-
Linker-
VL or VL-linker-VH orientations. The linker that is used in the scFv was the
linker of
SEQ ID NO: 7 described above. The scFv were used to generate bispecific
antibodies as
described in Example 7 or to generated CAR as described in Example 11.
Table 11 shows the HC amino acid sequences of selected anti-hK2 antibodies in
the mAb
format. Table 12 shows the LC amino acid sequences of selected anti-hK2
antibodies in a
mAb. Table 13 summaries the HC and LC DNA SEQ ID NOs of selected anti-hK2
antibodies in the mAb format. Table 14 shows the amino acid sequences of
selected scFvs
in VH-linker-VL or VL-linker-VH orientation.
199
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Table 11. Amino acid sequence of the HC (VH-CH1-linker C112-CH3 ) of selected
anti-
hK2antibodies in a mAb format.
KLK2 HC
PROTEIN
HEAVY HC AMINO ACID SEQUENCE
SEQ ID
CHAIN
NO:
DVQLQESGPGLVKPSQSLSLTCTVTGNSITSDYAWNWIR
QFPGNRLEWMGYISYSGSTTYSPSLKSRFSITRDTSKNQF
FLQLNSVTPEDTATYFCATGYYYGSGFWGQGTLVTVSS
AKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTL
TWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQ
SITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLL
m 11B6 HC 332 _
GGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQIS
WFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDW
MSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLP
PPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELN
YKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSV
VHEGLHNHHTTKSFSRTPGK
QVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNWIR
QPPGKGLEWIGYISYSGSTTYNPSLKSRVTMSRDTSKNQ
FSLKLSSVTAVDTAVYYCATGYYYGSGFWGQGTLVTVS
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
h11B6 HC 334 TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
_
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG
QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF
SCSVMHEALHNHYTQKSLSLSPGK
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQ
PPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFS
LKLSSVTAADTAVYYCAGTTIFGVVTPNFYYGMDVWG
QGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV
KL2B30 HC 185 TVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPP
_
CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ
PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQE
GNVFSCSVMHEALHNHYTQKSLSLSLGK
EVQLVESGGGVVQPGRSLRLSCVASGFTFSSYDIHWVR
QAPGKGLEWVAIISYDGSKKDYTDSVKGRFTISRDNSKN
TLYLQMDSLRVEDSAVYSCARESGWSHYYYYGMDVW
K2B53_HC 187 GQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLV
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
PCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
200
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ
PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQE
GNVFSCSVMHEALHNHYTQKSLSLSLGK
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWLRQ
PAGSGLEWIGRLYVSGFTNYNPSLKSRVTLSLDPSRNQL
SLKLSSVTAADTAVYYCAGDSGNYWGWFDPWGQGTL
VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
KL2B242 HC 189 SLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPE
_
AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPE
VQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQ
VYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLSLGK
QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHWV
RQAPGKGLEWVAFISYDGSNKYYADSVKGRFTISRDNS
KNTLYLQMNSLRAEDTAVYYCAHLPYSGSYWAFDYW
GQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
KL2B467_HC 191 VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH
TCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV
SVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
QVQLVESGGGLVQPGGSLRLSCAASGFTFSHYAMSWVR
QAPGKGLEWVSTIGGSGGSTYYADSVKGRFTISRDNSK
NTLYLQMNSLRAEDTAVYYCAKPHIVMVTALLYDGMD
VWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
KL2B494 HC 193 SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD
_
KTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTC
VVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Table 12. Amino acid sequences of the LC (VL-CL) of selected anti-hK2
antibodies in
a mAb (Fab-Fc) format.
KLK2 LC
LIGHT PROTEIN LC AMINO ACID SEQUENCE
CHAIN SEQ ID NO:
201
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
DIVLTQSPASLAVSLGQRATISCRASESVEYFGTSLMHW
YRQKPGQPPKLLIYAASNVESGVPARFSGSGSGTDFSLNI
QPVEEDDFSMYFCQQTRKVPYTFGGGTKLEIKRADAAP
m 11B6 LC 333 _
TVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGS
ERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNS
YTCEATHKTSTSPIVKSFNRNEC
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHW
YQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTI
h11B6 LC 335 SSLQAEDVAVYYCQQTRKVPYTFGQGTKLEIKRTVAAP
_
SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN
ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV
YACEVTHQGLSSPVTKSFNRGEC
DIQMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQK
PGKAPKFLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQP
KL2B30 LC 186 EDFATYYCQQLNSYPLTFGGGTKVEIKRTVAAPSVFIFPP
_
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
THQGLSSPVTKSFNRGEC
DIVMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQK
PGKVPKFLIYAASTLHSGVPSRFSGSGSGTDFTLTISSLQP
KL2B53 LC 188 EDVATYYCQKYNSAPYTFGQGTRLEIKRTVAAPSVFIFP
_
PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS
GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
VTHQGLSSPVTKSFNRGEC
SYELTQPPSVSVSPGETASITCSGDQLGENYACWYQQKP
GQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQA
KL2B242 190 LDEADYYCQAWDNSIVVFGGGTKLTVLGQPKAAPSVTL
LC _
FPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK
AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQ
VTHEGSTVEKTVAPTECS
QSVLTQPPSVSVAPGQTASITCGGDNIGSKSVHWYQQKP
GQAPVLVVYDNSDRPSGIPERFSGSNSGTTATLTISRVEA
KL2B467 LC 192 GDEADYYCQVWDSSSDHPVVFGGGTKVTVLGQPKAAP
_
SVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADS
SPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
SSELTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKP
GQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEA
KL2B494 194 GDEADYYCQVWDSSSDHVVFGGGTKLTVLGQPKAAPS
LC _
VTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSS
PVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSY
SCQVTHEGSTVEKTVAPTECS
Table 13. SEQ ID Nos of the cDNA sequences of HC and LC of selected hK2
antibodies
Antibody HC LC HC LC
Protein Protein cDNA cDNA
SEQ ID SEQ ID SEQ ID SEQ ID
NO: NO: NO: NO:
202
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
m11B6 332 333 336 337
hul 1B6 334 335 338 339
KL2B30 185 186 195 196
KL2B53 187 188 197 198
KL2B242 189 190 199 200
KL2B467 191 192 201 202
KL2B494 193 194 203 204
Table 14. Amino acid sequences of the variable domain of selected anti-hK2
scFvs
antibodies in VH-linker-VL (HL) or in VL-linker-VH (LH) format.
scFy Acronym Amino acid sequence of scFy SEQ
name ID
NO:
scFv1 HCG5_LDC6_HL QVQLQESGPGLVKPSDTL SLTCAVSGNSIT SD 8
YAWNWIRQFPGKGLEWMGYISYSGSTTYNP
SLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSSGGSEGKS
SGSGSESKSTGGSDIVLTQSPDSLAVSLGERA
TINCKASESVEYFGTSLMHWYQQKPGQPPKL
LIYAASNRESGVPDRFSGSGSGTDFTLTIQSV
QAEDVSVYFCQQTRKVPYTFGQGTKLEIK
scFv2 HCG5_hu11B6_H QVQLQESGPGLVKPSDTL SLTCAVSGNSIT SD 9
L YAWNWIRQFPGKGLEWMGYISYSGSTTYNP
SLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSSGGSEGKS
SGSGSESKSTGGSDIVLTQSPDSLAVSLGERA
TINCKASESVEYFGTSLMHWYQQKPGQPPKL
LIYAASNRESGVPDRFSGSGSGTDFTLTISSLQ
AEDVAVYYCQQTRKVPYTFGQGTKLEIK
scFv3 HCF3_hu11B6_HL QVQLQESGPGLVKPSDTL SLTCAVSGNSIT SD 10
YAWNWIRQFPGKGLEWIGYISYSGSTTYNPS
LKSRVTISRDTSKNQFSLKLSSVTPVDTAVYY
CATGYYYGSGFWGQGTLVTVSSGGSEGKSS
GSGSESKSTGGSDIVLTQSPDSLAVSLGERATI
NCKASESVEYFGTSLMHWYQQKPGQPPKLLI
YAASNRESGVPDRFSGSGSGTDFTLTISSVQA
EDVAVYYCQQTRKVPYTFGQGTKLEIK
scFv4 HCG5_LCB7_HL QVQLQESGPGLVKPSDTLSLTCAVSGNSITSD 11
YAWNWIRQFPGKGLEWMGYISYSGSTTYNP
SLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSSGGSEGKS
SGSGSESKSTGGSDIVLTQSPDSLAVSLGERA
TINCKASESVEYFGTSLMHWYQQKPGQPPKL
LIYAASNRESGVPDRFSGSGSGTDFTLTISSVQ
AEDVAVYYCQQTRKVPYTFGQGTKLEIK
scFv5 LCD6_HCG5_LH DIVLTQSPDSLAVSLGERATINCKASESVEYF 12
GTSLMHWYQQKPGQPPKLLIYAASNRESGVP
203
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
DRFSGSGSGTDFTLTIQSVQAEDVSVYFCQQT
RKVPYTFGQGTKLEIKGGSEGKSSGSGSESKS
TGGSQVQLQESGPGLVKPSDTLSLTCAVSGN
SITSDYAWNWIRQFPGKGLEWMGYISYSGST
TYNPSLKSRVTISRDTSKNQFSLKLSSVTPVD
TAVYYCATGYYYGSGFWGQGTLVTVSS
scFv6 hullB6_HCF3JH DIVLTQSPDSLAVSLGERATINCKASESVEYF 13
GTSLMHWYQQKPGQPPKLLIYAASNRESGVP
DRFSGSGSGTDFTLTISSLQAEDVAVYYCQQT
RKVPYTFGQGTKLEIKGGSEGKSSGSGSESKS
TGGSQVQLQESGPGLVKPSDTLSLTCAVSGN
SITSDYAWNWIRQFPGKGLEWIGYISYSGSTT
YNPSLKSRVTISRDTSKNQFSLKLSSVTPVDT
AVYYCATGYYYGSGFWGQGTLVTVSS
scFv7 hullB6_HCG5_L DIVLTQSPDSLAVSLGERATINCKASESVEYF 14
H GTSLMHWYQQKPGQPPKLLIYAASNRESGVP
DRFSGSGSGTDFTLTISSLQAEDVAVYYCQQT
RKVPYTFGQGTKLEIKGGSEGKSSGSGSESKS
TGGSQVQLQESGPGLVKPSDTLSLTCAVSGN
SITSDYAWNWIRQFPGKGLEWMGYISYSGST
TYNPSLKSRVTISRDTSKNQFSLKLSSVTPVD
TAVYYCATGYYYGSGFWGQGTLVTVSS
scFv8 LCB7_HCF3_LH DIVLTQSPDSLAVSLGERATINCKASESVEYF 15
GTSLMHWYQQKPGQPPKLLIYAASNRESGVP
DRFSGSGSGTDFTLTISSVQAEDVAVYYCQQ
TRKVPYTFGQGTKLEIKGGSEGKSSGSGSESK
STGGSQVQLQESGPGLVKPSDTLSLTCAVSG
NSITSDYAWNWIRQFPGKGLEWIGYISYSGST
TYNPSLKSRVTISRDTSKNQFSLKLSSVTPVD
TAVYYCATGYYYGSGFWGQGTLVTVSS
scFv9 LCB7_HCG5_LH DIVLTQSPDSLAVSLGERATINCKASESVEYF 16
GTSLMHWYQQKPGQPPKLLIYAASNRESGVP
DRFSGSGSGTDFTLTISSVQAEDVAVYYCQQ
TRKVPYTFGQGTKLEIKGGSEGKSSGSGSESK
STGGSQVQLQESGPGLVKPSDTLSLTCAVSG
NSITSDYAWNWIRQFPGKGLEWMGYISYSGS
TTYNPSLKSRVTISRDTSKNQFSLKLSSVTPV
DTAVYYCATGYYYGSGFWGQGTLVTVSS
scFv10 LCD6_HCF3_LH DIVLTQSPDSLAVSLGERATINCKASESVEYF 17
GTSLMHWYQQKPGQPPKLLIYAASNRESGVP
DRFSGSGSGTDFTLTIQSVQAEDVSVYFCQQT
RKVPYTFGQGTKLEIKGGSEGKSSGSGSESKS
TGGSQVQLQESGPGLVKPSDTLSLTCAVSGN
SITSDYAWNWIRQFPGKGLEWIGYISYSGSTT
YNPSLKSRVTISRDTSKNQFSLKLSSVTPVDT
AVYYCATGYYYGSGFWGQGTLVTVSS
scFv11 hullB6_LCB7_HL QVQLQESGPGLVKPSDTLSLTCAVSGNSIT SD 18
YAWNWIRQPPGKGLEWIGYISYSGSTTYNPS
LKSRVTMSRDTSKNQFSLKLSSVTAVDTAVY
YCATGYYYGSGFWGQGTLVTVSSGGSEGKS
204
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SGSGSESKSTGGSDIVLTQSPDSLAVSLGERA
TINCKASESVEYFGTSLMHWYQQKPGQPPKL
LIYAASNRESGVPDRFSGSGSGTDFTLTISSVQ
AEDVAVYYCQQTRKVPYTFGQGTKLEIK
scFv12 hul 1B6_LCD6_HL QVQLQESGPGLVKPSDTLSLTCAVSGNSIT SD 19
YAWNWIRQPPGKGLEWIGYISYSGSTTYNPS
LKSRVTMSRDTSKNQFSLKLSSVTAVDTAVY
YCATGYYYGSGFWGQGTLVTVSSGGSEGKS
SGSGSESKSTGGSDIVLTQSPDSLAVSLGERA
TINCKASESVEYFGTSLMHWYQQKPGQPPKL
LIYAASNRESGVPDRFSGSGSGTDFTLTIQSV
QAEDVSVYFCQQTRKVPYTFGQGTKLEIK
scFv13 hul 1B6_HL QVQLQESGPGLVKPSDTL SLTCAVSGNSIT SD 20
YAWNWIRQPPGKGLEWIGYISYSGSTTYNPS
LKSRVTMSRDTSKNQFSLKLSSVTAVDTAVY
YCATGYYYGSGFWGQGTLVTVSSGGSEGKS
SGSGSESKSTGGSDIVLTQSPDSLAVSLGERA
TINCKASESVEYFGTSLMHWYQQKPGQPPKL
LIYAASNRESGVPDRFSGSGSGTDFTLTISSLQ
AEDVAVYYCQQTRKVPYTFGQGTKLEIK
scFv14 DIVLTQSPDSLAVSLGERATINCKASESVEYF 21
LCD6_hu11B6_LH GTSLMHWYQQKPGQPPKLLIYAASNRESGVP
DRFSGSGSGTDFTLTIQSVQAEDVSVYFCQQT
RKVPYTFGQGTKLEIKGGSEGKSSGSGSESKS
TGGSQVQLQESGPGLVKPSDTLSLTCAVSGN
SITSDYAWNWIRQPPGKGLEWIGYISYSGSTT
YNPSLKSRVTMSRDTSKNQFSLKLSSVTAVD
TAVYYCATGYYYGSGFWGQGTLVTVSS
scFv15 hull B6_LH DIVLTQSPDSLAVSLGERATINCKASESVEYF 22
GTSLMHWYQQKPGQPPKLLIYAASNRESGVP
DRFSGSGSGTDFTLTISSLQAEDVAVYYCQQT
RKVPYTFGQGTKLEIKGGSEGKSSGSGSESKS
TGGSQVQLQESGPGLVKPSDTLSLTCAVSGN
SITSDYAWNWIRQPPGKGLEWIGYISYSGSTT
YNPSLKSRVTMSRDTSKNQFSLKLSSVTAVD
TAVYYCATGYYYGSGFWGQGTLVTVSS
scFv16 LCB7_hu11B6_LH DIVLTQSPDSLAVSLGERATINCKASESVEYF 23
GTSLMHWYQQKPGQPPKLLIYAASNRESGVP
DRFSGSGSGTDFTLTISSVQAEDVAVYYCQQ
TRKVPYTFGQGTKLEIKGGSEGKSSGSGSESK
STGGSQVQLQESGPGLVKPSDTLSLTCAVSG
NSITSDYAWNWIRQPPGKGLEWIGYISYSGST
TYNPSLKSRVTMSRDTSKNQFSLKLSSVTAV
DTAVYYCATGYYYGSGFWGQGTLVTVSS
scFv17 KL2B413_HL EVQLVESGGGLVQPGGSLRLSCAASGFTFSS 340
YWMTWVRQAPGKGLEWVANIKQDGSERYY
VDSVKGRFTISRDNAKNSLYLQMNSLRAEDT
205
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
AVYYCARDQNYDILTGHYGMDVWGQGTTV
TVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPS
FLSASVGDRVTITCRASQGISSYLSWYQQKPG
KAPKLLIYATSTLQSGVPSRFSGSGSGTEFTLT
IS SLQPEDFATYYCQQLNSYPRTFGQGTKVEI
K
scFv18 KL2B413_LH EIVLTQSPSFLSASVGDRVTITCRASQGISSYL 341
SWYQQKPGKAPKLLIYATSTLQSGVPSRFSGS
GSGTEFTLTISSLQPEDFATYYCQQLNSYPRT
FGQGTKVEIKGGSEGKSSGSGSESKSTGGSEV
QLVESGGGLVQPGGSLRLSCAASGFTFSSYW
MTWVRQAPGKGLEWVANIKQDGSERYYVD
SVKGRFTISRDNAKNSLYLQMNSLRAEDTAV
YYCARDQNYDILTGHYGMDVWGQGTTVTV
SS
scFv19 KL2B359_HL QVQLQESGPGLVKPSQTLSLTCTVSGNSIT SD 342
YAWNWIRQFPGKRLEWIGYISYSGSTTYNPS
LKSRVTISRDTSKNQFSLKLSSVTAADTAVYY
CATGYYYGSGFWGQGTLVTVSSGGSEGKSS
GSGSESKSTGGSEIVLTQSPATLSLSPGERATL
SCRASESVEYFGTSLMHWYQQKPGQPPRLLI
YAASNVESGIPARFSGSGSGTDFTLTISSVEPE
DFAVYFCQQTRKVPYTFGGGTKVEIK
scFv20 KL2B359_LH EIVLTQSPATLSLSPGERATLSCRASESVEYFG 343
TSLMHWYQQKPGQPPRLLIYAASNVESGIPA
RFSGSGSGTDFTLTISSVEPEDFAVYFCQQTR
KVPYTFGGGTKVEIKGGSEGKSSGSGSESKST
GGSQVQLQESGPGLVKPSQTLSLTCTVSGNSI
TSDYAWNWIRQFPGKRLEWIGYISYSGSTTY
NPSLKSRVTISRDTSKNQFSLKLSSVTAADTA
VYYCATGYYYGSGFWGQGTLVTVSS
scFv21 KL2B357_HL QVQLQESGPGLVKPSQTLSLTCTVSGNSIT SD 169
YAWNWIRQFPGKGLEWIGYISYSGSTTYNPS
LKSRVTISRDTSKNQFSLKLSSVTAADTAVYY
CATGYYYGSGFWGQGTLVTVSSGGSEGKSS
GSGSESKSTGGSDIVLTQSPDSLAVSLGERATI
NCRASESVEYFGTSLMHWYQQKPGQPPKLLI
YAASNVESGVPDRFSGSGSGTDFTLTISSLQA
EDVAVYFCQQTRKVPYTFGGGTKVEIK
scFv22 KL2B357_LH DIVLTQSPDSLAVSLGERATINCRASESVEYF 170
GTSLMHWYQQKPGQPPKLLIYAASNVESGVP
DRFSGSGSGTDFTLTISSLQAEDVAVYFCQQT
RKVPYTFGGGTKVEIKGGSEGKSSGSGSESKS
TGGSQVQLQESGPGLVKPSQTLSLTCTVSGN
SITSDYAWNWIRQFPGKGLEWIGYISYSGSTT
YNPSLKSRVTISRDTSKNQFSLKLSSVTAADT
AVYYCATGYYYGSGFWGQGTLVTVSS
scFv23 KL2B358_HL QVQLQESGPGLVKPSQTLSLTCTVSGNSIT SD 171
YAWNWIRQPPGKGLEWIGYISYSGSTTYNPS
LKSRVTISRDTSKNQFSLKLSSVTAADTAVYY
206
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
CATGYYYGSGFWGQGTLVTVSSGGSEGKSS
GSGSESKSTGGSEIVLTQSPATLSLSPGERATL
SCRASESVEYFGTSLMHWYQQKPGQPPRLLI
YAASNVESGIPARFSGSGSGTDFTLTISSVEPE
DFAVYFCQQTRKVPYTFGGGTKVEIK
scFv24 KL2B358_LH EIVLTQSPATLSLSPGERATLSCRASESVEYFG 172
TSLMHWYQQKPGQPPRLLIYAASNVESGIPA
RFSGSGSGTDFTLTISSVEPEDFAVYFCQQTR
KVPYTFGGGTKVEIKGGSEGKSSGSGSESKST
GGSQVQLQESGPGLVKPSQTLSLTCTVSGNSI
TSDYAWNWIRQPPGKGLEWIGYISYSGSTTY
NPSLKSRVTISRDTSKNQFSLKLSSVTAADTA
VYYCATGYYYGSGFWGQGTLVTVSS
scFv25 KL2B360_HL QVQLQESGPGLVKPSQTLSLTCTVSGNSITSD 173
YAWNWIRQFPGKGLEWIGYISYSGSTTYNPS
LKSRVTISRDTSKNQFSLKLSSVTAADTAVYY
CATGYYYGSGFWGQGTLVTVSSGGSEGKSS
GSGSESKSTGGSEIVLTQSPATLSLSPGERATL
SCRASESVEYFGTSLMHWYQQKPGQPPRLLI
YAASNVESGIPARFSGSGSGTDFTLTISSVEPE
DFAVYFCQQTRKVPYTFGGGTKVEIK
scFv26 KL2B360_LH EIVLTQSPATLSLSPGERATLSCRASESVEYFG 174
TSLMHWYQQKPGQPPRLLIYAASNVESGIPA
RFSGSGSGTDFTLTISSVEPEDFAVYFCQQTR
KVPYTFGGGTKVEIKGGSEGKSSGSGSESKST
GGSQVQLQESGPGLVKPSQTLSLTCTVSGNSI
TSDYAWNWIRQFPGKGLEWIGYISYSGSTTY
NPSLKSRVTISRDTSKNQFSLKLSSVTAADTA
VYYCATGYYYGSGFWGQGTLVTVSS
scFv27 KL2B3O_HL QVQLQESGPGLVKPSETLSLTCTVSGGSISSY 175
YWSWIRQPPGKGLEWIGYIYYSGSTNYNPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYY
CAGTTIFGVVTPNFYYGMDVWGQGTTVTVS
SGGSEGKSSGSGSESKSTGGSDIQMTQSPSFL
SASVGDRVTITCRASQGISSYLAWYQQKPGK
APKFLIYAASTLQSGVPSRFSGSGSGTEFTLTI
SSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK
scFv28 KL2B3O_LH DIQMTQSPSFLSASVGDRVTITCRASQGISSYL 176
AWYQQKPGKAPKFLIYAASTLQSGVPSRFSG
SGSGTEFTLTISSLQPEDFATYYCQQLNSYPLT
FGGGTKVEIKGGSEGKSSGSGSESKSTGGSQV
QLQESGPGLVKPSETLSLTCTVSGGSISSYYW
SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSR
VTISVDTSKNQFSLKLSSVTAADTAVYYCAG
TTIFGVVTPNFYYGMDVWGQGTTVTVSS
scFv29 KL2B53_HL EVQLVESGGGVVQPGRSLRLSCVASGFTFSS 177
YDIHWVRQAPGKGLEWVAIISYDGSKKDYT
DSVKGRFTISRDNSKNTLYLQMDSLRVEDSA
VYSCARESGWSHYYYYGMDVWGQGTMVT
VSSGGSEGKSSGSGSESKSTGGSDIVMTQSPS
207
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SLSASVGDRVTITCRASQDISNYLAWYQQKP
GKVPKFLIYAASTLHSGVPSRFSGSGSGTDFT
LTISSLQPEDVATYYCQKYNSAPYTFGQGTR
LEIK
scFv30 KL2B53_LH DIVMTQSPSSLSASVGDRVTITCRASQDISNY 178
LAWYQQKPGKVPKFLIYAASTLHSGVPSRFS
GSGSGTDFTLTISSLQPEDVATYYCQKYNSAP
YTFGQGTRLEIKGGSEGKSSGSGSESKSTGGS
EVQLVESGGGVVQPGRSLRLSCVASGFTFSS
YDIHWVRQAPGKGLEWVAIISYDGSKKDYT
DSVKGRFTISRDNSKNTLYLQMDSLRVEDSA
VY S CARES GWSHYYYY GMDVWGQ GTMVT
VS S
scFv31 KL2B242_HL QVQLQESGPGLVKPSETLSLTCTVSGGSISSY 179
YWSWLRQPAGSGLEWIGRLYVSGFTNYNPS
LKSRVTLSLDPSRNQLSLKLSSVTAADTAVY
YCAGDSGNYWGWFDPWGQGTLVTVSSGGS
EGKSSGSGSESKSTGGSSYELTQPPSVSVSPG
ETASITCSGDQLGENYACWYQQKPGQSPVLV
IYQDSKRPSGIPERFSGSNSGNTATLTISGTQA
LDEADYYCQAWDNSIVVFGGGTKLTVL
scFv32 KL2B242_LH SYELTQPPSVSVSPGETASITCSGDQLGENYA 180
CWYQQKPGQSPVLVIYQDSKRPSGIPERFSGS
NSGNTATLTISGTQALDEADYYCQAWDNSIV
VFGGGTKLTVLGGSEGKSSGSGSESKSTGGS
QVQL QESGPGLVKPSETL SLTCTVSGGSIS SY
YWSWLRQPAGSGLEWIGRLYVSGFTNYNPS
LKSRVTLSLDPSRNQLSLKLSSVTAADTAVY
YCAGDSGNYWGWFDPWGQGTLVTVSS
scFv33 KL2B467 HL QVQLVESGGGVVQPGRSLRL SCAASGFTF SY 181
YGMHWVRQAPGKGLEWVAFISYDGSNKYY
ADS VKGRFTISRDNSKNTLYLQMNSLRAEDT
AVYYCAHLPYSGSYWAFDYWGQGTQVTVS
SGGSEGKSSGSGSESKSTGGSQSVLTQPPSVS
VAPGQTASITCGGDNIGSKSVHWYQQKPGQ
APVLVVYDNSDRPSGIPERFSGSNSGTTATLTI
SRVEAGDEADYYCQVWDSSSDHPVVFGGGT
KVTV
scFv34 KL2B467 LH QSVLTQPPSVSVAPGQTASITCGGDNIGSKSV 182
HWYQQKPGQAPVLVVYDNSDRPSGIPERFSG
SNSGTTATLTISRVEAGDEADYYCQVWDSSS
DHPVVFGGGTKVTVGGSEGKSSGSGSESKST
GGSQVQLVESGGGVVQPGRSLRLSCAASGFT
FSYYGMHWVRQAPGKGLEWVAFISYDGSNK
YYADSVKGRFTISRDNSKNTLYLQMNSLRAE
DTAVYYCAHLPYSGSYWAFDYWGQGTQVT
VS S
scFv35 KL2B494_HL QVQLVESGGGLVQPGGSLRLSCAASGFTFSH 183
YAM SWVRQAPGKGLEWVST IGGS GGS TYYA
DSVKGRFTISRDNSKNTLYLQMNSLRAEDTA
208
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
VYYCAKPHIVMVTALLYDGMDVWGQGTMV
TVSS
GGSEGKSSGSGSESKSTGGSSSELTQPPSVSV
APGQTARITCGGNNIGSKSVHWYQQKPGQAP
VLVVYDDSDRPSGIPERFSGSNSGNTATLTIS
RVEAGDEADYYCQVWDSSSDHVVFGGGTKL
TVL
scFv36 KL2B494_LH SSELTQPPSVSVAPGQTARITCGGNNIGSKSV 184
HWYQQKPGQAPVLVVYDDSDRPSGIPERFSG
SNSGNTATLTISRVEAGDEADYYCQVWDSSS
DHVVFGGGTKLTVLGGSEGKSSGSGSESKST
GGSQVQLVESGGGLVQPGGSLRLSCAASGFT
FSHYAMSWVRQAPGKGLEWVSTIGGSGGST
YYADSVKGRFTISRDNSKNTLYLQMNSLRAE
DTAVYYCAKPHIVMVTALLYDGMDVWGQG
TMVTVSS
Example 12. Biophysical characterization of anti-hK2 antibodies
Affinity and thermal stability of anti-hK2 antibodies.
Affinity of selected hK2 antibodies for soluble hK2 was measured by surface
plasmon
resonance (SPR). SPR is a label-free technique to study the strength of an
interaction
between two binding partners by measuring the change in mass upon complex
formation
and dissociation. Antibodies were captured on a sensor chip coated with an
anti-Fc
antibody followed by injection of soluble hK2 at various concentrations and
specified
association and dissociation times. Post dissociation, the surface was
regenerated with an
appropriate solution to prepare for the next interaction. Kinetic information
(on-rate and
off-rate constants) were extracted by fitting sensorgrams to the 1:1 Langmuir
model.
Binding affinity (KD) are reported as the ratio of rate constants (koffikon).
KD values of
selected hK2 antibodies are listed in Table 15.
Thermal stability was determined by Differential Scanning Fluorimetry
(NanoDSF) using
an automated Prometheus instrument. NanoDSF was used to measure T. of
molecules at a
concentration of 0.5 mg/mL in Phosphate Buffered Saline, pH 7.4. Measurements
were
made by loading samples into 24 well capillary from a 384 well sample plate.
Duplicate
runs were performed for each sample. The thermal scans span from 20 C to 95 C
at a rate
of 1.0 C/minute. Intrinsic tryptophan and tyrosine fluorescence were monitored
at the
209
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
emission wavelengths of 330 nm and 350 nm, and the F350/F330 nm ratio were
plotted
against temperature to generate unfolding curves. Measured Tm values are
listed in Table
15.
Table 15. KD and Tm of selected molecules
Molecule Ko (nM) Tm ( C)
KL2B413 (scFv) 34.3 67
KL2B359 (scFv) 0.7 ¨ 1 67
KL2B30 (Fab) 0.460 >70
KL2B242 (Fab) 0.040 >70
KL2B53 (Fab) 0.080 >70
KL2B467 (Fab) 0.078 >70
KL2B494 (Fab) 0.053 >70
KL2B413 scFv generated from the Ablexis immunization campaign had a thermal
stability
(Tm) of 67 C as measured by Nano DSF and a binding affinity (KO to human hK2
of
about 34 nM. Clone KL2B359 obtained for the re-humanization campaign and which
had
maintained a binding affinity similar to murine 11B6 was converted to scFv-Fc
and CAR-
T for additional profiling. KL2B359 scFv shows a Tm of 67 C and a binding
affinity (KO
to hK2 of -0.7 - 1nM. KL2B30, KL2B242, KL2B53, KL2B467 and KL2B494 Fab
showed binding affinities below 0.5 nM and Tm values above 70 C.
Epitope mapping
The epitope on selected KL2B antibodies was determined by hydrogen-deuterium
exchange mass spectrometry (HDX-MS). Human KLK2 antigen was used for epitope
mapping experiment.
Briefly, purified the KLK2 antigen was incubated with and without anti-KLK2
antibodies
in deuterium oxide labeling buffer. The hydrogen-deuterium exchange (HDX)
mixture
210
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
was quenched at different time point by the addition of 8 M urea, 1M TCEP, pH
3Ø The
quenched sample was passed over an immobilized pepsin/FPXHI column at 600
pL/min
equilibrated with buffer A (1% acetonitrile, 0.1% FA in H20) at room
temperature. Peptic
fragments were loaded onto a reverse phase trap column at 600 pL/min with
buffer A and
desalted for 1 min (600 pL buffer A). The desalted fragments were separated by
a C18
column with a linear gradient of 8% to 35% buffer B (95% acetonitrile, 5% H20,
0.0025%
TFA) at 100 pL/min over 20 min and analyzed by mass spectrometry. Mass
spectrometric
analyses were carried out using an LTQTm Orbitrap Fusion Lumos mass
spectrometer
(Thermo Fisher Scientific) with the capillary temperature at 275 C,
resolution 150,000,
and mass range (m/z) 300 ¨ 1,800. BioPharma Finder 3.0 (Thermo Fisher
Scientific) was
used for the peptide identification of non-deuterated samples prior to the HDX
experiments. HDExaminer version 2.5 (Sierra Analytics, Modesto, CA) was used
to extract
centroid values from the MS raw data files for the HDX experiments.
Incubation of hK2 antibodies, hullB6, KL2B494, KL2B467, KL2B30, KL2B413 and
KL2B53 with soluble hK2 protein resulted in different patterns of hydrogen
exchange and
overall protection. The protected segments were mapped onto the sequence of
hK2 antigen
to visualize the binding epitopes (Figure 17B). KL2B494, KL2B467 and KL2B30
bound
to a common sequence consisting of residues 173-178 (SEQ ID NO: 346, KVTEF)
and
residue 230-234 (SEQ ID NO: 347, HYRKW). KL2B53 showed a different pattern of
protection and bound to a sequence consisting of residues 27-32 (Seq ID NO:
348,
SHGWAH), 60-75 (SEQ ID NO: 349, RHNLFEPEDTGQRVP) and 138-147 (SEQ ID
NO: 350, GWGSIEPEE).
Example 13. Generation and characterization of additional scFvs CAR constructs
The ectodomain of 11B6 cloned as scFv did not retain binding at elevated
temperature
(55 C) and hence additional campaigns were initiated to generate new humanized
antibodies from the parental 11B6.
hK2 CARs containing thermally stabilized scFvs derived from the antibody 11B6
were
generated. The description and SEQ ID NOs: of the CAR constructs containing
thermally
211
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
stabilized scFvs are provided in Table 16. The names in the description refer
back to the
VH or the VL chains identified above, 20AA refers to the 20 amino acid long
linker
between the VH/VL pairs in the scFv. The scFv in the CARs were cloned in
either VH-L-
VL or VL-L-VH orientation.
The generated scFvs KL2B413 KL2B413 LH, KL2B359 HL and KL2B359 LH
were also incorporated into CAR constructs and further characterized. Table 16
shows the
generated CAR constructs and their SEQ ID NOs. The signal sequence used was
MAWVWTLLFLMAAAQSIQA (SEQ ID NO: 24)
Table 16.
SEQ ID SEQ ID SEQ ID
NO: of NO: of NO: of
scFv full ECD CAR amino
Name of
amino domain of acid
CAR Description of scFv in the CAR
acid CAR sequence
construct
sequence (including
I the signal
CAR sequence)
CAR1 HL_HCG5_LCD6_20AA (scFv1) 8 273 46
CAR2 HL_HCG5_LCh11B6_20AA (scFv2) 9 274 47
CAR3 HL_HCF3_LCB7_20AA (scFv3) 10 275 48
CAR4 HL_HCG5_LCB7_20AA (scFv4) 11 276 49
CARS LH_LCD6_HCG5_20AA (scFv5) 12 277 50
CAR6 LH_LCHumanized_HCF3_20AA (scFv6) 13 278 51
CAR7 LH_LCHumanized_HCG5_20AA (scFv7) 14 279 52
CAR8 LH_LCB7_HCF3_20AA (scFv8) 15 280 53
CAR9 LH_LCB7_HCG5_20AA (scFv9) 16 281 54
CAR10 LH_LCD6_HCF3_20AA (scFv10) 17 282 55
CAR11 HL_HCHumanized_LCB7_20AA (scFv11) 18 283 56
CAR12 HL_HCHumanized_LCD6_20AA (scFv12) 19 284 57
CAR13 HL HCHumanized LCHumanized 20AA 20 285 58
(scFv13)
CAR14 LH_LCD6_HCHumanized_20AA (scFv14) 21 286 59
CAR15 LH LCHumanized HCHumanized 20AA 22 287 60
(scFv15)
212
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
CAR16 LH_LCB7_HCHumanized_20AA (scFv16) 23 288 61
CAR17 KL2B413 (scFv17) 340 289 82
CAR18 KL2B413 LH (scFv18) 341 290 83
CAR19 KL2B359 EL (scFv19) 342 291 84
CAR20 KL2B359 LH (scFv20) 343 292 85
CAR21 KL2B357 (scFv21) 169 319 205
CAR22 KL2B357 LH (scFv22) 170 320 206
CAR23 KL2B358 (scFv23) 171 321 207
CAR24 KL2B358 LH (scFv24) 172 322 208
CAR25 KL2B360 EL (scFv25) 173 323 209
CAR26 KL2B360 LH (scFv26) 174 324 210
CAR27 KL2B30 EL (scFv27) 175 325 211
CAR28 KL2B30 LH (scFv28) 176 326 212
CAR29 KL2B53 EL (scFv29) 177 327 213
CAR30 KL2B53 LH (scFv30) 178 328 214
CAR31 KL2B242 (scFv31) 179 329 215
CAR32 KL2B242 LH (scFv32) 180 330 216
CAR33 KL2B467 (scFv33) 181 331 217
CAR34 KL2B467 LH (scFv34) 182 332 218
CAR35 KL2B494 (scFv35) 183 333 219
CAR36 KL2B494 LH (scFv36) 184 334 220
LCHumanized refers to hu11B6_VL.
HCHumanized refers to hu11B6_VH
Example 14: Identification of different scFv-based CAR with anti2en-
independent
activation via JurkatLuciaTM NFAT cells.
Nuclear factor of activated T-cells (NFAT) is a family of transcription
factors first
identified as a regulator of immune cells. Without wishing to be bound by
theory, T cell
activation leads to calcium influx, which activates calcineurin that
dephosphorylates serine
rich nuclear localization signal at the N-terminus of NFAT, leading to nuclear
import of
NFAT. Tonic signaling due to scFv clustering could be subsequently detected by
Firefly
luciferase driven by NFAT promoter in JNL reporter cell line.
Jurkat cells containing the luciferase gene driven by the signaling-responsive
NFAT
promoter (termed JNL cells), were transduced with the various CAR constructs.
Binding
between the CAR construct and its cognate cellular antigen (hK2 on target
cells) leads to
luciferase expression in the JNL cells. Novel hK2 KL2B413 and rehumanized 11B6
CAR
213
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
clones were evaluated in the JNL reporter assay for antigen-dependent activity
according
to the following protocol.
Lentiviral transduction was performed as follows. JNL cells were harvested and
resuspended to 1E6/ml. 500 p1 JNL cells and lentiviral virus at MOI of 3 were
added, and
mixed by pipetting up and down. The mixture was placed in the 37 C incubator
for 24
hours. Then, 500 IA of JNL media was added to each well. Culturing was
continued in the
37 C incubator. The cells were transferred to a T25 flask on day 4. At day 5-
6,
transduction validation was performed. 150 IA of cells was harvested to
examine CAR
expression via appropriate detection reagent for the specific CAR of interest
(e.g. biotin-
hK2 Protein is used to detect hK2 CAR). The JNL cells were maintained at
5x105/m1 until
there were enough cells to freeze down or use for the JNL assay described
below.
A JNL assay was performed as follows. Co-culture with target cell lines was
undertaken at
the effector to target ratio of 2:1. JNL cells were spun down to remove any
secreted
luciferase in the medium, and resuspended in fresh media at 4x105/ml. The JNL
cells were
harvested. Both antigen positive and antigen negative target cell lines were
prepared at
2E5/ml. Then, 100 IA JNL was added to 100 IA target cells. For the JNL only
control, 100
IA of media was added instead of target cells. For the positive control, JNL
cells only or
CAR JNL cells were added to lx Cell Stimulation Cocktail, and incubated in a
37 C
incubator for 24 hours. 150 IA of supernatant was harvested into a 96-well
plate and
centrifuged to remove cells. 100 IA of supernatant was transferred from the
plate to a solid
bottom black plate, followed by addition of 100 IA QUANTI-luc lucia detection
reagent
and incubation at room temperature for 5 minutes before reading with Envision
multiplate
reader.
Jurkat cells containing the luciferase gene driven by the signaling-responsive
NFAT
.. promoter (termed JNL cells) were transduced with various hK2 CAR
constructs.
Expression was determined by biotinylated hK2 followed by streptavidin-
conjugated PE.
The data are shown in Figure 12A. CAR expression in transduced JNL cells was
confirmed for the selected clones, with 46-50% of cells expression on
rehumanized 11B6
KL2B359 CARs and 73.7-96% of cells on KL2B413 CARs.
214
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
The data in Figure 12B shows that binding between the hK2 CAR construct and
its
cognate cellular antigen (hK2 on target cells) leads to luciferase expression
in the JNL
cells. JNL cells containing the indicated CAR clones and JNL cells (UTD) were
co-
cultured with target cells lines (VCap, LNCap/Hk2, LNCap, C4-2B, 22Ry1 or
DU145
cells) and luciferase activity was measured as luminescence intensity. Clones
were
considered active when the luminescence intensity exceeded 1.5-fold the level
of UTD
cells in the presence of antigen-expressing cells. No antigen-dependent
activation was
found for the novel KL2B413 and rehumanized 11B6 HIL&LH CARS.
Example 15: HK2 CAR-T cells were evaluated in the real-time IncuCyte killing
assay
for antigen-dependent cytotoxicity.
HK2 CAR-T cells were co-incubated with HK2+ VCaP cells and HK2- DU145 cells
for 96
hours. The effector-to-target (ET) ratio was calculated based on CAR
expression data
shown in Figures 11A-11B. Target cells were stably expressing a red nuclear
dye, which
was measured by IncuCyte imaging system in a real-time fashion. The data is
shown in
Figure 13A for HK2 CAR-T cells co-incubated with HK2+ VCaP cells, and in
Figure
13B for HK2 CAR-T cells co-incubated with HK2- DU145 cells. In these figures,
tumor
cell growth inhibition (%) = (Initial Viable Target Cell Number-Current Viable
Target Cell
Number)/Initial Viable Cell Number*100 (%).
Example 16. Characterization of CAR-T cells transduced with KL2B413
KL2B413 LH, KL2B359 HL or KL2B359 LH.
215
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Activation of CAR-T cells is antigen-dependent
The generated CAR-T cells were evaluated in the JNL reporter assay for antigen-
dependent activity as described in Example 4. Briefly, Jurkat cells containing
the
luciferase gene driven by the signaling-responsive NFAT promoter (termed JNL
cells)
were transduced with CAR17 (KL2B413 HL) CAR18 (KL2B413 LH) CAR19
(KL2B359 EIL) or CAR20 (KL2B359 LH) constructs. Expression of each CAR was
determined by biotinylated hK2 followed by streptavidin-conjugated PE. CAR
expression in transduced JNL cells was confirmed for the selected clones with
46-50% of
cells expressing KL2B359-based CARs and 73.7-96% of cells expressing KL2B413-
based CARS as shown in Figure 6. The percent JNL cells expressing each CAR was
following: KL2B413 HL: 73.7%, KL2B413 LH: 93.6%, KL2B359 HL: 46%,
KL2B359 LH: 50.8%.
Binding between the hK2 CAR construct and its cognate cellular antigen (hK2 on
target
cells) leads to luciferase expression in the JNL cells. To that end, JNL cells
transduced
with the test CAR constructs or untransduced JNL cells (UTD) were co-cultured
with
target cells lines (VCap, LNCap/hK2 (LNCaP cells recombinantly expressing
hK2),
LNCaP, C4-2B, 22Rv1 or DU145 cells) and luciferase activity was measured as
luminescence intensity. Constructs were considered active when the
luminescence
intensity exceeded 1.5-fold the level of UTD cells in the presence of antigen-
expressing
cells. No antigen-dependent activation was found for the tested CAR
constructs. Figure
13A shows the RLU (relative light units) resulting from binding of CAR-T cells
to test
target cells ad indicated in the Figure.
CAR-T cells produce cytokines upon antigen stimulation
IFN-y produced by cytotoxic T cells is critical for exerting immune
surveillance of
tumors, which can directly inhibit proliferation and induce apoptosis of some
malignancies in vivo and in vitro. To determine whether hK2 CAR-modified human
T
cells were able to recognize and become activated by hK2 positive tumor cells,
primary T
cells transduced with indicated CAR clones and control untransduced T cells
(UTD) were
co-cultured with target cells lines (LNCaP/hK2, LNCaP, C4-2B, 22Rv1 or DU145
cells)
216
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
and supernatant were collected for IFN-y concentration measurement. As shown
in
Figure 14, CAR-T cells transduced with hK2 CARs cells secreted IFN-y during co-
culture with LNCaP cells recombinantly expressing hK2 (LNCap/hK2) cells and
also
during co-culture with very low hK2-expressing C4-2B and LNCap cells but not
hK2-
negative DU145 cells. Mean IFN-y concentration SD (pg/ml) from duplicate
cultures
is shown in Figure 14.
CAR-T cells proliferate in antigen-dependent manner
CAR-T cells were evaluated for their proliferation using T-cell proliferation
assay
protocol described in Example 4. hK2 CAR-T and untransduced (UTD) T cells were
labelled with CellTrace Violet(CTV; 51.1M) and co-cultured with hK2 positive
VCap and
hK2 negative DU145 cells. Five days post co-culture, cells were harvested and
stained
with CD3, CD25, NearIR live/dead Dye and hK2 CAR. Flow cytometric analysis was
performed on a Fortessa flow cytometer with Flowjo software. Lymphocytes were
identified by live CD3, and the frequencies of CAR-T cells with CTV dye
dilution and
activation marker CD25 were determined. By gating on CD3+ T cells, the hK2
positive
Vcap cells but not hK2 negative DU145 cells promoted proliferation of each
tested CAR-
T cell line, as shown in FIGS. 10C, 10D, and 10E, and upregulation of
activation marker
CD25 as shown in Figure 11B and Figure 12A. T cells only without any
stimulation did
not proliferate and CD3/28 beads stimulated T cells displayed equivalent
proliferation
pattern. hK2 CAR+ T cells proliferated more robustly than CD3/28 beads
positive
control after 5 days of coculture with VCap cells. Different tested CAR-T
cells had
different proliferation activity and displayed different CAR-T cells counts.
The
percentage of proliferating T cells and CD25 expressing T cells was based on
mean
absolute cell count +/- SEM from duplicate.
Example 17: Thl cytokine IFN-gamma production of antigen-stimulated CAR-T
Cells.
217
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Without wishing to be bound by theory, IFN-y produced by cytotoxic T cells is
critical
for exerting immune surveillance of tumors, which can directly inhibit
proliferation and
induce apoptosis of some malignancies in vivo and in vitro.
To determine whether hK2 CAR-modified human T cells were able to recognize and
activated by hK2 (+) tumor cells, primary T cells containing the indicated CAR
clones and
control untransduced T cells (UTD) were co-cultured with target cells lines
(LNCap/Hk2,
LNCap, C4-2B, 22Rv1 or DU145 cells) and supernatant were collected for IFN-g
concentration measurement. The data are shown in Figure 14 as the mean IFN-y
concentration SD (pg/ml) from duplicate cultures. As shown, hK2 CAR modified
T cells
secrete IFN-gamma during co-culture with hK2-expressing LNCap/hK2 cells, even
very
low Hk2 expressing C4-2B and LNCap cells but not hK2-negative DU145 cells.
Undisclosed control CAR secreted a much higher amount of IFN- y due to the
much higher
antigen expression level than hK2.
Example 18: CD107a Degranulation assay to evaluate hK2 CAR T cells' antitumor
activity.
Without wishing to be bound by theory, tumor cells can be recognized and
killed by
cytotoxic lymphocytes, such as CD8+ T lymphocytes and natural killer (NK)
cells,
mainly through the immune secretion of lytic granules that kill target cells.
This process
involves the fusion of the granule membrane with the cytoplasmic membrane of
the
immune effector cell, resulting in surface exposure of lysosomal-associated
proteins that
are typically present on the lipid bilayer surrounding lytic granules, such as
CD107a.
Therefore, membrane expression of CD107a constitutes a marker of immune cell
activation and cytotoxic degranulation.
The degranulation assay was performed as follows. Target cells (5 x 104) were
cocultured
with an equal number of effector cells in 0.1m1 per well in a 96-well plate.
Control wells
contained T cells alone. Anti-CD107a (50 per well) was added in addition to
1p.1/sample
of monensin (BD Biosciences), followed by incubation for 4 hours at 37 C.
Cells were
218
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
washed two times with PBS, stained for expression of the hK2 CAR, CD3, and CD8
and
analyzed on a flow cytometer BD Fortessa. The data are shown in Figure 15.
As shown, the presence of hK2 antigen on Vcap cells leads to an increase in
CD107A+
hK2 CAR(+) T cells, but not in hK2 CAR(-) and UTD T cells measured by flow
cytometry. Only the background staining(<2%) was seen in the CAR T cells
without
tumor cell stimulation. Phorbol 12-myristate 13-acetate (PMA) in combination
with
ionomycin (eBioscienceTM Cell Stimulation Cocktail; 500X) was a consistent
inducer of
CD107a cell surface expression in this 4-hour cell culture model, which was
used as a
positive control. The results shown in Figure 15 are for representative donor
T cells and
are reproducible in multiple donors.
Example 19: T-cell proliferation is an important in vitro parameter of in vivo
immune
function.
To further evaluate the function of novel KL2B413 and rehumanized 11B6
(KL2B359)
CAR T cells and to assist in picking the top candidate construct, CAR T cells
were labeled
with CellTraceTm Violet (CTV; 5uM) for the T cells proliferation assay. The
following
protocol was followed, with the results shown in Figures 16A-16D.
Tumor cells Vcap and DU145 were collected and washed twice with PBS. The cells
were
resuspended in 10E6/m1 in PBS containing 100ug/m1Mitomycin C (MMC) for 1.5
hours
in a 37 C incubator to block proliferation of tumor cells. 20 L DMSO was added
to a vial
of CTV staining solution. Then, 5 ul of solution was diluted into 5mL (1:1000)
of PBS
(warmed to 37 C) to yield a 5 uM staining solution. 2E6 T cells were counted
and
collected, washed with PBS twice, and then resuspended in 4E6/m1 (0.5m1). An
equal
volume (0.5 ml) of CTV staining solution was added. The cells were incubated
for 20
minutes at 37 C. After 20 minutes, 4 ml PRIVII+20% FBS was added to the cells
to absorb
any unbound dye, and the cells were incubated for 5 minutes. The cells were
centrifuged
for 5 minutes at 400 x g, followed by resuspension of the cell pellet in pre-
warmed
RPMI+10%FBS medium. The T cells were counted, andlE5 cells(1000) were seeded
in a
96-well flat bottom-plate.
219
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
In the meantime, MMC treated tumor cells hK2(+) VCap and EIK2(-) DU145 were
collected and counted post 1.5 hours, and then resuspended in 1E6/ml. 1E5
cells (100p1)
were co-cultured with T cells in 96-well plate. T cells alone and T cells
added in a 3:1
CD3/28 beads to cells ratio were used as negative and positive controls,
respectively.
After five days of co-culture, all the cells were collected from each well.
The cells were
centrifuged and washed for 5 minutes at 400 x g twice, and stained with
hK2CAR, CD3,
CD8 and CD25, live/dead (Near-IR) in 96-well U bottom plate. After washing,
all cells
were fixed for 10 minutes using BD CytofixTM Fixation Buffer (500 FACS buffer
+ 500
Fixation Buffer) in 100p1. Stained samples were analyzed by multicolor flow
cytometry
after the end of the incubation period.
Flow cytometric analysis was performed on a Fortessa flow cytometer with
Flowjo
software. Lymphocytes were identified by live CD3, and the frequencies of
CAR+T cells
with CTV dye dilution and activation marker CD25 were determined.
To prepare a CTV histogram, the CTV undiluted gate was set to encompass the
far-right
peak (CTV bright) of T cells cultured alone, and the CTV diluted gate to
capture the rest of
the population. This setting was applied to all samples. A statistic was added
to include
absolute # of cells in the CTV diluted population. A table was created with
this statistic,
followed by export of data (cell counts) to Excel for reformatting before
transferring to
Prism.
Figures 16A-16D show the results of a hK2 CAR T cell proliferation assay. By
gating on
CD3+ T cells, as shown in Figures 16A-16B, the hK2(+) Vcap cells but not hK2(-
)
DU145 cells promoted the proliferation of all CAR constructs engineered T
cells and
upregulation of activation marker CD25, as shown in Figures 16C-16D. CD3/28
beads
stimulated T cells were used as positive controls, and T cells only were used
as negative
controls. T cells only without any stimulation do not proliferate and CD3/28
beads
stimulated T cells displayed equivalent proliferation pattern. As shown, hK2
CAR+ T cells
proliferate more robustly than the CD3/28 beads positive control after 5 days
of coculture
with VCap cells. Different CAR construct-engineered T cells have different
proliferation
activity and displayed different CAR+ T cells counts. The summary of
percentage of
220
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
proliferating T cells and CD25 expressing T cells based on mean absolute cell
count +/-
SEM from duplicate is shown in Figures 16B and 16D.
Example 20: Construction and expression of hK2 scFv CARs
hK2 CAR constructs comprising the following scFv sequences are constructed:
KL2B357 HL:
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQFPGKGLEWIGYISYSGSTTY
NPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGTLVTVSSGG
SEGKSSGSGSESKSTGGSDIVLTQSPDSLAVSLGERATINCRASESVEYFGTSLMHWYQQ
KPGQPPKLLIYAASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQTRKVPYTF
GGGTKVEIK
(SEQ ID NO: 221)
KL2B357 LH:
DIVLTQSPDSLAVSLGERATINCRASESVEYFGTSLMHWYQQKPGQPPKLLIYAASNVES
GVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQTRKVPYTFGGGTKVEIKGGSEGKSSG
SGSESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQFPGKGLEWI
GYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQ
GTLVTVSS
(SEQ ID NO: 222)
KL2B358 HL:
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQPPGKGLEWIGYISYSGSTTY
NPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGTLVTVSSGG
SEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHWYQQK
PGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGG
TKVEIK
(SEQ ID NO: 223)
221
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
KL2B358 LH:
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHWYQQKPGQPPRLLIYAASNVESG
IPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGSEGKSSGSG
SESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQPPGKGLEWIGY
ISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSS
(SEQ ID NO: 224)
KL2B360 HL:
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQFPGKGLEWIGYISYSGSTTY
NPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGTLVTVSSGG
SEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHWYQQK
PGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGG
TKVEIK
(SEQ ID NO: 225)
KL2B360 LH:
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHWYQQKPGQPPRLLIYAASNVESG
IPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGSEGKSSGSG
SESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQFPGKGLEWIGY
ISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSS
(SEQ ID NO: 226)
KL2B30 HL:
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYN
PSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGTTIFGVVTPNFYYGMDVWGQGT
TVTVSSGGSEGKSSGSGSESKSTGGSDIQMTQSPSFLSASVGDRVTITCRASQGISSYLAW
222
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
YQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTEFTLTIS SLQPEDFATYYCQQLNSYPL
TFGGGTKVEIK
(SEQ ID NO: 227)
KL2B30 LH:
DIQMTQ SP SFL SASVGDRVTIT CRAS QGIS SYLAWYQQKPGKAPKFLIYAASTLQSGVPSR
FSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK GGSEGKSSGSGSESK
STGGSQVQLQESGPGLVKPSETLSLTCTVSGGSIS SYYWSWIRQPPGKGLEWIGYIYYSGS
TNYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCAGTTIFGVVTPNFYYGMDVW
GQGTTVTVS S
(SEQ ID NO: 228)
KL2B53 HL:
EVQLVESGGGVVQPGRSLRLSCVASGFTFS SYDIHWVRQAP GKGLEWVAII S YD GS KKD
YTDSVKGRFTISRDNSKNTLYLQMDSLRVED SAVYSCARESGWSHYYYYGMDVWGQG
TMVTVSSGGSEGKS SGS GSESKSTGGSDIVMTQ SP S SLSASVGDRVTITCRASQDISNYLA
WYQQKPGKVPKFLIYAASTLHS GVPSRFS GS GSGTDFTLTIS SLQPEDVATYYCQKYNSA
PYTFGQGTRLEIK
(SEQ ID NO: 229)
KL2B53 LH:
DIVMTQ SP S SL SASVGDRVTITCRAS QDISNYLAWYQQKPGKVPKFLIYAASTLHS GVPS
RFS GSGS GTDFTLTIS SLQPEDVATYYCQKYNSAPYTFGQGTRLEIKGGSEGKS SGSGSES
KS T GGS EVQLVE S GGGVVQPGRS LRL S CVA S GFTF S S YDIHWVRQAP GKGLEWVAII S Y
DGSKKDYTDSVKGRFTISRDNSKNTLYLQMDSLRVED SAVYSCARESGWSHYYYYGM
DVWGQGTMVTVS S
(SEQ ID NO: 230)
KL2B242 HL:
223
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWLRQPAGSGLEWIGRLYVSGFTNYN
PSLKSRVTLSLDPSRNQLSLKLS SVTAADTAVYYCAGDSGNYWGWFDPWGQGTLVTVS
SGGSEGKS SGSGSESKSTGGS SYELTQPPSVSVSPGETASITCSGDQLGENYACWYQQKP
GQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQALDEADYYCQAWDNSIVVFGG
GTKLTVL
(SEQ ID NO: 231)
KL2B242 LH:
SYELTQPPSVSVSPGETASITCSGDQLGENYACWYQQKPGQSPVLVIYQDSKRPSGIPERF
SGSNSGNTATLTISGTQALDEADYYCQAWDNSIVVFGGGTKLTVLGGSEGKSSGSGSES
KSTGGSQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWLRQPAGSGLEWIGRLYVS
GFTNYNPSLKSRVTLSLDPSRNQLSLKLSSVTAADTAVYYCAGDSGNYWGWFDPWGQG
TLVTVS S
(SEQ ID NO: 232)
KL2B467 HL:
QVQLVE S GGGVVQP GRSLRL S CAA S GFTF S YYGMHWVRQAP GKGLEWVAFI SYD GSNK
YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAHLPYSGSYWAFDYWGQGT
QVTVS SGGSEGKS S GS GSESKSTGGS Q SVLT QPP SVSVAPGQTASITCGGDNIGSKSVHW
YQQKPGQAPVLVVYDNSDRPSGIPERFSGSNSGTTATLTISRVEAGDEADYYCQVWDS S
SDHPVVFGGGTKVTV
(SEQ ID NO: 233)
KL2B467 LH:
QSVLTQPPSVSVAPGQTASITCGGDNIGSKSVHWYQQKPGQAPVLVVYDNSDRPSGIPER
FSGSNSGTTATLTISRVEAGDEADYYCQVWDSS SDHPVVFGGGTKVTVGGSEGKS S GS G
S E SKS T GGS QVQLVE S GGGVVQPGRSLRL S CAA S GFTF S YYGMHWVRQAP GKGLEWVA
FISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAHLPYSGSYWAF
DYWGQGTQVTVSS
(SEQ ID NO: 234)
224
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
KL2B494 HL:
QVQLVESGGGLVQPGGSLRL S CAA S GFTF S HYAM SWVRQAPGKGLEWV STI GGS GGST
YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPHIVMVTALLYDGMDVW
GQGTMVTVS SGGSEGKS SGSGSESKSTGGS SSELTQPPSVSVAPGQTARITCGGNNIGSKS
VHWYQ QKPGQAPVLVVYDD S DRP S GIPERF S G SN S GNTAT LTI SRVEAGDEADYYC QV
WDSS SDHVVFGGGTKLTVL
(SEQ ID NO: 235)
KL2B494 LH:
S SELTQPPSVSVAP GQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDD SDRPS GIPER
FSGSNSGNTATLTISRVEAGDEADYYCQVWDSS SDHVVFGGGTKLTVLGGSEGKS SGSG
S E SKS T GGS QVQLVE S GGGLVQPGGS LRL S CAA S GFTF S HYAM SWVRQAPGKGLEWV S
TIGGSGGSTYYADSVKGRFTISRDNSKNTLYL QMNSLRAEDTAVYYCAKPHIVMVTALL
YDGMDVWGQGTMVTVSS
(SEQ ID NO: 236)
The hK2 CAR constructs comprised the following sequences:
KL2B357 HL:
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQFPGKGLEWIGYISYSGSTTY
NPSLKSRVTISRDTSKNQFSLKL S SVTAADTAVYYCATGYYYGSGFWGQGTLVTVS SGG
SEGKSSGSGSESKSTGGSDIVLTQSPDSLAVSLGERATINCRASESVEYFGTSLMHWYQQ
KPGQPPKLLIYAASNVESGVPDRFSGSGSGTDFTLTIS SLQAEDVAVYFCQQTRKVPYTF
GGGTKVEIKTSTPAPRPPTPAPTIASQPL SLRPEACRPAAGGAVHTRGLDFACDIYIWAPL
AGTCGVLLL SLVITLYCKRGRKKLLYIFKQPFMRPVQTT QEED GC S CRFPEEEEGGCELR
VKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGL
YNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGL STATKDTYDALHMQALPPR
(SEQ ID NO: 205)
225
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
KL2B357 LH:
DIVLTQSPDSLAVSLGERATINCRASESVEYFGTSLMHWYQQKPGQPPKLLIYAASNVES
GVPDRFSGSGSGTDFTLTIS SLQAEDVAVYFCQQTRKVPYTFGGGTKVEIKGGSEGKSSG
SGSESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQFPGKGLEWI
GYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQ
GTLVTVS ST S TPAPRPPTPAPTIAS QPL SLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA
GT C GVL LL SLVITLYCKRGRKKLLYIFKQPFMRPVQTT QEED GC S CRFPEEEEGGCELRV
KFSRSADAPAYKQGQNQLYNELNL GRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY
NEL QKDKMAEAY S EI GMKGERRRGKGHD GLYQ GL S TATKDTYDALHMQALPPR
(SEQ ID NO: 206)
KL2B358 HL:
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQPPGKGLEWIGYISYSGSTTY
NPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCATGYYYGSGFWGQGTLVTVS SGG
SEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHWYQQK
PGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTIS SVEPEDFAVYFCQQTRKVPYTFGGG
TKVEIKTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT
C GVLLL S LVITLYCKRGRKKLLYIFKQPFMRPVQTT QEED GC S CRFPEEEEGGCEL RVKF
SRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE
L QKDKMAEAY S EIGMKGERRRGKGHD GLYQ GL STATKD TYDAL HM QALPPR
(SEQ ID NO: 207)
KL2B358 LH:
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHWYQQKPGQPPRLLIYAASNVESG
IPARFSGSGSGTDFTLTIS SVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGSEGKSSGSG
SESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQPPGKGLEWIGY
ISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVS ST S TPAPRPPTPAPTIA S QPL S LRPEACRPAAGGAVHTRGL DFACDIYIWAPLAGT
C GVLLL S LVITLYCKRGRKKLLYIFKQPFMRPVQTT QEED GC S CRFPEEEEGGCELRVKF
226
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE
L QKDKMAEAY S EIGMKGERRRGKGHD GLYQ GL STATKD TYDAL HM QALPPR
(SEQ ID NO: 208)
KL2B360 HL:
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQFPGKGLEWIGYISYSGSTTY
NPSLKSRVTISRDTSKNQFSLKLS SVTAADTAVYYCATGYYYGSGFWGQGTLVTVS SGG
SEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHWYQQK
PGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTIS SVEPEDFAVYFCQQTRKVPYTFGGG
TKVEIKTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT
C GVLLL S LVITLYCKRGRKKLLYIFKQPFMRPVQTT QEED GC S CRFPEEEEGGCEL RVKF
SRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE
L QKDKMAEAY S EIGMKGERRRGKGHD GLYQ GL STATKD TYDAL HM QALPPR
(SEQ ID NO: 209)
KL2B360 LH:
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHWYQQKPGQPPRLLIYAASNVESG
IPARFSGSGSGTDFTLTIS SVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGSEGKSSGSG
SESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQFPGKGLEWIGY
ISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVS ST S TPAPRPPTPAPTIA S QPL S LRPEACRPAAGGAVHTRGL DFACDIYIWAPLAGT
C GVLLL S LVITLYCKRGRKKLLYIFKQPFMRPVQTT QEED GC S CRFPEEEEGGCELRVKF
SRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE
L QKDKMAEAY S EIGMKGERRRGKGHD GLYQ GL STATKD TYDAL HM QALPPR
(SEQ ID NO: 210)
KL2B30 HL:
QVQLQESGPGLVKPSETLSLTCTVSGGSIS SYYWSWIRQPPGKGLEWIGYIYYSGSTNYN
P SLKS RVTI SVDT S KNQF S LKL S SVTAADTAVYYCAGTTIFGVVTPNFYYGMDVWGQ GT
TVTVS SGGSEGKS S GSGSESKSTGGSDIQMT Q SP SFL SASVGDRVTITCRAS QGIS SYLAW
227
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
YQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTEFTLTIS SLQPEDFATYYCQQLNSYPL
TFGGGTKVEIKTSTPAPRPPTPAPTIASQPL SLRPEACRPAAGGAVHTRGLDFACDIYIWA
PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCE
LRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQE
GLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGL STATKDTYDALHMQALPPR
(SEQ ID NO: 211)
KL2B30 LH:
DIQMTQ SP SFL SASVGDRVTITCRASQGIS SYLAWYQQKP GKAPKFLIYAASTL Q S GVP SR
FSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK GGSEGKSSGSGSESK
ST GGSQVQL QES GPGLVKP SETL SLTCTVSGGSIS SYYWSWIRQPPGKGLEWIGYIYYSGS
TNYNPSLKSRVTISVDTSKNQFSLKL S SVTAADTAVYYCAGTTIFGVVTPNFYYGMDVW
GQGTTVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP
LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEG
LYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGL STATKDTYDALHMQALPPR
(SEQ ID NO: 212)
KL2B53 HL:
EVQLVESGGGVVQPGRSLRL SCVASGFTFS SYDIHWVRQAP GKGLEWVAII S YD GS KKD
YTDSVKGRFTISRDNSKNTLYLQMDSLRVED SAVYSCARESGWSHYYYYGMDVWGQG
TMVTVSSGGSEGKS SGS GSESKST GGSDIVMTQ SP S SL SASVGDRVTITCRASQDISNYLA
WYQQKPGKVPKFLIYAASTLHS GVP SRFS GS GSGTDFTLTIS SLQPEDVATYYCQKYNSA
PYTFGQGTRLEIKTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW
APLAGTCGVLLL S LVIT LYCKRGRKKLLYIFKQPFMRPVQTT QEED GC S CRFPEEEEGGC
ELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ
EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGL STATKDTYDALHMQALPPR
(SEQ ID NO: 213)
KL2B53 LH:
228
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
DIVMTQ SP S SL SASVGDRVTITCRAS QDISNYLAWYQQKPGKVPKFLIYAASTLHS GVPS
RFS GSGS GTDFTLTI S SLQPEDVATYYCQKYNSAPYTFGQGTRLEIKGGSEGKS SGSGSES
KS T GGS EVQLVE S GGGVVQPGRS LRL SCVASGFTFSSYDIHWVRQAPGKGLEWVAIISY
DGSKKDYTDSVKGRFTISRDNSKNTLYLQMDSLRVED SAVYSCARESGWSHYYYYGM
DVWGQGTMVTVS ST S TPAPRPPTPAPTIAS QPL SLRPEACRPAAGGAVHTRGLDFACDIY
IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG
GCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKN
PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGL STATKDTYDALHMQALP
PR
(SEQ ID NO: 214)
KL2B242 HL:
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWLRQPAGSGLEWIGRLYVSGFTNYN
PSLKSRVTL SLDPSRNQL SLKLS SVTAADTAVYYCAGDSGNYWGWFDPWGQGTLVTVS
SGGSEGKS SGSGSESKSTGGS SYELTQPPSVSVSPGETASITCSGDQLGENYACWYQQKP
GQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQALDEADYYCQAWDNSIVVFGG
GTKLTVLTSTPAPRPPTPAPTIASQPL SLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAG
TCGVLLL S LVITLYCKRGRKKLLYIFKQPFMRPVQTT QEED GC S CRFPEEEEGGCELRVK
FSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYN
EL QKDKMAEAY S EIGMKGERRRGKGHD GLYQ GL STATKDTYDALHMQALPPR
(SEQ ID NO: 215)
KL2B242 LH:
SYELTQPPSVSVSPGETASITCSGDQLGENYACWYQQKPGQSPVLVIYQDSKRPSGIPERF
SGSNSGNTATLTISGTQALDEADYYCQAWDNSIVVFGGGTKLTVLGGSEGKSSGSGSES
KSTGGSQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWLRQPAGSGLEWIGRLYVS
GFTNYNPSLKSRVTL SLDPSRNQL SLKL SSVTAADTAVYYCAGDSGNYWGWFDPWGQG
TLVTVS ST S TPAPRPPTPAPTIA S QPL SLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAG
TCGVLLL S LVITLYCKRGRKKLLYIFKQPFMRPVQTT QEED GC S CRFPEEEEGGCELRVK
FSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYN
EL QKDKMAEAY S EIGMKGERRRGKGHD GLYQ GL STATKDTYDALHMQALPPR
229
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
(SEQ ID NO: 216)
KL2B467 HL:
QVQLVESGGGVVQPGRSLRL S CAA S GFTF S YYGMHWVRQAP GKGLEWVAFI SYD GSNK
YYAD SVKGRFTI SRDN S KNTLYL QMN S LRAEDTAVYYCAHL PY S GS YWAFDYWGQGT
QVTVS SGGSEGKS S GS GSESKST GGS Q SVLT QPP SVSVAPGQTASITCGGDNIGSKSVHW
YQQKPGQAPVLVVYDNSDRPSGIPERFSGSNSGTTATLTISRVEAGDEADYYCQVWDS S
SDHPVVFGGGTKVTVT STPAPRPPTPAPTIASQPL SLRPEACRPAAGGAVHTRGLDFACDI
YIWAPLAGTCGVLLL S LVITLYCKRGRKKLLYIFKQPFMRPVQTT QEED GC S CRFPEEEE
GGCELRVKFSRSADAPAYKQGQNQLYNELNL GRREEYDVLDKRRGRDPEMGGKPRRK
NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQ GL STATKDTYDALHMQAL
PPR
(SEQ ID NO: 217)
KL2B467 LH:
QSVLTQPPSVSVAPGQTASITCGGDNIGSKSVHWYQQKPGQAPVLVVYDNSDRPSGIPER
FSGSNSGTTATLTISRVEAGDEADYYCQVWDSS SDHPVVF GGGTKVTVGGSEGKS S GS G
S E SKS T GGS QVQLVE S GGGVVQPGRSLRL S CAA S GFTF S YYGMHWVRQAP GKGLEWVA
FISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAHLPYSGSYWAF
DYWGQGTQVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI
WAPLAGTCGVLLL S LVITLYCKRGRKKLLYIFKQPFMRPV QTT QEEDGC S CRFPEEEEGG
CELRVKFSRSADAPAYKQGQNQLYNELNL GRREEYDVLDKRRGRDPEMGGKPRRKNP
QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGL STATKDTYDALHMQALPP
R
(SEQ ID NO: 218)
KL2B494 HL:
QVQLVESGGGLVQPGGSLRL S CAA S GFTF S HYAM SWVRQAPGKGLEWV STI GGS GGST
YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPHIVMVTALLYDGMDVW
GQGTMVTVS SGGSEGKS SGSGSESKSTGGS SSELTQPPSVSVAPGQTARITCGGNNIGSKS
230
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
VHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQV
WDSSSDHVVFGGGTKLTVLTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLD
FACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFP
EEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP
RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM
QALPPR
(SEQ ID NO: 219)
KL2B494 LH:
SSELTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPER
FSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLGGSEGKSSGSG
SESKSTGGSQVQLVESGGGLVQPGGSLRLSCAASGFTFSHYAMSWVRQAPGKGLEWVS
TIGGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPHIVMVTALL
YDGMDVWGQGTMVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDF
ACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFP
EEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP
RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM
QALPPR
(SEQ ID NO: 220)
Dynabeads Human T-Expander CD3/CD28 stimulated T cells are subjected to
electroporation, then washed three times with OPTI-MEM (Invitrogen), and
resuspended in
OPTI-MEM at the final concentration of 50E6/ml. Subsequently, 0.1 ml of the
cells (5E6)
are mixed with bug of IVT CAR encoding RNA and electroporated in a 2-mm Gap
cuvette
(Harvard Apparatus BTX, Holliston, MA, USA) using BTX ECM830 (Harvard
Apparatus
BTX, Holliston, MA, USA) by pressing the "pulse" button one time. (Settings:
500 Volts,
750 nsec Pulse Length and single(1) pulse, 100mSec interval.) Post
electroporation, the T
cells are transferred to a 6-well plate and immediately put back into a 37 C
incubator.
Primary human T cells are electroporated with no mRNA (MOCK) or lOng of mRNA
expressing either the hK2 scFy CAR or irrelevant control CAR 24 hours post-
231
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
electroporation CAR surface expression is measured by flow cytometry following
staining
with 2 pg/mlbiotinylated L-protein and streptavidin-conjugated PE, or
biotinylated hK2 (1
pg/m1) and streptavidin-conjugated PE.
Twenty-four hours post electroporation, the T cells are counted. 1E5 T cells
are collected
for each. The cells are washed with FACS buffer twice using 200 L/well of
FACS buffer
for microtiter plates, with the supernatant discarded. All wells are stained
with 100 pi
staining buffer containing Protein L (Genscript, Cat. No. M000971:500;2ug/m1),
and
incubated for at least 30 minutes at 4 C while being protected from light. The
cells are
washed by adding FACS Buffer twice, using 150 L/well for microtiter plates
with FACS
buffer. Centrifugation at 400x g is performed for 4 minutes at room
temperature. The
supernatant is then discarded. All wells are stained with 100 pi Streptavidin-
R-
Phycoerythrin (SA-PE;1:250) and Live/dead Fixable Near-IR Dead Cell Stain dye
(1:1000), incubated for at least 30 minutes at 4 C while being protected from
light. The
cells are then ready for flow cytometry analysis.
Observation of protein L staining is seen for the hK2 CARs, whereas only the
background
staining (-5.5%) is seen in the control T cells that were T cells without mRNA
electroporation. CAR expression on primary human T cells also can be detected
via J&J
internal biotin-labeled recombinant KLK2 protein followed by SA-PE. As shown,
T cells
efficiently express hK2 CARs as measured by flow cytometry, whereas only the
background staining is seen in the control T cells that are T cells without
mRNA
electroporation or undisclosed control CAR (non-hK2 specific).
Example 21: Tumor cell killing by hK2 CAR-T cells
Co-culture for CellTrace Violet (CTV, Thermo Fisher Scientific Catalog
number: C34557) based cytotoxicity assay using flow cytometer is performed as
follows.
The T cells are prepared as follows. Twenty-four hours post EP, T cells are
counted and
resuspended at the concentration needed for the most concentrated/desired E:T.
The T
cells are added at 100 p1/well of assay (2x106 cells/ml; plated 100 pl in a
10:1 E:T ratio,
i.e., 2E5 T cells per 2E4 target cells). A stock of the 10:1 E:T concentration
is made, with
232
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
two-fold serial dilutions made with complete T cell media (Optimizer w/CTS, 5%
Human
Serum, 1% GlutaMax) to 0.3125:1. The T cells are plated (100u1/well) in
triplicate using a
96 well round bottom tissue culture treated plate.
CTV labeled target cells are prepared as follows. 20 [IL DMSO is added to a
vial of CTV
staining solution. This stock solution is diluted into 20 mL of PBS (warmed to
37 C) for a
5 [IM staining solution. 10E6 tumor cells are collected, washed with PBS twice
and
resuspended in 4E6/m1 (2.5m1). An equal volume (2.5m1) of CTV staining
solution is
added. The cells are incubated for 20 minutes in a 37 C incubator. 40 ml
PRMI+20%
FBS are added to the cells to absorb any unbound dye. The cells are incubated
for 5
minutes. The cells are centrifuged for 5 minutes at 400 x g. The cell pellet
is resuspended
in pre-warmed RPMI+10%FBS medium. In the meantime, T cells are seeded at the
desired E/T ratio described above. hK2+ tumor cell lines and a hK2- tumor cell
line are
recounted, and then the cells are resuspended in 2E5/m1 and 100u1 in
duplicate. The cells
are co-incubated with labelled tumor cell lines in a flat-bottom 96-well
plate.
A cytotoxicity assay is performed as follows using a flow cytometer. After 20
hours of co-
culture, all of the cells are transferred to a U-bottom 96-well plate and
washed. After 20
hours of co-culture all of the cells are collected from a flat-bottom 96-well
plate and
transferred to a U-bottom 96-well plate, and then washed. 301.11 of 0.25%
trypsin is added
to all the wells and incubated for 5 minutes in a 37 C incubator. After 5
minutes, all of the
tumor cells are collected to a U-bottom 96-well plate. The cells are
centrifuged and washed
for 5 minutes at 400 x g twice. The cell pellet is then resuspended in diluted
(1:1000)
LIVE/DEADTM Fixable Near-IR staining dye (100 p1). The cells are incubated for
30 mins
at 4 C, and washed with FACS buffer twice by centrifuging the cells for 5
minutes at 400
x g. After washing, all of the cells are fixed for 10 minutes using 100p1 of
BD CytofixTM
Fixation Buffer (50u1 FACS buffer +50u1Fixation Buffer). The cells are
centrifuged and
washed for 5 minutes at 400 x g once. The cell pellet is resuspended in FACS
buffer.
Stained samples are analyzed by multicolor flow cytometry after the end of the
incubation
period. The percentage of cytotoxic activity is calculated using the following
equation:
% specific death = % Near IR+CTV+(dead) cells - % spontaneous Near IR
+CTV+ / (100% - % spontaneous Near IR +CTV+ (dead) cells) x 100%.
233
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Twenty-four hours after transient transfection, target cells (hK2positive Vcap
and hK2
negative DU145 cells) are labeled with Cell Trace Violet (CTV) fluorescent dye
and then
co-cultured with hK2 CAR-T cells. Mock T cells serve as negative effector
controls. Cells
are co-cultured for 20 hours at the effector-to-target cell (E/T) ratios
ranging from
0.3125:1 to 10:1. The percent killing is measured as the ratio of the absolute
number of
live (viability dye negative) target (CTV positive) cells remaining in the co-
culture relative
to the number of live target cells cultured without CAR-T cells. As shown, hK2
CAR T
cells specifically and efficiently lyse the hK2(+) human cancer cell lines,
but not hK2(-)
cells at E/T ratios of 10:1 to 0.3125:1, whereas only the background
cytotoxicity is seen in
the T cells that were Mock or hK2 CAR.
hK2 CAR-T cells are also tested for real-time cytotoxicity using xCELLigence
as a real-
time cell analysis system as a potency assay for immune cell-mediated
cytolysis of target
cells.
50 pL of target cancer cell culturing media is added to each well of the 96-
well E-Plates
(ACEA Biosciences), and the background impedance is measured and displayed as
a Cell
Index. Then, adherent target cells hK2(+) and hK2(-) are dissociated and
seeded at a
density of 5E4 (VCap), 5E3 cells/well of the E-Plate in a volume of 100 pL,
and allowed
to passively adhere on the electrode surface. Post seeding, the E-Plate is
kept at ambient
temperature inside a laminar flow hood for 30 minutes and then transferred to
the RTCA
MP instrument inside a cell culture incubator. Data recording is initiated
immediately at
15-minute intervals for the entire duration (96 hours) of the experiment.
At the time treatment is applied (24 hours post cancer cells seeding), data
acquisition is
paused, 50 pL of media is removed from each well, and effector CAR-T cells are
added at
different effector to target (E:T) ratios in a volume of 50 pL. hK2(+) CAR-T
and
undisclosed control CAR (non- hK2 specific) T cells are resuspended. Two-fold
dilutions
are then performed in duplicate in a 96-well plate (from 5:1 to 0.156:1 E/T
ratio). Target
plus Mock effector controls (no RNA electroporation T cells) are also added to
the target
cells.
234
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Target cells hK2(+) and hK2(-) are incubated with Mock, 10[Ig mRNA
electroporated (24
hours post transfection) into hK2(+) and hK2(-) CAR-T cells at different E/T
ratios for
approximately 72 hours. Normalized cell index (CI) plots for hK2(+) and hK2(-)
are
generated. When seeded alone, target cells adhered to the plate and
proliferated, increasing
the CI readout.
Example 22: Cytokine production by hK2 CAR-T cells
IFN-y produced by cytotoxic T cells allows for exertion of immune surveillance
of tumors,
which can directly inhibit proliferation and induce apoptosis of some
malignancies in
vivo and in vitro. To determine whether hK2 CAR-T cells are able to recognize
and be
activated by hK2 (+) tumor cells, the supernatant was collected from
xCELLigence-based
killing assay, as described in Example 21. After about 70 hours co-culture,
the supernatant
was collected and assayed by ELISA according to the directions provided with
the ELISA
kit (Human IFN-y ELISA M3(TM Deluxe, BioLegend, Cat#:430106).
IFN-y production of antigen-stimulated CAR-T cells occurs. hK2 CAR and control
CAR-T
cells secreted IFN-y during co-culture with hK2-expressing cells in an E:T
ratio-dependent
manner, but not during co-culture with hK2-negative cells. Undisclosed control
CAR
secreted much higher amount of IFN- y due to the much higher antigen
expression level
than hK2.
Example 21: Tumor cell killing by hK2 CAR-T cells
hK2 CAR-T cells are evaluated in the real-time IncuCyte tumor killing assay
for antigen-
dependent cytotoxicity. hK2 CAR-T cells are co-incubated with target cells for
88 hours at
effector:target ratio of 1:1 or 0.5:1 which was calculated based on CAR
expression data.
Target cells are identified that are stably expressing a red nuclear dye as
measured by
IncuCyte imaging system in a real-time fashion. The following calculation is
performed:
Tumor cell growth inhibition (%) = (Initial Viable Target Cell Number-Current
Viable
Target Cell Number)/Initial Viable Cell Number*100 (%).
Example 22: Cytokine production by hK2 CAR-T cells
235
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Supernatant is collected from overnight (approximately 20 hours) co-culture of
hK2CAR-
T cells with cells at 1:1 of E/T ratio and was analyzed using 13-plex
Milliplex Human
High Sensitivity T cell kit (HSTCMAG28SPMX13). hK2 CAR modified T cells
secreted
cytokines during co-culture with hK2-expressing cells, but minimal for un-
transduced T
cells (UTD). The results of cytokine release by hK2 CAR-T cells.
Supernatant was collected from overnight (approximately 20 hours) co-culture
of hK2
CAR-T cells with cells at 1:1 of E/T ratio. hK2 CAR-T cells secreted IFN-y
during co-
culture with hK2-expressing cells, but not during co-culture with hK2-negative
cells.
CD3/28 beads stimulated T cells and T cells only were used as positive and
negative
controls, respectively. IFN-y release by hK2 CAR-T cells. Mean IFN-y
concentration
SD (pg/ml) from duplicate cultures is shown. Different thermally stabilized
CAR-T cells
produced different amount of IFN- y when co-culture with hK2 (+) cells.
Example 23: Proliferation of hK2 CAR-T cells
hK2 CAR-T cells are evaluated in a proliferation assay. T-cell proliferation
is an
important in vitro parameter of in vivo immune function. To further evaluate
the function
of hK2 CAR-T cells, the hK2 CAR -T cells are labeled with CTV to assess T
cells
proliferation.
hK2 CAR-T and un-transduced (UTD) T cells are labelled with CellTrace Violet
(CTV;
5[1M) and co-cultured with hK2(+) and hK2(-) cells. Five days post co-culture,
cells are
harvested and stained with CD3, CD25, NearIR live/dead Dye and hK2 CAR. Flow
cytometric analysis is performed on a Fortessa flow cytometer with Flowjo
software.
Lymphocytes are identified by live CD3, and the frequencies of CAR-T cells
with CTV
dye dilution and activation marker CD25 are determined. By gating on hK2 CAR+
T cells,
as shown, the hK2 (+) cells but not hK2 (-) cells promote the all CAR
constructs. CD3/28
beads stimulated T cells and T cells only are used as positive and negative
controls,
respectively. T cells only without any stimulation do not proliferate and
CD3/28 beads
stimulated T cells displayed equivalent proliferation pattern. hK2CAR-T cells
proliferated
more robustly than CD3/28 beads positive control after 5 days of co-culture
with cells.
Different CAR constructs engineered T cells have different proliferation
activity and
236
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
displayed different CAR-T cells counts. The CAR-T cells counts are based on
mean
absolute cell count +/- SEM from three technical replicates.
The protocol is performed as follows. The tumor cells are collected, washed
twice with
PBS, and resuspended in 10E6/m1 in PBS containing 100ug/m1Mitomycin C (MMC)
for
1.5 hours in a 37 C incubator so as to block tumor cells proliferation. 20 [IL
of DMSO is
added to a vial of CTV staining solution. 5 IA of the solution is diluted into
5mL (1:1000)
PBS (warmed to 37 C) to provide a 5 [IM staining solution. The 2E6 T cells are
counted,
collected, washed with PBS twice, and resuspended in 4E6/m1 (0.5m1). An equal
volume
(0.5 ml) of CTV staining solution is added. The cells are incubated for 20
minutes at
37 C. Then, 4 ml PRIVII+20% FBS is added to the cells to absorb any unbound
dye. The
cells are incubated for 5 minutes, and centrifuged for 5 minutes at 400 x g.
The cell pellet
is resuspended in pre-warmed RPMI+10%FBS medium. The T cells are counted, and
1E5
cells (100u1) are seeded in 96-wells flat bottom-plate.
In the meantime, MMC-treated tumor cells are collected and counted after 1.5
hours, and
then resuspended at 1E6/ml. 1E5 of the cells (100 p1) are cocultured with T
cells in a 96-
well plate. T cells alone, and T cells added 3:1 CD3/28 beads to cells ratio,
are used as
negative and positive controls, respectively.
After 5 days of co-culture, all of the cells are collected from each well. The
cells are
centrifuged and washed for 5 minutes at 400 x g twice, then stained hK2 CAR,
CD3, CD8
and CD25, live/dead (Near-IR) in 96-well U bottom plate. After washing, all
cells are
fixed for 10 minutes using 100 p1BD CytofixTM Fixation Buffer (50u1FACS buffer
+50u1Fixation Buffer). The stained samples are analyzed by multicolor flow
cytometry
after the end of the incubation period.
Data analysis is performed as follows. A CTV histogram is prepared. The CTV
undiluted
gate is set to encompass the far-right peak (CTV bright) of T cells cultured
alone, and the
CTV diluted gate to capture the rest of the population. This is applied to all
samples.
Example 24: Characterization of CAR-T cells transduced with various constructs
described herein.
237
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
The generated CAR-T cells are evaluated in the JNL reporter assay for antigen-
dependent
activity. Briefly, Jurkat cells containing the luciferase gene driven by the
signaling-
responsive NFAT promoter (termed JNL cells) are transduced with any construct
comprising one or more nucleic acid sequences of SEQ ID NOS: 153-160, 161-168,
195-
204, 320-325, 326-331, and 336-339.
Alternatively, the construct may comprise a nucleic acid sequence encoding:
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 1 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID
NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 2 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 2 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 1 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 5;
238
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 1 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 2 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 3 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 74 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 76;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 75 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 77;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 147 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 140;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 75 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 141;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 75 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 140;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 148 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 142;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 149 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 143;
239
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 150 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 144;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 151 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 145;
a light chain variable region comprising an amino acid sequence of SEQ ID
NO: 152 and a heavy chain variable region comprising an amino acid sequence of
SEQ ID NO: 146;
a light chain variable region comprising an amino acid sequence of SEQ ID NO:
318 and a
heavy chain variable region comprising an amino acid sequence of SEQ ID NO:
317.
Expression of each CAR is determined by biotinylated hK2 followed by
streptavidin-
conjugated PE.
Binding between the hK2 CAR construct and its cognate cellular antigen (hK2 on
target
cells) leads to luciferase expression in the JNL cells. To that end, JNL cells
transduced
with the test CAR constructs or untransduced JNL cells (UTD) are co-cultured
with target
tumor cell lines and luciferase activity was measured as luminescence
intensity.
Constructs are considered active when the luminescence intensity exceeded 1.5-
fold the
level of UTD cells in the presence of antigen-expressing cells.
CAR-T cells mediate tumor cell killing in antigen-dependent manner
CAR-T cells are transduced with CAR17, CAR18, CAR19 and CAR20 are co-incubated
with hK2 positive cells and hK2 negative cells for 96 hours at effector-to-
target (ET) ratio
of 1:1 or 0.5:1 which was calculated based on CAR expression on T cells.
Target cells
stably express a red nuclear dye, which is measured by IncuCyte imaging system
in a real-
time fashion. Tumor cell growth inhibition (TGI) (%) = (Initial Viable Target
Cell
Number-Current Viable Target Cell Number)/Initial Viable Cell Number*100 (%).
Tested
CAR-T cells may achieve approximately 100% TGI whereas the untransduced
control may
240
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
not demonstrate any TGI. No TGI may be observed with the tested CAR-T cells in
hK2
negative cells.
CAR-T cells produce cytokines upon antigen stimulation
IFN-y produced by cytotoxic T cells is critical for exerting immune
surveillance of tumors,
which can directly inhibit proliferation and induce apoptosis of some
malignancies in
vivo and in vitro. To determine whether hK2 CAR-modified human T cells are
able to
recognize and become activated by hK2 positive tumor cells, primary T cells
are
transduced with indicated CAR clones and control untransduced T cells (UTD)
were co-
cultured with target cells lines and supernatant were collected for IFN-y
concentration
measurement. CAR-T cells transduced with hK2 CARs cells secrete IFN-y during
co-
culture with LNCaP cells recombinantly express hK2 cells and also during co-
culture with
very low hK2-expressing cells but not hK2-negative cells.
CAR-T cells are activated and upregulate markers of degranulation in antigen-
dependent manner
Tumor cells can be recognized and killed by cytotoxic lymphocytes, such as
CD8+ T
lymphocytes and natural killer (NK) cells mainly through the immune secretion
of lytic
granules that kill the target tumor cells. This process involves the fusion of
the granule
.. membrane with the cytoplasmic membrane of the immune effector cell,
resulting in surface
exposure of lysosomal-associated proteins that are typically present on the
lipid bilayer
surrounding lytic granules, such as CD107a. Therefore, membrane expression of
CD107a
constitutes a marker of immune cell activation and cytotoxic degranulation.
The degranulation assay is performed as described below. Target cells (5 x
104) are co-
cultured with an equal number of effector cells in 0.1m1 per well in a 96-well
plate.
Control wells contained T cells alone. Anti-CD107a (50 per well) are added in
addition to
11.d/sample of monensin (BD Biosciences) and incubated for 4 hours at 37 C.
Cells are
washed two times with PBS, stained for expression of the hK2 CAR, CD3, and CD8
and
analyzed on a flow cytometer BD Fortessa.
241
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
hK2 CAR-T cells proliferate in antigen-dependent manner
CAR-T cells are evaluated for their proliferation using T-cell proliferation
assay protocol
described in Example 23. hK2 CAR-T and untransduced (UTD) T cells are labelled
with
CellTrace Violet(CTV; 5 M) and co-cultured with hK2 positive and hK2 negative
cells.
Five days post co-culture, cells are harvested and stained with CD3, CD25,
NearIR
live/dead Dye and hK2 CAR Flow cytometric analysis is performed on a Fortessa
flow
cytometer with Flowjo software. Lymphocytes are identified by live CD3, and
the
frequencies of CAR-T cells with CTV dye dilution and activation marker CD25
were
determined. The percentage of proliferating T cells and CD25 expressing T
cells is based
on mean absolute cell count +/- SEM from duplicate.
The teachings of all patents, published applications and references cited
herein are
incorporated by reference in their entirety.
While example embodiments have been particularly shown and described, it will
be
understood by those skilled in the art that various changes in form and
details may be
made therein without departing from the scope of the embodiments encompassed
by the
appended claims.
242
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQUENCE LISTING
SEQ ID NO: 1 - VL 1 (LCD6)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHWYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTIQSVQAEDVSVYFCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 2- VL 2 (LCHumanized)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHWYQQKPGQPPKLLIYAAS
NRES GVPDRFS GSGSGTDFTLTIS SLQAEDVAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 3- VL 3 (LCB7)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHWYQQKPGQPPKLLIYAAS
NRES GVPDRFS GSGSGTDFTLTIS SVQAEDVAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 4- VII 1 (HCG5)
QVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNWIRQFPGKGLEWMGYISYS
GSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVYYCATGYYYGSGFWGQG
TLVTVSS
SEQ ID NO: 5- VII 2 (HCHumanized)
243
1717Z
NITINID OD JIAcIANNIO ODAAAVA
CUVOIS SIIIIKEID SD SD S121C[cIA9 SMINSVVAITINcIdO9cDIOOAMEITAIISIDJA 0
AASASVNONIIV):0-DISAVIS GIS OfIAIGSDDI SNSASD SD S SNDASODS SAINTE
9 ODAUD SDAAADIVOAAAVI GAdIAS S'INIS JONNSI MIS IIAHSNIS (MALL SD
SA S IADINAGION9c1,40):11MNAWAGS IISND SA-YOE-NIL GS cINNID(19 S AOIOAO
(VVOZ foz!umunHYI SODH rIH) Z Mas - 6 :ON 01 OIS SZ
NITINID OD JIAcIANNIO OD JAASA
GgVOAS OIIII JaLD SD SD S DIGclAD S MINSVVAITINcIdOpcINO OAMHIN'IS ID JA
AASASVNONIIV)iggISAVIS GIS OfIAIGSDDI SNSASD SD S SNDASODS SAINTE OZ
9 ODAUD SDAAADIVOAAAVI GAdIAS S'IN'IS JONNSI MIS IIAHSN'IS (MALL SD
SA SIADINAGION9c1,40):11MNAWAGS IISND SA-YOE-NIL GS cINA'19(19 S AO'IOAO
(VVOZ 9(131 SODH 111) 1 Mas - 8 :ON 01 OHS
CI
SODI SNSASD SD S SNDASOD
aauanbas iamun - L ________________________________________ :ON 01 01S
01
S SAINI
ID ODAUD SDAAADIVOAAAVI GAdIAS S'IN'IS JONNSI MIS IIAHSN'IS (MALL S
9 SA SIADIMAIDN9cIJOHIMNAWAGS IISND SA-YOE-NIL GS cI)LA'19(19 S AO'IOAO
(43H) HA - 9 :ON 01 OIS C
S SAINTE
9 ODAUD SDAAADIVOAAAVI GAVIAS S'INIS JONNS I (INSINIAHSN'IS (MALL S
9 SA SIADIMAIDN9c1c10):11MNAWAGS IISND SA-YOE-NIL GS cINA'19(19 S AO'IOAO
9969SO/OZOZE11/13c1 98610/1Z0Z OM
SZ-TO-ZZOZ SEL8VTE0 VD
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 10- scFV 3 (HL HCF3 LCB7 20AA)
QVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVYYCATGYYYGSGFWGQGT
LVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPDSLAVSLGERATINCKASESVEY
FGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSVQAEDV
AVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 11- scFV 4 (HL HCG5 LCB7 20AA)
QVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVVIRQFPGKGLEWMGYISYS
GSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVYYCATGYYYGSGFWGQG
TLVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPDSLAVSLGERATINCKASESVE
YFGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSVQAED
VAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 12- scFV 5 (LH LCD6 HCG5 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTIQSVQAEDVSVYFCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 13- scFV 6 (LH LCHumanized HCF3 20AA)
245
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRES GVPDRFS GS GS GTDF TL TI S SLQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKS S GS GSESKS TGGS QVQLQES GPGLVKP SD TL SLTCAVS GNSIT SDYAWNVV
IRQFPGKGLEWIGYI S YS GS TTYNP SLKSRVTI SRD TS KNQF SLKLS SVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVS S
SEQ ID NO: 14- scFV 7 (LH LCHumanized HCG5 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRES GVPDRFS GS GS GTDF TL TI S SLQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKS S GS GSESKS TGGS QVQLQES GPGLVKP SD TL SLTCAVS GNSIT SDYAWNVV
IRQFPGKGLEWMGYI S YS GS TTYNP SLKSRVTI SRD TS KNQF SLKLS SVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVS S
SEQ ID NO: 15- scFV 8 (LH LCB7 HCF3 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRES GVPDRFS GS GS GTDF TLTI S SVQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKS S GS GSESKS TGGS QVQLQES GPGLVKP SD TL SLTCAVS GNSIT SDYAWNVV
IRQFPGKGLEWIGYI S YS GS TTYNP SLKSRVTI SRD TS KNQF SLKLS SVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVS S
SEQ ID NO: 16- scFV 9 (LH LCB7 HCG5 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRES GVPDRFS GS GS GTDF TLTI S SVQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKS S GS GSESKS TGGS QVQLQES GPGLVKP SD TL SLTCAVS GNSIT SDYAWNVV
246
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
IRQFPGKGLEWMGYI S YS GS TTYNP SLKSRVTI SRD TS KNQF SLKLS SVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVS S
SEQ ID NO: 17- scFV 10 (LH LCD6 HCF3 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRES GVPDRFS GS GS GTDF TLTIQ SVQAEDVSVYF CQ Q TRKVPYTF GQ GTKLEIKG
GSEGKS S GS GSESKS TGGS QVQLQES GPGLVKP SD TL SLTCAVS GNSIT SDYAWNVV
IRQFPGKGLEWIGYI S YS GS TTYNP SLKSRVTI SRD TS KNQF SLKLS SVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVS S
SEQ ID NO: 18- scFV 11 (IIL HCHumanized LCB7 20AA)
QVQLQESGPGLVKP SD TL SLTCAVS GNSIT SDYAWNVVIRQPPGKGLEWIGYI S YS G
STTYNPSLKSRVTMSRDTSKNQFSLKLS SVTAVDTAVYYCATGYYYGSGFWGQG
TLVTVS SGGSEGKS S GS GSESKS TGGSDIVLTQSPDSLAVSLGERATINCKASESVE
YF GT SLMHVVYQ QKPGQPPKLLIYAASNRE S GVPDRF S GS GS GTDF TLTI S SVQAED
VAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 19- scFV 12(111 HCHumanized LCD6 20AA)
QVQLQESGPGLVKP SD TL SLTCAVS GNSIT SDYAWNVVIRQPPGKGLEWIGYI S YS G
STTYNPSLKSRVTMSRDTSKNQFSLKLS SVTAVDTAVYYCATGYYYGSGFWGQG
TLVTVS SGGSEGKS S GS GSESKS TGGSDIVLTQSPDSLAVSLGERATINCKASESVE
YF GT SLMHVVYQ QKPGQPPKLLIYAASNRE S GVPDRF S GS GS GTDF TLTIQ SVQAED
VSVYFCQQTRKVPYTFGQGTKLEIK
247
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 20- scFV 13 (HL HCHumanized LCHumanized 20AA)
QVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVVIRQPPGKGLEWIGYISYSG
STTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAVYYCATGYYYGSGFWGQG
TLVTVSSGGSEGKSSGSGSESKS TGGSDIVLTQSPDSLAVSLGERATINCKASESVE
YFGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSLQAED
VAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 21- scFV 14 (LH LCD6 HCHumanized 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTIQSVQAEDVSVYFCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKS TGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQPPGKGLEWIGYISYSGSTTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAV
YYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 22- scFV 15 (LH LCHumanized HCHumanized 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKS TGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQPPGKGLEWIGYISYSGSTTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAV
YYCATGYYYGSGFWGQGTLVTVSS
SE() ID NO: 23- scFV 16 (LH LCB7 HCHumanized 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
248
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
GSEGKSSGSGSESKS TGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQPPGKGLEWIGYISYSGSTTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAV
YYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 24 - Si2nal sequence
MAWVWTLLFLMAAAQSIQA
SEQ ID NO: 25 - CD8a-hin2e
TSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD
SEQ ID NO: 26- CD8a-TM
IYIWAPLAGTCGVLLLSLVITLYC
SEQ ID NO: 27- CD137
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
SEQ ID NO: 28- CD3zeta
RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKN
PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGEIDGLYQGLSTATKDTYDALEIM
QALPPR
249
OSZ
(VVOZ LEIDI SODH rIH) 17 uTumP Bu!Pu!cl-uaB!luu juInIPauilx1 - Z :ON 01 OHS
0
NITINIDO-DJIAcIANNIOODAAAV
AGHVOASSIIIIKEIDSDSDSDIGdADSMINSVVAITINcicIO-DcINOOAMHIATISIDJ
AHASHSVNONIIV?1A-DISAVISCHSOIIAIGSDDISNSASDSDSSNDASDDSSAINI SZ
IDO-DAUDSDAAADIVOAAAVIGAcTIASSINISJONNSIMISIIAHSNIScINALLS
OSASIADIMAIDNOcIJOHIMNAWAGSIISNDSAVOIISIIGScINAI-DcIDSHOIOAO
(VVOZ LEIDI 43H rIH) uluumP Bu!Pu!cl-uaB9uu juInItamilx1 - I :ON 01 OHS
OZ
NITINIDO-DJIAcIANNIOODAAAVA
C[HVOIS SIIIIKEID SD SD S121C[cIA9 sgumsvvArnmadboamOOArnmilsioJA
HASHSVNONIIV)IHDISAVISCHSOIIAIGSDDISNSASDSDSSNDASDDSSAINII
DO-DAUDSDAAADIVOAAAVIGAcTIASSINISJONNSIMISIIAHSNIScINKLISD CI
SASIADINAGIOND(1,46):11MNAWAGSIISNDSAV3IISIIGScINNIDcIDSHOIOAO
(VVOZ Paz!uuumHDI SODH MU
z _____________________ ulutuop Buwupi-uaB9u0 AUinipauilxa - pc :ON 01 OHS
OI
NITINIDO-DJIAcIANNIOODJAASA
GHVOASOIIIIKEIDSDSDSDIGdADSMINSVVAITINcicIO-DcINOOAMHIATISIDJA
HASHSVNONIIV)IHDISAVISCHSOIIAIGSDDISNSASDSDSSNDASDDSSAINII
DO-DAUDSDAAADIVOAAAVIGAcTIASSINISJONNSIMISIIAHSNIScINKLISD C
SASIADINAGIDNOcIJO):11MNAWAGSIISNDSAV3LISIIGScINNIDcIDSHOIOAO
(VVOZ 9(131 SODH rIH) 1 ulutuop Buwupi-uaB9u0 AUinipauilxa - 6Z :ON 01 OHS
9969SO/OZOZE11/13c1 98610/1Z0Z OM
SZ-TO-ZZOZ SEL8VTE0 VD
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
QVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVVIRQFPGKGLEWIVIGYISYS
GSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVYYCATGYYYGSGFWGQG
TLVTVSSGGSEGKSSGSGSESKS TGGSDIVLTQSPDSLAVSLGERATINCKASESVE
YFGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSVQAED
VAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 33- Extracellular anti2en-bindin2 domain 5 (LH LCD6 HCG5 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTIQSVQAEDVSVYFCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKS TGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 34 - Extracellular anti2en-bindin2 domain 6
(LH LCHumanized HCF3 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKS TGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 35 - Extracellular anti2en-bindin2 domain 7
(LH LCHumanized HCG5 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
251
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
GSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 36- Extracellular anti2en-bindin2 domain 8 (LH LCB7 HCF3 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 37 - Extracellular anti2en-bindin2 domain 9 (LH LCB7 HCG5 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 38- Extracellular anti2en-bindin2 domain 10 (LH LCD6 HCF3 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTIQSVQAEDVSVYFCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSS
252
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 39 - Extracellular anti2en-bindin2 domain 11
(In HCHumanized LCB7 20AA)
QVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVVIRQPPGKGLEWIGYISYSG
STTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAVYYCATGYYYGSGFWGQG
TLVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPDSLAVSLGERATINCKASESVE
YFGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSVQAED
VAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 40 - Extracellular anti2en-bindin2 domain 12
(In HCHumanized LCD6 20AA)
QVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVVIRQPPGKGLEWIGYISYSG
STTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAVYYCATGYYYGSGFWGQG
TLVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPDSLAVSLGERATINCKASESVE
YFGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTIQSVQAED
VSVYFCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 41 - Extracellular anti2en-bindin2 domain 13
(In HCHumanized LCHumanized 20AA)
QVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVVIRQPPGKGLEWIGYISYSG
STTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAVYYCATGYYYGSGFWGQG
TLVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPDSLAVSLGERATINCKASESVE
YFGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSLQAED
VAVYYCQQTRKVPYTFGQGTKLEIK
253
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 42 - Extracellular anti2en-bindin2 domain 14
(LH LCD6 HCHumanized 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTIQSVQAEDVSVYFCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQPPGKGLEWIGYISYSGSTTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAV
YYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 43 - Extracellular anti2en-bindin2 domain 15
(LH LCHumanized HCHumanized 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQPPGKGLEWIGYISYSGSTTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAV
YYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 44 - Extracellular anti2en-bindin2 domain 16
(LH LCB7 HCHumanized 20AA)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQPPGKGLEWIGYISYSGSTTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAV
YYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 45 - Intracellular si2nalin2 domain
254
ssz
licknvOwErwcuucrxivISIDOKIDGH
9N9112121ADNIAIDIASAVJVIAINCNOIANKIDAOcINN2121(DIDDINAcIMIDIRDICIIAG OE
AammolviaNKIONODONAvavcrvslisammtiaappaaaactRosapaaaOLLO
AcINTAIJcIONJIATDDRIMDIDAIIINISITIADDIDICIcIVAUAIGOVJG'IMIIHAVD
OVV(MOVAcIYIS'IcIOSVIIcIVdickfficIVaiSINITINIDO-DILAcIANNIOODAAAVA
CUVOIS SIIIIKEID SD SD S121C[cIA9 saumsvvArnmadboamOOArnumsioJA
AASASVNONIIV?HaISAVIS GIS OfIAIGSDDI SNSAS9 SD S SNDASOD S SAINTE SZ
9 ODA1,49 SDAAADIVOAAAVI GAdIA S S'INIS JONNSI MIS IIA?ISN'IS cINAII SD
SA S IADINAGION9cIJZMPANAWAGS IISND SAVDEISII GS cINA'19(19 S AO'1OAO
(Z178000011aa :VVOZ Paz!uuumilDr1 S0311 rill) Z 11V3 - Lt :ON 01 OIS
OZ
licknvOwErwcuucr)IivISIDOKIDGH
9N9112121ADNIAIDIASAVJVIAINCNOIANKIDAOcINN2121(DIDDINAcIMIDIRDICIIAG
AammolviaNKIONODONAvavcrvslisammtiaappaaaactRosapaaaOLLO sT
AcINTAIJcIONJIATDDRIMDIDAIIINISITIADDIDICIcIVAUAIGOVJG'IMIIHAVD
9 VIVaDVAcIYIS'Id 0 S VlicTIMI ckfficTIMI SINITINI9 OD IL AcIANNIO OD JAA S A
GAV OA S OLL'IL JaL9 SD SD S DICHAD S MINS VIVAITINcIdO9 cINO OAMHINIS ID JA
AASASIVNONIIV?M'ISAVIS GIS OfIAIGSDDI SNSAS9 SD S SNDASOD S SAINTE
9 ODAV49 SDAAADIVOAAAVI GAcTIA S S'INIS JONNSI MIS IIA?ISN'IS cINAII SD 0 1
SA S IADINAGION9cIJZMPANAWAGS IISND SAVDEISII GS cINA'19(19 S AO'1OAO
(iE17E8000011W :VVOZ 9a3r1 S0311 rill) 1 11V3 - 917 :ON 01 OIS
S
licknvOwErwcuucaivISIDOKIDGH9N9112121ADNIAIDIASAVJV
wmaxOlaNAIDAO&\mmaxpowadauolffixcrincnammolviaNAIONODO
NAVcIVGVSHSJNAYIAD-D-DAAAAcIDIDSD-DCEAOLLOAcDMIJcIONJIATDDRIMDI
9969SO/OZOZE11/13c1 98610/1Z0Z OM
SZ-TO-ZZOZ SEL8VTE0 VD
9SZ
0
(8E17E80000111' !VVOZ SODH 9a31 HI) S 11V3 - OS :ON 01 OIS
licknvOwErwcuucrxivISIDOKIDGH
9N9112121ADNIAIDIASAVJVIAINCNOIANKIDAOcINN2121cDIDDINAcIMIDIRDICIIAG sz
AammolviaNKIONODONAvavcrvslisammtiaappaaaactRosapaaaOLLO
AcINTAIJcIONJIATDDRIMDIDAIIINISITIADDIDICIcIVAUAIGOVJG'IMIIHAVD
OVV(MOVAcffi'l S'IcIO S VII &MI cicfficIV di S INITINI9 OD ILAcIANNIO 0 DAAAVA
GAV OA S S IIII JaL9 SD SD S DIGclA9 S MINS VIVAITINcicIOD cINO OAMHIAI'l S ID
JA
AAS ASVNONIIV?HaISAVIS GIS OfIAIGSDDI SNS AS9 SD S SNDASODS SAINTE 0 Z
9 ODA1,49 SDAAADIV DAAAVI GAcTIA S S'INIS JONNSI MIS IIA?IS N'1S cINAII SD
SA S IADINAGIOND(WMPANAWAGS IISND SAVDEISII GS cINA'19(19 S AO'1OAO
(L178000011aa !VVOZ LaDr1 SODH r111) 17 11V3 - 617 :ON 01 OHS
CI
licknvOwErwcuucaiviSIDOKIDG
HONMDINADNIAIDIASAVAVIAINGNOIANKIDAOcINN?fficINDDIAIAKPIMRDIGIA
cnamma-iviaNAIONODONAvavcrvslisamAlnaappaaaactRosapaaaOil
OAcINTAIJcIONJIATDDRIMDIDAIIINISTTIADDIDICIcTIMIAIGOVJG'IMILHAV 01
DOVV(MOVAcIYIS'IcIO S VII clVdickfficIWIS INITINI9 OD JIAcIANNIO 0 3 AAAV
AGAVOAS S IIII JaL9 SD SD S DIGclA9 S MINS VIVAITINcicIOD cINO OAMHIAI'l S ID
J
AAAS ASIVNONIIV?M'ISAVIS GIS OfIAIGSDDI SNS AS9 SD S SNDASODS SAIN1
ID ODA1,49 SDAAADIVOAAAVI GAcTIAS S'INIS JONNSI MIS IIA?ISN'IS (MALL S
9 SA RAD PATIOND cIJO?IPANAWAGSIISND SAVO EIS 'II GS cINA'19 cl9 S AO'1 OAO C
(9E17E80000H1cI :VVOZ LEIDI 43H 111) 11V3 - 817 :ON 01 OIS
9969SO/OZOZE11/13c1 98610/1Z0Z OM
SZ-TO-ZZOZ SEL8VTE0 VD
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTIQSVQAEDVSVYFCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKS TGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGG
AVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQ
TTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH
DGLYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 51 - CAR 6 (LH LCHumanized HCF3 20AA; pDR000083440)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKS TGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGG
AVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQ
TTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH
DGLYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 52 - CAR 7 (LH LCHumanized HCG5 20AA; pDR000083441)
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKSSGSGSESKS TGGSQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNVV
IRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGG
257
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
AVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQ
TTQEED GC S CRFPEEEEGGCELRVKF SRSADAPAYKQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI GMKGERRRGKGH
DGLYQGLS TATKDTYDALEIMQALPPR
SEQ ID NO: 53- CAR 8 (LH LCB7 HCF3 20AA; pDR000083443)
DIVLTQ SPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRES GVPDRF S GS GS GTDF TLTI S SVQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKS S GS GSESKS TGGS QVQLQES GPGLVKP SD TL SLTCAVS GNSIT SDYAWNVV
IRQFPGKGLEWIGYI S YS GS TTYNP SLKSRVTI SRD TS KNQF SLKLS SVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVS S TS TPAPRPPTPAPTIASQPLSLRPEACRPAAGG
AVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQ
TTQEED GC S CRFPEEEEGGCELRVKF SRSADAPAYKQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI GMKGERRRGKGH
DGLYQGLS TATKDTYDALEIMQALPPR
SEQ ID NO: 54 - CAR 9 (LH LCB7 HCG5 20AA; pDR000083444)
DIVLTQ SPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRES GVPDRF S GS GS GTDF TLTI S SVQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKS S GS GSESKS TGGS QVQLQES GPGLVKP SD TL SLTCAVS GNSIT SDYAWNVV
IRQFPGKGLEWMGYI S YS GS TTYNP SLKSRVTI SRD TS KNQF SLKLS SVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVS S TS TPAPRPPTPAPTIASQPLSLRPEACRPAAGG
AVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQ
TTQEED GC S CRFPEEEEGGCELRVKF SRSADAPAYKQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI GMKGERRRGKGH
DGLYQGLS TATKDTYDALEIMQALPPR
258
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 55- CAR 10 (LH LCD6 HCF3 20AA; pDR000083446)
DIVLTQ SPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRES GVPDRF S GS GS GTDF TLTIQ SVQAEDVSVYFCQQTRKVPYTFGQGTKLEIKG
GSEGKS S GS GSESKS TGGS QVQLQES GPGLVKP SD TL SLTCAVS GNSIT SDYAWNVV
IRQFPGKGLEWIGYI S YS GS TTYNP SLKSRVTI SRD TS KNQF SLKLS SVTPVDTAVY
YCATGYYYGSGFWGQGTLVTVS S TS TPAPRPPTPAPTIASQPLSLRPEACRPAAGG
AVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQ
TTQEED GC S CRFPEEEEGGCELRVKF SRSADAPAYKQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI GMKGERRRGKGH
DGLYQGLS TATKDTYDALEIMQALPPR
SEQ ID NO: 56 - CAR 11 (In HCHumanized LCB7 20AA; pDR000083433)
QVQLQESGPGLVKP SD TL SLTCAVS GNSIT SDYAWNVVIRQPPGKGLEWIGYI S YS G
S TTYNPSLKSRVTMSRDTSKNQFSLKLS SVTAVDTAVYYCATGYYYGSGFWGQG
TLVTVS SGGSEGKS S GS GSESKS TGGSDIVLTQ SPDSLAVSLGERATINCKASESVE
YF GT SLMHVVYQ QKPGQPPKLLIYAASNRE S GVPDRF S GS GS GTDF TLTI S SVQAED
VAVYYCQQTRKVPYTFGQ GTKLEIKTS TPAPRPPTPAPTIASQPLSLRPEACRPAAG
GAVHTRGLDFACDIYIWAPLAGTC GVLLL SLVITLYCKRGRKKLLYIFKQPFMRPV
Q TTQEED GC S CRFPEEEEGGCELRVKF SRSADAPAYKQGQNQLYNELNLGRREEY
DVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG
HD GLYQ GLS TATKDTYDALEIMQALPPR
SEQ ID NO: 57 - CAR 12 (In HCHumanized LCD6 20AA; pDR000083434)
QVQLQESGPGLVKP SD TL SLTCAVS GNSIT SDYAWNVVIRQPPGKGLEWIGYI S YS G
S TTYNPSLKSRVTMSRDTSKNQFSLKLS SVTAVDTAVYYCATGYYYGSGFWGQG
259
09Z
AcINIAIJcIONJIATDDINMDIDAIIIAISITIADDIDVIcIVMIAIGOVJGIMILHAVD
OVV&DVAcnIISIc10 Slat clVcII cicniclIMISIS SAINTED 09A1,49 SDAAADIV DAA OE
AVI GAVIA S SINIS JONNSI MISIAIIA?ISNIS cINKLI SD S A S IADIMAIDN9 cic10?1I
MNAWAGSIISNOSAVaLISIIGScINA'19(19SA010A0 SDDI SNSAS9 SD S SNDAS9
DNITINI9 09 IIAcIANRIO OD JAA S AGAV OA S OLLIE JGID SD SD S DIGclA9 SMIN
S VIVA ITINcic109 cD10 OAMEIKI SID JAAA S A S VNONIIIOTADIS AVIS Gc1S OrIAIG
SZ
(6E17E80000111' :VVOZ Paz!uuum11311 9a31 111) 171 11V3 - 6S :ON 01 OIS
licknvOwErwcuucrxivISIDOKIDGH
9N9112121ADNIAIDIASAVJVIAINGNOIANAIDA0c11\IN2121(DIDDIAIAcIG219112DIGIAG oz
AammolviaNKIONODONAvavcrvslisammtiaappaaaactRosapaaaOLLO
AcINIAIJcIONJIATDDINMDIDAIIIAISITIADDIDVIcIVMIAIGOVJGIMILHAVD
OVV&I3VAcIYISIcIOSVIIcIVcacknicIVcitSINITINIDO9IIAcIANNI003AAAVA
GJVOIS SIIIIKEID SD SD S121GclA9 saumsvvArnmadboamOOArnumsioJA
AASASVNONIIV?M'ISAVIS GIS OrIAIGSDDI SNSAS9 SOS SNDASOD S SAINTE SI
9 09A1,49 SDAAADIVOAAAVI GAVIAS SINISJONNSIGNSINIA?ISNIScINALL S
9 SA S IADIMAIDN9c1c10?1PANAWAGS IISND SAVaLISII GS cINA'19c19 S A010A0
(SC17E8000011(1(1
!VVOZ PaziuuttmHDr1 Paz!uuum11311 rIH) CI 11V3 - 8S :ON 01 OIS OT
licknvOwErwcuucrxivISIDOKIDGH
9N9112121ADNIAIDIASAVJVIAINGNOIANAIDA0c11\IN2121(DIDDIAIAcIG219112DIGIAG
AammolviaNKIONODONAvavcrvslisammtiaappaaaactRosapaaaOLLO s
AcINIAIJcIONJIATDDINMDIDAIIIAISITIADDIDVIcIVMIAIGOVJGIMILHAVD
9 VV(INDVAcINISIc10 S VlIcIVclicknicIVcII SINITINI9 09 IIAcIANNIO OD JAA S A
GAVOA S OIIII JGID SD SD S DIGclA9 S MINS VVAITINcic109 cD10 OAMEIMIS ID JA
AASASVNONIIV?1ADISAVIS GIS OrIAIGSDDI SNSAS9 SD S SNDASOD S SAINTE
9969SO/OZOZE11/13c1 98610/1Z0Z OM
SZ-TO-ZZOZ SEL8VTE0 VD
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
Q TTQEED GC S CRFPEEEEGGCELRVKF SRSADAPAYKQGQNQLYNELNLGRREEY
DVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG
EID GLYQ GLS TATKDTYDALEIMQALPPR
SEQ ID NO: 60- CAR 15 (LH LCHumanized HCHumanized 20AA;
pDR000083442)
DIVLTQ SPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRES GVPDRF S GS GS GTDF TLTI S SLQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKS S GS GSESKS TGGS QVQLQES GPGLVKP SD TL SLTCAVS GNSIT SDYAWNVV
IRQPPGKGLEWIGYI S YS GS TTYNPSLKSRVTMSRDTSKNQF SLKLS SVTAVDTAV
YYCATGYYYGSGFWGQGTLVTVS S TS TPAPRPPTPAPTIASQPLSLRPEACRPAAG
GAVHTRGLDFACDIYIWAPLAGTC GVLLL SLVITLYCKRGRKKLLYIFKQPFMRPV
Q TTQEED GC S CRFPEEEEGGCELRVKF SRSADAPAYKQGQNQLYNELNLGRREEY
DVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG
EID GLYQ GLS TATKDTYDALEIMQALPPR
SEQ ID NO: 61 - CAR 16 (LH LCB7 HCHumanized 20AA; pDR000083445)
DIVLTQ SPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRES GVPDRF S GS GS GTDF TLTI S SVQAEDVAVYYCQQTRKVPYTFGQGTKLEIKG
GSEGKS S GS GSESKS TGGS QVQLQES GPGLVKP SD TL SLTCAVS GNSIT SDYAWNVV
IRQPPGKGLEWIGYI S YS GS TTYNPSLKSRVTMSRDTSKNQF SLKLS SVTAVDTAV
YYCATGYYYGSGFWGQGTLVTVS S TS TPAPRPPTPAPTIASQPLSLRPEACRPAAG
GAVHTRGLDFACDIYIWAPLAGTC GVLLL SLVITLYCKRGRKKLLYIFKQPFMRPV
Q TTQEED GC S CRFPEEEEGGCELRVKF SRSADAPAYKQGQNQLYNELNLGRREEY
DVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG
EID GLYQ GLS TATKDTYDALEIMQALPPR
261
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 62 ¨ human Kallikrein-2 sequence (si2nal sequence: amino acids 1-
18)
MWDLVLSIALSVGCTGAVPLIQ SRIVGGWECEKHS QPWQVAVYSHGWAHCGGV
LVEIPQWVLTAAHCLKKNSQVWLGRHNLFEPEDTGQRVPVSHSFPHPLYNMSLLK
HQ SLRPDED S SHDLMLLRL SEPAKITDVVKVLGLPTQEPALGT TCYAS GWGSIEPE
EFLRPRSLQCVSLEILLSNDMCARAYSEKV ___________________________________________
l'EFMLCAGLWTGGKDTCGGDSGGPL
VCNGVLQGITSWGPEPCALPEKPAVYTKVVHYRKWIKDTIAANP
SEQ ID NO: 63¨ heavy chain CDR1 sequence
SDYAWN
SEQ ID NO: 64¨ heavy chain CDR2 sequence
YISYSGSTTYSPSLKS
SEQ ID NO: 65¨ heavy chain CDR2 sequence
YISYSGSTTYNPSLKS
SEQ ID NO: 66¨ heavy chain CDR3 sequence
GYYYGSGF
SEQ ID NO: 67 ¨1i2ht chain CDR1 sequence
262
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
RASESVEYFGTSLMH
SEQ ID NO: 68¨ li2ht chain CDR1 sequence
KASESVEYFGTSLMH
SE() ID NO: 69 ¨1i2ht chain CDR2 sequence
AASNVES
SEQ ID NO: 70¨ li2ht chain CDR2 sequence
AASNRES
SEQ ID NO: 71¨ li2ht chain CDR3 sequence
QQTRKVPYT
SEQ ID NO: 72¨ heavy chain CDR1 sequence
GNSITSDYAWN
SEQ ID NO: 73¨ heavy chain CDR1 sequence
YISYSGSTT
263
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 74- VL 4 (KL2B413)
EIVLTQ SP SFLSA SVGDRVTITCRAS Q GIS SYLSWYQQKPGKAPKLLIYATSTLQSG
VP SRF S GS GS GTEF TL TIS SLQPEDFATYYCQQLNSYPRTFGQGTKVEIK
SEQ ID NO: 75- VL 5 (KL2B359)
EIVLTQ SPATLSL SPGERATL S CRA SESVEYF GT SLMHWYQ QKP GQPPRLLIYAASN
VES GIPARF S GS GS GTDF TL TIS SVEPEDFAVYFCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 76- VII 4 (KL2B413)
EVQLVE S GGGLVQP GGSLRL S C AA S GF TF S S YWMTWVRQ AP GKGLEWVANIKQD
GSERYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDQNYDILTGH
YGMDVWGQGTTVTVS S
SEQ ID NO: 77- VHS (KL2B359)
QVQL QES GP GLVKP S Q TL SLTC TVS GNSIT SDYAWNWIRQFP GKRLEWIGYIS YS G
STTYNPSLKSRVTISRDTSKNQFSLKLS SVTAAD TAVYY CAT GYYYGS GFWGQ GT
LVTVS S
SEQ ID NO: 78 - Extracellular anti2en-bindin2 domain 17 (KL2B413 In)
EVQLVE S GGGLVQP GGSLRL S C AA S GF TF S S YWMTWVRQ AP GKGLEWVANIKQD
GSERYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDQNYDILTGH
YGMDVWGQ GT TVTVS SGGSEGKS S GS GSESKS TGGSEIVLTQ SP SFLSAS VGDRVT
ITCRAS Q GIS S YLSWYQ QKPGKAPKLLIYAT S TLQ S GVP SRF S GS GS GTEF TLTI S SL
QPEDFATYYCQQLNSYPRTFGQGTKVEIK
264
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 79 - Extracellular anti2en-bindin2 domain 18 (KL2B413 LH)
EIVLTQSPSFLSASVGDRVTITCRASQGISSYLSWYQQKPGKAPKLLIYATSTLQSG
VPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPRTFGQGTKVEIKGGSEGKS
SGSGSESKSTGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVVMTWVRQAPG
KGLEWVANIKQDGSERYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC
ARDQNYDILTGHYGMDVWGQGTTVTVSS
SE() ID NO: 80 - Extracellular anti2en-bindin2 domain 19 (KL2B359-HL)
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIRQFPGKRLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYF
GTSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAV
YFCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 81 - Extracellular anti2en-bindin2 domain 20 (KL2B359-LH)
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAAS
NVESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGG
SEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVI
RQFPGKRLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVY
YCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 82 - CAR 17 (KL2B413 IlL; pBD000091628)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVVMTWVRQAPGKGLEWVANIKQD
GSERYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDQNYDILTGH
YGMDVWGQGTTVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPSFLSASVGDRVT
ITCRASQGIS SYLSWYQQKPGKAPKLLIYATSTLQSGVPSRFSGSGSGTEFTLTISSL
QPEDFATYYCQQLNSYPRTFGQGTKVEIKTSTPAPRPPTPAPTIASQPLSLRPEACRP
265
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
AAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPF
MRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGR
REEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR
RGKGEIDGLYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 83 - CAR 18 (KL2B413 LH; pBD000091623)
EIVLTQSPSFLSASVGDRVTITCRASQGISSYLSWYQQKPGKAPKLLIYATSTLQSG
VPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPRTFGQGTKVEIKGGSEGKS
SGSGSESKSTGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVVMTWVRQAPG
KGLEWVANIKQDGSERYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC
ARDQNYDILTGHYGMDVWGQGTTVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACR
PAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPF
MRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGR
REEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR
RGKGEIDGLYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 84 - CAR 19 (KL2B359-11L; pBD000091576)
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIRQFPGKRLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYF
GTSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAV
YFCQQTRKVPYTFGGGTKVEIKTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV
HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTT
QEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVL
DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGEIDG
LYQGLSTATKDTYDALEIMQALPPR
266
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEO ID NO: 85 - CAR 20 (KL2B359-LH; roBD000091577)
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAASN
VESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGS
EGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIR
QFPGKRLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYC
ATGYYYGSGFWGQGTLVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV
HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTT
QEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVL
DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGEIDG
LYQGLSTATKDTYDALEIMQALPPR
SEO ID NO: 86¨ heavy chain CDR1 sequence
GFTFSSYVV
SEO ID NO: 87¨ heavy chain CDR2 sequence
IKQDGSER
SEO ID NO: 88¨ heavy chain CDR3 sequence
ARDQNYDILTGHYGMDV
SEO ID NO: 89¨ 1i2ht chain CDR1 sequence
267
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
QGISSY
SEQ ID NO: 90¨ li2ht chain CDR2 sequence
ATS
SEQ ID NO: 91¨ li2ht chain CDR3 sequence
QQLNSYPRT
SEQ ID NO: 92¨ heavy chain CDR1 sequence
GNSITSDYA
SEQ ID NO: 93¨ heavy chain CDR2 sequence
ISYSGST
SEQ ID NO: 94¨ heavy chain CDR3 sequence
ATGYYYGSGF
SEQ ID NO: 95¨ li2ht chain CDR1 sequence
ESVEYFGTSL
268
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SEO ID NO: 96 ¨1i2ht chain CDR2 sequence
AAS
SEO ID NO: 97¨ li2ht chain CDR3 sequence
GGNNIGSKSVH
SEO ID NO: 98 - Linker sequence
GTSGSSGSGSGGSGSGGGG
SEO ID NO: 99 - Linker sequence
GKPGSGKPGSGKPGSGKPGS
SEO ID NO: 100 - heavy chain CDR2 sequence
YISYSGSTTYNPSLKS
SEO ID NO: 101 - heavy chain CDR1 sequence
GNSITSDYAWN
269
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SEQ ID NO: 102 - heavy chain CDR1 sequence
SYYVVS
SEQ ID NO: 103 - heavy chain CDR2 sequence
YIYYSGSTNYNPSLKS
SEQ ID NO: 104 - heavy chain CDR3 sequence
TTIFGVVTPNFYYGMDV
SE() ID NO: 105 - heavy chain CDR1 sequence
GGSISSYYVVS
SE() ID NO: 106 - heavy chain CDR2 sequence
YIYYSGSTN
SEQ ID NO: 107 - heavy chain CDR1 sequence
SYDIH
SEQ ID NO: 108 - heavy chain CDR2 sequence
270
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
IISYDGSKKDYTDSVKG
SEQ ID NO: 109 - heavy chain CDR3 sequence
ESGWSHYYYYGMDV
SEQ ID NO: 110- heavy chain CDR1 sequence
GFTFSSYDIH
SEQ ID NO: 111 - heavy chain CDR2 sequence
IISYDGSKKD
SEQ ID NO: 112 - heavy chain CDR2 sequence
RLYVSGFTNYNPSLKS
SEQ ID NO: 113 - heavy chain CDR3 sequence
DSGNYVVGWFDP
SEQ ID NO: 114 - heavy chain CDR2 sequence
271
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
RLYVSGFTN
SEQ ID NO: 115- heavy chain CDR1 sequence
YYGMH
SE() ID NO: 116 - heavy chain CDR2 sequence
FISYDGSNKYYADSVKG
SEQ ID NO: 117 - heavy chain CDR3 sequence
LPYSGSYVVAFDY
SEQ ID NO: 118 - heavy chain CDR1 sequence
GFTFSYY
SEQ ID NO: 119 - heavy chain CDR2 sequence
FISYDGSNKY
SEQ ID NO: 120 - heavy chain CDR1 sequence
HYAMS
272
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SEQ ID NO: 121 - heavy chain CDR2 sequence
TIGGSGGSTYYADSVKG
SEQ ID NO: 122 - heavy chain CDR3 sequence
PHIVMVTALLYDGMDV
SEQ ID NO: 123 - heavy chain CDR1 sequence
GFTFSHYAMS
SEQ ID NO: 124 - heavy chain CDR3 sequence
TIGGSGGSTYY
SEQ ID NO: 125 - li2ht chain CDR1 sequence
RASQDISNYLA
SEQ ID NO: 126 - li2ht chain CDR2 sequence
AASNVES
273
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SEQ ID NO: 127 - light chain CDR3 sequence
DDSDRPS
SEQ ID NO: 128 - light chain CDR1 sequence
RASQGISSYLA
SEQ ID NO: 129 - light chain CDR2 sequence
AASTLQS
SE() ID NO: 130 - light chain CDR3 sequence
QQLNSYPLT
SE() ID NO: 131 - light chain CDR2 sequence
AASTLHS
SEQ ID NO: 132 - light chain CDR3 sequence
QKYNSAPYT
SEQ ID NO: 133 - light chain CDR1 sequence
274
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SGDQLGENYAC
SEQ ID NO: 134 - 112ht chain CDR2 sequence
QDSKRPS
SEQ ID NO: 135 - 112ht chain CDR3 sequence
QAWDNSIVV
SEQ ID NO: 136 - 112ht chain CDR1 sequence
GGDNIGSKSVH
SEQ ID NO: 137 - li2ht chain CDR2 sequence
DNSDRPS
SEQ ID NO: 138 - 112ht chain CDR3 sequence
QVWDSSSDHPVV
SEQ ID NO: 139 - 112ht chain CDR3 sequence
275
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
QVWDSSSDHVV
SEQ ID NO: 140 ¨ VII (KL2B357, KL2B357 and KL2B360))
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSS
SEQ ID NO: 142 ¨ VII (KL2B30)
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWIRQPPGKGLEWIGYIYYSGST
NYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGTTIFGVVTPNFYYGM
DVWGQGTTVTVSS
SEQ ID NO: 143 ¨ VII (KL2B53)
EVQLVESGGGVVQPGRSLRLSCVASGFIFSSYDIHVVVRQAPGKGLEWVAIISYDG
SKKDYTDSVKGRFTISRDNSKNTLYLQMDSLRVED SAVYSCARESGWSHYYYYG
MDVWGQGTMVTVSS
SEQ ID NO: 144 ¨ VII (KL2B242)
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWLRQPAGSGLEWIGRLYVSGF
TNYNPSLKSRVTLSLDPSRNQLSLKLSSVTAADTAVYYCAGDSGNYVVGWFDPWG
QGTLVTVSS
276
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 145 - VII (KL2B467)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHVVVRQAPGKGLEWVAFISYD
GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAHLPYSGSYVVAF
DYVVGQGTQVTVSS
SEQ ID NO: 146 - VII (KL2B494)
QVQLVESGGGLVQPGGSLRLSCAASGFTFSHYAMSWVRQAPGKGLEWVSTIGGS
GGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPHIVMVTALL
YDGMDVWGQGTMVTVSS
SEQ ID NO: 147 - VL (KL2B357)
DIVLTQSPDSLAVSLGERATINCRASESVEYFGTSLIVIHVVYQQKPGQPPKLLIYAAS
NVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 148 - VL (KL2B30)
DIQMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKFLIYAASTLQS
GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK
SEQ ID NO: 149 - VL (KL2B53)
DIVIVITQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKVPKFLIYAASTLHS
GVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPYTFGQGTRLEIK
277
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 150 - VL (KL2B242)
SYELTQPPSVSVSPGETASITCSGDQLGENYACWYQQKPGQSPVLVIYQDSKRPSGI
PERFSGSNSGNTATLTISGTQALDEADYYCQAWDNSIVVFGGGTKLTVL
SEQ ID NO: 151 - VL (KL2B467)
QSVLTQPPSVSVAPGQTASITCGGDNIGSKSVHWYQQKPGQAPVLVVYDNSDRPS
GIPERFSGSNSGTTATLTISRVEAGDEADYYCQVWDSSSDHPVVFGGGTKVTV
SEQ ID NO: 152 - VL (KL2B494)
SSELTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS
GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL
SEQ ID NO: 153- VII (KL2B357)
CAGGTTCAGCTGCAAGAGTCTGGACCAGGCCTGGTCAAGCCCTCTCAGACCCT
GTCTCTGACCTGTACCGTGTCCGGCAACTCCATCACCTCTGACTACGCCTGGAA
CTGGATTCGGCAGTTCCCTGGCAAGGGCCTTGAGTGGATCGGCTACATCTCCT
ACTCCGGTTCCACCACCTACAACCCCAGCCTGAAGTCCCGGGTCACCATCTCCC
GCGACACCTCCAAGAACCAGTTCTCCCTGAAGCTGTCCTCCGTGACCGCTGCT
GATACCGCCGTGTACTACTGTGCCACCGGCTACTACTACGGCTCCGGCTTTTGG
GGACAGGGCACACTGGTTACCGTGTCTAGT
SEQ ID NO: 154- VII (KL2B358)
278
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
CAGGTTCAGCTGCAAGAGTCTGGACCAGGCCTGGTCAAGCCCTCTCAGACCCT
GTCTCTGACCTGTACCGTGTCCGGCAACTCCATCACCTCTGACTACGCCTGGAA
CTGGATTCGGCAGCCACCTGGCAAGGGCCTTGAGTGGATCGGCTACATCTCCT
ACTCCGGTTCCACCACCTACAACCCCAGCCTGAAGTCCCGGGTCACCATCTCCC
GCGACACCTCCAAGAACCAGTTCTCCCTGAAGCTGTCCTCCGTGACCGCTGCT
GATACCGCCGTGTACTACTGTGCCACCGGCTACTACTACGGCTCCGGCTTTTGG
GGACAGGGCACACTGGTTACCGTGTCTAGT
SEQ ID NO: 155- VII (KL2B360)
CAGGTTCAGCTGCAAGAGTCTGGACCAGGCCTGGTCAAGCCCTCTCAGACCCT
GTCTCTGACCTGTACCGTGTCCGGCAACTCCATCACCTCTGACTACGCCTGGAA
CTGGATTCGGCAGTTCCCTGGCAAGGGCCTTGAGTGGATCGGCTACATCTCCT
ACTCCGGTTCCACCACCTACAACCCCAGCCTGAAGTCCCGGGTCACCATCTCCC
GCGACACCTCCAAGAACCAGTTCTCCCTGAAGCTGTCCTCCGTGACCGCTGCT
GATACCGCCGTGTACTACTGTGCCACCGGCTACTACTACGGCTCCGGCTTTTGG
GGACAGGGCACACTGGTTACCGTGTCTAGT
SEQ ID NO: 156- VII (KL2B30)
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCT
GTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTG
GATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGATATATCTATTACA
GTGGGAGCACCAACTACAACCCCTCCCTCAAGAGTCGAGTCACCATATCAGTA
GACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGGA
CACGGCCGTGTATTACTGTGCGGGGACTACGATTTTTGGAGTGGTTACCCCCA
ACTTCTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCC
TCA
279
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 157- VII (KL2B53)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCT
GAGACTCTCCTGTGTAGCCTCTGGATTCACCTTCAGTAGTTATGACATACACTG
GGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAATTATTTCATATG
ATGGAAGTAAAAAAGACTATACAGACTCCGTGAAGGGCCGATTCACCATCTCC
AGAGACAATTCCAAGAACACGCTGTATCTGCAAATGGACAGCCTGAGAGTTGA
GGACTCGGCTGTGTATTCCTGTGCGAGAGAAAGTGGCTGGTCCCACTACTACT
ATTACGGTATGGACGTCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA
SEQ ID NO: 158- VII (KL2B242)
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCT
GTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTATTGGAGCTG
GCTCCGGCAGCCCGCCGGGTCGGGACTGGAGTGGATTGGGCGTTTATATGTCA
GTGGGTTCACCAACTACAACCCCTCCCTCAAGAGTCGAGTCACCTTGTCACTA
GACCCGTCCAGGAACCAGTTGTCCCTGAAACTGAGTTCTGTGACCGCCGCGGA
CACGGCCGTATATTATTGTGCGGGAGATAGTGGGAACTACTGGGGTTGGTTCG
ACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA
SEQ ID NO: 159- VII (KL2B467)
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCT
GAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTTACTATGGCATGCACTG
GGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTTATATCATATG
ATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCC
AGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTG
280
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
AGGACACGGCTGTGTATTACTGTGCCCACCTCCCTTATAGTGGGAGCTACTGG
GCCTTTGACTACTGGGGCCAGGGAACCCAGGTCACCGTCTCTTCA
SEQ ID NO: 160 - VII (KL2B494)
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCT
GAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTCATTATGCCATGAGCTG
GGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAACTATTGGTGGTA
GTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCC
AGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCG
AGGACACGGCCGTATATTACTGTGCGAAACCTCATATTGTAATGGTGACTGCT
CTTCTCTACGACGGTATGGACGTCTGGGGCCAAGGGACAATGGTCACCGTCTC
CTCA
SEQ ID NO: 161 - VL (KL2B357)
GACATCGTGCTGACCCAGTCTCCAGACTCTCTGGCTGTGTCTCTGGGCGAGAG
AGCCACCATCAACTGCAGAGCCTCCGAGTCCGTGGAATACTTCGGCACCTCTC
TGATGCACTGGTACCAGCAGAAGCCCGGCCAGCCTCCTAAGCTGCTGATCTAC
GCCGCCTCCAACGTGGAATCTGGCGTGCCCGATAGATTTTCCGGCTCTGGCTCT
GGCACCGACTTTACCCTGACCATCAGCTCTCTGCAGGCCGAGGATGTGGCCGT
GTACTTCTGTCAGCAGACCCGGAAGGTGCCCTACACATTTGGCGGCGGAACAA
AGGTGGAAATCAAG
SEQ ID NO: 162 - VL (KL2B358)
GAGATCGTGCTGACCCAGTCTCCTGCCACACTGTCACTGTCTCCAGGCGAGAG
AGCCACCCTCTCTTGTAGAGCCTCCGAGTCCGTGGAATACTTCGGCACCTCTCT
281
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
GATGCACTGGTACCAGCAGAAGCCCGGCCAGCCTCCTAGACTGCTGATCTACG
CCGCCTCCAACGTCGAATCTGGCATCCCCGCTAGATTCTCCGGCTCTGGCTCTG
GCACAGACTTTACCCTGACCATCTCCTCCGTGGAACCCGAGGATTTCGCTGTGT
ACTTTTGCCAGCAGACCCGGAAGGTGCCCTACACATTTGGCGGCGGAACAAAG
GTGGAAATCAAG
SEQ ID NO: 163 - VL (KL2B360)
GAGATCGTGCTGACCCAGTCTCCTGCCACACTGTCACTGTCTCCAGGCGAGAG
AGCCACCCTCTCTTGTAGAGCCTCCGAGTCCGTGGAATACTTCGGCACCTCTCT
GATGCACTGGTACCAGCAGAAGCCCGGCCAGCCTCCTAGACTGCTGATCTACG
CCGCCTCCAACGTCGAATCTGGCATCCCCGCTAGATTCTCCGGCTCTGGCTCTG
GCACAGACTTTACCCTGACCATCTCCTCCGTGGAACCCGAGGATTTCGCTGTGT
ACTTTTGCCAGCAGACCCGGAAGGTGCCCTATACATTTGGCGGCGGAACAAAG
GTGGAAATCAAG
SEQ ID NO: 164 - VL (KL2B30)
GACATCCAGATGACCCAGTCTCCTTCCTTCCTGTCTGCATCTGTAGGAGACAGA
GTCACCATCACTTGCCGGGCCAGTCAGGGCATTAGCAGTTATTTAGCCTGGTAT
CAGCAAAAACCAGGGAAAGCCCCTAAGTTCCTGATCTATGCTGCATCCACTTT
GCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCA
CTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAAC
AGCTTAATAGTTACCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAAATCAAA
SEQ ID NO: 165 - VL (KL2B53)
282
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
GACATCGTGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCGAGTCAGGACATTAGCAATTATTTAGCCTGGT
ATCAGCAGAAACCAGGGAAAGTTCCTAAGTTCCTGATCTATGCTGCATCCACT
TTGCACTCTGGGGTCCCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGATTTC
ACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTCAA
AAGTATAACAGTGCCCCGTACACTTTTGGCCAAGGGACACGACTGGAGATTAA
A
SEQ ID NO: 166 - VL (KL2B242)
TCCTATGAGCTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGAGAGACAGC
CAGCATCACCTGCTCTGGAGATCAATTGGGGGAAAATTATGCTTGCTGGTATC
AGCAGAAGCCAGGCCAGTCCCCTGTGTTGGTCATCTATCAAGATAGTAAGCGG
CCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACACAGCCAC
TCTGACCATCAGCGGGACCCAGGCTCTGGATGAGGCTGACTATTACTGTCAGG
CGTGGGACAACAGTATTGTGGTATTCGGCGGAGGGACCAAGCTGACCGTCCTA
SEQ ID NO: 167 - VL (KL2B467)
CAGTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCCGGGCAGACGGC
CAGTATTACCTGTGGGGGAGACAACATTGGAAGTAAAAGTGTGCACTGGTACC
AGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTCGTCTATGATAATAGCGACCGG
CCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGACCACGGCCAC
CCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCAGG
TGTGGGATAGTAGTAGTGATCATCCTGTGGTATTCGGCGGAGGGACCAAGGTC
ACCGTCCTA
SEQ ID NO: 168 - VL (KL2B494)
283
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
TCTTCTGAGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGC
CAGGATTACCTGTGGGGGAAACAACATTGGAAGTAAAAGTGTGCACTGGTACC
AGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTCGTCTATGATGATAGCGACCGG
CCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACACGGCCAC
CCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCAGG
TGTGGGATAGTAGTAGTGATCATGTGGTATTCGGCGGAGGGACCAAGCTGACC
GTCCTA
SEQ ID NO: 169 ¨ KL2B357 ScFv-IIL
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPDSLAVSLGERATINCRASESVEY
FGTSLMHVVYQQKPGQPPKLLIYAASNVESGVPDRFSGSGSGTDFTLTISSLQAEDV
AVYFCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 170 ¨ KL2B357 ScFv-LH
DIVLTQSPDSLAVSLGERATINCRASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQTRKVPYTFGGGTKVEIKG
GSEGKSSGSGSESKS TGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVV
IRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVY
YCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 171 ¨ KL2B358 ScFv-IIL
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIRQPPGKGLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
284
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
LVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYF
GTSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAV
YFCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 172 ¨ KL2B358 ScFv-LH
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAASN
VESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGS
EGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIR
QPPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYC
ATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 173 ¨ KL2B360 ScFv-IIL
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYF
GTSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAV
YFCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 174 ¨ KL2B360 ScFv-LH
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAASN
VESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGS
EGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIR
QFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYC
ATGYYYGSGFWGQGTLVTVSS
285
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 175 ¨ KL2B30 ScFv-HL
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWIRQPPGKGLEWIGYIYYSGST
NYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGTTIFGVVTPNFYYGM
DVWGQGTTVTVSSGGSEGKSSGSGSESKSTGGSDIQMTQSPSFLSASVGDRVTITC
RASQGISSYLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQP
EDFATYYCQQLNSYPLTFGGGTKVEIK
SEQ ID NO: 176 ¨ KL2B30 ScFv-LH
DIQMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKFLIYAASTLQS
GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIKGGSEGK
SSGSGSESKSTGGSQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWIRQPPGK
GLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGTTI
FGVVTPNFYYGMDVWGQGTTVTVSS
SEQ ID NO: 177 ¨ KL2B53 ScFv-HL
EVQLVESGGGVVQPGRSLRLSCVASGFTFSSYDIHVVVRQAPGKGLEWVAIISYDG
SKKDYTDSVKGRFTISRDNSKNTLYLQMDSLRVEDSAVYSCARESGWSHYYYYG
MDVWGQGTMVTVS SGGSEGKSSGSGSESKSTGGSDIVMTQSPSSLSASVGDRVTI
TCRASQDISNYLAWYQQKPGKVPKFLIYAASTLHSGVPSRFSGSGSGTDFTLTISSL
QPEDVATYYCQKYNSAPYTFGQGTRLEIK
SEQ ID NO: 178 ¨ KL2B53 ScFv-LH
DIVNITQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKVPKFLIYAASTLHS
GVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPYTFGQGTRLEIKGGSEGK
286
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SSGSGSESKSTGGSEVQLVESGGGVVQPGRSLRLSCVASGFTFSSYDIHVVVRQAPG
KGLEWVAIISYDGSKKDYTDSVKGRFTISRDNSKNTLYLQMDSLRVEDSAVYSCA
RESGWSHYYYYGMDVWGQGTMVTVSS
SEQ ID NO: 179 ¨ KL2B242 ScFv-IIL
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWLRQPAGSGLEWIGRLYVSGF
TNYNPSLKSRVTLSLDPSRNQLSLKLSSVTAADTAVYYCAGDSGNYVVGWFDPWG
QGTLVTVSSGGSEGKSSGSGSESKSTGGSSYELTQPPSVSVSPGETASITCSGDQLG
ENYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQALDEAD
YYCQAWDNSIVVFGGGTKLTVL
SEQ ID NO: 180 ¨ KL2B242 ScFv-LH
SYELTQPPSVSVSPGETASITCSGDQLGENYACWYQQKPGQSPVLVIYQDSKRPSGI
PERFSGSNSGNTATLTISGTQALDEADYYCQAWDNSIVVFGGGTKLTVLGGSEGK
SSGSGSESKSTGGSQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWLRQPAG
SGLEWIGRLYVSGFTNYNPSLKSRVTLSLDPSRNQLSLKLSSVTAADTAVYYCAG
DSGNYVVGWFDPWGQGTLVTVSS
SEQ ID NO: 181 ¨ KL2B467 ScFv-IIL
QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHVVVRQAPGKGLEWVAFISYD
GSNKYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAVYYCAHLPYSGSYVVAF
DYVVGQGTQVTVSSGGSEGKSSGSGSESKSTGGSQSVLTQPPSVSVAPGQTASITCG
GDNIGSKSVHVVYQQKPGQAPVLVVYDNSDRPSGIPERFSGSNSGTTATLTISRVEA
GDEADYYCQVWDSSSDHPVVFGGGTKVTV
287
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 182 ¨ KL2B467 ScFv-LH
QSVLTQPPSVSVAPGQTASITCGGDNIGSKSVHVVYQQKPGQAPVLVVYDNSDRPS
GIPERFSGSNSGTTATLTISRVEAGDEADYYCQVWDSSSDHPVVFGGGTKVTVGG
SEGKSSGSGSESKSTGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHVVV
RQAPGKGLEWVAFISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDT
AVYYCAHLPYSGSYVVAFDYVVGQGTQVTVSS
SEQ ID NO: 183 ¨ KL2B494 ScFv-IIL
QVQLVESGGGLVQPGGSLRLSCAASGFTFSHYAMSWVRQAPGKGLEWVSTIGGS
GGSTYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAVYYCAKPHIVMVTALL
YDGMDVWGQGTMVTVSSGGSEGKSSGSGSESKSTGGSSSELTQPPSVSVAPGQTA
RITCGGNNIGSKSVHVVYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTI
SRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL
SEQ ID NO: 184 ¨ KL2B494 ScFv-LH
SSELTQPPSVSVAPGQTARITCGGNNIGSKSVHVVYQQKPGQAPVLVVYDDSDRPS
GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLGG
SEGKSSGSGSESKSTGGSQVQLVESGGGLVQPGGSLRLSCAASGFTFSHYAMSWV
RQAPGKGLEWVSTIGGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA
VYYCAKPHIVMVTALLYDGMDVVVGQGTMVTVSS
SEQ ID NO: 185 ¨ KL2B30 HC I2G4
288
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
QVQLQESGPGLVKP SETL SLTC TVS GGSI S S YYVVSWIRQPPGKGLEWIGYIYYS GS T
NYNPSLKSRVTISVDTSKNQF SLKLS SVTAADTAVYYCAGTTIFGVVTPNFYYGM
DVWGQ GTTVTVS S AS TKGP SVFPLAPC SRS TSE S TAALGCLVKDYFPEPVTVSWNS
GAL T S GVHTFPAVL Q S SGLYSLS SVVTVPS S SLGTKTYTCNVIDEIKPSNTKVDKRVE
SKYGPPCPPCPAPEAAGGP SVFLFPPKPKD TLMI SRTPEVTCVVVDVS QEDPEVQFN
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLP
S SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG
QPENNYKTTPPVLD SD GSFFLYSRLTVDKSRWQEGNVF SCSVMHEALHNHYTQKS
LSLSLGK
SEQ ID NO: 186- KL2B30 LC I2G4
DI QMTQ SP SFLS AS VGDRVTITCRAS Q GI S SYLAWYQQKPGKAPKFLIYAASTLQS
GVPSRF S GS GS GTEF TLTIS SLQPEDFATYYCQQLNSYPLTFGGGTKVEIKRTVAAP
SVFIFPP SDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQ S GN S QESVTEQD S
KDS TYSLS STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
SEQ ID NO: 187 - KL2B53 HC I2G4
EVQLVESGGGVVQPGRSLRLSCVAS GFTF S S YDIHVVVRQ AP GKGLEWVAIIS YD G
SKKD YTD SVKGRF TI SRDNSKNTLYLQMD SLRVED S AVYS CARES GWSHYYYYG
MDVWGQGTMVTVS S AS TKGP S VFPLAPC SRS TSE S TAALGCLVKDYFPEPVTVSW
.. NS GALT S GVHTFPAVLQ S SGLYSLS SVVTVPS S SLGTKTYTCNVIDEIKPSNTKVDKR
VE SKYGPPCPPCPAPEAAGGP S VFLFPPKPKD TLMI SRTPEVTCVVVDVS QEDPEV
QFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
GLPS SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLD SD GSFFLYSRLTVDKSRWQEGNVF SCSVMHEALHNHYT
QKSLSLSLGK
289
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 188- KL2B53 LC I2G4
DIVIVITQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKVPKFLIYAASTLHS
GVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPYTFGQGTRLEIKRTVAAP
SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEKEIKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO: 189 - KL2B242 HC I2G4
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWLRQPAGSGLEWIGRLYVSGF
TNYNPSLKSRVTLSLDPSRNQLSLKLSSVTAADTAVYYCAGDSGNYVVGWFDPWG
QGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALT
SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDEIKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNVVY
VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSI
EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL
SLGK
SEQ ID NO: 190 - KL2B242 LC I2G4
SYELTQPPSVSVSPGETASITCSGDQLGENYACWYQQKPGQSPVLVIYQDSKRPSGI
PERFSGSNSGNTATLTISGTQALDEADYYCQAWDNSIVVFGGGTKLTVLGQPKAA
PSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQS
NNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
SEQ ID NO: 191 - KL2B467 HC I2G4
290
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHVVVRQAPGKGLEWVAFISYD
GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAHLPYSGSYVVAF
DYVVGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNEIKPSNTKVDKKV
EPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVSVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS
NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE
WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
HYTQKSLSLSPGK
SEQ ID NO: 192 - KL2B467 LC I2G4
QSVLTQPPSVSVAPGQTASITCGGDNIGSKSVHVVYQQKPGQAPVLVVYDNSDRPS
GIPERFSGSNSGTTATLTISRVEAGDEADYYCQVWDSSSDHPVVFGGGTKVTVLG
QPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTT
PSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
SEQ ID NO: 193 - KL2B494 HC I2G4
QVQLVESGGGLVQPGGSLRLSCAASGFTFSHYAMSWVRQAPGKGLEWVSTIGGS
GGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPHIVMVTALL
YDGMDVWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNEIKPSNTK
VDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVSV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGK
291
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 194 - KL2B494 LC I2G4
SSELTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPS
GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLGQ
PKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTP
SKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
SEQ ID NO: 195 - ICL2B30 HC DNA
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCT
GTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTG
GATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGATATATCTATTACA
GTGGGAGCACCAACTACAACCCCTCCCTCAAGAGTCGAGTCACCATATCAGTA
GACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCTGCGGA
CACGGCCGTGTATTACTGTGCGGGGACTACGATTTTTGGAGTGGTTACCCCCA
ACTTCTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCC
TCAGCTTCCACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGC
ACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCT
TCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCG
TGCCCTCCAGCAGCTTGGGCACGAAAACCTACACTTGCAACGTAGATCACAAG
CCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATG
CCCACCATGCCCAGCACCTGAGGCCGCCGGGGGACCATCAGTCTTCCTGTTCC
CCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGC
GTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGT
GGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTC
AACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCT
GAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCA
TCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTA
292
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
CACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCT
GCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACG
GCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGATGGCAGGAG
GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACAC
ACAGAAGAGCCTCTCCCTGTCTCTGGGTAAA
SEO ID NO: 196 - KL2B30 LC DNA
GACATCCAGATGACCCAGTCTCCTTCCTTCCTGTCTGCATCTGTAGGAGACAGA
GTCACCATCACTTGCCGGGCCAGTCAGGGCATTAGCAGTTATTTAGCCTGGTAT
CAGCAAAAACCAGGGAAAGCCCCTAAGTTCCTGATCTATGCTGCATCCACTTT
GCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCA
CTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAAC
AGCTTAATAGTTACCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAAATCAAA
CGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTG
AAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAG
GCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGG
AGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCAC
CCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAA
GTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGA
GTGT
SEO ID NO: 197 - KL2B53 HC DNA
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCT
GAGACTCTCCTGTGTAGCCTCTGGATTCACCTTCAGTAGTTATGACATACACTG
GGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAATTATTTCATATG
ATGGAAGTAAAAAAGACTATACAGACTCCGTGAAGGGCCGATTCACCATCTCC
293
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
AGAGACAATTCCAAGAACACGCTGTATCTGCAAATGGACAGCCTGAGAGTTGA
GGACTCGGCTGTGTATTCCTGTGCGAGAGAAAGTGGCTGGTCCCACTACTACT
ATTACGGTATGGACGTCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGCT
TCCACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCC
GAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGT
GACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGG
CTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT
CCAGCAGCTTGGGCACGAAAACCTACACTTGCAACGTAGATCACAAGCCCAGC
AACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACC
ATGCCCAGCACCTGAGGCCGCCGGGGGACCATCAGTCTTCCTGTTCCCCCCAA
AACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTG
GTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATG
GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAG
CACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACG
GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAG
AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCC
TGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTG
GTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC
AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCC
TTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGATGGCAGGAGGGGA
ATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAG
AAGAGCCTCTCCCTGTCTCTGGGTAAA
SEQ ID NO: 198 - 1CL2B53 LC DNA
GACATCGTGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCGAGTCAGGACATTAGCAATTATTTAGCCTGGT
ATCAGCAGAAACCAGGGAAAGTTCCTAAGTTCCTGATCTATGCTGCATCCACT
TTGCACTCTGGGGTCCCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGATTTC
ACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTCAA
294
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
AAGTATAACAGTGCCCCGTACACTTTTGGCCAAGGGACACGACTGGAGATTAA
ACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTT
GAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGA
GGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAG
GAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCA
CCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGA
AGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAG
AGTGT
SEQ ID NO: 199 - KL2B242 HC DNA
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCT
GTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTATTGGAGCTG
GCTCCGGCAGCCCGCCGGGTCGGGACTGGAGTGGATTGGGCGTTTATATGTCA
GTGGGTTCACCAACTACAACCCCTCCCTCAAGAGTCGAGTCACCTTGTCACTA
GACCCGTCCAGGAACCAGTTGTCCCTGAAACTGAGTTCTGTGACCGCCGCGGA
CACGGCCGTATATTATTGTGCGGGAGATAGTGGGAACTACTGGGGTTGGTTCG
ACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTTCCACCAAGGGC
CCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGC
CGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGT
GGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG
TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTG
GGCACGAAAACCTACACTTGCAACGTAGATCACAAGCCCAGCAACACCAAGG
TGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCATGCCCAGCA
CCTGAGGCCGCCGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGA
CACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGA
GCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGT
GCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGT
GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTA
CAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCT
295
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
CCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCC
CAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCT
TCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAA
CAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTA
CAGCAGGCTAACCGTGGACAAGAGCAGATGGCAGGAGGGGAATGTCTTCTCA
TGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTC
CCTGTCTCTGGGTAAA
SEQ ID NO: 200- KL2B242 LC DNA
TCCTATGAGCTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGAGAGACAGC
CAGCATCACCTGCTCTGGAGATCAATTGGGGGAAAATTATGCTTGCTGGTATC
AGCAGAAGCCAGGCCAGTCCCCTGTGTTGGTCATCTATCAAGATAGTAAGCGG
CCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACACAGCCAC
TCTGACCATCAGCGGGACCCAGGCTCTGGATGAGGCTGACTATTACTGTCAGG
CGTGGGACAACAGTATTGTGGTATTCGGCGGAGGGACCAAGCTGACCGTCCTA
GGTCAGCCCAAGGCTGCACCCAGTGTCACTCTGTTCCCGCCCTCCTCTGAGGA
GCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGG
GAGCCGTGACAGTGGCCTGGAAGGCCGATAGCAGCCCCGTCAAGGCGGGAGT
GGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGC
TATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCA
GGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGT
TCA
SEQ ID NO: 201 - KL2B467 HC DNA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCT
GAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTTACTATGGCATGCACTG
GGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTTATATCATATG
296
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
ATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCC
AGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTG
AGGACACGGCTGTGTATTACTGTGCCCACCTCCCTTATAGTGGGAGCTACTGG
GCCTTTGACTACTGGGGCCAGGGAACCCAGGTCACCGTCTCTTCAGCCTCCAC
CAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGG
GCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACG
GTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGT
CCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAG
CAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACA
CCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGC
CCACCGTGCCCAGCACCTGAAGCCGCCGGGGGACCGTCAGTCTTCCTCTTCCC
CCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCG
TGGTGGTGAGCGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTG
GACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACA
ACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCAT
CGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTG
CCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATG
GGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGG
CTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGATGGCAGCAGG
GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
CAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
SEQ ID NO: 202 - KL2B467 LC DNA
CAGTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCCGGGCAGACGGC
CAGTATTACCTGTGGGGGAGACAACATTGGAAGTAAAAGTGTGCACTGGTACC
AGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTCGTCTATGATAATAGCGACCGG
CCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGACCACGGCCAC
297
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
CCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCAGG
TGTGGGATAGTAGTAGTGATCATCCTGTGGTATTCGGCGGAGGGACCAAGGTC
ACCGTCCTAGGTCAGCCCAAGGCTGCACCCAGTGTCACTCTGTTCCCGCCCTCC
TCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTT
CTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCCGATAGCAGCCCCGTCAAG
GCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGG
CCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTAC
AGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTA
CAGAATGTTCA
SEQ ID NO: 203 - KL2B494 HC DNA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCT
GAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTCATTATGCCATGAGCTG
GGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAACTATTGGTGGTA
GTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCC
AGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCG
AGGACACGGCCGTATATTACTGTGCGAAACCTCATATTGTAATGGTGACTGCT
CTTCTCTACGACGGTATGGACGTCTGGGGCCAAGGGACAATGGTCACCGTCTC
CTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAG
CACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG
AACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACC
TTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACC
GTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAA
GCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAA
ACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCCGGGGGACCGTCAGT
CTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGA
GGTCACATGCGTGGTGGTGAGCGTGAGCCACGAAGACCCTGAGGTCAAGTTCA
ACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGA
GGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC
298
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCT
CCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAA
CCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGT
CAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGT
GGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCT
GGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCA
GATGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCAC
AACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
SEQ ID NO: 204 ¨ KL2B494 LC DNA
TCTTCTGAGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGC
CAGGATTACCTGTGGGGGAAACAACATTGGAAGTAAAAGTGTGCACTGGTACC
AGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTCGTCTATGATGATAGCGACCGG
CCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACACGGCCAC
CCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCAGG
TGTGGGATAGTAGTAGTGATCATGTGGTATTCGGCGGAGGGACCAAGCTGACC
GTCCTAGGTCAGCCCAAGGCTGCACCCAGTGTCACTCTGTTCCCGCCCTCCTCT
GAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTA
CCCGGGAGCCGTGACAGTGGCCTGGAAGGCCGATAGCAGCCCCGTCAAGGCG
GGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCA
GCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGC
TGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAG
AATGTTCA
SEQ ID NO: 205 ¨ CAR (KL2B357 HL and KL2B357 LH)
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQFPGKGLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
299
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
LVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPDSLAVSLGERATINCRASESVEY
FGTSLMHVVYQQKPGQPPKLLIYAASNVESGVPDRFSGSGSGTDFTLTISSLQAEDV
AVYFCQQTRKVPYTFGGGTKVEIKTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGG
AVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQ
TTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH
DGLYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 207 - CAR (KL2B358 HL)
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIRQPPGKGLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYF
GTSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAV
YFCQQTRKVPYTFGGGTKVEIKTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV
HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTT
QEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVL
DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGEIDG
LYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 208 - CAR (KL2B358 LH)
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAASN
VESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGS
EGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIR
QPPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYC
ATGYYYGSGFWGQGTLVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV
HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTT
QEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVL
300
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHIDG
LYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 209 - CAR (KL2B360 HL)
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYF
GTSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAV
YFCQQTRKVPYTFGGGTKVEIKTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV
HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTT
QEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVL
DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGEIDG
LYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 210 - CAR (KL2B360 LH)
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAASN
VESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGS
EGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIR
QFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYC
ATGYYYGSGFWGQGTLVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV
HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTT
QEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVL
DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGEIDG
LYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 211 - CAR (KL2B30 HL)
301
ZOE
ISSIIIIKEIDS9S9SDIScIADSEMSVIVAIIJNcIAND(INOOAMICIANSIGOSIOIDI
IIAWDASVSIS S (IS OIIAIAIG SDDI SNSAS9 SD S SNDA SODS SAIAIALLOODMAGIA1 0
DAAAAHSMDSMIVOSAAVS GAAYISMAIOIKIINNSNMISIIDIDNASGIAGNNS
9GASIIVAMAIDN9cIVO?lAMHIGASSILJOSVADSIXIS?19cIOAADD-DSANIOAA
(111 ESEIZIM)11V3 - EIZ :ON (11 OIS
SZ
licknvOwirwcuucrxivISIDOKIDGHON
9112121ADNINDIASAVJVW>IGNOIANKIDAOcII\DI2121(DIDDINAcIG219112DIGIAGAA
MINDIVIANKIONODONAVcIVGIVS?ISJNANIAD-D-DAAAAcIDIDSODGAAOLLOAcI
IITAIJcIONJIATDDRIDIDIDAIIINISITIADDIDVIcIWAIAIGOVJG1911IHAVDDIV OZ
VaIDIVAcnIISIcIOSIVIIcIVcackificIIMISISSAIALLOODMAGIAIDAAJNcIIAADJII
IDVDAAAVIGIVVIASSINISJONNSIGASIIA?ISNIScINANISOSAMADIMAIDN
9cIcIO?IPASMAAS SISDD SAIDEISIIAS cINN19cI9 S AOIOAO SDDI SNS AS9 SD S SN
DASOD NonxiDoolukust\nO03A)uvJaadOlsSIIIIJAIDS9S9SRIScIA9
SOIISVIVAMNcIVN9cINOOAMICIASSIDOSV?IDILLAWDASVSIJScISOIINOIG SI
(111 OCEIZ131) IIVD - ZIZ :ON 01 OIS
licknvOwErwcuucrxivISIDOKIDGHON OI
9112121ADNINDIASAVJVW>IGNOIANKIDAOcII\DI2121(DIDDINAcIG219112DIGIAGAA
MINDIVIANKIONODONAVcIVGIVS?ISJNANIAD-D-DAAAAcIDIDSODGAAOLLOAcI
IITAIJcIONJIATDDRIDIDIDAIIINISITIADDIDVIcIWAIAIGOVJG1911IHAVDDIV
vcmovacnns-mOsvnavdickmavcit siNHANIDooluicust\n003A)uvJaa
dOlssIIIIJAIDS9S9S121ScIADSOTtsvvAnaxavNaiNOOArninAssmOsvu s
DILLAWDASVSIJS (IS OIINOIGSDDI SNS AS9 SD S SNDASODS SAIALLDODMAG
IAIDAAJI\MIAADJIII9V3AAAVIGIVVIASSINISJONNSIGASIIA?ISNIScINAN
ISOSAMADIMAIDN9cIaMPASMAASSISDOSAI3EISIIAScINA'19cIDSAOIOAO
9969SO/OZOZE11/13c1 98610/1Z0Z OM
SZ-TO-ZZOZ SEL8VTE0 VD
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
QPEDVATYYCQKYNSAPYTFGQGTRLEIKTSTPAPRPPTPAPTIASQPLSLRPEACR
PAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPF
MRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGR
REEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR
RGKGHDGLYQGLSTATKDTYDALHMQALPPR
SEQ ID NO: 214 - CAR (KL2B53 LH)
DIVIVITQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKVPKFLIYAASTLHS
GVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPYTFGQGTRLEIKGGSEGK
SSGSGSESKSTGGSEVQLVESGGGVVQPGRSLRLSCVASGFTFSSYDIHVVVRQAPG
KGLEWVAIISYDGSKKDYTDSVKGRFTISRDNSKNTLYLQMDSLRVED SAVYSCA
RESGWSHYYYYGMDVWGQGTMVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACRP
AAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPF
MRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGR
REEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR
RGKGHDGLYQGLSTATKDTYDALHMQALPPR
SEQ ID NO: 215 - CAR (KL2B242 HL)
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWLRQPAGSGLEWIGRLYVSGF
TNYNPSLKSRVTLSLDPSRNQLSLKLSSVTAADTAVYYCAGDSGNYVVGWFDPWG
QGTLVTVSSGGSEGKSSGSGSESKSTGGSSYELTQPPSVSVSPGETASITCSGDQLG
ENYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQALDEAD
YYCQAWDNSIVVFGGGTKLTVLTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA
VHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQT
TQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDV
LDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGEID
GLYQGLSTATKDTYDALEIMQALPPR
303
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 216 - CAR (KL2B242 LH)
SYELTQPPSVSVSPGETASITCSGDQLGENYACWYQQKPGQSPVLVIYQDSKRPSGI
PERFSGSNSGNTATLTISGTQALDEADYYCQAWDNSIVVFGGGTKLTVLGGSEGK
SSGSGSESKSTGGSQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWLRQPAG
SGLEWIGRLYVSGFTNYNPSLKSRVTLSLDPSRNQLSLKLSSVTAADTAVYYCAG
DSGNYVVGWFDPWGQGTLVTVSSTSTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA
VHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQT
TQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDV
LDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGEID
GLYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 217 - CAR (KL2B467 HL)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHVVVRQAPGKGLEWVAFISYD
GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAHLPYSGSYVVAF
DYVVGQGTQVTVSSGGSEGKSSGSGSESKSTGGSQSVLTQPPSVSVAPGQTASITCG
GDNIGSKSVHVVYQQKPGQAPVLVVYDNSDRPSGIPERFSGSNSGTTATLTISRVEA
GDEADYYCQVWDSSSDHPVVFGGGTKVTVTSTPAPRPPTPAPTIASQPLSLRPEAC
RPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQP
FMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLG
RREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGER
RRGKGEIDGLYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 218 - CAR (KL2B467 LH)
304
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
QSVLTQPPSVSVAPGQTASITCGGDNIGSKSVHVVYQQKPGQAPVLVVYDNSDRPS
GIPERFSGSNSGTTATLTISRVEAGDEADYYCQVWDSSSDHPVVFGGGTKVTVGG
SEGKSSGSGSESKSTGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHVVV
RQAPGKGLEWVAFISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDT
AVYYCAHLPYSGSYVVAFDYVVGQGTQVTVSSTSTPAPRPPTPAPTIASQPLSLRPEA
CRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQ
PFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNL
GRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGE
RRRGKGEIDGLYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 219 - CAR (KL2B494 HL)
QVQLVESGGGLVQPGGSLRLSCAASGFTFSHYAMSWVRQAPGKGLEWVSTIGGS
GGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPHIVMVTALL
YDGMDVWGQGTMVTVSSGGSEGKSSGSGSESKSTGGSSSELTQPPSVSVAPGQTA
RITCGGNNIGSKSVHVVYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTI
SRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLTSTPAPRPPTPAPTIASQPLSL
RPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLL
YIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLY
NELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG
MKGERRRGKGEIDGLYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 220 - CAR (KL2B494 LH)
SSELTQPPSVSVAPGQTARITCGGNNIGSKSVHVVYQQKPGQAPVLVVYDDSDRPS
GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLGG
SEGKSSGSGSESKSTGGSQVQLVESGGGLVQPGGSLRLSCAASGFTFSHYAMSWV
RQAPGKGLEWVSTIGGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA
VYYCAKPHIVMVTALLYDGMDVWGQGTMVTVSSTSTPAPRPPTPAPTIASQPLSL
305
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
RPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLL
YIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLY
NELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG
MKGERRRGKGEIDGLYQGLSTATKDTYDALEIMQALPPR
SEQ ID NO: 221 ¨ Extracellular anti2en-bindin2 domain (KL2B357 HL)
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPDSLAVSLGERATINCRASESVEY
FGTSLMHVVYQQKPGQPPKLLIYAASNVESGVPDRFSGSGSGTDFTLTISSLQAEDV
AVYFCQQTRKVPYTFGGGTKVEIK
SE() ID NO: 222 ¨ Extracellular anti2en-bindin2 domain (KL2B357 LH)
DIVLTQSPDSLAVSLGERATINCRASESVEYFGTSLIVIHVVYQQKPGQPPKLLIYAAS
NVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQTRKVPYTFGGGTKVEIKG
GSEGKSSGSGSESKS TGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVV
IRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVY
YCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 223 ¨ Extracellular anti2en-bindin2 domain (KL2B358 HL)
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIRQPPGKGLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYF
GTSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAV
YFCQQTRKVPYTFGGGTKVEIK
306
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 224 ¨ Extracellular anti2en-bindin2 domain (KL2B358 LH)
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAASN
VESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGS
EGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIR
QPPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYC
ATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 225 ¨ Extracellular anti2en-bindin2 domain (KL2B360 HL)
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSG
STTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGT
LVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYF
GTSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAV
YFCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 226 ¨ Extracellular anti2en-bindin2 domain (KL2B360 LH)
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAASN
VESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGS
EGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNVVIR
QFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYC
ATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 227 ¨ Extracellular anti2en-bindin2 domain (KL2B30 HL)
307
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWIRQPPGKGLEWIGYIYYSGST
NYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGTTIFGVVTPNFYYGM
DVWGQGTTVTVSSGGSEGKSSGSGSESKSTGGSDIQMTQSPSFLSASVGDRVTITC
RASQGISSYLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQP
EDFATYYCQQLNSYPLTFGGGTKVEIK
SEQ ID NO: 228 ¨ Extracellular anti2en-bindin2 domain (KL2B30 LH)
DIQMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKFLIYAASTLQS
GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK GGSEG
KSSGSGSESKSTGGSQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWIRQPPG
KGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGT
TIFGVVTPNFYYGMDVWGQGTTVTVSS
SEQ ID NO: 229 ¨ Extracellular anti2en-bindin2 domain (KL2B53 HL)
EVQLVESGGGVVQPGRSLRLSCVASGFTFSSYDIHVVVRQAPGKGLEWVAIISYDG
SKKDYTDSVKGRFTISRDNSKNTLYLQMDSLRVED SAVYSCARESGWSHYYYYG
MDVWGQGTMVTVSSGGSEGKSSGSGSESKSTGGSDIVNITQSPSSLSASVGDRVTI
TCRASQDISNYLAWYQQKPGKVPKFLIYAASTLHSGVPSRFSGSGSGTDFTLTISSL
QPEDVATYYCQKYNSAPYTFGQGTRLEIK
SEQ ID NO: 230 ¨ Extracellular anti2en-bindin2 domain (KL2B53 LH)
DIVIVITQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKVPKFLIYAASTLHS
GVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPYTFGQGTRLEIKGGSEGK
SSGSGSESKSTGGSEVQLVESGGGVVQPGRSLRLSCVASGFTFSSYDIHVVVRQAPG
308
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
KGLEWVAIISYDGSKKDYTDSVKGRFTISRDNSKNTLYLQMDSLRVED SAVYSCA
RESGWSHYYYYGMDVWGQGTMVTVSS
SEQ ID NO: 231 ¨ Extracellular anti2en-bindin2 domain (KL2B242 HL)
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWLRQPAGSGLEWIGRLYVSGF
TNYNPSLKSRVTLSLDPSRNQLSLKLSSVTAADTAVYYCAGDSGNYVVGWFDPWG
QGTLVTVSSGGSEGKSSGSGSESKSTGGSSYELTQPPSVSVSPGETASITCSGDQLG
ENYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQALDEAD
YYCQAWDNSIVVFGGGTKLTVL
SEQ ID NO: 232 ¨ Extracellular anti2en-bindin2 domain (KL2B242 LH)
SYELTQPPSVSVSPGETASITCSGDQLGENYACWYQQKPGQSPVLVIYQDSKRPSGI
PERFSGSNSGNTATLTISGTQALDEADYYCQAWDNSIVVFGGGTKLTVLGGSEGK
SSGSGSESKSTGGSQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYVVSWLRQPAG
SGLEWIGRLYVSGFTNYNPSLKSRVTLSLDPSRNQLSLKLSSVTAADTAVYYCAG
DSGNYVVGWFDPWGQGTLVTVSS
SEQ ID NO: 233 ¨ Extracellular anti2en-bindin2 domain (KL2B467 HL)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHVVVRQAPGKGLEWVAFISYD
GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAHLPYSGSYVVAF
DYVVGQGTQVTVSSGGSEGKSSGSGSESKSTGGSQSVLTQPPSVSVAPGQTASITCG
GDNIGSKSVHVVYQQKPGQAPVLVVYDNSDRPSGIPERFSGSNSGTTATLTISRVEA
GDEADYYCQVWDSSSDHPVVFGGGTKVTV
309
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 234 ¨ Extracellular anti2en-bindin2 domain (KL2B467 LH)
QSVLTQPPSVSVAPGQTASITCGGDNIGSKSVHVVYQQKPGQAPVLVVYDNSDRPS
GIPERFSGSNSGTTATLTISRVEAGDEADYYCQVWDSSSDHPVVFGGGTKVTVGG
SEGKSSGSGSESKSTGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHVVV
RQAPGKGLEWVAFISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDT
AVYYCAHLPYSGSYVVAFDYVVGQGTQVTVSS
SEQ ID NO: 235 ¨ Extracellular anti2en-bindin2 domain (KL2B494 HL)
QVQLVESGGGLVQPGGSLRLSCAASGFTFSHYAMSWVRQAPGKGLEWVSTIGGS
GGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPHIVMVTALL
YDGMDVWGQGTMVTVSSGGSEGKSSGSGSESKSTGGSSSELTQPPSVSVAPGQTA
RITCGGNNIGSKSVHVVYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTI
SRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL
SEQ ID NO: 236 ¨ Extracellular anti2en-bindin2 domain (KL2B494 LH)
SSELTQPPSVSVAPGQTARITCGGNNIGSKSVHVVYQQKPGQAPVLVVYDDSDRPS
GIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLGG
SEGKSSGSGSESKSTGGSQVQLVESGGGLVQPGGSLRLSCAASGFTFSHYAMSWV
RQAPGKGLEWVSTIGGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA
VYYCAKPHIVMVTALLYDGMDVWGQGTMVTVSS
SE() ID NO: 237 - Linker sequence
GGGSGGGS
310
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SEO ID NO: 238 - Linker sequence
GGGS GGGS GGGS
SE() ID NO: 239 - Linker sequence
GGGS GGGS GGGS GGGS
SE() ID NO: 240 - Linker sequence
GGGS GGGS GGGS GGGS GGGS
SE() ID NO: 241 - Linker sequence
GGGGS GGGGS GGGGS
SE() ID NO: 242 - Linker sequence
GGGGS GGGGS GGGGS GGGGS
SE() ID NO: 243 - Linker sequence
GGGGS GGGGS GGGGS GGGGS GGGGS
311
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SEQ ID NO: 244 - Linker sequence
GS TSGSGKPGSGEGS TKG
SEQ ID NO: 245 - Linker sequence
IRPRAIGGSKPRVA
SEQ ID NO: 246 - Linker sequence
GKGGSGKGGSGKGGS
SEQ ID NO: 247 - Linker sequence
GGKGSGGKGSGGKGS
SEQ ID NO: 248 - Linker sequence
GGGKSGGGKSGGGKS
SEQ ID NO: 249 - Linker sequence
GKGKSGKGKSGKGKS
SEQ ID NO: 250 - Linker sequence
312
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
GGGKSGGKGSGKGGS
.. SEQ ID NO: 251 - Linker sequence
GKPGSGKPGSGKPGS
.. SEQ ID NO: 252 - Linker sequence
GKPGSGKPGSGKPGSGKPGS
SEQ ID NO: 253 - Linker sequence
GKGKSGKGKSGKGKSGKGKS
SEQ ID NO: 254 - Linker sequence
STAGDTHLGGEDFD
SEQ ID NO: 255 - Linker sequence
GEGGSGEGGSGEGGS
SEQ ID NO: 256 - Linker sequence
313
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
GGEGSGGEGSGGEGS
SEQ ID NO: 257 - Linker sequence
GE GE S GE GE S GE GE S
SEQ ID NO: 258 - Linker sequence
GGGESGGEGSGEGGS
SEQ ID NO: 259 - Linker sequence
GE GE S GE GE S GE GE S GE GE S
SEQ ID NO: 260 - Linker sequence
GS TSGSGKPGSGEGS TKG
SEQ ID NO: 261 - Linker sequence
PRGASKSGSASQTGSAPGS
SEQ ID NO: 262 - Linker sequence
GTAAAGAGAAGGAAAGAAG
314
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SEQ ID NO: 263 - Linker sequence
GTSGSSGSGSGGSGSGGGG
SEQ ID NO: 264 - Linker sequence
GKPGSGKPGSGKPGSGKPGS
SEQ ID NO: 265 - Linker sequence
GSGS
SEQ ID NO: 266 - Linker sequence
APAPAPAPAP
SEQ ID NO: 267 - Linker sequence
APAPAPAPAPAPAPAPAPAP
SEQ ID NO: 268 - Linker sequence
AEAAAKEAAAKEAAAAKEAAAAKEAAAAKAAA
315
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 269 ¨ CAR hinge sequence
EPKSCDKTHTCPPCP
SEQ ID NO: 270 ¨ CAR hinge sequence
ERKCCVECPPCP
SEQ ID NO: 271 ¨ CAR hinge sequence
ELKTPLGDTTHTCPRCP(EPKSCDTPPPCPRCP)3
SEQ ID NO: 272 ¨ CAR hinge sequence
ESKYGPPCPSCP
SEQ ID NO: 273 ¨ Extracellular antigen-binding domain 1
(IIL HCG5 LCD6 20AA) with signal peptide
MAWVWTLLFLMAAAQSIQAQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAW
NVVIRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDT
AVYYCATGYYYGSGFWGQGTLVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPD
SLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPD
RFSGSGSGTDFTLTIQSVQAEDVSVYFCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 274 ¨ Extracellular antigen-binding domain 2
(IIL HCG5 LCHumanized 20AA) with signal peptide
316
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
MAWVWTLLFLMAAAQSIQAQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAW
NVVIRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDT
AVYYCATGYYYGSGFWGQGTLVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPD
SLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPD
RFSGSGSGTDFTLTISSLQAEDVAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 275 ¨ Extracellular anti2en-bindin2 domain 3 (HL HCF3 LCB7 20AA)
with si2nal peptide
MAWVWTLLFLMAAAQSIQAQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAW
NVVIRQFPGKGLEWIGYISYSGS TTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDTA
VYYCATGYYYGSGFWGQGTLVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPDS
LAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPDR
FSGSGSGTDFTLTISSVQAEDVAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 276 ¨ Extracellular anti2en-bindin2 domain 4
(IIL HCG5 LCB7 20AA) with si2nal peptide
MAWVWTLLFLMAAAQSIQAQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAW
NVVIRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTPVDT
AVYYCATGYYYGSGFWGQGTLVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPD
SLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPD
RFSGSGSGTDFTLTISSVQAEDVAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 277 ¨ Extracellular anti2en-bindin2 domain 5
(LH LCD6 HCG5 20AA) with si2nal peptide
MAWVWTLLFLMAAAQSIQADIVLTQSPDSLAVSLGERATINCKASESVEYFGTSL
MEIVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTIQSVQAEDVSVYF
CQQTRKVPYTFGQGTKLEIKGGSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSD
317
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
TLSLTCAVSGNSITSDYAWNVVIRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISR
DTSKNQFSLKLSSVTPVDTAVYYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 278 ¨ Extracellular anti2en-bindin2 domain 6
(LH LCHumanized HCF3 20AA) with si2nal peptide
MAWVWTLLFLMAAAQSIQADIVLTQSPDSLAVSLGERATINCKASESVEYFGTSL
MEIVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYY
CQQTRKVPYTFGQGTKLEIKGGSEGKS SGSGSESKSTGGSQVQLQESGPGLVKPSD
TLSLTCAVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRD
TSKNQFSLKLSSVTPVDTAVYYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 279 ¨ Extracellular anti2en-bindin2 domain 7
(LH LCHumanized HCG5 20AA) with si2nal peptide
MAWVWTLLFLMAAAQSIQADIVLTQSPDSLAVSLGERATINCKASESVEYFGTSL
MEIVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYY
CQQTRKVPYTFGQGTKLEIKGGSEGKS SGSGSESKSTGGSQVQLQESGPGLVKPSD
TLSLTCAVSGNSITSDYAWNVVIRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISR
DTSKNQFSLKLSSVTPVDTAVYYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 280 ¨ Extracellular anti2en-bindin2 domain 8 (LH LCB7 HCF3 20AA)
with si2nal peptide
MAWVWTLLFLMAAAQSIQADIVLTQSPDSLAVSLGERATINCKASESVEYFGTSL
MEIVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYY
CQQTRKVPYTFGQGTKLEIKGGSEGKS SGSGSESKSTGGSQVQLQESGPGLVKPSD
TLSLTCAVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRD
TSKNQFSLKLSSVTPVDTAVYYCATGYYYGSGFWGQGTLVTVSS
318
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 281 ¨ Extracellular anti2en-bindin2 domain 9
(LH LCB7 HCG5 20AA) with si2na1 peptide
MAWVWTLLFLMAAAQSIQADIVLTQSPDSLAVSLGERATINCKASESVEYFGTSL
MEIVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYY
CQQTRKVPYTFGQGTKLEIKGGSEGKS SGSGSESKSTGGSQVQLQESGPGLVKPSD
TLSLTCAVSGNSITSDYAWNVVIRQFPGKGLEWMGYISYSGSTTYNPSLKSRVTISR
DTSKNQFSLKLSSVTPVDTAVYYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 282 ¨ Extracellular anti2en-bindin2 domain 10
(LH LCD6 HCF3 20AA) with si2nal peptide
MAWVWTLLFLMAAAQSIQADIVLTQSPDSLAVSLGERATINCKASESVEYFGTSL
MEIVVYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTIQSVQAEDVSVYF
CQQTRKVPYTFGQGTKLEIKGGSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSD
TLSLTCAVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRD
TSKNQFSLKLSSVTPVDTAVYYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 283 ¨ Extracellular anti2en-bindin2 domain 11
(IIL HCHumanized LCB7 20AA) with si2nal peptide
MAWVWTLLFLMAAAQSIQAQVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAW
NVVIRQPPGKGLEWIGYISYSGSTTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDT
AVYYCATGYYYGSGFWGQGTLVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPD
SLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAASNRESGVPD
RFSGSGSGTDFTLTISSVQAEDVAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 284 ¨ Extracellular anti2en-bindin2 domain 12
(IIL HCHumanized LCD6 20AA) with si2nal peptide
319
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
MAWVWTLLFLMAAAQ SIQAQVQL QE S GP GLVKP SD TLSLTCAV S GNSITS DYAW
NVVIRQPP GKGLEWI GYIS YS GS TTYNP SLKSRVTMSRD T SKNQF SLKL S SVTAVDT
AVYY CAT GYYYGS GFWGQGTLVTVS SGGSEGKS S GS GSESKSTGGSDIVLTQSPD
SLAVSLGERATINCKASE SVEYF GT SLMHVVYQ QKPGQPPKLLIYAASNRE S GVPD
RF S GS GS GTDF TLTIQ S VQ AEDV S VYF C Q Q TRKVPYTF GQ GTKLEIK
SEQ ID NO: 285 ¨ Extracellular anti2en-bindin2 domain 13
(In HCHumanized LCHumanized 20AA) with si2nal peptide
MAWVWTLLFLMAAAQ SIQAQVQL QE S GP GLVKP SD TLSLTCAV S GNSITS DYAW
NVVIRQPP GKGLEWI GYIS YS GS TTYNP SLKSRVTMSRD T SKNQF SLKL S SVTAVDT
AVYY CAT GYYYGS GFWGQGTLVTVS SGGSEGKS S GS GSESKSTGGSDIVLTQSPD
SLAVSLGERATINCKASE SVEYF GT SLMHVVYQ QKPGQPPKLLIYAASNRE S GVPD
RF S GS GS GTDF TLTIS SLQAEDVAVYYCQQTRKVPYTFGQGTKLEIK
SEQ ID NO: 286 ¨ Extracellular anti2en-bindin2 domain 14
(LH LCD6 HCHumanized 20AA) with si2nal peptide
MAWVWTLLFLMAAAQ SIQADIVLTQ SPD SLAVSLGERATINCKASESVEYF GT SL
MEIVVY Q QKP GQPPKLLIYAA SNRE S GVPDRF S GS GS GTDF TLTIQ S VQ AEDV S VYF
CQQTRKVPYTFGQGTKLEIKGGSEGKS S GS GSESKS TGGS QVQL QES GP GLVKP SD
TL SLTCAVS GNSIT SDYAWNVVIRQPP GKGLEWI GYIS YS GS TTYNP SLKSRVTMSR
DTSKNQFSLKLS SVTAVDTAVYYCATGYYYGSGFWGQGTLVTVS S
SEQ ID NO: 287 ¨ Extracellular anti2en-bindin2 domain 15
(LH LCHumanized HCHumanized 20AA) with si2nal peptide
MAWVWTLLFLMAAAQ SIQADIVLTQ SPD SLAVSLGERATINCKASESVEYF GT SL
MEIVVY Q QKP GQPPKLLIYAA SNRE S GVPDRF S GS GS GTDF TL TI S SLQAEDVAVYY
CQQTRKVPYTFGQGTKLEIKGGSEGKS S GS GSESKS TGGS QVQL QES GP GLVKP SD
320
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
TL SLTCAVS GNSIT SDYAWNVVIRQPPGKGLEWI GYI S YS GS TTYNP SLKSRVTMSR
DTSKNQF SLKLS SVTAVDTAVYYCATGYYYGSGFWGQGTLVTVS S
SEQ ID NO: 288 ¨ Extracellular anti2en-bindin2 domain 16
(LH LCB7 HCHumanized 20AA) with si2nal peptide
MAWVWTLLFLMAAAQ SI QADIVLTQ SPD SLAVSLGERATINCKASESVEYF GT SL
MEIVVYQQKPGQPPKLLIYAASNRESGVPDRF S GS GS GTDFTLTIS SVQAEDVAVYY
CQQTRKVPYTFGQGTKLEIKGGSEGKS S GS GSE SKS TGGS QVQLQE S GPGLVKP SD
TL SLTCAVS GNSIT SDYAWNVVIRQPPGKGLEWI GYI S YS GS TTYNP SLKSRVTMSR
DTSKNQF SLKLS SVTAVDTAVYYCATGYYYGSGFWGQGTLVTVS S
SEQ ID NO: 289 ¨ Extracellular anti2en-bindin2 domain 17 (KL2B413 HL) with
si2nal peptide
MAWVWTLLFLMAAAQ SIQAEVQLVES GGGLVQPGGSLRL S CAAS GF TF S SYVVMT
WVRQAPGKGLEWVANIKQDGSERYYVDSVKGRF TISRDNAKNSLYLQMNSLRAE
DTAVYYCARDQNYDILTGHYGMDVWGQ GTTVTVS SGGSEGKS S GS GSE SKS TGG
SEIVLTQ SP SFL S ASVGDRVTITCRAS Q GIS SYLSWYQQKPGKAPKLLIYATSTLQSG
VP SRF S GS GS GTEF TLTI S SLQPEDFATYYCQQLNSYPRTFGQGTKVEIK
SEQ ID NO: 290 ¨ Extracellular anti2en-bindin2 domain 18 (KL2B413 LH) with
si2nal peptide
MAWVWTLLFLMAAAQ SIQAEIVLTQ SP SFLS A SVGDRVTITCRAS Q GI S SYLSWYQ
QKPGKAPKLLIYATS TLQSGVPSRF S GS GS GTEF TLTIS SLQPEDFATYYCQQLNSY
PRTFGQGTKVEIKGGSEGKS S GS GSE SKS TGGSEVQLVE S GGGLVQPGGSLRL S CA
AS GF TF S SYWMTWVRQAPGKGLEWVANIKQDGSERYYVDSVKGRFTISRDNAKN
SLYLQMNSLRAED TAVYYCARD QNYDILTGHYGMDVWGQ GTTVTV S S
321
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 291 ¨ Extracellular anti2en-bindin2 domain 19 (KL2B359-1IL) with
si2na1 peptide
MAWVWTLLFLMAAAQSIQAQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAW
NVVIRQFPGKRLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTA
VYYCATGYYYGSGFWGQGTLVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATL
SLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFS
GSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 292 ¨ Extracellular anti2en-bindin2 domain 20 (KL2B359-LH) with
si2nal peptide
MAWVWTLLFLMAAAQSIQAEIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLM
HVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQ
TRKVPYTFGGGTKVEIKGGSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLS
LTCTVSGNSITSDYAWNVVIRQFPGKRLEWIGYISYSGSTTYNPSLKSRVTISRDTSK
NQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 293 ¨ Extracellular anti2en-bindin2 domain (KL2B357 fIL) with
si2nal
peptide
MAWVWTLLFLMAAAQSIQAQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAW
NVVIRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTA
VYYCATGYYYGSGFWGQGTLVTVSSGGSEGKSSGSGSESKSTGGSDIVLTQSPDS
LAVSLGERATINCRASESVEYFGTSLIVIHVVYQQKPGQPPKLLIYAASNVESGVPDR
FSGSGSGTDFTLTISSLQAEDVAVYFCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 294 ¨ Extracellular anti2en-bindin2 domain (KL2B357 LH) with si2na1
peptide
322
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
MAWVWTLLFLMAAAQSIQADIVLTQSPDSLAVSLGERATINCRASESVEYFGTSL
MEIVVYQQKPGQPPKLLIYAASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYF
CQQTRKVPYTFGGGTKVEIKGGSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQ
TLSLTCTVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRD
TSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 295 ¨ Extracellular anti2en-bindin2 domain (KL2B358 In) with si2nal
peptide
MAWVWTLLFLMAAAQSIQAQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAW
NVVIRQPPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTA
VYYCATGYYYGSGFWGQGTLVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATL
SLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFS
GSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 296 ¨ Extracellular anti2en-bindin2 domain (KL2B358 LH) with si2na1
peptide
MAWVWTLLFLMAAAQSIQAEIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLM
HVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQ
TRKVPYTFGGGTKVEIKGGSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLS
LTCTVSGNSITSDYAWNVVIRQPPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSK
NQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 297 ¨ Extracellular anti2en-bindin2 domain (KL2B360 In) with si2nal
Peptide
MAWVWTLLFLMAAAQSIQAQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAW
NVVIRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTA
VYYCATGYYYGSGFWGQGTLVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATL
323
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFS
GSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 298 ¨ Extracellular anti2en-bindin2 domain (KL2B360 LH) with si2nal
peptide
MAWVWTLLFLMAAAQSIQAEIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLM
HVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQ
TRKVPYTFGGGTKVEIKGGSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLS
LTCTVSGNSITSDYAWNVVIRQFPGKGLEWIGYISYSGSTTYNPSLKSRVTISRDTSK
NQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGTLVTVSS
SEQ ID NO: 299 ¨ Extracellular anti2en-bindin2 domain (KL2B30 HL) with si2nal
peptide
MAWVWTLLFLMAAAQSIQAQVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWS
WIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTA
VYYCAGTTIFGVVTPNFYYGMDVWGQGTTVTVSSGGSEGKSSGSGSESKSTGGSD
IQMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKFLIYAASTLQSG
VPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK
SEQ ID NO: 300 ¨ Extracellular anti2en-bindin2 domain (KL2B30 LH) with si2nal
peptide
MAWVWTLLFLMAAAQSIQADIQMTQSPSFLSASVGDRVTITCRASQGISSYLAWY
QQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNS
YPLTFGGGTKVEIKGGSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSETLSLTCT
VSGGSISSYYVVSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSL
KLSSVTAADTAVYYCAGTTIFGVVTPNFYYGMDVWGQGTTVTVSS
324
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 301 ¨ Extracellular anti2en-bindin2 domain (KL2B53 HL) with si2nal
peptide
MAWVWTLLFLMAAAQ SIQAEVQLVESGGGVVQPGRSLRLSCVASGFTF S SYDIH
WVRQAPGKGLEWVAIISYDGSKKDYTDSVKGRFTISRDNSKNTLYLQMDSLRVE
D S AVYS CARE S GWSHYYYYGMDVWGQ GTMVTVS SGGSEGKS S GS GSE SKS TGG
SDIVMTQ SP S SLSASVGDRVTITCRASQDISNYLAWYQQKPGKVPKFLIYAAS TLH
SGVPSRF S GS GS GTDF TLTI S SLQPEDVATYYCQKYNSAPYTFGQGTRLEIK
SEQ ID NO: 302 ¨ Extracellular anti2en-bindin2 domain (KL2B53 LH) with si2nal
peptide
MAWVWTLLFLMAAAQ SIQADIVIVITQ SP S SLSASVGDRVTITCRASQDISNYLAWY
QQKPGKVPKFLIYAAS TLHSGVPSRF S GS GS GTDF TLTI S SLQPEDVATYYCQKYNS
APYTFGQGTRLEIKGGSEGKS S GS GSE SKS TGGSEVQLVESGGGVVQPGRSLRLSC
VAS GFTF S SYDIHVVVRQAPGKGLEWVAIISYDGSKKDYTDSVKGRFTISRDNSKNT
LYLQMD SLRVED S AVYS CARE S GWSHYYYYGMDVWGQ GTMVTVS S
SEQ ID NO: 303 ¨ Extracellular anti2en-bindin2 domain (KL2B242 In) with si2nal
peptide
MAWVWTLLFLMAAAQ SIQAQVQLQESGPGLVKPSETLSLTCTVSGGSIS SYYWS
WLRQPAGS GLEWIGRLYVS GF TNYNP SLKSRVTL SLDP SRNQLS LKL S SVTAAD TA
VYYCAGDSGNYWGWFDPWGQGTLVTVS SGGSEGKS S GS GSE SKS TGGS SYELTQ
PP SVSVSPGETASITC S GD QLGENYACWYQ QKPGQ SPVLVIYQDSKRPSGIPERF SG
SNSGNTATLTISGTQALDEADYYCQAWDNSIVVFGGGTKLTVL
SEQ ID NO: 304 ¨ Extracellular anti2en-bindin2 domain (KL2B242 LH) with si2na1
peptide
325
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
MAWVWTLLFLMAAAQSIQASYELTQPPSVSVSPGETASITCSGDQLGENYACWY
QQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQALDEADYYCQAWD
NSIVVEGGGTKLTVLGGSEGKSSGSGSESKSTGGSQVQLQESGPGLVKPSETLSLTC
TVSGGSISSYYWSWLRQPAGSGLEWIGRLYVSGFTNYNPSLKSRVTLSLDPSRNQL
SLKLSSVTAADTAVYYCAGDSGNYVVGWFDPWGQGTLVTVSS
SEQ ID NO: 305 ¨ Extracellular anti2en-bindin2 domain (KL2B467 In) with si2nal
peptide
MAWVWTLLFLMAAAQSIQAQVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGM
HVVVRQAPGKGLEWVAFISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA
EDTAVYYCAHLPYSGSYWAFDYVVGQGTQVTVSSGGSEGKSSGSGSESKSTGGSQ
SVLTQPPSVSVAPGQTASITCGGDNIGSKSVHVVYQQKPGQAPVLVVYDNSDRPSGI
PERFSGSNSGTTATLTISRVEAGDEADYYCQVWDSSSDHPVVFGGGTKVTV
SE() ID NO: 306 ¨ Extracellular anti2en-bindin2 domain (KL2B467 LH) with
si2na1
peptide
MAWVWTLLFLMAAAQSIQAQSVLTQPPSVSVAPGQTASITCGGDNIGSKSVHWY
QQKPGQAPVLVVYDNSDRPSGIPERFSGSNSGTTATLTISRVEAGDEADYYCQVW
DSSSDHPVVFGGGTKVTVGGSEGKSSGSGSESKSTGGSQVQLVESGGGVVQPGRS
LRLSCAASGFTFSYYGMHVVVRQAPGKGLEWVAFISYDGSNKYYADSVKGRFTIS
RDNSKNTLYLQMNSLRAEDTAVYYCAHLPYSGSYVVAFDYVVGQGTQVTVSS
SEQ ID NO: 307 ¨ Extracellular anti2en-bindin2 domain (KL2B494 In) with si2nal
peptide
MAWVWTLLFLMAAAQSIQAQVQLVESGGGLVQPGGSLRLSCAASGFTF SHYAMS
WVRQAPGKGLEWVSTIGGSGGS TYYADSVKGRFTISRDNSKNTLYLQMNSLRAE
DTAVYYCAKPHIVMVTALLYDGMDVWGQGTMVTVSSGGSEGKSSGSGSESKST
326
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
GGSSSELTQPPSVSVAPGQTARITCGGNNIGSKSVHVVYQQKPGQAPVLVVYDDSD
RPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL
SEQ ID NO: 308 ¨ Extracellular anti2en-bindin2 domain (KL2B494 LH) with si2nal
peptide
MAWVWTLLFLMAAAQSIQASSELTQPPSVSVAPGQTARITCGGNNIGSKSVHWY
QQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVW
DSSSDHVVFGGGTKLTVLGGSEGKSSGSGSESKSTGGSQVQLVESGGGLVQPGGS
LRLSCAASGFTFSHYAMSWVRQAPGKGLEWVSTIGGSGGSTYYADSVKGRFTISR
DNSKNTLYLQMNSLRAEDTAVYYCAKPHIVMVTALLYDGMDVWGQGTMVTVS
S
SEQ ID NO: 309 ¨ heavy chain CDR1 sequence
GFTFSSYVVMT
SEQ ID NO: 310 ¨ heavy chain CDR2 sequence
NIKQDGSERY
SEQ ID NO: 311 ¨ heavy chain CDR3 sequence
DQNYDILTGHYGMDV
SEQ ID NO: 312 ¨ li2ht chain CDR1 sequence
RASQGISSYLS
SEQ ID NO: 313 ¨ li2ht chain CDR2 sequence
327
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
ATSTLQS
SEQ ID NO: 314 ¨ heavy chain CDR1 sequence
SYVVIVIT
SEQ ID NO: 315 ¨ heavy chain CDR2 sequence
NIKQDGSERYYVDSVKG
SEQ ID NO: 316 ¨ heavy chain CDR2 sequence
YISYSGSTTYSPSLKS
SEQ ID NO: 317¨ VII (m11B6)
DVQLQESGPGLVKPSQSLSLTCTVTGNSITSDYAWNWIRQFPGNRLEWIVIGYISYSG
STTYSPSLKSRFSITRDTSKNQFFLQLNSVTPEDTATYFCATGYYYGSGFWGQGTLV
TVSS
SEQ ID NO: 318¨ VL (m11B6)
DIVLTQSPASLAVSLGQRATISCRASESVEYFGTSLMHVVYRQKPGQPPKLLIYAASN
VESGVPARFSGSGSGTDFSLNIQPVEEDDFSMYFCQQTRKVPYTFGGGTKLEIK
SEQ ID NO: 319 ¨ human Kallikrein-2 6-His protein
VPLIEGRIVGGWECEKHS QPWQVAVYSHGWAHCGGVLVEIPQWVLTAAHCLKKN
S QVWLGRHNLFEPEDTGQRVPVSHSFPEIPLYNMSLLKHQ SLRPDED S SHDLMLLR
L SEPAKITDVVKVLGLPTQEPALGTTCYAS GWGS IEPEEFLRPRS LQ CV S LHYS EKV
328
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
TEFMLCAGLWTGGKDTCGGDSGGPLVCNGVLQGITSWGPEPCALPEKPAVYTKV
VHYRKWIKDTIAANITIREIHHH
SEQ ID NO: 320¨ VII cDNA (m11B6)
GATGTGCAGCTTCAGGAGTCTGGACCCGGACTTGTTAAACCAAGTCAGTCTCTG
TCCCTGACCTGTACCGTCACCGGCAACAGCATCACAAGCGATTACGCATGGAA
CTGGATCAGGCAGTTCCCTGGAAATCGACTCGAATGGATGGGCTACATTTCATA
CTCCGGTTCAACCACTTACTCTCCATCCTTGAAATCTAGGTTCAGCATCACCCG
TGATACCTCAAAGAACCAATTTTTTCTGCAACTGAATAGCGTAACTCCAGAGGA
CACAGCCACATATTTCTGCGCCACTGGGTATTACTATGGCTCAGGTTTCTGGGG
TCAGGGCACTCTCGTCACCGTCAGCAGC
SEQ ID NO: 321 ¨ VII cDNA (hullB6)
CAGGTCCAACTGCAAGAGAGCGGACCGGGCCTGGTAAAGCCATCCGACACATT
GTCCCTGACGTGTGCGGTAAGTGGAAACTCTATCACTAGCGACTATGCGTGGA
ATTGGATAAGACAACCGCCGGGCAAGGGGCTGGAATGGATAGGATATATCAGC
TATTCCGGTTCTACGACATACAATCCTTCCCTGAAAAGCAGAGTCACTATGTCA
CGCGACACGTCCAAGAATCAGTTCTCATTGAAATTGTCATCCGTAACGGCCGTT
GACACTGCGGTTTATTATTGCGCAACCGGATATTACTACGGCTCTGGTTTTTGG
GGACAGGGAACACTTGTTACTGTTAGTTCA
SEQ ID NO: 322 ¨ VII cDNA (HCF3-LCD6)
CAGGTGCAGCTGCAGGAGAGCGGCCCAGGCCTGGTGAAGCCAAGCGACACCCT
GAGCCTGACCTGCGCCGTGAGCGGCAACAGCATCACCAGCGACTACGCCTGGA
ACTGGATCCGCCAGTTCCCAGGCAAGGGCCTGGAGTGGATCGGCTACATCAGC
TACAGCGGCAGCACCACCTACAACCCAAGCCTGAAGAGCCGCGTCACCATCAG
CCGCGACACCAGCAAGAACCAGTTCAGCCTGAAGCTGAGCAGCGTGACCCCTG
329
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
TGGACACCGCCGTGTACTACTGCGCCACCGGCTACTACTACGGCAGCGGCTTCT
GGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
SEQ ID NO: 323 ¨ VII cDNA (HCG5-LCB7)
CAGGTGCAGCTGCAGGAGAGCGGCCCAGGCCTGGTGAAGCCAAGCGACACCCT
GAGCCTGACCTGCGCCGTGAGCGGCAACAGCATCACCAGCGACTACGCCTGGA
ACTGGATCCGCCAGTTCCCAGGCAAGGGCCTGGAGTGGATGGGCTACATCAGC
TACAGCGGCAGCACCACCTACAACCCAAGCCTGAAGAGCCGCGTCACCATCAG
CCGCGACACCAGCAAGAACCAGTTCAGCCTGAAGCTGAGCAGCGTGACCCCTG
TGGACACCGCCGTGTACTACTGCGCCACCGGCTACTACTACGGCAGCGGCTTCT
GGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
SEQ ID NO: 324 ¨ VII cDNA (KL2B359)
CAGGTTCAGCTGCAAGAGTCTGGACCAGGCCTGGTCAAGCCCTCTCAGACCCT
GTCTCTGACCTGTACCGTGTCCGGCAACTCCATCACCTCTGACTACGCCTGGAA
CTGGATTCGGCAGTTCCCTGGCAAGCGCCTTGAGTGGATCGGCTACATCTCCTA
CTCCGGTTCCACCACCTACAACCCCAGCCTGAAGTCCCGGGTCACCATCTCCCG
CGACACCTCCAAGAACCAGTTCTCCCTGAAGCTGTCCTCCGTGACCGCTGCTGA
TACCGCCGTGTACTACTGTGCCACCGGCTACTACTACGGCTCCGGCTTTTGGGG
ACAGGGCACACTGGTTACCGTGTCTAGT
SEQ ID NO: 325 ¨ VII cDNA (KL2B413)
GAGGTGCAACTTGTGGAGAGCGGCGGAGGTCTGGTCCAACCCGGAGGAAGTCT
CCGTCTCTCCTGTGCTGCTAGTGGCTTCACTTTCAGCTCATATTGGATGACATGG
GTGAGACAAGCCCCAGGAAAGGGGCTCGAGTGGGTAGCTAACATTAAACAGG
ACGGCTCCGAACGGTACTATGTTGATTCTGTGAAGGGACGGTTCACTATATCCA
GGGATAATGCAAAAAATTCACTCTATCTTCAAATGAACTCACTCAGAGCAGAG
330
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
GACACTGCCGTGTATTATTGCGCCAGGGATCAAAATTATGACATACTGACCGGT
CATTATGGAATGGATGTTTGGGGCCAGGGAACAACCGTTACCGTCTCAAGT
SEQ ID NO: 326¨ \IL cDNA (m11B6)
GACATTGTGCTGACACAGAGTCCAGCATCCTTGGCAGTATCTTTGGGGCAGCG
GGCAACAATTTCATGCCGTGCATCTGAAAGTGTGGAGTATTTTGGAACTTCTCT
TATGCACTGGTATCGCCAGAAGCCTGGGCAGCCTCCCAAACTCCTTATATATGC
CGCTTCCAACGTGGAGTCCGGAGTACCAGCACGCTTTTCCGGCTCTGGGTCCGG
CACAGACTTTTCCCTCAATATCCAACCTGTTGAAGAAGACGATTTTTCCATGTA
TTTTTGCCAACAGACACGCAAGGTTCCATATACATTCGGCGGCGGCACTAAACT
TGAGATCAAA
SEQ ID NO: 327¨ \IL cDNA (hullB6)
GACATAGTCTTGACTCAGAGCCCGGATTCCCTTGCTGTGTCTCTGGGAGAACGA
GCTACGATCAACTGCAAGGCAAGTGAATCCGTAGAATACTTCGGGACATCATT
GATGCATTGGTATCAACAGAAACCGGGGCAACCGCCCAAATTGCTGATATATG
CGGCTAGTAATAGAGAATCAGGAGTACCGGATAGGTTTAGTGGTTCAGGATCA
GGTACAGATTTCACCCTGACAATAAGTAGCTTGCAAGCCGAAGACGTAGCAGT
GTATTACTGCCAACAAACCCGAAAGGTGCCATATACGTTTGGACAGGGTACAA
AGTTGGAAATCAAA
SEQ ID NO: 328 ¨ \IL cDNA (HCF3-LCD6)
GACATCGTGCTGACCCAGAGCCCAGACAGCCTGGCCGTGAGCCTGGGCGAGCG
CGCCACCATCAACTGCAAGGCCAGCGAGAGCGTGGAGTACTTCGGCACCAGCC
TGATGCACTGGTACCAGCAGAAGCCAGGCCAGCCACCAAAGCTGCTGATCTAC
GCTGCCAGCAACCGCGAGAGCGGCGTGCCAGACCGCTTCAGCGGCAGCGGCAG
CGGCACCGACTTCACCCTGACCATCCAGAGCGTGCAGGCCGAGGACGTCTCCG
331
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
TGTACTTCTGCCAGCAGACCCGCAAGGTGCCATACACCTTCGGCCAGGGCACC
AAGCTGGAGATCAAG
SEQ ID NO: 329 ¨ \IL cDNA (HCG5-LCB7)
GACATCGTGCTGACCCAGAGCCCAGACAGCCTGGCCGTGAGCCTGGGCGAGCG
CGCCACCATCAACTGCAAGGCCAGCGAGAGCGTGGAGTACTTCGGCACCAGCC
TGATGCACTGGTACCAGCAGAAGCCAGGCCAGCCACCAAAGCTGCTGATCTAC
GCTGCCAGCAACCGCGAGAGCGGCGTGCCAGACCGCTTCAGCGGCAGCGGCAG
CGGCACCGACTTCACCCTGACCATCAGCAGCGTGCAGGCCGAGGACGTCGCCG
TGTACTACTGCCAGCAGACCCGCAAGGTGCCATACACCTTCGGCCAGGGCACC
AAGCTGGAGATCAAG
SEQ ID NO: 330 ¨ \IL cDNA (KL2B359)
GAGATCGTGCTGACCCAGTCTCCTGCCACACTGTCACTGTCTCCAGGCGAGAGA
GCCACCCTCTCTTGTAGAGCCTCCGAGTCCGTGGAATACTTCGGCACCTCTCTG
ATGCACTGGTACCAGCAGAAGCCCGGCCAGCCTCCTAGACTGCTGATCTACGC
CGCCTCCAACGTCGAATCTGGCATCCCCGCTAGATTCTCCGGCTCTGGCTCTGG
CACAGACTTTACCCTGACCATCTCCTCCGTGGAACCCGAGGATTTCGCTGTGTA
CTTTTGCCAGCAGACCCGGAAGGTGCCCTACACATTTGGCGGCGGAACAAAGG
TGGAAATCAAG
SEQ ID NO: 331 ¨ \IL cDNA (KL2B413)
GAAATCGTACTGACCCAGTCCCCTTCTTTCTTGAGTGCATCAGTTGGGGATAGA
GTGACCATTACTTGTAGAGCATCTCAAGGTATTTCTTCATACTTGTCTTGGTATC
AACAAAAACCTGGCAAGGCACCCAAACTCTTGATCTACGCCACCTCTACATTG
CAAAGTGGGGTTCCTTCTAGGTTTTCAGGCTCCGGCTCTGGTACCGAGTTCACC
CTCACTATAAGCAGTCTCCAACCTGAAGATTTCGCTACTTATTATTGTCAGCAG
CTTAATTCTTATCCCCGAACCTTTGGTCAAGGAACTAAGGTCGAGATCAAA
332
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
SEQ ID NO: 332- m11B6 HC I2G4
DVQLQESGPGLVKPSQ SLSLTCTVTGNSITSDYAWNWIRQFPGNRLEWMGYISYSG
STTYSPSLKSRF SITRD T SKNQFFLQLNSVTPED TATYF CATGYYYGS GFWGQ GTLV
TVS S AKT TAP S VYPLAPVC GD T T GS SVTLGCLVKGYFPEPVTLTWNSGSLS SGVHT
FPAVLQ SDLYTLS S SVTVTS STWPSQ SITCNVAEIPAS STKVDKKIEPRGPTIKPCPPC
KCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEV
HTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPK
GSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNT
EPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVEIEGLHNEIHTTKSF SRTPGK
SEQ ID NO: 333- m11B6 LC I2G4
DIVLTQ SPASLAVSLGQRATI S CRASESVEYF GT SLMHVVYRQKPGQPPKLLIYAASN
VESGVPARF S GS GS GTDF SLNIQPVEEDDF SMYFCQQTRKVPYTFGGGTKLEIKRA
DAAPTVSIFPP S SE QLT S GGAS VVCFLNNFYPKDINVKWKID GSERQNGVLNS WTD
QDSKDSTYSMS STLTLTKDEYERHNSYTCEATEIKTSTSPIVKSFNRNEC
SEQ ID NO: 334- h11B6 HC I2G4
QVQLQE S GPGLVKP SD TL SLTCAVS GNSIT SDYAWNWIRQPPGKGLEWIGYI S YS G
STTYNPSLKSRVTMSRDTSKNQF SLKLS SVTAVDTAVYYCATGYYYGSGFWGQGT
LVTVS S AS TKGPSVFPLAP S SKS T S GGTAALGCLVKD YFPEPVTVSWNS GALTS GV
HTFPAVLQ S SGLYSLSSVVTVPS S SLGTQTYICNVNEIKPSNTKVDKKVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNVVYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE
KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTPPVLD SD GSFFLYSKLTVDKSRWQ Q GNVF S C SVM HEALHNHYTQKSL SLS
PGK
333
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SEQ ID NO: 335- h11B6 LC I2G4
DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHVVYQQKPGQPPKLLIYAAS
NRES GVPDRF S GS GS GTDF TLTIS SLQAEDVAVYYCQ Q TRKVPYTFGQ GTKLEIKRT
5 VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV IE
QDSKDSTYSLSSTLTLSKADYEKEIKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO: 336- m11B6 HC DNA
GATGTGCAGCTTCAGGAGTCTGGACCCGGACTTGTTAAACCAAGTCAGTCTCTG
TCCCTGACCTGTACCGTCACCGGCAACAGCATCACAAGCGATTACGCATGGAA
CTGGATCAGGCAGTTCCCTGGAAATCGACTCGAATGGATGGGCTACATTTCATA
CTCCGGTTCAACCACTTACTCTCCATCCTTGAAATCTAGGTTCAGCATCACCCG
TGATACCTCAAAGAACCAATTTTTTCTGCAACTGAATAGCGTAACTCCAGAGGA
CACAGCCACATATTTCTGCGCCACTGGGTATTACTATGGCTCAGGTTTCTGGGG
TCAGGGCACTCTCGTCACCGTCAGCAGCGCCAAAACAACAGCACCAAGTGTCT
ATCCACTGGCCCCTGTGTGTGGAGATACAACTGGCTCCTCGGTGACTCTAGGAT
GCCTGGTCAAGGGTTATTTCCCTGAGCCAGTGACCTTGACCTGGAACTCTGGAT
CCCTGTCCAGTGGTGTGCACACCTTCCCAGCTGTCCTGCAGTCTGACCTCTACA
CCCTCAGCAGCTCAGTGACTGTAACCTCGAGCACCTGGCCCAGCCAGTCCATCA
CCTGCAATGTGGCCCACCCGGCAAGCAGCACCAAGGTGGACAAGAAAATTGAG
CCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAA
CCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACT
CATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGG
ATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACA
GCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAG
TGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGCA
AGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAACCC
AAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGA
GATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACCGACTTCATGCCTG
AAGACATTTACGTGGAGTGGACCAACAACGGGAAAACAGAGCTAAACTACAA
334
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
GAACACTGAACCAGTCCTGGACTCTGATGGTTCTTACTTCATGTACAGCAAGCT
GAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCAGTG
GTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCC
GGGTAAA
SEQ ID NO: 337- mullB6 LC DNA
GACATTGTGCTGACACAGAGTCCAGCATCCTTGGCAGTATCTTTGGGGCAGCG
GGCAACAATTTCATGCCGTGCATCTGAAAGTGTGGAGTATTTTGGAACTTCTCT
TATGCACTGGTATCGCCAGAAGCCTGGGCAGCCTCCCAAACTCCTTATATATGC
CGCTTCCAACGTGGAGTCCGGAGTACCAGCACGCTTTTCCGGCTCTGGGTCCGG
CACAGACTTTTCCCTCAATATCCAACCTGTTGAAGAAGACGATTTTTCCATGTA
TTTTTGCCAACAGACACGCAAGGTTCCATATACATTCGGCGGCGGCACTAAACT
TGAGATCAAACGGGCTGATGCTGCACCGACTGTGTCCATCTTCCCACCATCCAG
TGAGCAGTTAACATCTGGAGGTGCCTCAGTCGTGTGCTTCTTGAACAACTTCTA
CCCCAAAGACATCAATGTCAAGTGGAAGATTGATGGCAGTGAACGACAAAATG
GCGTCCTGAACAGTTGGACTGATCAGGACAGCAAAGACAGCACCTACAGCATG
AGCAGCACCCTCACGTTGACCAAGGACGAGTATGAACGACATAACAGCTATAC
CTGTGAGGCCACTCACAAGACATCAACTTCACCCATTGTCAAGAGCTTCAACA
GGAATGAGTGT
SEQ ID NO: 338 - hullB6 HC DNA
CAGGTCCAACTGCAAGAGAGCGGACCGGGCCTGGTAAAGCCATCCGACACATT
GTCCCTGACGTGTGCGGTAAGTGGAAACTCTATCACTAGCGACTATGCGTGGA
ATTGGATAAGACAACCGCCGGGCAAGGGGCTGGAATGGATAGGATATATCAGC
TATTCCGGTTCTACGACATACAATCCTTCCCTGAAAAGCAGAGTCACTATGTCA
CGCGACACGTCCAAGAATCAGTTCTCATTGAAATTGTCATCCGTAACGGCCGTT
GACACTGCGGTTTATTATTGCGCAACCGGATATTACTACGGCTCTGGTTTTTGG
GGACAGGGAACACTTGTTACTGTTAGTTCAGCCTCCACCAAGGGCCCATCGGTC
TTCCCCCTGGCACCCTCCTCCAAGAGCACCTCT
ACAGCGGCCCTGGGC
335
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
TGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGG
CGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACT
CTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGAC
CTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAG
TTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCC
TCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCAC
GAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAA
TGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTG
CAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAG
CCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAG
GAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCC
CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAG
CTCACCGTGGACAAGAGCAGATGGCAGCAGGGGAACGTCTTCTCATGCTCCGT
GATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCC
GGGTAAA
SEQ ID NO: 339 - hullB6 LC DNA
GACATAGTCTTGACTCAGAGCCCGGATTCCCTTGCTGTGTCTCTGGGAGAACGA
GCTACGATCAACTGCAAGGCAAGTGAATCCGTAGAATACTTCGGGACATCATT
GATGCATTGGTATCAACAGAAACCGGGGCAACCGCCCAAATTGCTGATATATG
CGGCTAGTAATAGAGAATCAGGAGTACCGGATAGGTTTAGTGGTTCAGGATCA
GGTACAGATTTCACCCTGACAATAAGTAGCTTGCAAGCCGAAGACGTAGCAGT
GTATTACTGCCAACAAACCCGAAAGGTGCCATATACGTTTGGACAGGGTACAA
AGTTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCAT
CTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACT
TCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG
GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACA
336
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
GCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTC
TACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTT
CAACAGGGGAGAGTGT
SEQ ID NO: 340¨ scFv 17 (KL2B413 HL)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVVMTWVRQAPGKGLEWVANIKQD
GSERYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDQNYDILTGHY
GMDVWGQGTTVTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPSFLSASVGDRVTIT
CRASQGISSYLSWYQQKPGKAPKLLIYATSTLQSGVPSRFSGSGSG1EFTLTISSLQP
EDFATYYCQQLNSYPRTFGQGTKVEIK
SEQ ID NO: 341 ¨ scFv 18 (KL2B413 LH)
EIVLTQSPSFLSASVGDRVTITCRASQGISSYLSWYQQKPGKAPKLLIYATSTLQSGV
PSRFSGSGSG1EFTLTISSLQPEDFATYYCQQLNSYPRTFGQGTKVEIKGGSEGKSSG
SGSESKSTGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMTWVRQAPGKG
LEWVANIKQDGSERYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR
DQNYDILTGHYGMDVWGQGTTVTVSS
SEQ ID NO: 342 ¨ scFv 19 (KL2B359 HL)
QVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQFPGKRLEWIGYISYSGS
TTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATGYYYGSGFWGQGTL
VTVSSGGSEGKSSGSGSESKSTGGSEIVLTQSPATLSLSPGERATLSCRASESVEYFG
TSLMHVVYQQKPGQPPRLLIYAASNVESGIPARFSGSGSGTDFTLTISSVEPEDFAVY
FCQQTRKVPYTFGGGTKVEIK
SEQ ID NO: 343 ¨ scFv 20 (KL2B359 LH)
337
CA 03148735 2022-01-25
WO 2021/019386 PCT/IB2020/056966
EIVLTQSPATLSLSPGERATLSCRASESVEYFGTSLMHVVYQQKPGQPPRLLIYAASN
VESGIPARFSGSGSGTDFTLTISSVEPEDFAVYFCQQTRKVPYTFGGGTKVEIKGGSE
GKSSGSGSESKSTGGSQVQLQESGPGLVKPSQTLSLTCTVSGNSITSDYAWNWIRQF
PGKRLEWIGYISYSGSTTYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCAT
GYYYGSGFWGQGTLVTVSS
SEQ ID NO: 344 VII consensus sequence
QVQLQESGPGLVKPSX1TLSLTCX2VSGNSITSDYAWNVVIRQX3PGKGLEWX4GYIS
YSGSTTYNPSLKSRVTIVISRDTSKNQFSLKLSSVTX5X6DTAVYYCATGYYYGSGF
WGQGTLVTVSS
X1 is D or Q; X2 is A or T; X3 is P or F; X4 is I or M; X5 is A or P; or X6 is
V or A.
HCDR residues are underlined.
SEQ ID NO: 345 VIA consensus sequence
X1IVLTQSPX2x3LX4X5SX6GERATX6X8CX9ASESVEYFGTSLMEIVVYQQKPGQPPX10
LLIYAASNXi iESGX12PX13RFSGSGSGTDFTLTIX14SLQX15EDX16AVYX17CQQTRKV
PYTFG X sGTKX19EIK
X1 is D or E; X2 is D or A; X3 is S or T; X4 is A or S; X5 is V or L; X6 is L
or P; X7 is I
or L; X8 is N or S; X9 is R or K; X10 is K or R; X11 is V or R; X12 is V or I;
X13 is A or
D; X14 is Q or S; X15 is P or A; X16 is F or V; X17 is Y or F; X18 is Q or G;
and X19 is
L or V. LCDR residues are underlined.
SEQ ID NO: 346 ¨ epitope
KVTEF
SEQ ID NO: 347 ¨ epitope
HYRKW
338
CA 03148735 2022-01-25
WO 2021/019386
PCT/IB2020/056966
SE() ID NO: 348 ¨ epitope
SHGWAH
SEQ ID NO: 349 ¨ epitope
RHNLFEPEDTGQRVP
SEQ ID NO: 350¨ epitope
GWGSIEPEE
339
